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Abstract 
 
Real-World Evidence (RWE) refers to any “data used for decision-making that are not 
collected in conventional Randomised Controlled Trials (RCTs) and is increasingly used in 
Health Technology Assessment (HTA) as an adjustment to the evidence coming from 
Randomised Controlled Trials (RCTs).  
 
RWE can provide additional evidence concerning treatment safety and effectiveness, 
facilitate the identification of relevant subpopulations, and permit the inclusion and 
analysis of clinical endpoints not expected in RCTs but observed in real life. However, the 
use RWE in the context of HTA is still limited.  
 
The aim of this thesis is to explore the role of RWE in economic evaluation by exploring 
methods to use with observational data and the role of RWE for a case study of direct oral 
anticoagulants (DOACs); a class of drugs, including apixaban, dabigatran and rivaroxaban, 
used for the prevention of stroke in the population affected by atrial fibrillation (AF). In 
addition to quantifying resource use and associated healthcare expenditure for the AF 
population in Scotland and evaluating propensity score methods for estimating the Average 
Treatment Effect (ATE), specific objectives are assessing cost as well as effectiveness and 
safety of DOACs using Scottish linked data. 
 
Two cohorts, one consisting of patients with a diagnosis of AF or atrial flutter, and the other 
of patients on any oral anticoagulant (OAC) were identified from inpatient hospital records 
and prescribing data for the 1997 – 2015 study period. These data were complemented by 
outpatient attendances, the care home census and mortality records using individual patient 
data linkage.   
 
v 
 
As a first step, this thesis assessed the predictors of costs and estimated inpatient, 
outpatient, prescribing and care-home costs associated with AF, using population-based 
individual-level linked data. Inpatient admissions accounted for the majority of total costs 
and these were the main cost driver across all age groups.  
 
Overall, inpatient cost contributions (~75 %) were constant across age groups. This is 
offset by increasing care-home cost contributions. The inclusion of all available cost 
components is crucial for establishing overall costs, as these often extend beyond 
hospitalisation. Most importantly, the thesis found that patients’ age has a limited impact 
on overall AF-related cost, and therefore may not be the main driver of future growth of 
AF-related costs in an ageing Scottish population.    
 
In order to identify an appropriate method for the comparative-effectiveness analysis, 
propensity score (PS) based method, such as PS matching, covariate adjustment including 
PS as covariate, and a series of Inverse Probability Weighting (IPW) methods were tested. 
A cohort of patients were followed from their first oral anticoagulant prescription to first 
clinical event (stroke and major bleeding) or death, and censoring was applied to treatment 
switching or discontinuation. In this methodological chapter, the approach that uses 
propensity scores (PS) as a covariate was identified as the most robust method to be used 
in the more comprehensive comparative-effectiveness analysis.  
 
The comparative-effectiveness analysis, including additional clinical outcomes that were 
also used in the pivotal RCTs assessing the efficacy of DOACs versus warfarin in the AF 
population, found no statistically significant differences in risk of stroke for apixaban, 
dabigatran and rivaroxaban compared with warfarin. There were however, concerns over 
safety aspects of rivaroxaban, as it was associated with increased risk of all-cause 
mortality.  
vi 
 
 
The hazard ratios estimated from the comparative-effectiveness analysis were used to 
populate a Markov model to evaluate the lifetime cost- effectiveness of DOACs compared 
to warfarin; one-way and probabilistic sensitivity analyses were carried out to assess the 
uncertainty around the findings and identify key drivers. At the £20,000 threshold, 
apixaban and dabigatran were found to be cost-effective in AF patients who are 50 years 
old when starting anticoagulation. Rivaroxaban, being the least effective intervention, was 
dominated by warfarin, being less costly but more effective than rivaroxaban.  
 
This thesis shows the potential of RWE in general and within the Scottish healthcare 
setting. The findings highlight the importance of taking into account resource utilisation 
beyond hospital care, and assessing several comparative-effectiveness methods to 
understand strengths and limitation of each. Most importantly, the findings from this thesis 
have the potential to inform future research, prescribing patterns and provide real-world 
evidence for other healthcare settings, especially where rivaroxaban is the DOAC most 
widely prescribed.  
 
Finally, this thesis shows that RWE generated from routinely collected linked data in 
Scotland, may well support the reassessment of prescription drugs accepted conditionally 
by the Scottish Medicine Consortium (SMC), an independent organisation that advises the 
NHS Health Boards about medicines, and would therefore support the SMC in making the 
final acceptance decision.  
 
 
 
 
 
vii 
 
Table of contents 
 
Acknowledgments ..............................................................................................................................i 
Publications, working papers and presentations .......................................................................... ii 
Abstract .............................................................................................................................................iv 
List of Tables .................................................................................................................................. xii 
List of Figures .................................................................................................................................xiv 
Abbreviations .................................................................................................................................. xv 
Author’s declaration .................................................................................................................... xvii 
 
Chapter 1 Introduction ..................................................................................................................... 1 
1.1 Real-world evidence ................................................................................................................. 1 
1.2 Real-world evidence in Scotland .............................................................................................. 4 
1.3 Case study ................................................................................................................................. 6 
1.4 Epidemiology of Atrial Fibrillation .......................................................................................... 6 
1.5 AF management pathway ......................................................................................................... 9 
1.6 Clinical and pharmacological aspects of anticoagulants ......................................................... 12 
1.7 Direct oral anticoagulants in Scotland .................................................................................... 15 
1.8 Current evidence from randomised control trials and real-world evidence ............................ 16 
1.8.1 Randomised control trails ................................................................................................ 16 
1.8.2 Evidence from network meta-analysis ............................................................................. 24 
1.8.3 Real-world evidence ........................................................................................................ 31 
1.9 Conclusion .............................................................................................................................. 39 
 
Chapter 2 Aim and objective ......................................................................................................... 40 
2.1 Aim of the thesis ..................................................................................................................... 40 
 
Chapter 3 Data source .................................................................................................................... 43 
3.1 Introduction ............................................................................................................................. 43 
3.2. Data linkage ........................................................................................................................... 43 
3.3 Data source.............................................................................................................................. 44 
3.3.1 Inpatient admissions ......................................................................................................... 44 
3.3.2 Outpatient attendance ....................................................................................................... 45 
3.3.3 Prescribing information system ....................................................................................... 46 
3.3.4 Care home census............................................................................................................. 48 
3.3.5 Mortality records .............................................................................................................. 48 
3.4 Cohort identification ............................................................................................................... 48 
3.5 Data cleaning .......................................................................................................................... 51 
3.6 Cohort descriptive ................................................................................................................... 53 
viii 
 
 
Chapter 4 The inpatient, outpatient, prescribing and care home costs associated with Atrial 
Fibrillation ....................................................................................................................................... 58 
4.1 Introduction ............................................................................................................................. 58 
4.2 Existing evidence on cost of AF ............................................................................................. 59 
4.2.1 Population ........................................................................................................................ 59 
4.2.2 Data .................................................................................................................................. 60 
4.2.3 Covariates ........................................................................................................................ 61 
4.2.4 Statistical methods ........................................................................................................... 61 
4.2.5 Cost components and results ............................................................................................ 64 
4.3. Regression models for healthcare expenditure ...................................................................... 67 
4.4 Methods................................................................................................................................... 70 
4.4.1 Data preparation ............................................................................................................... 71 
4.4.2 Costing ............................................................................................................................. 73 
4.4.3 Econometric model .......................................................................................................... 77 
4.4.4 Econometric model covariates ......................................................................................... 79 
4.5 Results ..................................................................................................................................... 82 
4.5.1 Cohort characteristics ....................................................................................................... 82 
4.5.2 Econometric modelling diagnostic tests ........................................................................... 87 
4.5.3 Econometric modelling results ......................................................................................... 87 
4.5.4 Cost estimates .................................................................................................................. 90 
4.6 Discussion ............................................................................................................................... 95 
4.6.1 Cohort characteristics ....................................................................................................... 95 
4.6.2 Estimated cost of AF ........................................................................................................ 96 
4.7 Conclusions ............................................................................................................................. 98 
 
Chapter 5 Methods for comparative-effectiveness analysis ...................................................... 100 
5.1 Introduction ........................................................................................................................... 100 
5.2 Propensity score based techniques ........................................................................................ 103 
5.2.1 Propensity score ............................................................................................................. 103 
5.2.2 Matching ........................................................................................................................ 108 
5.2.3 Inverse Probability Weighting ....................................................................................... 110 
5.2.4 Covariate adjustment with propensity score .................................................................. 111 
5.3 Unobserved confounding ...................................................................................................... 112 
5.4 Methods................................................................................................................................. 116 
5.4.1 Data sources and cohort ................................................................................................. 116 
5.4.2 Propensity score model .................................................................................................. 117 
5.4.3 Outcome model .............................................................................................................. 124 
5.5 Results ................................................................................................................................... 126 
5.5.1 Cohort characteristics ..................................................................................................... 126 
ix 
 
5.5.2 Propensity score distribution .......................................................................................... 130 
5.5.3 Covariate balance assessment ........................................................................................ 133 
5.6 Discussion ............................................................................................................................. 141 
5.7 Limitations ............................................................................................................................ 143 
5.8 Conclusions ........................................................................................................................... 144 
 
Chapter 6 Comparative-effectiveness analysis ........................................................................... 145 
6.1 Introduction ........................................................................................................................... 145 
6.2 Methods – data ...................................................................................................................... 145 
6.2.1 Clinical outcomes ........................................................................................................... 146 
6.2.3 PS model ........................................................................................................................ 147 
6.3 Methods – model ................................................................................................................... 148 
6.3.1Proportionality assumption assessment .......................................................................... 149 
6.3.2 Methods for addressing proportionality violation .......................................................... 150 
6.3.3 Time-to-event analysis ................................................................................................... 152 
6.3.4 Sensitivity analysis ......................................................................................................... 155 
6.4 Results ................................................................................................................................... 156 
6.4.1 Cohort characteristics ..................................................................................................... 156 
6.4.2 Comparative-effectiveness ............................................................................................. 158 
6.4.3 Sensitivity analysis ......................................................................................................... 162 
6.5 Discussion ............................................................................................................................. 165 
6.6 Limitations ............................................................................................................................ 169 
6.7 Conclusions ........................................................................................................................... 171 
 
Chapter 7 Economic evaluation ................................................................................................... 172 
7.1 Introduction ........................................................................................................................... 172 
7.1.1 Cost utility analysis ........................................................................................................ 172 
7.1.2 Data source ..................................................................................................................... 175 
7.1.3 Models in economic evaluation ..................................................................................... 176 
7.2 Review of economic models ................................................................................................. 179 
7.2.1 Review - methods........................................................................................................... 182 
7.2.2 Review - results .............................................................................................................. 183 
7.2.3 Review - discussion ....................................................................................................... 191 
7.3 Methods................................................................................................................................. 193 
7.3.2 Model structure .............................................................................................................. 195 
7.3.3 Model inputs .................................................................................................................. 198 
7.3.4 Cost and utility inputs .................................................................................................... 203 
7.3.5 Model assumptions ........................................................................................................ 208 
7.3.6 Model uncertainty .......................................................................................................... 209 
7.4 Results ................................................................................................................................... 211 
x 
 
7.4.1 Base-case analysis .......................................................................................................... 211 
7.4.2 Base-case uncertainty ..................................................................................................... 212 
7.4.3 Subgroup analysis .......................................................................................................... 217 
7.5 Discussion ............................................................................................................................. 225 
7.6 Limitations ............................................................................................................................ 229 
7.7 Conclusions ........................................................................................................................... 232 
 
Chapter 8 Summary of main findings, policy implications and future research .................... 233 
8.1 Main findings ........................................................................................................................ 233 
8.1.1 The inpatient, outpatient, prescribing and care home costs associated with Atrial 
Fibrillation............................................................................................................................... 234 
8.1.2 Methods for comparative-effectiveness analysis ........................................................... 236 
8.1.3 Comparative-effectiveness analysis ............................................................................... 237 
8.1.4 Economic evaluation ...................................................................................................... 239 
8.2 Limitations ............................................................................................................................ 240 
8.3 Policy implications ................................................................................................................ 242 
8.4 Future research ...................................................................................................................... 244 
8.5 Conclusions ........................................................................................................................... 246 
 
Appendices ..................................................................................................................................... 247 
Appendix I: Econometric modelling test to identify family and link function ............................... 247 
Appendix II: Regression interactions and Odd Ratios conversion ................................................. 248 
Appendix III: Conditional standardised difference ......................................................................... 251 
Appendix IV: Collinearity test (Table I) ......................................................................................... 253 
Appendix V: Baseline characteristics for patients on anticoagulants ............................................. 254 
Appendix VI: Proportionality hazard assumption (number of events, event rates and HRs estimates 
with time intervals) ......................................................................................................................... 257 
Appendix VII: Baseline characteristics for patients on anticoagulants (standard and reduced dose)
 ........................................................................................................................................................ 259 
Appendix VIII: Proportionality hazard assumption (plots of goodness of fit) ............................... 262 
Appendix IX: Kaplan Meier curves ................................................................................................ 274 
Appendix X: Cumulative incidence curves .................................................................................... 285 
Appendix XI: Hazard ratios for 6 years follow-up ......................................................................... 296 
Appendix XII: Proportionality hazard assumption (plots of goodness of fit for standard and reduced 
dose) ................................................................................................................................................ 297 
Appendix XIII: Kaplan Meier curves (standard and reduced dose)................................................ 312 
Appendix XIV: Cumulative incidence curves (standard and reduced dose) .................................. 325 
Appendix XV: Hazard ratios for 6 years follow-up (standard and reduced dose) .......................... 338 
Appendix XVI: Comparison of results with RCTs and observational studies ................................ 340 
Appendix XVII: Literature search strategy ..................................................................................... 343 
xi 
 
Appendix XVIII:  CHEERS Checklist of items to include when reporting economic evaluations of 
health interventions ......................................................................................................................... 344 
Appendix XIX: Cumulative incidence curves (cost-effectiveness) ................................................ 352 
Appendix XX: DOACs HRs for AF patients 70 years or older (Table I) ....................................... 358 
 
References ....................................................................................................................................... 359 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Tables 
 
Table 1.1 Baseline characteristics ..................................................................................................... 20 
Table 1.2 RCT clinical outcomes - event rates (per 100 person years) ............................................ 21 
Table 1.3 RCT clinical outcomes - Hazard Ratios ............................................................................ 22 
Table 1.4 Odd ratios from network-meta analysis comparing DOACs to DOACs .......................... 30 
Table 1.5 Meta-analysis results ................................................................................................... …..33 
Table 1.6 Hazard ratios from additional RWE observational studies – DOACs vs. warfarin .......... 37 
 
Table 3.1 Baseline characteristics of OAC and AF patients - SMR01 (1997-2015) ........................ 55 
Table 3.2 Baseline characteristics of OAC and AF patients - SMR00 (1997-2015) ........................ 57 
 
Table 4.1 Costing methodologies...................................................................................................... 63 
Table 4.2 Distributional families ...................................................................................................... 69 
Table 4.3 Baseline characteristics and outcomes of AF patients 50 years or older .......................... 84 
Table 4.4 Regression results: probability of healthcare resources utilisation and cost estimation ... 89 
Table 4.5 Average annual cost per AF patient by health board, geography and SIMD.................... 91 
Table 4.6 Average annual cost per AF patient by sex and healthcare or care home sector .............. 92 
Table 4.7 Average annual cost per AF patient by age and healthcare or care home sector .............. 94 
Table 4.8 Average annual cost per AF patient by CCI and healthcare or care home sector ............. 94 
 
Table 5.1 PS methods ..................................................................................................................... 105 
Table 5.2 Inclusion and exclusion criteria ...................................................................................... 117 
Table 5.3 CHA2DS2-VASc - ICD-10 and OPCS-4 codes ............................................................. 120 
Table 5.4 HAS-BLED - ICD-10 and OPCS-4 and BNF codes ....................................................... 121 
Table 5.5 Baseline characteristics ................................................................................................... 129 
Table 5.6 Treatment discontinuation or switching .......................................................................... 130 
Table 5.7 Covariate imbalance assessment for combined DOACs vs. warfarin ............................. 134 
Table 5.8 Covariate imbalance assessment for apixaban vs. warfarin ............................................ 136 
Table 5.9 Covariate imbalance assessment for dabigatran vs. warfarin ......................................... 138 
Table 5.10 Covariate imbalance assessment for rivaroxaban vs. warfarin ..................................... 140 
 
Table 6.1 Clinical outcomes - ICD-10 and OPCS-4 codes ............................................................. 147 
Table 6.2 Baseline characteristics (standard and reduced dose) ..................................................... 158 
Table 6.3 Number of events and event rates for DOACs and warfarin .......................................... 160 
Table 6.4 Number of events and event rates for 2 years since first prescription, apixaban standard 
(5 mg) and reduced dose (2.5 mg) .................................................................................................. 163 
Table 6.5 Number of events and event rates for 2 years since first prescription, rivaroxaban 
standard (20 mg) and reduced dose (15 mg) ................................................................................... 164 
xiii 
 
Table 7.1 Cost-effectiveness studies identified in the review ......................................................... 188 
Table 7.2 Warfarin event rates and transition probabilities ............................................................ 199 
Table 7.3 DOACs HRs and transition probabilities ........................................................................ 202 
Table 7.4 Effect of previous events on future events (HRs) ........................................................... 203 
Table 7.5 Costs of clinical events ................................................................................................... 205 
Table 7.6 Cost of prescription drugs ............................................................................................... 206 
Table 7.7 Utility and disutility ........................................................................................................ 207 
Table 7.8 General population utility values by age and gender ...................................................... 207 
Table 7.9 Base-case deterministic analysis ..................................................................................... 211 
Table 7.10 Uncertainty of base-case analysis ................................................................................. 213 
Table 7.11 Uncertainty sensitivity analysis .................................................................................... 214 
Table 7.12 Deterministic subgroup analysis (standard dose) .......................................................... 217 
Table 7.13 Uncertainty subgroup analysis (standard dose) ............................................................ 219 
Table 7.14 Deterministic subgroup analysis (reduced dose) .......................................................... 220 
Table 7.15 Uncertainty subgroup analysis (reduced dose) ............................................................. 221 
Table 7.16 Deterministic subgroup analysis (AF patients 70 years or older) ................................. 223 
Table 7.17 Uncertainty subgroup analysis (AF patients 70 years or older) .................................... 224 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
List of Figures 
 
Figure 1.1 Management pathway to prevent stroke in people with atrial fibrillation ....................... 10 
 
Figure 3.1 Cohort identification and data extraction ........................................................................ 50 
Figure 3.2 Data cleaning ................................................................................................................... 52 
 
Figure 4.1 Data preparation .............................................................................................................. 72 
Figure 4.2 Deriving a cost per CIS using per episode costing .......................................................... 75 
 
Figure 5.1 Propensity score model selection .................................................................................. 124 
Figure 5.2 Study population ............................................................................................................ 127 
Figure 5.3 PS distribution for combined DOACs and warfarin ...................................................... 131 
Figure 5.4 PS distribution for apixaban and warfarin ..................................................................... 131 
Figure 5.5 PS distribution for dabigatran and warfarin................................................................... 132 
Figure 5.6 PS distribution for rivaroxaban and warfarin ................................................................ 132 
 
Figure 6.1  Hazard ratios since first prescription, DOACs vs. warfarin ......................................... 161 
Figure 6.2 Hazard ratios since first prescription, apixaban standard (5 mg) and reduced dose (2.5 
mg) vs. warfarin .............................................................................................................................. 163 
Figure 6.3 Hazard ratios since first prescription, rivaroxaban standard (20 mg) and reduced dose 
(15 mg) vs. warfarin ........................................................................................................................ 165 
 
Figure 7.1 Results of literature search ............................................................................................ 183 
Figure 7.2 Multi-state Markov model for the prevention of stroke in the AF population .............. 197 
Figure 7.3  Cost-effectiveness plane base-case analysis ................................................................. 212 
Figure 7.4 CEACs base-case analysis ............................................................................................. 213 
Figure 7.5 Apixaban vs. warfarin sensitivity analysis .................................................................... 215 
Figure 7.6 Dabigatran sensitivity analysis ...................................................................................... 216 
Figure 7.7 Cost-effectiveness plane subgroup analysis (standard dose) ......................................... 218 
Figure 7.8 CEACs subgroup analysis (standard dose) .................................................................... 219 
Figure 7.9 Cost-effectiveness plane subgroup analysis (reduced dose) .......................................... 221 
Figure 7.10 CEACs subgroup analysis (reduced dose) ................................................................... 222 
Figure 7.11 Cost-effectiveness plane subgroup analysis (AF patients 70 or older) ........................ 224 
Figure 7.12 CEACs subgroup analysis (70 years or older AF patients) ......................................... 225 
 
 
 
xv 
 
Abbreviations  
 
AF: Atrial Fibrillation 
AIC: Akaike Information Criterion 
ARISTOTLE: Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial 
Fibrillation 
ATE: Average Treatment Effect 
BNF: British National Formulary  
CCI: Charlson Comorbidity Index  
CEAC: Cost-Effectiveness Acceptability Curves 
CHEERS: Consolidated Health Economic Evaluation Reporting Standards 
CHI: Community Health Index  
CIS: Continuous Inpatient Stay  
CUA: Cost Utility Analysis  
DES: Discrete Event Simulation  
DOACs: Direct Oral Anticoagulants  
DSU: Decision Support Unit 
ERG: Evidence Review Group  
GI: Gastro Intestinal 
GLM: Generalised Linear Model  
HRGs: Healthcare Resource Groups  
HRQoL: Health Related Quality of Life  
HTA: Health Technology Assessment  
ICD-10: International Classification of Diseases, Tenth Revision  
ICER: Incremental Cost-Effectiveness Ratio  
ICH: Intracranial Haemorrhage  
INMB: Incremental Net Monetary Benefit  
INR: International Normalised Ratio  
IPCW: Inverse Probability of Censoring Weighting  
IPTW: Inverse Probability of Treatment Weighting 
IPW: Inverse Probability Weighting  
ISD: Information Services Division  
ITT: Intention To Treat  
MI: Myocardial Infarction  
NHS: National Health Service  
NICE: National Institute for Health and Care Excellence  
NMA: Network Meta-Analysis  
NRS: National Records of Scotland  
NVAF: Non-Valvular Atrial Fibrillation  
xvi 
 
OAC: Oral Anticoagulant  
OLS: Ordinary Least Square  
OPCS-4: Office of Population Censuses and Surveys, Fourth Revision  
PCT: Pragmatic Controlled Trials 
PIS: Prescribing Information System  
PS: Propensity Score  
PSA: Probability Sensitivity Analysis  
QALY: Quality Adjusted Life Years  
QHES: Quality of Health Economics Analyses 
QOF: Quality and Outcomes Framework 
RCTs: Randomised Control Trials 
RE-LY: Randomized Evaluation of Long-Term Anticoagulation Therapy  
ROCKET-AF: Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin 
K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation  
RWE: Real Word Evidence  
SE: Systemic Embolism  
SIMD: Scottish Index of Multiple Deprivation 
SMC: Scottish Medicine Consortium  
SMR00: Outpatient Attendance Scottish Morbidity Records 
SMR01: General Acute Inpatient and Day Case Scottish Morbidity Records  
SNT: Scottish National Tariff  
SSCA: Scottish Stroke Care Audit  
TIA: Transient Ischaemic Attack  
VKA: Vitamin K Antagonist  
VTE: Venous Thromboembolism  
WHO: World Health Organisation  
WTP: Willingness To Pay 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
 
Author’s declaration 
 
I declare that, except where explicit reference is made to contribution of others, that 
this dissertation is the result of my own work and has not been submitted for any 
other degree at the University of Glasgow or any other institution.  
 
Signature: 
 
Printed name: Giorgio Ciminata 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1                                                                                                                                                        1 
 
Chapter 1 Introduction 
 
1.1 Real-world evidence 
 
Real word evidence (RWE) refers to any “data used for decision-making that are not 
collected in conventional randomised control trials (RCTs)” [1]. Typically, RWE data are 
collected from a wide range of sources including Pragmatic Controlled Trials (PCT), 
registries, administrative data, health surveys and electronic health records. Pragmatic 
Controlled Trials measure treatment effectiveness in routine clinical practice.  
 
The design of PCTs should reflect variations in patient characteristics that would occur in 
clinical practice; thus, PCTs should represent the patients to whom the treatment will be 
applied [1, 2]. When randomisation is introduced in the design, PCTs are referred as 
pragmatic RCTs. A recent example of this is the Salford Lung Study investigating safety 
and efficacy of a once-daily dry powder inhaler reducing asthma and chronic obstructive 
pulmonary disease exacerbations. In this study, patients were randomised to either receive 
the once-daily dry powder inhaler or continue their optimised usual care based on the 
assessment of the asthma control test [3].  
 
Registries collect patient level data that focus on a specific diagnosis or condition, while 
administrative data, generally collected at a national level, are primarily collected for 
administrative purposes. RWE may also be obtained from health surveys, carried out to 
collect data that are representative of the health of a given population, and electronic health 
records providing patient’s clinical information in a digital format [2, 4]. 
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The evidence from real-world scenarios is usually drawn from observational prospective 
and retrospective studies. A study design utilising a prospective approach investigates over 
time whether a given cohort of patients experience the outcome under scrutiny. The 
retrospective approach, typically adopted in case-control studies, looks back at exposure to 
risk factors leading to the actual disease state; thus, the outcome of interest has already 
occurred at the time of study initiation [5].  
 
Historically, RWE has been used for clinical epidemiologic investigations, quality 
improvement, and safety surveillance [2].Evidence from real-world scenarios is 
increasingly used in health technology assessment (HTA), a process that systematically 
evaluates evidence concerning safety, clinical and cost-effectiveness of health 
technologies; in some instances social, legal and ethical aspects are factored in to the 
multidisciplinary evaluation process [2, 6]. The main purpose of HTA is to inform 
reimbursement and coverage decisions, thus RWE may play a crucial role in the pre- and 
post-marketing authorisation process that grant access of new health technologies to the 
market.   
 
In particular, in the pre-authorisation process RWE may facilitate the identification of 
subpopulations that may enable better understanding of underlying prevalence of disease.  
In the post-marketing authorisation process, RWE may provide a more comprehensive 
understanding of treatment safety and effectiveness by allowing for the inclusion and 
analysis of clinical endpoints not measured in RCTs but observed in real life. For instance, 
a given side effect to a treatment may not be contemplated in a RCT but may be 
experienced by patients outside of the controlled RCT environment, where drugs are being 
used in a large population and beyond the specified RCT follow-up time [2].  
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Within this context, RWE may also improve the understanding of treatment sequences, 
treatment pathways in real life, and allow for comparisons of treatments against relevant 
comparators not employed in registration trials.  Treatment adherence, and interactions 
with concomitant treatments, are other important aspects that can be investigated in RWE 
studies [2, 7].   
 
In the UK, RWE is increasingly used as supplementary evidence to Phase II and Phase III 
of RCTs, and in “accelerated market access” where initial decisions are conditional on 
additional randomised and non-randomised evidence generated over time [8]. However, it 
could prove problematic generating additional evidence from further RCTs; as patients 
already having access to a given treatment, may be reluctant to taking part in any other 
clinical study. Although, randomised evidence could be generated from RCT, carried out 
in different countries, there may be generalisability issues for the study results due to 
differences in the target population and treatment standards [2, 4].  
 
Despite the advantage of using RWE as a supplement to the evidence coming from RCTs 
in the context of HTA, its use is still limited. This is certified by a study indicating that in 
the UK, up to 2016, non-randomised evidence has only been used in 36% of the appraisals 
carried out by the National Institute for health and Care Excellence (NICE): an advisory 
body responsible for issuing guidelines concerning the use of new health technologies 
within the National Health Service (NHS) in England [9]. Nevertheless, thanks to 
methodological advances and increased data sources and data availability, the scope of 
RWE is broadening, and its use is increasing.  
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Still, the use of RWE provides challenges and limitations. Real-world evidence may be 
inconsistently collected, and missing elements may lead to reduced statistically validity or 
may limit the potential for answering research questions. Most importantly, RWE studies 
are subject to bias (e.g. confounding factors) [2]. In RCTs, these issues are controlled for 
by randomisation. Confounding, in general, is a distortion that modifies an association 
between an exposure and an outcome [10]. The main source of confounding in newly 
marketed medications is confounding by indication occurring when the prognostic factors, 
such as disease severity, used for treatment selection also affect the outcome. For instance, 
patients with more severe conditions are likely to receive more intense treatments. 
However, when comparing treatment effectiveness, the more intensive treatment may 
produce poorer outcomes [11].  
 
Confounding, if not controlled for, may give rise to bias, a systematic error resulting from 
incorrect estimate of the true effect of an exposure on a given outcome [10]. A common 
type of bias using RWE is selection bias, occurring when therapies are differently 
prescribed according to disease severity and patient characteristics. Other types of bias are 
information bias, potentially caused by misclassification of data, and detection bias 
occurring when an outcome is more likely to be detected in one treatment group than 
another [12]. 
 
1.2 Real-world evidence in Scotland 
 
In Scotland, the Farr Institute (now part of the Health Data Research UK), is involved in 
the use of linked electronic data to generate RWE that supports a better understanding of 
health at the patient and population level.  The institute is based on the collaboration 
between Scottish universities (including the University of Glasgow, Strathclyde, Dundee, 
Edinburgh, St Andrews, and Aberdeen), and NHS Scotland.  
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The Farr institute was formerly the Scottish health informatics programme (SHIP) 
experience,  a “Scotland-wide research platform for the collation, management, 
dissemination and analysis of Electronic Patient Records” funded by the Wellcome Trust, 
the Medical Research Council and the Economic and Social Research Council [13].  
 
Scotland has long been at the forefront of research where routinely collected real-world 
data linkage is involved. While in in the late 1960s patient level data on hospitalisation, 
death and cancer were already available, only the advance of computing in the late 1980s 
has allowed for an advanced process of data linkage [14].   
 
Health care data are gathered as Scottish Morbidity Records (SMR) reflecting the status 
and type of healthcare that patients receive. For instance, General Acute Inpatient and Day 
Case Scottish Morbidity Records (SMR01) contains all general acute admissions, 
categorized as inpatients or day cases, discharged from non-obstetric and non-psychiatric 
specialties; Outpatient Attendance Scottish Morbidity Records (SMR00) records include, 
at patient level, information on new and follow-up appointments at outpatient clinics for 
any clinical specialty. More detail on SMR01 and SMR00 are provided in Chapter 3.  
Other examples include the Scottish cancer registry SMR06, and records on maternity 
inpatient and day case collected in SMR02.  
 
Patient level records are submitted by hospitals and health boards to the Information 
Services Division (ISD), a division of National Service Scotland, part of NHS Scotland. 
The information services division supports NHS planning, quality improvement activities 
and decision making by providing services in the field of health information, health 
intelligence and statistical services [15].  
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1.3 Case study 
 
Direct Oral Anticoagulants (DOACs) including apixaban, dabigatran and rivaroxaban, 
have all been accepted for use in Scotland with an indication for the prevention of stroke in 
the Atrial Fibrillation (AF) population [16-18]. However, evidence from clinical practice 
on the effectiveness and safety of DOACs for AF patients is still limited. Further, as 
records from primary care are not available, the sample size of the AF population is 
potentially underestimated; therefore, this thesis focuses on patients who have a diagnostic 
code of AF from hospital codes. Based on these challenges, DOACs were identified a good 
case study for exploring the data in HTA.  
 
1.4 Epidemiology of Atrial Fibrillation 
 
Atrial fibrillation is the most common form of arrhythmia, increasing significantly with 
age, and linked to the development of highly debilitating conditions such as congestive 
heart failure, ischemic heart disease and stroke [19]. The risk of these conditions is 
significantly greater in individuals affected by AF. Therefore, AF, linked to an ageing 
population especially across high-income countries, is likely to have a substantial impact 
on the economic burden of any healthcare system [19, 20].  As per the World Health 
Organisation (WHO) definition,   stroke is “rapidly developing clinical signs of focal (or 
global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or 
leading to death, with no apparent cause other than of vascular origin” [21]. A stroke, also 
referred to as cerebrovascular accident, usually occurs when a blood vessel bursts or a clot 
causes the interruption of blood supply to the brain, thus causing damage to the brain tissue 
deprived of oxygen and nutrients. This in turn affects the part of the body controlled by the 
portion of the brain injured [21].  
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Stroke is typically classified as ischemic or haemorrhagic. The first typology, accounting 
for the majority of strokes, is caused by atherosclerotic obstruction within a blood vessel 
supplying blood to the brain. Strokes caused by temporal obstruction are classified as 
“mini strokes” or TIAs. While patients experiencing TIA may recover within an hour, 
symptoms of TIA should be regarded as a warning sign for a future major stroke. By 
contrast, haemorrhagic stroke is caused by the burst of a blood vessel generally happening 
because of uncontrolled hypertension.  Although less common, the burst may also be 
caused by aneurysms or arteriovenous malformations [21].  
 
A systematic review of studies on the epidemiology of AF in Europe, published between 
2005 and 2014, estimated an AF prevalence of 2%, and an incidence rate ranging between 
0.23 and 0.41 cases per 1,000 person/years [20]. Of these individuals, only 50% would 
develop permanent AF, and the remaining may experience paroxysmal AF (typically stop 
within 48 hours without any treatment) or persistent AF ( each episode may last for more 
than seven days, or less if treated) [20]. The same study, estimated that over a population 
of about 500 million individuals, approximately 10  million people may experience AF 
[20].  
 
Atrial fibrillation, occurring mostly in males, varies substantially according to age.  While 
only 0.12% - 0.16% of the European population younger than 49 years is affected, for the 
age groups 60 - 70 and 80 years or older, the proportion rises noticeably to 3.7% - 4.2% 
and 10% - 17% respectively. Thus, in an ageing population the prevalence of AF is 
expected to grow significantly, though the main contributor is the number of elderly 
patients hospitalised with a secondary diagnosis of AF. Indeed AF, representing the main 
risk factor for ischaemic stroke, often exists with comorbidities [22].  
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The increase in the number of new cases, however, is not only attributable to ageing, but 
also to improved diagnostic capabilities allowing for a more accurate detection of AF, and 
improved outcomes in the treatment of AF comorbidities [22]. This, in combination with 
the European population growth of 0.2% - 0.3% per year on average, would bring the 
prevalence of AF to 2.7% - 3.3% by the year 2030 and over a population of 516 – 525 
million individuals. Hence, according to Berisso and colleagues, by 2030 in Europe there 
will be about 14 - 17 million individuals affected by any form of AF [20].  
 
However, an important distinction has to be made between individuals with a known 
diagnosis of AF, and those who are potentially at risk of AF, but are not captured because 
of a series of factors such as data miscoding and lack of primary care data.  For instance 
Public Health England, reported for the year 2015/2016 a prevalence of 1.7% reflecting the 
proportion of patients with a diagnosis of AF over the total English population [23]. 
The prevalence was derived from the outputs of the Quality and Outcomes Framework 
(QOF), based on a pay for performance mechanism and designed to incentivise good 
practice in primary care [24]. However, Public Health England acknowledged that out of 
an estimated 1.4 million individuals at risk of AF in England, only about 985,000 were 
diagnosed with AF between 2015 and 2016. Therefore, the rather conservative prevalence 
of 1.7% was more likely to be in the proximity of 2.5% indicating that AF was 
undiagnosed for over 425,000 individuals across England [23]. A more recent study 
reported a very similar estimate (2.7%) confirming that AF is largely  underdiagnosed [24].  
 
Similarly, QOF data showed a prevalence of 1.8% in Scotland, indicating that about 
96,000 individuals were diagnosed with AF in a Scottish population of about 5.5 million 
people in 2016. However, a report from the Cross Party Group on Heart Disease and 
Stroke, investigating issues concerning diagnosis, treatment and care of patients with AF in 
Scotland, indicated a more plausible prevalence in the proximity of 2.6%.  
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This would suggest that in 2016 there were 145,000 AF diagnosis, and that almost 50,000 
individuals with undiagnosed AF were potentially at a greater risk of experiencing a stroke 
[25].  
 
Treatments, such as beta-blockers and statins, used for the primary prevention of AF exist. 
However, evidence on the effectiveness of first line pharmacological treatments, and the 
knowledge on the pathophysiology of AF are still limited [26].Globally, at present, the 
main approach is focused on secondary prevention by means of pharmacological and non-
pharmacological interventions aimed at controlling rhythm and rate of the heart. More 
specifically, anticoagulants, which are the main pharmacological intervention, aim at 
preventing complications, such as stroke and cardiovascular conditions [27]. Non-
pharmacological interventions include electrical cardioversion used to restore the heart to 
its normal rhythm. Other non-pharmacological approaches include catheter and surgical 
ablation employed to stop abnormal electrical impulses responsible for AF [28]. 
 
1.5 AF management pathway 
 
The management of AF is a crucial part in the prevention of stroke.  Clinical guidelines 
have highlighted the steps that should be carried out in the management of AF, and under 
which circumstances anticoagulation should be administered. The full NICE AF 
management pathway for the prevention of stroke is presented in Figure 1.1 [29].  
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Figure 1.1 Management pathway to prevent stroke in people with atrial fibrillation 
Source: Adapted from, National Institute for Health and Care Excellence. Preventing stroke in 
people with atrial fibrillation, 2015.  
 
Firstly, in patients who are 18 years or older and with a known diagnosis of AF, the risk of 
ischaemic stroke and major bleeding are assessed with the use of CHA2DS2-VASc [30] 
and HAS-BLED [31] respectively. CHA2DS2-VASc and HAS-BLED are bespoke tools, 
accounting for a series of clinical and patient characteristics, used to estimate the 
probability of having a stroke and major bleeding in patients affected by AF.  
According to the International Society on Thrombosis and Haemostasis criteria, major 
bleeding is defined as a clinical fatal event occurring in non-surgical patients [32].  
The event should be caused by one of the following: bleeding in a critical area or organ, 
(e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or 
intramuscular with compartment syndrome) bleeding causing a reduction in haemoglobin 
level of ≥2g/dL and requiring two or more blood transfusions [32].  
Person aged 18 or over with 
atrial fibrillation
Assessing stroke risk Assessing bleeding risk
Preventing stroke
Anticoagulation No anticoagulation
Left atrial           
appendage occlusion 
Reviewing stroke          
and bleeding risk 
Anticoagulation treatment 
Assessing 
anticoagulation control 
with vitamin K antagonist
Review anticoagulation
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In particular, CHA2DS2-VASc should be used in people with any of the following: 
symptomatic or asymptomatic paroxysmal, persistent or permanent atrial fibrillation, atrial 
flutter and a continuing risk of arrhythmia recurrence after cardioversion back to sinus 
rhythm [29]. In general, antiplatelet or anticoagulation should be considered for patients 
with CHA2DS2-VASc score of 1 indicating a low to moderate risk of stroke, also a 
different dose regimen should be considered for patients who are 80 years or older. 
Anticoagulation is recommended in patients with a CHA2DS2-VASc score of 2 or greater 
and reflecting moderate to high risk of stroke [30]. Nevertheless, for those patients eligible 
for anticoagulation, risk bleeding scores as those obtained from HAS-BLED, should be 
used to determine the bleeding risk associated with patients characteristics. Typically, 
anticoagulation should be considered for patients with HAS-BLED score ranging from 0 to 
2, which reflects a relatively low to moderate risk of major bleeding [31]. More details on 
how these scores were calculated are provided in Chapter 6. 
 
Whenever the use of anticoagulants is recommended, the need for anticoagulation should 
be reviewed annually, or more frequently, to identify the presence of any clinically 
relevant events for which anticoagulation is contraindicated. Anticoagulation control is 
generally assessed by time in therapeutic range, indicating how long International 
Normalised Ratio (INR) values stay within a desired range [29]. 
 
International normalised ratio is a measurement indicating the time the blood needs to clot 
after adding a tissue factor, and given by the ratio between the normal mean prothrombin 
time and patient’s prothrombin time; INR is therefore used to establish the optimal 
anticoagulant dose [33]. Anticoagulation should be reassessed in patients showing poor 
anticoagulation control; generally determined by factors such as therapy adherence, 
anticoagulants interaction with other drugs or diet, cognitive function and alcohol 
consumption.  
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In case of poor anticoagulation control persistence, alternative stroke prevention strategies 
should be explored. For people on warfarin, risk and benefit associated with switching to 
DOACs should be taken into consideration. Compliance should also be considered when 
switching, poor compliance might expose patients to a greater risk of experiencing stroke 
or any other relevant clinical event [16-18].  
 
As indicated by NICE guidelines, anticoagulation should not be offered to AF patients 
aged 65 years or younger with a low risk of stroke.  For these people, the risk of stroke 
should be reviewed past the age of 65, or whenever any of the following clinical events are 
experienced: diabetes, heart failure, peripheral arterial disease, coronary heart disease, TIA 
or SE. Risk of stroke and bleeding should be assessed annually in patients who are on 
anticoagulants because of bleeding risk or other factors. As an alternative to 
anticoagulation, left atrial appendage occlusion should be considered; however, this 
treatment option should be offered whenever anticoagulants are contraindicated or not 
tolerated [29]. 
 
1.6 Clinical and pharmacological aspects of anticoagulants 
 
Warfarin, to date the main pharmacological treatment for the management of AF as a 
preventive measure for stroke, is a Vitamin K Antagonist (VKA) working by limiting the 
availability of vitamin K, which in turn inhibits the synthesis of vitamin K dependent 
factors essential for the blood coagulation process [28]. By contrast, the DOACs, including 
apixaban, dabigatran, rivaroxaban and edoxaban, work directly on the coagulation factors. 
More specifically, apixaban and rivaroxaban directly inhibit the formation of factor Xa 
responsible for the conversion of prothrombin to thrombin, thus preventing the formation 
of fibrin clots.  
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In a similar mechanism of action where the drug is selective for one specific vitamin K 
dependent factor, dabigatran works directly on thrombin, where the inhibition disrupts the 
coagulation cascade and consequently prevents the formation of clots [27, 34].  
 
Aside from the different mechanism of action, DOACs offer important advantages over 
warfarin and in general over any VKA drug. Compared to VKAs, the number of drug 
interactions of DOACs with any other drug is relatively small. However, DOACs cannot 
be used in concomitance with inhibitors or inducers of P-glycoprotein, a transporter 
responsible for the excretion of drugs from the body [28]. Similarly, the combination of 
DOACs with inhibitors or inducers of CYP34A (an enzyme helping metabolise drugs in 
the body) should be avoided. In particular, CYP3A4 inhibitors may increase serum 
concentration leading to increased risk of bleeding. On the other hand, CYP3A4 inducers 
could increase the DOACs metabolism affecting their anticoagulation effect.  
As pointed out, VKAs work by limiting the availability of vitamin K, therefore food 
containing this vitamin may interfere with VKAs mechanism of action disrupting the 
anticoagulation effect. Because DOACs act directly on coagulation factors, patients have 
no dietary restriction as DOACs do not interact with food [27, 28].  
 
The predictability of pharmacodynamics and pharmacokinetics is perceived to be another 
distinct advantage of DOAC over VKAs. While pharmacodynamics assesses the 
biochemical and physiological effect of the drug on the body, pharmacokinetics 
investigates how a drug is metabolised in the body.  Because data on pharmacodynamics 
and pharmacokinetics have shown to be independent of body weight, age, and sex, DOACs 
could be used at a fixed dose without requirement for routine anticoagulant monitoring [27, 
28, 34].However, anticoagulation assessment is typically carried out if urgent surgical 
intervention or parenteral administration are needed.  
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Furthermore, the rapid onset of action, following oral administration, is one of the main 
assets of DOACs. Equally important is the rapid offset of action, which is critical in cases 
where surgical intervention is required [34]. Nevertheless, important contraindications and 
limitations are associated with the use DOACs. Notably, DOACs may not be appropriate 
for patients with chronic kidney conditions as a high proportion is eliminated from the 
body through the kidneys. This is particularly true for dabigatran where over two thirds are 
expelled as an active drug [34].  
 
Apixaban and rivaroxaban may be used cautiously at reduced doses in patients with 
moderate or severe renal insufficiency, with levels of creatinine clearance between 30 - 50 
mL/min and 10 - 30 mL/min respectively, combined with one of the following: 80 years of 
age or over, body weight greater than 60 kg [16, 17, 35, 36]. The use of DOACs is also 
contraindicated in patients with a severe chronic liver disease. However, if hepatic 
conditions are mild or moderate, DOACs may still be used prudently at reduced doses. In 
addition, DOACs may not be suitable for patients with mechanical mitral valve issues or 
malignant disease, as they may trigger bleeding complications [16-18, 35-37]. Another 
important limitation of DOACs, with an exception for dabigatran, is the availability of an 
antidote to reverse coagulation in case of overdose or an urgent surgical intervention is 
needed [27].  
 
Compliance is another important aspect that poses some limitation to the use of DOACs 
making VKAs the treatment of choice for some patients. In cases of a poor compliance, 
due to the short half-life of DOACs, patients will be exposed to a greater risk of 
experiencing stroke or any other relevant clinical event [27, 38].  
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1.7 Direct oral anticoagulants in Scotland 
 
Direct oral anticoagulants have been approved throughout the UK for the prevention of 
stroke in the AF population [16-18, 35-37, 39]. Edoxaban, approved in Scotland in 2015,  
by the Scottish Medicine Consortium (SMC), an independent organisation that advises the 
NHS Health Boards about medicines in Scotland [40], is currently in use for the prevention 
of stroke in the AF population [39]. However, data availability from clinical practice is still 
limited. Therefore, the focus on this thesis will be on apixaban, dabigatran and rivaroxaban. 
DOACs are currently used as an alternative to warfarin, to date the main oral 
thromboprophylactic treatment for the management of AF as a preventive measure for 
stroke [33].   
 
In line with other parts of the world, warfarin has been for decades the main oral 
anticoagulation treatment used to prevent stroke in the AF population in Scotland.  
In 2011, dabigatran was the first DOAC accepted by the SMC, with an indication for the 
prevention of stroke and Systemic Embolism (SE) in patients with a diagnosis of Non-
Valvular Atrial Fibrillation (NVAF) and associated risk factors: history of stroke Transient 
Ischaemic Attack (TIA) or SE, left ventricular ejection fraction (<40%), symptomatic heart 
failure and age ≥ 75 years. Patients aged 65 years and older were considered at risk if one 
of the following was present: diabetes mellitus, coronary artery disease or hypertension. A 
reduced twice-daily dose of 110 mg, as an alternative to the standard 150 mg, was 
recommended for patients with a high risk of bleeding, and in particular for patients aged 
80 years or older [18]. 
 
 
 
Chapter 1                                                                                                                                                        16 
 
Rivaroxaban was initially accepted for use by the SMC and indicated for the prevention of 
Venous Thromboembolism (VTE) in adult patients who had hip or knee replacement 
surgery. In 2012, rivaroxaban was accepted for use by the SMC, with a different indication 
aimed at preventing SE in patients with a diagnosis of NVAF plus one of the following risk 
factors: history of stroke or TIA, age ≥75 years, hypertension, diabetes mellitus and 
congestive heart failure, was obtained with a second HTA evaluation. However, the use of 
rivaroxaban was restricted only to patients with poor INR control or intolerance to 
warfarin. In addition to the 20 mg once daily standard dose, a reduced dose of 15 mg was 
recommended for patients with moderate to severe renal impairment 
 
As for rivaroxaban, the –acceptance of apixaban by the SMC, for the prevention of stroke 
and SE in patients with a NVAF and one of the following risk factors: history of stroke or 
TIA, age ≥75 years, hypertension, diabetes mellitus or symptomatic heart failure, was 
obtained with a second HTA evaluation in 2013. In addition to a standard daily dose of 5 
mg, a reduced dose of 2.5 mg was recommended for patients with a combination of the 
following characteristics: aged 80 years or older, body weight ≤60kg and serum creatinine 
level≥1.5mg/dL indicating abnormal renal function [16]. 
 
 
1.8 Current evidence from randomised control trials and real-world evidence 
 
1.8.1 Randomised control trails 
 
The efficacy of DOACs was estimated from clinical studies with respect to anticoagulation 
by looking primarily at ischaemic or haemorrhagic stroke and SE as the primary outcomes 
[41-43]. The pivotal RCTs measuring the efficacy of DOACs are described in the next 
paragraphs.  
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Apixaban 
The main evidence supporting the indication of apixaban for the prevention of stroke or SE 
came from the “Apixaban for Reduction In Stroke and Other Thromboembolic Events in 
Atrial Fibrillation” (ARISTOTLE) clinical trial. The population of 18,201 patients with AF 
and risk factors for stroke had a median age of 70 years, with the male being greater than 
the female population. Overall patients were classified as having a moderate to high risk of 
stroke according to the CHAD2 score of 2.1. The CHADS2 is the precursor of the most 
widely used CHA2DS2-VASc risk calculator. The details of this tool, used to predict the 
potential risk of stroke in patients with AF, will be discussed in Chapter 6. Approximately 
19% of patients had a history of stroke, TIA or SE. Hypertension was the risk factor for 
stroke, observed in over 80% for both treatment groups. In the ARISTOTLE study, both 
first time warfarin users and on-going users were enrolled with the objective of including a 
minimum of 40% first time users.  
 
The study, using a non-inferiority design, evaluated the efficacy of apixaban (9,120 
patients) compared to warfarin (9,081 patients) for ischemic or haemorrhagic stroke or SE. 
Patients were randomised to receive apixaban standard 5 mg twice daily standard dose (or 
reduced dose as previously discussed), or dose-adjusted warfarin to maintain the INR 
between a range of 2.0 and 3.0.  The follow-up analyses were conducted following an 
Intention To Treat (ITT) approach, where all randomised patients are included, regardless 
of their adherence to protocol.  
 
After a median follow-up of 1.8 years, apixaban 5 mg showed significant reduction in the 
rate of stroke or SE (HR 0.79 (95% CI 0.66, 0.95)) [42]. Apixaban was also associated 
with a significant reduction in risk of the primary safety outcome of major bleeding (HR 
0.69 (95% CI 0.60, 0.80)) compared to warfarin [42].  
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Full details on baseline characteristics, events rates and HRs are presented in Table 1.1, 
Table 1.2 and Table 1.3 respectively.  
 
Dabigatran 
The main evidence supporting the indication of dabigatran for the prevention of stroke or 
SE came from the “Randomized Evaluation of Long-Term Anticoagulation Therapy” (RE-
LY) clinical trial. The population of 18,113 patients with AF and an increased risk of 
stroke had a mean age of 71 years; males represented the majority in both treatment 
groups.  
 
The study, using a non-inferiority design, evaluated the efficacy of apixaban (6,015 
patients for the 110 mg reduced dose, and 6,076 for the 150 mg standard dose) compared 
to warfarin (6,022 patients) for ischemic or haemorrhagic stroke or SE. Similarly, RE-LY, 
in line with the inclusion criteria outlined in the ARISTOTLE study, enrolled on-going and 
first-time warfarin users. Patients were randomised to receive either 110 mg or reduced 
150 mg dose of dabigatran as an alternative to dose-adjusted warfarin to maintain the INR 
between a range of 2.0 and 3.0. Follow-up analyses were conducted following the ITT 
approach [41]. 
   
After a median follow-up of 2 years, patients receiving dabigatran had a significantly 
reduced risk of stroke or SE (HR 0.65 (95% CI 0.52, 0.81)) when compared with patients 
on warfarin; but no risk difference was observed for the 110 mg reduced dose (HR 0.90 
(95% CI 0.74, 1.10)). The rate of Myocardial Infarction (MI) was found to be higher in 
dabigatran (at any dose) than with warfarin. This may be due to a greater protection against 
coronary ischaemic events that warfarin may have compared to dabigatran [41]. Full 
details on baseline characteristics, events rates and HRs are presented in Table 1.1, Table 
1.2 and Table 1.3 respectively.  
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Rivaroxaban 
The main evidence supporting the indication of rivaroxaban for the prevention of stroke or 
SE came from the “Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared 
with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation” (ROCKET-AF) clinical trial. The population of 14,624 patients with AF and 
moderate-to-high risk of stroke had a mean age of 73 years; males represented the majority 
in both treatment groups.  
 
The study, using a non-inferiority design, evaluated the efficacy of rivaroxaban (7,131 
patients) compared to warfarin (7,133 patients) for ischemic or haemorrhagic stroke or SE.  
The study evaluated a 20 mg oral dose of rivaroxaban (or reduced dose in case of abnormal 
renal function) as an alternative to dose-adjusted warfarin to maintain the INR between a 
range of 2.0 and 3.0.  
 
After a median follow-up of 1.9 years, patients receiving rivaroxaban had a significantly 
reduced risk of stroke or SE compared to patients on warfarin in the safety on treatment 
population (HR 0.79 (95% CI 0.65, 0.95)) where individuals are grouped for the analysis 
based on the treatment received, rather than being allocated to treatments by means of 
randomisation. The same level of risk reduction was observed in the per protocol 
population (HR 0.79 (95% CI 0.66, 0.96)) where the analysis is carried out on patients who 
did not discontinue or switch from the treatment they were originally allocated. 
Nevertheless, rivaroxaban was shown to be non-inferior to warfarin in the ITT analysis 
(HR 0.88 (95% CI 0.75–1.03)) [43]. The risk of stroke or SE in the ROCKET-AF was also 
estimated with the safety on treatment and the ITT approach. The risk for the primary 
outcome in the ARISTOTLE and RELY was solely estimated with the ITT approach. Full 
details on baseline characteristics, events rates and HRs are presented in Table 1.1, Table 
1.2 and Table 1.3 respectively.
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Table 1.1 Baseline characteristics 
  ARISTOTLE RE-LY ROCKET-AF 
Baseline characteristics Apixaban                        Warfarin Dabigatran (110mg) Dabigatran (150mg) Warfarin Rivaroxaban Warfarin 
  N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Patients 9,120 9,081 6,015 6,076 6,022 7,131 7,133 
Age median*(IQR) **(SD) 70 *(63 - 76) 70 *(63-76) 71.4 **(8.6) 71.5 **(8.8) 71.6 **(8.6) 73 *(65-78) 73 *(65-78) 
Female   3,234 (35.5) 3,182 (35.0) 2,150 (35.7) 2,236 (36.8) 2,213 (36.7) 2,831 (39.7) 2,832 (39.7) 
Age ≥75 year (SD) 2,850 (31.3) 2,829 (31.1)           
CHAD2 score mean (SD) 2.1 (1.1) 2.1 (1.0)           
0 or 1 3,100 (34.0) 3,083 (34.0) 1,958 (32.6) 1,958 (32.2) 1,859 (30.9)     
2 3,262 (35.8) 3,254 (35.8) 2,088 (34.7) 2,137 (35.2) 2,230 (37.0) 925 (13.0) 934 (13.1) 
≥3 2,758 (30.2) 2,744 (30.2) 1,968 (32.7) 1,981 (32.6) 1,933 (32.1) 6,205 (87.0) 6,197 (86.9) 
Prior myocardial infarction  1,319 (14.5) 1,266 (13.9) 1,008 (16.8) 1,029 (16.9) 968 (16.1) 1,182 (16.6) 1,286 (18.0) 
Prior clinically relevant or spontaneous bleeding  1,525 (16.7) 1,515 (16.7)           
Prior stroke, TIA, or SE 1,748 (19.2) 1,790 (19.7) 1,195 (19.9) 1,233 (20.3) 1,195 (19.8) 3,916 (54.9) 3,895 (54.6) 
Heart failure     1,937 (32.2) 1,934 (31.8) 1,922 (31.9) 4,467 (62.6) 4,441 (62.3) 
Peripheral vascular disease           401 (5.6) 438 (6.1) 
Ventricular disease 3,235 (35.5) 3,216 (35.4)           
Diabetes  2,284 (25.0) 2,263 (24.9) 1,409 (23.4) 1,402 (23.1) 1,410 (23.4) 2,878 (40.4) 2,817 (39.5) 
Hypertension  7,962 (87.3) 7,954 (87.6) 4,738 (78.8) 4,795 (78.9) 4,750 (78.9) 6,436 (90.3) 6,474 (90.8) 
Drugs causing bleeding 3,781 (41.5) 3,709 (40.8) 2,404(40.0) 2,352 (38.7) 2,442 (40.6) 2,586 (36.3) 2,619 (36.7) 
Renal function, creatinine clearance (IQR)           67 (52-88) 67 (52-86) 
Normal, >80 ml/min  3,761 (41.2) 3,757 (41.4)           
Mild impairment, >50 to 80 ml/min  3,817 (41.9) 3,770 (41.5)           
Moderate impairment (>30 to 50 ml/min) 1,365 (15.0) 1,382 (15.2)           
Severe impairment (≤30 ml/min) 137 (1.5) 133 (1.5)           
 
  Abbreviations:  TIA= transient ischaemic attack, SE=systemic embolism. 
  Source : Granger et al (2011), Connolly et al. (2009), Patel et al. (2011). 
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Table 1.2 RCT clinical outcomes - event rates (per 100 person years) 
  ARISTOTLE RE-LY ROCKET-AF 
Outcome Apixaban                        Warfarin Dabigatran (110mg) Dabigatran (150mg) Warfarin Rivaroxaban Warfarin 
  
Events and  
(event rates) 
Events and  
(event rates) 
Events and 
(event rates) 
Events  
(event rates) 
Events  
(event rates) 
Events  
(event rates) 
Events 
 (event rates) 
Stroke or SE (ITT) 212 (1.27) 265 (1.60)  182 (1.53) 134 (1.11) 199 (1.69) 269 (2.1) 306 (2.4) 
Stroke or SE (per-protocol population)           188 (1.7) 241 (2.2) 
Stroke or SE (safety on treatment population)           189 (1.7) 243 (2.2) 
Stroke or SE or major bleeding 521 (3.17) 666 (4.11)           
Stroke or SE or major bleeding or mortality (all-cause) 1,009 (6.13) 1,168 (7.2)           
Stroke or SE or mortality (cardiovascular)           346 (3.11) 410 (3.63) 
Stroke or SE or mortality (cardiovascular) or MI           433 (3.91) 519 (4.62) 
Stroke  199 (1.19) 250 (1.51) 171 (1.44) 122 (1.01) 185 (1.57) 184 (1.65) 221 (1.96) 
Ischaemic or unspecified stroke 162 (0.97) 175 (1.05) 159 (1.34) 111 (0.92) 142 (1.20) 149 (1.34) 161 (1.42) 
Haemorrhagic stroke 40 (0.24) 78 (0.47) 14 (0.12) 12 (0.1) 45 (0.38) 29 (0.26) 50 (0.44) 
SE 15 (0.09) 17 (0.1) 15 (0.13) 13 (0.11) 21 (0.18) 5 (0.04) 22 (0.19) 
ICH 52 (0.33) 122 (0.8) 27 (0.23) 36 (0.3) 87 (0.74) 55 (0.5) 84 (0.7) 
MI 810 (4.85) 906 (5.49) 86 (0.72) 89 (0.74) 63 (0.53) 101 (0.91) 126 (1.12) 
GI bleeding 105 (0.76) 119 (0.86) 133 (1.12) 182 (1.51) 120 (1.02)     
Major bleeding 327 (2.13) 462 (3.09) 322 (2.71) 375 (3.11) 397 (3.36) 395 (3.6)  386 (3.4) 
Major or clinically non-major bleeding 613 (4.07) 877 (6.01)       1,475 (14.9) 1,449 (14.5) 
Any bleeding 2,356 (18.1) 3,060 (25.8)        386 (3.4) 
Critical bleeding     145 (1.22) 175 (1.45) 212 (1.8) 91 (0.8) 133 (1.2) 
Fatal bleeding           27 (0.2) 55 (0.5) 
Mortality (all-cause)     446 (3.75) 438 (3.64) 487 (4.13) 208 (1.87) 250 (2.21) 
Mortality (cardiovascular)     289 (2.43) 274 (2.228) 317 (2.69) 170 (1.53) 193 (1.71) 
 
Abbreviations: ITT= intention to treat, SE=systemic embolism, ICH=intracranial haemorrhage, MI=myocardial infarction, GI=gastrointestinal. 
Source : Granger et al (2011), Connolly et al. (2009), Patel et al. (2011). 
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                 Table 1.3 RCT clinical outcomes - Hazard Ratios    
    
ARISTOTLE                           
Apixaban                            
vs. warfarin 
 
RE-LY 
Dabigatran (110 mg)       
vs. warfarin 
RE-LY 
Dabigatran (150 mg)       
vs. warfarin 
 
ROCKET-AF 
Rivaroxaban                          
vs. warfarin Outcome 
  HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Stroke or SE (ITT) 0.79 (0.66, 0.95) 0.90 (0.74, 1.10) 0.65 (0.52, 0.81) 0.88 (0.75, 1.03) 
Stroke or SE (per-protocol population)       0.79 (0.66, 0.96) 
Stroke or SE (safety on treatment population)       0.79 (0.65, 0.95) 
Stroke or SE or major bleeding 0.77 (0.69, 0.86)       
Stroke or SE or major bleeding or mortality (all-cause) 0.85 (0.78, 0.92)       
Stroke or SE or mortality (cardiovascular)       0.86 (0.74, 0.99) 
Stroke or SE or mortality (cardiovascular) or MI       0.85 (0.74, 0.96) 
Stroke  0.79 (0.65, 0.95) 0.91 (0.74, 1.12) 0.64 (0.51, 0.81) 0.85 (0.70, 1.03) 
Ischaemic or unspecified stroke 0.92 (0.74, 1.13) 1.11 (0.88, 1.39) 0.76 (0.59, 0.97) 0.94 (0.75, 1.17) 
Haemorrhagic stroke 0.51 (0.35, 0.75) 0.31 (0.17, 0.56) 0.26 (0.14, 0.49) 0.59 (0.37, 0.93) 
SE 0.87 (0.44, 1.75) 0.71 (0.37, 1.38) 0.61 (0.30, 1.21) 0.23 (0.09, 0.61) 
ICH 0.42 (0.30, 0.58) 0.30 (0.19, 0.45) 0.41 (0.28, 0.60) 0.67 (0.47, 0.93) 
MI 0.88 (0.80, 0.97) 1.35 (0.98, 1.87) 1.38 (1.00, 1.91) 0.81 (0.63, 1.06) 
GI bleeding 0.89 (0.70, 1.15) 1.10 (0.86, 1.41) 1.50 (1.19, 1.89)   
Major bleeding 0.69 (0.60, 0.80) 0.80 (0.69, 0.93) 0.93 (0.81, 1.07)  1.04 (0.90, 1.20) 
Major or clinically non-major bleeding 0.68 (0.61, 0.75)     1.03 (0.96, 1.11) 
Any bleeding 0.71 (0.68, 0.75)      
Critical bleeding   0.67 (0.54, 0.82) 0.67 (0.54, 0.82) 0.69 (0.53, 0.91) 
Fatal bleeding       0.50 (0.31, 0.79) 
Mortality (all-cause) 0.89 (0.80, 1.00) 0.91 (0.80, 1.03) 0.88 (0.77, 1.00) 0.85 (0.70, 1.02) 
Mortality (cardiovascular)   0.90 (0.77, 1.06) 0.90 (0.77, 1.06) 0.89 (0.73, 1.10) 
                
                Abbreviations: SE=systemic embolism, ICH=intracranial haemorrhage, MI=myocardial infarction, GI=gastrointestinal 
                Source : Granger et al (2011), Connolly et al. (2009), Patel et al. (2011). 
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Overall, heterogeneity of patient populations between studies, and definition of outcomes 
are the key limitations of the pivotal RCTs. In particular, while the outcomes used for 
defining efficacy are comparable across the studies, the definition of bleeding events 
differs considerably [41-43]. For instance, the RE-LY study defined bleeding in terms of 
minor bleeding, while ROCKET-AF and ARISTOTLE defined bleeding in terms of non-
major clinically relevant bleeding. This was reflected in the bleeding rates being evidently 
higher in ROCKET-AF and RE-LY than in the ARISTOTLE study [41-43].  
 
Further, important baseline characteristics of patients included in the ROCKET-AF trial 
differed substantially from those reported in the ARISTOTLE and RE-LY trials. Although, 
rivaroxaban and warfarin baseline characteristics were balanced, over 80 % of patients in 
the ROCKET-AF study were at higher risk of stroke (CHAD2 score ≥ 3) compared to less 
than 33% in the ARISTOTLE and RE-LY clinical studies. Similarly, the proportion of 
patients with previous stroke, TIA or SE in the RE-LY was almost threefold higher than in 
patients included in the other two trials. A discrepancy was also observed in the proportion 
of patients with heart failure and diabetes, being almost double in the ROCKET-AF 
compared to those in the ARISTOTLE and RE-LY clinical trials [41-43]. 
 
In addition, as Al-Katib and colleagues indicated, there is uncertainty regarding the effect 
of apixaban compared to warfarin according to type and variation of AF. In particular, it is 
uncertain to what extent apixaban reduces the risk of stroke or SE, bleeding and mortality 
among patients with paroxysmal versus permanent AF [44]. 
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1.8.2 Evidence from network meta-analysis  
 
In addition to pivotal RCTs discussed in the previous sections  (ARISTOTLE, RE-LY and 
ROCKET-AF), ten additional clinical studies [45-54] were analysed in a Network Meta-
Analysis (NMA) to produce further evidence on the efficacy of DOACs [55]. Of those, 
five studies assessed the safety and the efficacy of either apixaban, dabigatran or 
rivaroxaban [47-50, 54] In NMA, multiple treatments are compared by means of direct and 
indirect comparison. In the latter case, comparison across trials is based on a common 
comparator [56]. For example, in most cases, the efficacy of DOACs in preventing stroke 
in the AF population was generated by comparing each DOAC against warfarin. Because 
warfarin is the common comparator, NMA allows conducting a series of indirect 
comparisons where, for instance, dabigatran or rivaroxaban could be compared against 
apixaban.  
 
Only Phase II and Phase III trials evaluating the effectiveness of DOACs, VKA or 
antiplatelet drugs for the prevention of stroke in the AF population were included. Phase II 
are typically smaller than Phase III trials but still provide evidence on the efficacy of new 
treatments whenever findings from Phase III studies are not available.  The network meta-
analysis focused on five main oral anticoagulants namely: apixaban, dabigatran, 
rivaroxaban, edoxaban and betrixaban; but reporting the findings on the efficacy of 
betrixaban compared to warfarin was limited by insufficient evidence. Other 
anticoagulants (eribaxaban, otamixaban, darexaban, letaxaban and ximelagatran) were 
excluded from the analysis because administered parenterally or any other issue such as 
discontinuation or lack of info on the stage of clinical development [55].  
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Phase II studies included in the Network Meta-Analysis  
Three out of seven Phase II studies included in the NMA compared either apixaban 
dabigatran or rivaroxaban with warfarin [48, 50, 54]   
 
The ARISTOTLE-J study explored safety and efficacy of apixaban (2.5 and 5 mg) against 
warfarin in Japanese patients with non-valvular AF. The study population consisted of 222 
patients aged 20 years or older with AF and at least one of the following risk factors for 
stroke: age 75 years or older, congestive heart failure, hypertension, diabetes and history of 
cerebral infarction or TIA. As in the ARISTOTLE study, both first time warfarin users and 
on-going users were enrolled [50]. The partially blinded study, (double blinded for 
apixaban, but open-label for warfarin), evaluated the safety of apixaban compared to 
warfarin for major and clinically relevant non-major bleeding. The efficacy was evaluated 
for the composites of stroke including SE and all-cause mortality, and the composite of MI 
or all-cause mortality. In the study, patients were randomised to receive apixaban 2.5 mg 
(74 patients), apixaban 5 mg (74 patients) or dose adjusted warfarin to obtain an INR <2.0 
prior to entering the 12-week treatment period (74 patients). After a follow-up of 12 weeks, 
the occurrence of major and clinically relevant non-major bleeding was lower in the 
apixaban group (14% for both 2.5mg and 5 mg) compared to the warfarin group (5.3%). 
Apixaban also showed as better “safety profile” (a term generally used to refer to the safety 
of a drug) compared to warfarin, as no events of stroke, SE, MI, or all-cause mortality were 
observed in either apixaban group. On the contrary, two events of ischemic stroke and one 
event of subarachnoid haemorrhage were observed in the warfarin group [50].  
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The PETRO study assessed the safety of dabigatran, with or without concomitant aspirin, 
compared to warfarin in patients with non-valvular AF to identify the optimal doses for the 
Phase III clinical study. The study population consisted of 502 patients with AF at high 
risk for thromboembolic events and at least one of the following risk factors for stroke: age 
75 years or older, symptomatic heart failure or left ventricular dysfunction, hypertension, 
diabetes and history of stroke or TIA [48]. The partially blinded study (double blinded for 
apixaban, but open-label for warfarin and concomitant aspirin) evaluated the safety of 
dabigatran (with or without aspirin) compared to warfarin for the primary outcome of 
major or clinically relevant bleeding. In the study, patients were randomised to receive 
twice-daily dabigatran 50 mg (105 patients), dabigatran 150 mg (166 patients), dabigatran 
300 mg (161 patients), aspirin 81 or 325 mg (alone or in concomitance with dabigatran) or 
dose adjusted warfarin to maintain the INR between a range of 2.0 and 3.0 (70 patients) 
[48].  
 
After a follow-up of 12 weeks, major bleeding events were experienced only by patients on 
dabigatran 300 mg plus aspirin (2.4%). The rate of the major bleeding, irrespective of the 
aspirin assignment, was lower in the dabigatran 50 mg group (1.9%), but higher in the 150 
mg (7.7%) and 300mg (10%) groups respectively, compared to the warfarin group (5.7%).  
However, when aspirin assignment was taken into account, there was a significant 
difference in the rate of major or clinically relevant bleeding in the dabigatran 50 mg plus 
aspirin group (4.2%), compared to the group of patients treated with dabigatran 50 mg 
only, where no primary outcome events were observed [48]. Similar patterns were 
observed between patients on the dabigatran 300 mg plus aspirin and those who were on 
dabigatran 300 mg only, with the rate of the primary outcome being higher for the former 
group (17.2% versus 5.7%). However, the patterns were inverted for the dabigatran 150 
mg plus aspirin group (5.8%) compared with the group on dabigatran 150 mg only (9%).  
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The overall rate of bleeding, irrespective of the aspirin assignment, was again lower in the 
dabigatran 50 mg group (6.5%), but higher in the 150 mg (17.8%) and 300mg (23.1%) 
groups respectively, compared to the warfarin group (17.1%).  Further, stroke events were 
only experienced by patients on dabigatran 50 mg (1.9%), and the concomitance with 
aspirin did not seem to have a significant effect [48].  
 
The third Phase II study, comparing a DOAC with warfarin, explored the dose response of 
dabigatran in patients with non-valvular AF in comparison with warfarin. The study 
population consisted of 166 patients 20 years or older with AF and at least one of the 
following risk factors for stroke: age 75 years or older, left side heart, hypertension, 
diabetes, history of coronary artery diseases, and history of stroke or TIA [54]. In the 
exploratory dose response study, patients were randomised to receive dabigatran 110 mg 
twice daily (46 patients), dabigatran 150 mg twice daily (58 patients) or dose-adjusted 
warfarin to maintain the INR between a range of 2.0 and 3.0 (or between 1.6 and 2.6 for 70 
years or older patients) (62 patients) [54]. After a follow-up of 12 weeks, major bleeding 
events were only experienced by patients on dabigatran 150 mg (1.7%) and warfarin 
(3.2%). These patients were also receiving aspirin. The rate of major or clinically relevant 
bleeding was lower for the dabigatran plus aspirin patients (4.3% for the 110 mg and 8.6% 
for the 150 mg dabigatran) than in the warfarin treatment group (11.3%). The overall rate 
of bleeding was lower in the dabigatran 110 mg group (21.7%), but higher in the 150 mg 
(34.5%), compared to the warfarin group (24.2%). Further, stroke events were only 
experienced by patients on warfarin (3.2%) [54].  
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Phase III studies included in the Network Meta-Analysis  
In addition to the main RCTs and Phase II studies, two additional Phase III studies 
comparing apixaban with aspirin and dabigatran with warfarin met the inclusion criteria of 
the NMA.  
 
The J-ROCKET AF assessed the efficacy of rivaroxaban compared to warfarin in the AF 
Japanese population [49]. The study population consisted of 1,280 patients aged 20 years 
or older with AF, previous history of ischaemic stroke, TIA or SE or more than 2 of the 
following thromboembolism risk factors: age 75 years or older, congestive heart failure, 
and/or left ventricular ejection fraction, hypertension, diabetes. The study, using a non-
inferiority design evaluated the efficacy of rivaroxaban (637 patients) compared to 
warfarin (637 patients) for the primary safety outcome of major non-major clinical 
bleeding and the primary efficacy composite outcome including stroke and SE.  Patients 
were randomised to receive rivaroxaban 15 mg once daily dose, or dose adjusted warfarin 
to maintain the INR between a range of 2.0 and 3.0 (in patients younger than 70 years) or 
1.6 and 2.6 (in patients 70 years or older) according to Japanese guidelines. Within the pre-
specified maximum exposure period and the expected study duration of 2.5 years, no risk 
difference of the primary safety outcome was observed (HR 1.11 (95% CI 0.87, 1.42)); 
thus, the non-inferiority of rivaroxaban to warfarin in the safety on treatment population 
was confirmed. Rivaroxaban was also associated with a significant reduction in risk of the 
primary efficacy composite outcome (HR 0.49 (95% CI 0.24, 1.00)) compared to warfarin 
[49]. 
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The AVERROES clinical study investigated the efficacy of apixaban compared to 
acetylsalicylic acid (Aspirin) in preventing stroke in the AF population unsuitable for 
vitamin K antagonist treatment [47]. The study population consisted of 5,599 patients aged 
50 years or older with AF and at least one of the following stroke risk factors: age 75 years 
or older, symptomatic heart failure, left ventricular dysfunction or peripheral artery 
disease, hypertension, diabetes and history of stroke or TIA. The study, using a superiority 
design evaluated the efficacy of apixaban (2,808 patients) compared to aspirin (2,791 
patients) for the primary outcome of stroke or SE.  Patients were randomised to receive 
apixaban 5 mg twice-daily dose, or aspirin 81 to 324 mg once daily [47]. After a median 
follow-up of 1.1 years, apixaban 5mg showed a significant reduction in the primary 
outcome (HR 0.45 (95% CI 0.32, 0.62)) compared to aspirin. However, no risk difference 
of major bleeding (HR 1.13 (95% CI 0.74, 1.75)) and mortality (HR 0.79 (95% CI 0.62, 
1.02)) was found for apixaban compared with aspirin [47].  
 
The network meta-analysis evaluated the effectiveness of standard dose DOACs in 
different head-to-head comparisons, where dabigatran and rivaroxaban were compared 
with apixaban, and rivaroxaban with dabigatran. Based upon their consistency across 
studies, the amount of data available and the clinical relevance, the outcomes selected for 
the network meta-analysis were the following: stroke or SE, ischaemic stroke, MI, major 
bleeding, ICH, GI bleeding, clinically relevant bleeding and all-cause mortality [55].  
 
Overall, the study found no risk difference of stroke or SE when dabigatran and 
rivaroxaban were compared with apixaban. However, rivaroxaban (OR 1.35 (95% CI 1.03, 
1.78)) was associated with an increased risk of stroke and SE when compared against 
dabigatran. No difference in risk of MI was found across the DOAC to DOAC 
comparisons.  
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For what concerns the safety aspect, a significant risk increase of major bleeding compared 
with apixaban was found for dabigatran (OR 1.33 (95% CI 1.09, 1.62)) and rivaroxaban 
(OR 1.45 (95% CI 1.19, 2.33)). While there was no risk difference in ICH across all 
DOAC to DOAC comparisons, dabigatran (OR 1.71 (95% CI 1.21, 2.43)) and rivaroxaban, 
(OR 1.66 (95% CI 1.19, 2.33)) showed an increased risk of GI bleeding compared to 
apixaban. No risk difference in mortality was observed between DOACs. The NMA also 
looked at efficacy of Edoxaban, however as the focus of this thesis is on apixaban, 
dabigatran and rivaroxaban only, the findings on Edoxaban are not reported [55]. All 
findings on the efficacy of DOACs are reported in Tables 1.4  
 
 
Table 1.4 Odd ratios from network-meta analysis comparing DOACs to DOACs   
  Dabigatran (150 mg)                          
vs. apixaban (5 mg) 
Rivaroxaban (20 mg)              
vs. apixaban (5 mg) 
Rivaroxaban (20 mg)              
vs. dabigatran (150 mg) Outcome 
  Odd ratio 95% CI Odd ratio 95% CI Odd ratio 95% CI 
Stroke or SE  0.82 (0.62, 1.08) 1.11 (0.87, 1.41) 1.35 (1.03, 1.78) 
Ischaemic stroke 0.83 (0.59, 1.16) 1.01 (0.74, 1.38) 1.22 (0.87, 1.73) 
MI 1.48 (0.98, 2.22) 0.92 (0.63, 1.34) 0.62 (0.41, 0.93) 
Major bleeding 1.33 (1.09, 1.62) 1.45 (1.19, 1.78) 1.10 (0.90, 1.34) 
ICH 0.96 (0.58, 1.60) 1.55 (0.97, 2.49) 1.61 (0.96, 2.72) 
GI bleeding 1.71 (1.21, 2.43) 1.66 (1.19, 2.33) 0.97 (0.71, 1.33) 
Clinically relevant bleeding 2.32 (0.74, 8.63) 1.53 (1.33, 1.75) 0.66 (0.18, 2.07) 
Mortality (all-cause) 1.00 (0.84, 1.19) 0.94 (0.76, 1.17) 0.94 (0.74, 1.18) 
 
Abbreviations: SE=systemic embolism, MI=myocardial infarction, ICH=intracranial haemorrhage, 
GI=gastrointestinal. 
Source: Lopez et al (2017).  
 
Standard dose apixaban was ranked as the most effective intervention for stroke, SE, MI 
and all-cause mortality. On the contrary, rivaroxaban was ranked the least effective. 
Apixaban was also ranked as the safest DOAC associated with the lowest incidence of 
major and GI bleeding [55].  These important findings provide further evidence that is 
added to the existing body of evidence.  
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The main limitations of the network meta-analysis were inherent to the primary data 
available and the assumptions made for the analysis. For instance, as few comparisons 
were present in more than one trial, it was not possible to fit a random effect model, thus 
allowing for heterogeneity in treatment effect determined by differences between treatment 
groups such patient characteristics or  follow-up [55, 57]. Further, the reporting of the 
outcomes extracted for the review was incomplete; this not only reduces precision but also 
threatens the validity of the results of the NMA. However, the complete reporting of the 
relevant outcomes (stroke or SE, ischaemic stroke, MI, all-cause mortality, major bleeding, 
intracranial bleeding, and gastrointestinal bleeding) in the pivotal RCTs [41-43], gave 
some reassurance that bias due to selective reporting of outcomes was unlikely to affect the 
findings of the NMA [55]. Nevertheless, clinical relevant bleeding was not reported by the 
RE-LY trial [41]; this outcome however could be identified in real-world data, as RWE 
allows for the inclusion and analysis of clinical endpoints not measured in RCTs but 
observed in real life.  
 
1.8.3 Real-world evidence 
 
The health outcomes measured in a controlled environment, as in a RCT, may not reflect 
what happens in clinical practice, where the random allocation of treatments cannot be 
scientifically planned. While an RCT is typically the first step for evaluating the efficacy 
and the safety of a given intervention, estimating the effectiveness for the same 
intervention in a real-world scenario is equally important. RWE may provide a more 
comprehensive understanding of treatment safety and effectiveness by allowing for the 
inclusion and analysis of clinical endpoints not measured in RCTs but observed in real life.  
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In addition to the pivotal RCTs of DOACs, several RWE studies have been carried out.  
An existing systematic review (Ntaios, 2017) [58] identified 28 RWE studies evaluating 
safety and effectiveness of DOACs compared to any VKAs treatment (mainly warfarin) in 
the AF population. Only studies, identified in PubMed and the Web of Science until the 7th 
of January 2017, comparing more than one DOAC against VKA, and adequately 
addressing confounding by indication were included in the meta-analysis carried out in the 
existing systematic review [58]. Whenever two or more studies employed data coming 
from the same source, only the study with the longest study period was selected.  
 
The outcomes assessed were ischaemic stroke, ischemic stroke or SE, all stroke (including 
ischaemic and haemorrhagic) SE, MI, ICH, GI bleeding, major bleeding and mortality.  
All DOACs were associated with a reduction in risk of ischaemic stroke or SE, but only 
the risk for the apixaban versus warfarin comparison was statistically significant. The 
statistically significant reduction in risk of ICH was observed across all treatment groups 
compared to VKA. While the reduction in risk for ICH confirms the findings from RCTs, 
no risk difference of ischaemic stroke or SE observed between apixaban and warfarin 
group diverged from the risk reduction reported in the ARISTOTE trial [42].  
 
In the rivaroxaban treatment group, the risk of stroke or SE is matching that reported in the 
ROCKET-AF study only for the risk estimated with the ITT approach. Nevertheless, the 
meta-analysis supports the clinical non-inferiority for all DOACs in reducing the risk of 
stroke and composite compared to VKAs. The effect on reducing the risk of MI was not 
reported for apixaban, and no reduction in risk was found for dabigatran and rivaroxaban 
compared to VKAs. The finding provides further evidence against the supposed correlation 
between dabigatran and MI as observed in the RE-LY trial [58]. 
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When evaluating the safety aspect of DOACs, the reduction and increase in risk of GI 
bleeding associated with apixaban and dabigatran respectively, compared with VKAs, was 
in line with the risk reported in the ARISTOTLE and RE-LY (dabigatran 150 mg) RCTs. 
The risk of major bleeding also matched the risk reported in the clinical studies, where a 
significant reduction in major bleeding is observed for apixaban, whereas dabigatran and 
rivaroxaban compared to VKAs are associated with a similar bleeding risk [41-43]. 
Similarly, the results on the risk of mortality are consistent with those reported in the 
RCTs. In the meta-analysis, apixaban and dabigatran were found to have a lower risk of 
mortality, but no statistically significant risk reduction was observed for rivaroxaban 
compared to VKAs [58]. Likewise, the ARISTOTLE and RE-LY (dabigatran 150 mg) 
trials reported a mortality risk reduction of 11% and 10% respectively; however, 
rivaroxaban was not associated with a reduction in the risk of mortality in the ROCKET-
AF clinical study. Overall, the findings from the meta-analysis, reported on Table 5.1, 
suggest that DOACs are at least as safe as VKA in the AF population [58]. 
 
Table 1.5 Meta-analysis results   
Outcome 
Apixaban                            
vs. warfarin 
Dabigatran                            
vs. warfarin 
Rivaroxaban                          
vs. warfarin 
  HR 95% CI HR 95% CI HR 95% CI 
Studies (N) 7 24 14 
Ischaemic stroke 0.95 (0.75, 1.19) 0.96 (0.80, 1.16) 0.89 (0.76, 1.04) 
Ischaemic stroke or SE 1.07 (0.87, 1.31) 1.17 (0.92, 1.50) 0.73 (0.52, 1.04) 
All stroke or SE 0.67 (0.46, 0.98) 0.93 (0.77, 1.14) 0.87 (0.71, 1.07) 
MI not reported 0.96 (0.77, 1.21) 1.02 (0.54, 1.89) 
ICH 0.45 (0.31, 0.63) 0.42 (0.37, 0.49) 0.64 (0.47, 0.86) 
GI bleeding 0.63 (0.42, 0.95) 1.20 (1.06, 1.36) 1.24 (1.08, 1.41) 
Major bleeding 0.55 (0.48, 0.63) 0.83 (0.65, 1.05) 1.00 (0.92, 1.08) 
Mortality 0.65 (0.56, 0.75) 0.63 (0.52, 0.76) 0.67 (0.35, 1.30) 
 
Abbreviations: SE=systemic embolism, MI=myocardial infarction, ICH=intracranial haemorrhage, 
GI=gastrointestinal. 
Source: Ntaios et al. (2017) 
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Important strengths in the systematic review and meta-analysis, such as large sample size 
and the inclusion of studies adequately addressing confounding by indication, are 
acknowledged. However, several limitations inherent to the nature of administrative data 
such as residual confounding, a distortion that persist after controlling for confounding, 
still persist [58, 59].   
 
In addition, missing information on patient characteristics, patient adherence and 
compliance to treatment, and details on the therapeutic range for warfarin users may 
undermine the robustness of the reported findings [58]. Another important limitation is the 
lack of distinction between different dose regimens in the analysis. As observed in in the 
RE-LY trial reduced dose of dabigatran did not have the same effect as the standard dose 
in reducing the risk of stroke [41]. Presumably, the risk of several outcomes associated 
with reduced doses may vary substantially in clinical practice.  
 
Despite the limitations, the main results from Ntaios’s systematic review and meta-
analysis, support the main conclusions of the pivotal RCTs [41-43], and therefore 
strengthen their validity [58]. While, further evidence from RWE will still be likely to be 
limited by potential residual confounding, issues such as treatment adherence and 
compliance should be investigated, as poor compliance might expose patients to a greater 
risk of experiencing stroke or any other relevant clinical event [16-18]. In addition, info 
regarding the time spent within therapeutic range for patients on warfarin would allow for 
a more accurate comparative effectiveness analysis of DOACs versus warfarin in real life. 
In RCTs, the effect of DOACs may have been overestimated, as the therapeutic INR 
between a range of 2.0 and 3.0, was not maintained for some patients randomised to 
warfarin [41-43]. Further, estimating the treatment effect of DOACs according to different 
dose regimens may provide additional insights on how the risks of standard and reduced 
dose of DOACs, compared to warfarin, differ in clinical practice.  
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The effect of DOACs reduced dose in real-world settings was evaluated in two RWE 
studies, Gorst Rasmussen (2016) [60]and Nielsen (2017) [61]. Differentiating dose 
regimen in DOACs may be important as some evidence suggests a dose dependent effect. 
This was shown in the RE-LY trial assessing the efficacy of dabigatran standard (150mg) 
and reduced (110mg) dose [41].    
 
The two Danish studies [60, 61], obtained the study data by merging three nationwide 
Danish registries: the Danish Civil Registration System covering demographic info, the 
Danish National Prescription Registry covering all prescription purchased since 1995, and  
the Danish National Patient Register covering all hospitalisation records since 1976 [60, 
61]. Although these studies share many similarities in terms of study design and research 
questions, Gorst-Rasmussen (2016) evaluated the effectiveness of rivaroxaban against 
warfarin and dabigatran between February 2012 and August 2014 [60]. By contrast, 
Nielsen (2017) explored the effectiveness of any DOACs between August 2011 and 
February 2016, therefore assessing effectiveness in clinical practice within a much broader 
time-frame [61]. 
 
Gorst-Rasmussen (2016) found that at 2.5-year follow-up, rivaroxaban 15 mg, compared 
against warfarin, was associated with risk reduction for the composite of stroke or SE or 
TIA; but no risk difference was observed between warfarin and rivaroxaban standard dose. 
When evaluating the safety aspect by means of any bleeding, a risk difference compared to 
warfarin was not observed for either the standard or the reduced rivaroxaban dose.  
However, an important difference was seen between drug regimens with respect to the risk 
of all-cause mortality. While no difference in the risk of mortality was observed between 
rivaroxaban standard dose and warfarin, rivaroxaban 15 mg showed a statistically 
significant increase, Table 1.5 [60]. These findings were supported by the additional 
evidence coming from Nielsen’s study (2017), also reported in Table 1.5 [61].  
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Unlike, the two Danish studies [60, 61], Vinogradova (2018) [62], assessed the 
effectiveness of DOACs (excluding edoxaban) for different indications, and analysed the 
effectiveness of DOACs standard and reduced doses in patients with or without AF 
between 2011 and 2016, using UK primary care databases QResearch and Clinical Practice 
Research Datalink [62]. In the standard dose analyses comparing individual DOACs 
against warfarin, no difference in risk was found across the outcomes assessed. However, 
when assessing at the reduced doses, a reduction in the risk of ICH was observed for each 
DOAC. Further, the effect of apixaban on reducing the risk of major bleeding was reported 
but no reduction in risk was found for dabigatran compared to warfarin; however, patients 
on reduced dose rivaroxaban were found to be at greater risk of experiencing major 
bleeding than those on warfarin. Nevertheless, both reduced dose apixaban and 
rivaroxaban were associated with an increased risk of all-cause mortality [62].  
 
While the findings may rise some concerns over the use of rivaroxaban, Larsen (2016) and 
Nielsen (2017) acknowledged that despite having controlled for confounding, residual 
confounding from unobserved factors may persist. Therefore, further research will be 
needed to access whether the association between the use of rivaroxaban and the risk of 
mortality is a true association [61, 63].  
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Table 1.6 Hazard ratios from additional RWE observational studies – DOACs vs. warfarin  
Study  Outcome  
Apixaban Apixaban Dabigatran Dabigatran Rivaroxaban Rivaroxaban 
(5 mg) (2.5 mg) (150 mg) (110 mg) (20 mg) (15 mg) 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Nielsen, 2017 (Denmark) Ischaemic stroke   1.14 (0.89 - 1.46)   1.07 (0.92 - 1.23)   1.02 (0.77 - 1.34) 
Vinogradova, 2018 (UK) Ischaemic stroke 1.07 (0.79 -1.46) 1.16 (0.81 - 1.67) 1.37 (0.92 - 2.05) 1.06 (0.76 - 1.48) 0.97 (0.78 - 1.20) 1.27 (0.92 - 1.75) 
Nielsen, 2017 (Denmark) Ischaemic stroke or SE   1.15 (0.9 - 1.47)   1.07 (0.93 - 1.23)   0.99 (0.76 - 1.3) 
Gorst-Rasmussen, 2016 (Denmark) Stroke or SE or TIA          0.72 (0.51 - 1.01) 0.46 (0.26 - 0.82) 
Nielsen, 2017 (Denmark) Haemorrhagic stroke   0.76 (0.4 - 1.42)   0.60 (0.42 - 0.84)   1.25 (0.67 - 2.36) 
Vinogradova, 2018 (UK) ICH 0.41 (0.22 - 0.76) 0.44 (0.23 - 0.82)   0.48 (0.26 - 0.91) 0.85 (0.63 - 1.14) 0.86 (0.52 - 1.42) 
Vinogradova, 2018 (UK) GI bleeding 0.81 (0.58 - 1.13) 0.70 (0.45 - 1.09) 0.86 (0.51 - 1.44) 1.28 (0.94 - 1.74) 1.14 (0.93 - 1.40) 1.34 (0.98 - 1.83) 
Gorst-Rasmussen, 2016 (Denmark) Any bleeding         1.18 (0.90 - 1.55) 0.90 (0.59 - 1.35) 
Nielsen, 2017 (Denmark) Major bleeding   1.02 (0.74 - 1.41)   0.93 (0.80 - 1.08)   1.18 (0.93 - 1.5) 
Vinogradova, 2018 (UK) Major bleeding 0.62 (0.49 - 0.79)  0.68 (0.52 - 0.90) 0.79 (0.56 - 1.10) 0.93 (0.74 - 1.17) 1.06 (0.92 - 1.21) 1.25 (1.01 - 1.55) 
Gorst-Rasmussen, 2016 (Denmark) Mortality (all-cause)         0.93 (0.75 - 1.16) 1.47 (1.19 - 1.82) 
Nielsen, 2017 (Denmark) Mortality (all-cause)   1.61 (1.43 - 1.82)   1.05 (0.98 - 1.13)   1.43 (1.27 - 1.61) 
Vinogradova, 2018 (UK) Mortality (all-cause) 0.98 (0.83 - 1.15) 1.27 (1.12 - 1.45) 0.90 (0.68 - 1.19) 1.01 (0.87 - 1.18) 1.10 (0.99 - 1.21) 1.29 (1.14 - 1.45) 
 
Note: only outcomes relevant to atrial fibrillation are reported. 
SE=systemic embolism, TIA= transient ischaemic attack, ICH=intracranial haemorrhage, GI=gastrointestinal. 
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Additional evidence on the effectiveness of standard and reduced dose apixaban in real-
world settings was provided by Proietti and colleagues (2018) [64]. The meta-analysis and 
systematic review identified 16 RWE studies evaluating the safety and effectiveness of 
apixaban compared to other DOACs and warfarin in patients with established AF 
diagnosis. Only studies, identified in PubMed and the Scopus database until the 6th of 
March 2017, comparing apixaban with warfarin or other DOACs were included in the 
analysis. The study evaluated the effectiveness of apixaban for stroke, major bleeding, any 
bleeding and ICH [64].  
 
Although the study compared the effectiveness of apixaban with warfarin and other 
DOACs, because of the focus of this thesis, only results of the apixaban versus warfarin 
comparison are reported. In particular, Proietti’s study found that apixaban was as effective 
as warfarin in reducing stroke; this was the case for both standard (OR 0.84 (95% CI 0.69, 
1.01)) and reduced dose (OR 0.63 (95% CI 0.14, 2.81)) apixaban. Further, the risk of major 
bleeding was significantly lower for patients on standard (OR 0.64 (95% CI 0.51, 0.80)) 
and reduced dose apixaban (OR 0.55 (95% CI 0.36, 0.86)) than warfarin. Similarly, 
patients on apixaban had a lower risk of experiencing any bleeding with standard (OR 0.58 
(95% CI 0.42, 0.81)) and reduced dose (OR 0.66 (95% CI 0.58, 0.76)) than those on 
warfarin [64]. 
 
 
 
 
 
 
 
 
Chapter 1                                                                                                                                                        39 
 
1.9 Conclusion 
 
This Chapter has discussed the role of RWE in the context of HTA; and has highlighted 
strength and limitations of RWE, which should be a seen as supplement to RCTs, where 
treatment efficacy is measured under specific conditions. Hence, RWE should be used for 
validating the robust evidence coming from RCTs; however, conflicting evidence may 
sometimes emerge. For instance, in Ntaio’s study (2017) no risk difference of stroke or SE 
between apixaban and warfarin was observed, however the ARISTOTLE trial reported a 
statistically significant risk reduction [42]. Similarly, Gorst-Rasmussen (2016), Nielsen 
(2017), and Vinogradova (2018) reported an increased risk of all-cause mortality 
associated with reduced dose rivaroxaban. This finding diverged substantially from the risk 
reported in ROCKET-AF trial, where no risk difference of mortality was found for 
rivaroxaban compared to warfarin [43].  
 
In these cases, clinicians should balance the evidence and assess whether RCTs and RWE 
studies look at the same population, patients characteristics and outcomes. In particular, 
clinicians may be interested the case-mix, treatment adherence, interactions with 
concomitant treatments [2, 7] or, as in the case of DOACs, the effect of standard and 
reduced dose apixaban and rivaroxaban compared to warfarin not investigated in the 
pivotal RCTs [41-43]. Thus, although residual confounding will always be a threat to the 
validity of RWE, important findings such as the increased risk of mortality with 
rivaroxaban should not automatically be discarded.   
 
This Chapter has provided some background information propaedeutic for generating 
additional effectiveness evidence as pointed out in the research questions postulated in the 
next Chapter. 
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Chapter 2 Aim and objective 
 
2.1 Aim of the thesis 
This thesis aims to explore opportunities and challenges in using RWE to support HTA, 
and in particular, to explore the feasibility of using Scottish link health data in supporting 
HTA decision-making in Scotland. This will be achieved by introducing a case study of 
DOACs used for the prevention of stroke in the AF population. 
 
This thesis intends to meet the following objectives: 
 
Objective 1: Estimate and examine the composition of direct and indirect medical costs in 
AF using Scottish linked health data. 
Objective 2: Explore, with a focus on PS based methods and the DOACs case study, 
methodological challenges in using RWE to estimate comparative-effectiveness.  
Objective 3: Estimate the comparative-effectiveness of DOACs to understand their 
effectiveness in Scottish clinical practice.  
Objective 4: Update, with RWE data, existing cost-effectiveness analysis of DOACs for 
the prevention of stroke in patients with AF in Scotland. The introduction offers an 
overview of all available evidence on DOACs in preventing stroke and other relevant 
clinical events in the AF population.  The remaining thesis is structured as follows: 
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Chapter 3: introduces typical data linkage processes. In particular, the data used in the 
different analyses of this thesis are presented and data characteristics, strength and 
limitations are discussed.  
 
Chapter 4: describes different regression models typically employed in healthcare costing 
studies, these are then empirically tested and compared. The AF cost analysis, carried out 
using the best fitting model identified, assesses how AF related healthcare costs vary 
according to demographics, comorbidities, geography and socio-economic status. The 
analysis also estimates how different cost components contribute to the overall healthcare 
cost.   
 
Chapter 5: describes the different propensity score methods typically used in health 
research to balance patients’ baseline characteristics between treatment groups, and 
estimate the treatment effect. The choice of one approach over another should not be 
arbitrary and all possible options should be tested. Thus, different methods are compared 
and applied to the linked Scottish data; the most robust method is selected for addressing 
objectives of Chapter 6.   
 
Chapter 6: evaluates effectiveness and safety of DOACs in a time-to-event analysis at 2- 
and 6-year follow-up. In addition, assumptions for the validity of the model are tested, and 
alternatives to the chosen model discussed. The findings are compared against the existing 
evidence reported in other observational studies and pivotal RCTs.  
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Chapter 7: focuses on the economic evaluation of DOACs, where DOACs are compared 
pairwise and incrementally against warfarin, to date the main thromboprophylactic 
treatment for the prevention of stroke in patients affected by AF. Firstly, a review of 
existing cost-effectiveness models allows for the identification of a cost-effectiveness 
model reflecting clinical, costs and utility assumptions pertinent to Scotland. Then, the 
economic evaluation assesses, with the identified cost-effectiveness model, whether 
DOACs improve the quality of life of patients; and if so, to what extent and at what 
additional cost.  
 
Chapter 8: summarises, with a focus on strengths and limitations, the main findings of this 
thesis. It discusses the possible direction of future research, and the implication these 
results may have on healthcare policies and clinical guidelines related to AF. 
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Chapter 3 Data source  
 
3.1 Introduction 
 
The data used for this thesis were obtained from ISD, and all the analyses were carried out 
in the National-Safe-Haven platform, a secure environment  used to maintain the privacy 
and confidentiality of the personal information held [15]. This Chapter will describe the 
different ISD databases and cohorts used in this thesis, and the different steps carried out in 
the data cleaning process.    
 
3.2. Data linkage  
 
Data linkage is a complex technique used for linking records from one or more datasets by 
means of personal identifiers such as medical record number and demographic data 
including name, sex, and date of birth. In the data linkage process, the personal identifiers 
are matched, deterministically or probabilistically, to a population spine representing the 
core dataset to which other datasets can be linked [65, 66]. ISD datasets are accurately 
linked by means of the Community Health Index (CHI), used in Scotland to uniquely 
identify a person for healthcare purposes, and through well-established probability 
matching techniques based on Howard Newcombe principles [14, 67].  
 
With the deterministic approach, unique personal identifiers such as social security or 
electoral number are regarded as truly unique, thus generating definite matches between 
any two records. However, due to potential coding errors, some true matches may be 
missed; this may happen for instance, when a unique identifier common to two datasets is 
used, but coding errors in one dataset may prevent records matching. The more commonly 
used probabilistic approach employs non-unique identifiers such as name and date of birth, 
in a weighting system indicating the likelihood that two records belong to the same 
individual [65, 66].  
Chapter 3                                                                                                                                                        44 
 
3.3 Data source  
 
3.3.1 Inpatient admissions 
 
SMR01 records contain all general acute admissions, categorized as inpatients or day 
cases, discharged from non-obstetric and non-psychiatric specialties. While inpatient 
admission implies a hospital stay overnight, day cases refer to a planned attendance to a 
specialty for clinical care and generally, it does not require patients to stay in the hospital 
overnight. Upon completion of a hospital episode defined from date of admission to the 
date of discharge, and regardless of whether it is inpatient or day case, an SMR01 record is 
generated [68]. Each episode includes non-clinical data reflecting demographic and 
episode management details describing date, reason, type of admission, and structures 
where patients were admitted from or transferred to. In particular, the type of admission 
would indicate whether a patient was admitted as a planned (elective) or with an 
emergency admission (non-elective). The details on admission/transfer would give an 
indication on the type of location, such as private residence, institution, same or different 
clinical specialty, from which an individual came from prior to hospital admission.  
Each episode would also include the date, type of discharge and from where patients were 
discharged or transferred to. The discharge type specifies whether discharge from an 
inpatient or day case episode was regular or resulted from self-discharge or death [68]. 
In addition, the discharge/transfer aspect of an episode indicates, as for admission, type of 
location to which a patient is discharged or transferred to following an episode of care, or 
whether a patient has died. Further, for every episode the diagnostic code is recorded using 
the International Classification of Diseases, Tenth Revision (ICD-10) developed in 1992 
by the WHO and implemented in Scotland in 1996. ICD-10 is an index of diseases and 
injuries used to compare conditions for epidemiological and health management purposes.  
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Within the SMR01 context, ICD-10 codes are reported for the main diagnosed condition 
(primary diagnostic position) followed by up to five additional diagnostic codes, which can 
describe co-morbidities [15, 68]. While ICD-10 seems to be an accurate coding system, it 
is argued that the increase from 17,000 codes in the previous version ICD-9 to 141,000 
codes may have introduced some unnecessary complexity [69, 70]. Similarly, operations, 
procedures and interventions are recorded using the Office of Population Censuses and 
Surveys, fourth revision (OPCS-4) index. Maintained and developed by the Health and 
Social Care Information Centre classification service in 1987, OPCS-4, now in its sixth 
revision, was implemented in NHS Scotland in 2014 [71]. Further, each episode in SMR01 
includes details on patients’ demographics and socio-economic status such as the Scottish 
Index of Multiple Deprivation (SIMD). Details on health boards and geographical location 
expressed as urban rural classifications are also included. SMR01 also comprises 
Healthcare Resource Groups (HRGs) used for costing each hospital episode.  
 
3.3.2 Outpatient attendance 
 
SMR00 records include, at patient level, information on new and follow-up appointments 
at outpatient clinics for any clinical specialty. Outpatient clinics are generally located 
within hospital outpatient departments or a health centre [72]. As opposed to inpatient 
admissions, outpatient attendances do not imply a hospital overnight stay.  This however 
differs from day cases where, although staying in hospital overnight is not required, the use 
of a bed is needed. Further, each episode in SMR00 includes two typologies of data: non-
clinical and clinical. While the first typology includes appointment management data, 
attendance status, and as in SMR01, patients’ demographics, socio-economic status, health 
board area and geographical location; the second typology indicates the referral reason and 
operations/ procedures recorded using the ICD-10 and OPCS-4 systems.  
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Although, there has been provision to record outpatient procedures since 1997, only from 
the 1st of April 2003 recording became mandatory. However, at the present time, the poor 
level of completeness of CHI numbers or other patient identifiers, still makes linking 
SMR00 with other datasets rather challenging. In addition, because not all fields are 
mandatory, such as length of waiting list, patients’ ethnicity and referral reason, the 
information present in SMR00 is still limited. Nevertheless, improving the procedure 
recording system aimed at reducing the inconsistency in recording practice between health 
boards is on-going [72]. 
 
3.3.3 Prescribing information system  
 
The PIS database includes prescribing records for all medicines and their associated costs, 
which are prescribed and dispensed by community pharmacies, dispensing doctors and a 
small number of specialist appliance suppliers [73]. Although the PIS database includes 
information starting from 1993, it is only possible to carry out analyses involving CHI 
related data since April 2009. In addition to the CHI number, PIS also includes prescription 
drugs related information such as cost, dosage, formulation code and strength, as well as 
details on prescribers and dispensers. Prescriptions issued in hospitals and dispensed in the 
community are also recorded in PIS, prescriptions dispensed in hospitals however are not 
included [73]. Another important aspect of the database is the inclusion of data indicating 
whether a prescription was prescribed and dispensed. While prescribing authorizes the use 
of prescriptions, dispensing indicates the actual number of prescriptions dispensed. The 
quality of PIS data is guaranteed by an electronic system, which has eliminated errors 
linked to manual data entry processes, and by several stages of record quality checking 
before and after they are submitted to PIS [74].  
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Further, the reimbursement system, which allows dispensers to be reimbursed only by 
submitting prescriptions for payment, guarantees a high level of individual level data 
completeness and availability. Nevertheless, some differences exist depending on the type 
of prescribers and prescriptions. For instance, for the year 2014, 98.7% of prescription data 
coming from general practitioners were complete and available, while those coming from 
dentists stayed at 1.6%. Similarly, and for the same year, the proportion of complete 
prescription data for cardiovascular drugs was 98.6%, comparatively for immunological 
products and vaccines was 71.5% [74]. In terms of coverage, PIS includes all age and sex 
groups, as well as socioeconomic status and geographical locations.  
 
Although PIS population-level longitudinal data, are essential for answering research 
questions related to drug utilization and health outcomes, weaknesses regarding data not 
captured and their availability, may limit some applications. For instance, prescriptions 
administered to patients during inpatient stays and short-term post discharge periods, are 
not captured by PIS.  The same applies to some specialist drugs such as growth hormone 
therapy and biologics administered for chronic conditions, or outpatient supplies produced 
by the hospital service. In addition, records on vaccines are limited, as the majority of the 
information may be captured by the childhood immunization database. Also, PIS does not 
hold information on drugs indications; for instance, DOACs may either be prescribed to 
AF patients or to those affected by deep vein thrombosis. Further, the low percentage of 
patient identifiers captured before 2009, poses limitations for carrying out longitudinal 
studies with PIS individual-level data for any time-period between 1993 and 2008 [73, 74]. 
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3.3.4 Care home census 
 
The Scottish Care Home Census is collected on an annual basis, and covers all adult care 
home institutions registered with the Care Inspectorate, which is responsible for regulating 
several social services across Scotland. The census, firstly issued by the Scottish 
Government in 2003, combines the former Residential Care Home Census (run by the 
Scottish Government) and the Private Nursing Homes Census (run by ISD Scotland) [75].   
This came as a result of integrating health and social care services in Scotland according to 
the Public Bodies (Joint Working) (Scotland) Act 2014. The integration should guarantee a 
consistent provision of quality and sustainable care services in particular for the increasing 
number of individuals in Scotland with long-term conditions [76].  Typical items collected 
for the care home census are discharge dates to care home residency such as NHS and 
private nursing home, as well as indication on whether nursing care is required.  
 
3.3.5 Mortality records 
 
Mortality records for deaths occurring between 1997 and 2015 were obtained from the 
NRS, a database including date of death, and information on: demography, civil status. 
Each death in Scotland is registered with an allocated ICD-10 code.  
In 2015, systems were introduced for improving the quality of data collection through 
independent checks on the accuracy of medical certificates of the cause of death, and there 
is already evidence that NRS  data are of higher quality compared to NHS data [77]. 
 
3.4 Cohort identification 
 
The data for cohort identification and the analyses addressing the objectives outlined in 
Chapter 2 were obtained from ISD of NHS Scotland. The data extraction process carried 
out by ISD is presented graphically in Figure 3.1.  
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Two cohorts where specified, one consisting of patients with a diagnosis of AF or atrial 
flutter (ICD10 code I48), the other consisting of patients on any Oral Anticoagulant (OAC) 
according to British National Formulary (BNF) section 2.8.2. 
 
The initial AF cohort consisting of 279,883 patients with a known diagnosis of AF or atrial 
flutter were identified from the general acute inpatient and day case Scottish morbidity 
records 01 (SMR01) for the 1997 – 2015 study period [68]. The rationale for starting data 
extraction from 1997 was determined, not only by the necessity of gathering information 
on patients’ prior medical history, but also by coding consistency issues. For instance, 
coding and record formatting of ICD-10 codes in SMR01 for diagnostic purposes, 
implemented in Scotland in 1996, have started to be consistent since 1997 [15].  
 
A cohort of patients receiving any OAC consisting of 166,182 individuals was identified 
from the Scottish Prescribing Information System (PIS) for the 2009 – 2015 study period 
[72]. Of those on OAC, 160,630 had hospital records; this indicates that 5,552 patients who 
have been on OAC have never been admitted to hospital during the study period.  
Further, of the OAC patients with a hospital record, 92,916 patients were admitted to 
hospital with AF in any diagnostic position. The ISD, by means of CHI numbers (a unique 
10-character numeric identifier allocated to each patient) the specified AF and OAC 
cohorts to PIS, SMR00, SMR01, the care home census and the National Records of 
Scotland (NRS) [75].
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Figure 3.1 Cohort identification and data extraction 
Note: Patients on any OAC and patients with AF or atrial flutter are identified from PIS and SMR01. Patients are then linked, by CHI number, to PIS, SMR00, SMR01, 
care home census and NRS to obtain info on demographics, outcomes events and prescribing. 
Abbreviations: OAC= oral anticoagulant, PIS=prescribing information system, SMR01=Scottish morbidity records - general/acute inpatient day case dataset, 
SMR00=Scottish morbidity records - outpatient appointments and attendances, NRS=national health records.
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3.5 Data cleaning  
 
Prior to the analyses, the morbidity records (SMR01 and SMR00) where checked for 
quality and consistency. Records from health boards other than Scotland were removed. 
Precisely, 6,949 and 6,840 records were removed from SMR01 and SMR00 respectively. 
Further, duplicates were removed from SMR01 if date of admission, date of discharge, 
name of specialty, and ICD code for the first diagnosis were the same when comparing two 
or more episodes for the same patient. Similarly, SMR00 records were removed if clinic 
attendance date and specialty of the outpatient clinic attended of two or more episodes 
were identical. Including referral reason could have also been useful in identifying 
duplicates; however, as entering this variable is not compulsory when recording outpatient 
attendances, referral reason was missing for the majority of patients. Following quality 
control, the final number of hospital records was 4,223,817 representing 345,881 patients. 
While the total number of outpatient records was 7,532,181 for 337,600 patients (Figure 
3.2). These cohorts were instrumental for identifying the relevant patients for this thesis 
and were further refined for analyses in the next Chapters.   
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Figure 3.2 Data cleaning   
Abbreviations: SMR01=Scottish morbidity records - general/acute inpatient day case dataset, SMR00=Scottish morbidity records - outpatient appointments and attendances.
SMR01 Dataset 
episodes (N=4,232,829)
patients (N=347,597)  
SMR01 Dataset 
after removing healthboards
records (N=4,225,880)
patients (N=345,881)
SMR01 Dataset 
after removing duplicates
records (N=4,223,817)
patients (N=345,881)
SMR00 Dataset 
records (N=7,605,235)  
patients (N=338,112)  
SMR00 Dataset 
after removing healthboards
records (N=7,598,395) 
patients (N=337,600)  
SMR00 Dataset 
after removing duplicates
records (N=7,532,181) 
patients (N=337,600)  
SMR01 healthboards removed
(England, Wales,Nother 
Irland,not fixed abode,
not known, outside UK)
records (N=6,949)  
patients (N=1,714)  
SMR01 duplicates removed
records (N=2,063)  
patients (N=0)  
SMR00 healthboards removed
(England, Wales,Nother 
Irland,not fixed abode,
not known, outside UK)
episodes (N=6,840) 
patients (N=511)  
SMR00 duplicates removed
records (N=66,214) 
patients (N=0)  
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3.6 Cohort descriptive 
 
SMR01 – inpatient admissions  
Cohort characteristics of patients who have been admitted to hospital are presented in 
Table 3.1. Of the 160,405 patients on any OAC attending outpatient clinics and with a 
mean age of 68 years (SD 14.6), the majority were identified in the two largest health 
board areas accounting for 20.7% and 13.7% respectively. This is also reflected in the 
categorisation of geographical areas, where large urban represented 35.8% and other urban 
areas represented 29.8% of the total OAC cohort. No clear distinction was observed in the 
proportion of patients living in the most or the least deprived areas; however, there seem to 
be a lesser concentration of patients in the least deprived area. Among the OAC cohort, 
general medicine (32.1%) followed by cardiology (9.1%) were the most frequently 
attended hospital specialties.  
 
As recorded in the data, most patients were on OAC treatment as a result of being 
diagnosed with AF (278,286); therefore, similar baseline characteristics were observed. 
This was particularly evident for health boards and the categorisation of geographical 
areas. However, the AF cohort was on average older than the OAC cohort. Comparatively 
to what is observed for the OAC cohort, geriatric medicine (10.3) was the second most 
attended hospital specialty. Further, a clear distinction between the proportions of AF 
patients living in the most and least deprived was observed. The greatest proportion live in 
areas belonging to the most deprived category 22.5%, while those living in the least 
deprived areas account for 16.6% of the total AF cohort. 
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In addition, the distribution suggest that the comorbidities are more severe in the AF cohort 
than in the OAC cohort. The comorbidities were assessed by means of the Charlson 
Comorbidity Index (CCI), and categorised, according to clinical advise, in a way to 
indicate absence of comorbidities, presence of only a single comorbidity, and the presence 
of more than one comorbidity [78]. More details on the CCI is presented in the next 
chapter.  
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Table 3.1 Baseline characteristics of OAC and AF patients - SMR01 (1997-2015) 
 
Baseline characteristics and outcomes 
(at the time of first inpatient admission)  
Oral anticoagulants 
N (%)  
Atrial fibrillation 
N (%) 
Number of patients 160,405 278,286 
BASELINE CHARACTERISTICS 
  
Mean age *(SD)**(range) 68 *(14.6) **(0-105) 74 *(11.9) **(0-105) 
Sex     
Male  86,318 (53.8) 139,928 (50.3) 
Female  74,087 (46.2) 138,358 (49.7) 
Health Boards      
Greater Glasgow & Clyde 33,250 (20.7) 61,822 (22.2) 
Lothian 21,478 (13.4) 41,169 (14.8) 
Lanarkshire 18,529 (11.6) 31,049 (11.2) 
Grampian 16,677 (10.4) 25,728 (9.3) 
Tayside 14,930 (9.3) 22,003 (7.9) 
Ayrshire & Arran 11,816 (7.4) 25,003 (9.0) 
Highland 11,808 (7.4) 17,954 (6.5) 
Fife 10,242 (6.4) 18,929 (6.9) 
Forth valley 8,458 (5.3) 13,664 (4.9) 
Dumfries & Galloway 6,152 (3.8) 9,798 (3.5) 
Borders 4,333 (2.7) 7,222 (2.6) 
Western isles 1,241 (0.8) 1,868 (0.7) 
Shetland 764 (0.48) 1,036 (0.4) 
Orkney 727 (0.5) 1,041 (0.4) 
Geography     
Large/urban 57,368 (35.8) 106,868 (38.4) 
Other/urban 47,845 (29.8) 82,601 (29.7) 
Accessible small towns 14,366 (9.0) 24,938 (9.0) 
Remote small towns 4,919 (3.1) 8,272 (3.0) 
Very remote small towns 2,499 (1.6) 3,828 (1.4) 
Accessible rural 19,506 (12.2) 30,826 (11.1) 
Remote rural 6,606 (4.1) 10,371 (3.7) 
Very remote rural 6,945 (4.3) 10,087 (3.6) 
SIMD (Scottish index of multiple deprivation)       
1 32,213 (20.1) 62,730 (22.5) 
2 33,765 (21.1) 62,632 (22.5) 
3 33,163 (20.7) 55,943 (20.1) 
4 31,926 (20.0) 50,691 (18.2) 
5 29,337 (18.3) 46,279 (16.6) 
Comorbidity     
no comorbidity 45,629 (28.5) 40,502 (14.6) 
1 comorbidity 32,919 (20.5) 53,651 (19.3) 
>1 comorbidity 81,857 (51.0) 184,133 (66.2) 
OUTCOMES   
Median length of stay 3.6 (2.3 - 5.8) 5.4 (3.1 - 9.6) 
Five most frequent specialties attended      
General medicine 630,112 (32.1) 1,207,536 (34.7) 
Cardiology 178,656 (9.1) 280,577 (8.1) 
General surgery (no vascular) 132,567 (6.7) 203,767 (5.9) 
General surgery 120,116 (6.1) 187,530 (5.4) 
Geriatric medicine 115,218 (5.9) 359,027 (10.3) 
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SMR00 – outpatient attendances 
The baseline characteristics for patients on any OAC or with a known diagnose of AF and 
that have been attending outpatient clinics are presented in Table 3.2.  Similar patient 
characteristics were observed between those who had been hospitalised, and those who had 
also been attending outpatient clinics. Of the 163,654 patients on any OAC attending 
outpatient clinics and with a mean age of 66 years (SD 14.3), the majority were identified 
in the two largest health board areas accounting for 20.7% and 13.6% respectively. When 
looking at geographical areas, large urban and other urban areas represented respectively 
36.6% and 29.3% of the total OAC cohort attending outpatient clinics. No clear distinction 
was observed in the proportion of patients living in the most or the least deprived areas. 
Cardiology represented the second most attended outpatient clinic (10.3%) preceded by 
trauma and orthopaedic surgery (13.5%).  
 
Baseline characteristics similarities and differences, between the OAC and AF cohorts, are 
similar to the ones observed in the SMR01 inpatient admissions. While this is true for age, 
health boards, geography and SIMD, there were differences concerning the most frequent 
outpatient clinic attended. Comparatively to what is observed for the OAC cohort, 
ophthalmology (13.1) was the second most attended outpatient clinic. 
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Table 3.2 Baseline characteristics of OAC and AF patients - SMR00 (1997-2015) 
Baseline characteristics and outcomes 
(at the time of first outpatient attendance) 
Oral anticoagulants 
N (%) 
Atrial fibrillation 
N (%) 
Number of patients 163,654 266,122 
BASELINE CHARACTERISTICS 
 
  
Mean age *(SD)**(range) 66*(14.2) **(0 -105) 72*(11.8) **(0 - 108) 
Sex     
Male  88,315 (54.0) 134,967 (50.7) 
Female  75,339 (46.0) 131,155 (49.3) 
Health Boards 
 
  
Greater Glasgow & Clyde 33,891 (20.7) 59,926 (22.5) 
Lothian 22,328 (13.6) 40,026 (15.0) 
Lanarkshire 18,712 (11.4) 29,492 (11.1) 
Grampian 17,044 (10.4) 24,743 (9.3) 
Tayside 15,144 (9.3) 20,943 (7.9) 
Ayrshire & Arran 12113 (7.4) 17,248 (6.5) 
Highland 11,889 (7.3) 23,235 (8.7) 
Fife 10,542 (6.4) 18,138 (6.8) 
Forth valley 8,609 (5.3) 12,665 (4.8) 
Dumfries & Galloway 6,230 (3.8) 9,160 (3.4) 
Borders 4,437 (2.7) 6,992 (2.6) 
Western isles 1,234 (0.8) 1,648 (0.6) 
Shetland 761 (0.5) 952 (0.4) 
Orkney 720 (0.4) 954 (0.4) 
Geography     
Large/urban 59,863 (36.6) 104,732 (39.4) 
Other/urban 48,009 (29.3) 77,679 (29.2) 
Accessible small towns 14,256 (8.7) 23,223 (8.7) 
Remote small towns 4,803 (2.9) 7,494 (2.8) 
Very remote small towns 2,465 (1.5) 3,510 (1.3) 
Accessible rural 19,977 (12.2) 29,451 (11.1) 
Remote rural 6,853 (4.2) 9,982 (3.8) 
Very remote rural 7,103 (4.3) 9,587 (3.6) 
SIMD  (Scottish index of multiple deprivation)     
1 32,969 (20.2) 60,124 (22.6) 
2 34,485 (21.1) 59,938 (22.5) 
3 33,832 (20.7) 53,675 (20.8) 
4 32,525 (19.9) 48,194 (18.1) 
5 29,843 (18.2) 44,186 (16.6) 
OUTCOMES   
Outpatient attendance per year (IQR) 5.7 (3.3 -7.6)  3.4 (2.1 - 5.5) 
Five most frequent outpatient clinic attended      
Trauma & orthopaedic surgery 22,059 (13.5) 32,140 (12.1) 
Cardiology 16,773 (10.3) 25,837 (9.7) 
Ophthalmology 15,769 (9.6) 34,775 (13.1) 
General medicine 13,847 (8.5) 23,805 (9.0) 
General surgery 11097 (6.8)  n/a 
Ear & nose & throat (ENT)  n/a 18,326 (6.9) 
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Chapter 4 The inpatient, outpatient, prescribing and care home costs associated with 
Atrial Fibrillation  
 
4.1 Introduction 
 
As highlighted in Chapter 1, AF is the most common form of arrhythmia affecting 1.8% of 
the adult Scottish population and rising to 6% in individuals aged over 65 years [79].  The 
risk of stroke, a highly debilitating condition, is significantly greater in individual affected 
by AF. Therefore, AF, in an ageing population, is likely to have an important impact on the 
economic burden of the healthcare system. A number of cost analyses on estimating the 
economic burden of AF exist.  The majority of these studies are of selective cohorts of AF 
patients, based on data sourced from administrative database [80-82], health insurance 
databases [80, 83-85], hospital records [86, 87] and surveys [88].  Direct medical costs 
related to inpatient admissions, outpatient visits, as well as prescriptions have been 
included in these estimates; [80-88] indirect costs related to loss of productivity have been 
estimated among patients who were at working ages [84, 85].  
 
Many of these studies included relatively young patients – those aged 18-20 years or older 
[80, 82-84, 86-88], or those under the age of 65 years [85]. However, the prevalence of AF 
increases significantly with age, and in particular in the 50 years or older age groups; in 
patients under the age of 50, AF is often associated with  structural heart disease, 
hyperthyroidism, or alcohol excess [89]. Hence, inclusion of younger patients and the 
exclusion of older patients may result in imprecise cost estimates.  There is a lack of 
generalisable studies based on large national population datasets that examine the total and 
the distribution of costs associated with AF [90].  
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To address the first Objective formulated in Chapter 2, the cost analysis carried out in this 
Chapter quantifies the inpatient, outpatient, prescribing and care home costs associated 
with AF over a five-year period. In addition, the composition of costs that are attributable 
to AF are examined using record-linkage of national datasets from Scotland described in 
Chapter 3.  
 
4.2 Existing evidence on cost of AF 
 
Different cost off illness studies exist that have used different approaches to estimate the 
cost of AF. This section describes the identified studies according to the following: 
population, data source, covariates, cost components and statistical method used. A 
summary is presented in Table 4.1. 
 
4.2.1 Population 
 
In the majority of the studies on cost estimation, the population comprises AF patients who 
are 18 years or older [80, 82-84, 86, 88]; while the remaining studies included the over 65 
age group [81, 85, 87] or the entire AF population [91]. Further, among those studies 
patients were included according to certain characteristics. For instance, Ghate (2011) 
included AF patients with and without bleeding events for their analysis of healthcare costs 
related to warfarin-associated bleeding [83]. In an additional American study, the cohort 
included individuals diagnosed with AF and at least one pharmacy claim for warfarin [82].  
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4.2.2 Data 
 
Across the different country specific studies, costs were primarily estimated with health 
insurance and hospital based administrative data. For instance, Bennel and collegues 
(2015) analysed the Ontario Health Insurance Program for extracting data on physician 
services. Data on prescription drugs were obtained from the Ontario Drug Benefit database 
[80]. Ghate (2011) extracted data from Thomson Reuters Medstat MarketScan Commercial 
Claims & Encounters and Medicare Supplemental & Coordination of Benefits database. 
These databases include inpatient, outpatient and prescription drug services patient level 
data obtained from health plans, government and public organisation [83, 92]. Four other 
additional US studies obtained data from different sources [82, 84, 85, 87]. In detail, 
Nelson and colleagues (2015), extracted the data from the Veterans Health Administration 
database, the largest integrated healthcare system in the USA, providing care for veterans 
across the country [82]. Reynolds (2017) obtained data from an AF bespoke database 
covering costs, therapies, adverse events and lifestyle related to AF [87]; while data in 
Rohrbacker (2010) and Wu (2005) studies were obtained from privately insured 
administrative databases [84, 85].  
 
Amongst the European studies, Hallinen and colleagues (2006), in a Finnish study, 
estimated AF related costs using health service administrative data [81], while Holstenson 
(2011) employed hospital based administrative data from different European countries 
[86], and Jonsson patient and physician surveys [88].Stewart’s study (2004) [91], also 
obtained data from different sources. In particular, data on prevalence, costs and healthcare 
utilisation were extracted from epidemiological studies and government datasets. More 
specifically, costs regarding community-based healthcare, hospital based healthcare and 
long-term care were used for estimating the overall cost of AF for the years 1995/1996.   
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For the community-based healthcare, Scottish healthcare costs were used to estimate the 
cost of a visit to a hospital outpatient clinic. Further, the costs for prescription drugs were 
obtained from Intercontinental Medical Statistics Ltd and crosschecked with government 
prescription data. The average cost of a visit to an anticoagulation clinic and any additional 
cost for monitoring of INR) for each visit were extracted from the Unit Costs of Health, 
and Social Care 1998 report produced by the Personal Social Services Research Unit [91]. 
 
4.2.3 Covariates 
 
The entirety of the cost estimation models [80-88], aside from Stewart‘s model [91], were 
adjusted for demographics and baseline comorbidities and risk factors such as 
hypertension, diabetes, history of stroke, and any underlying heart disease. Wu and 
colleagues (2005) also looked at the insured population but focused more on the 
employment status for estimating healthcare related costs taking into account, in addition 
to demographic and comorbidities, indirect costs associated with unemployment.  
 
4.2.4 Statistical methods 
 
The majority of the studies used a Generalised Linear Model (GLM) model with a log link 
distribution [80-84, 88]. While different methods are used for estimating cost data, GLM 
take into account the characteristics of healthcare cost data, which in general do not follow 
a normal distribution and often present a skewed distribution to the right. This suggests 
that a small number of patients are making use of healthcare resources with very high costs 
[93]. 
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Hallinen and colleagues (2006) tested GLM among OLS and log-transformed OLS, and 
found the latter as the best fitting cost model for their data [81]. OLS was also the model of 
choice for the European study predicting the related to cardiovascular disease in patients 
with AF [86], and the American study estimating the healthcare resource utilisation and 
costs associated with recurrent episodes of AF [87]. By contrast, Wu (2005) employed a 
multivariate two-part regression model. The study, did not specify whether a probit or a 
logit  model was employed for estimating the probability of using a healthcare service, or 
whether a OLS or GLM was fitted in the second part of the model for estimating costs 
conditional on having incurred positive costs [85]. The technical aspects of these methods 
will be further discussed in the next section.
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Table 4.1 Costing methodologies  
Study  Population  Data Covariates Cost components Statistical method 
Bennell, 2015 
(Canada) 
AF patients                      
(20 years or older) 
Health insurance program, 
administrative data,                     
Drug Benefit database 
Demographics and comorbidities 
Inpatient and outpatient visits and 
services, prescribing, long‐term care 
services 
GLM with gamma 
distribution and log link   
Ghate, 2011         
(USA) 
AF patients (18 years or 
older) with and without 
bleeding events 
Medstat Market Scan 
Commercial Claims, Medicare 
Supplemental & Coordination of 
Benefits database 
Demographics, insurance status, 
comorbidities 
Inpatient and outpatient visits and 
services, prescribing  
GLM with gamma 
distribution and log link 
Hallinen, 2006 
(Finland) 
AF patients                      
(65 years or older) 
Finnish administrative data Age and gender and comorbidities 
Inpatient and outpatient visits and 
services, prescribing, nursing staff, 
traveling by the patient  
GLM, OLS with and 
without logarithmic 
transformation 
Holstenson, 2011 
(Europe) 
AF patients                      
(18 years or older) 
Hospital based administrative 
data from different European 
countries 
Age, gender and risk factors 
Inpatient and outpatient visits and 
services, prescribing  
OLS 
Jonsson,2010               
(Sweden and 
Germany) 
AF patients                      
(18 years or older) 
Patient and physician surveys 
Age, medical history, treatment, 
medical and non-medical resource 
use, employment status 
Inpatient, outpatient, prescribing, 
direct non-medical costs, indirect 
costs 
GLM, with log normal 
distribution and log link  
Nelson, 2015                
(USA) 
AF patients (18 years or 
older) with at least one 
pharmacy claim for 
warfarin 
VHA administrative data 
Baseline demographics, clinical 
characteristics   for warfarin 
Inpatient and outpatient visits and 
services, prescribing  
GLM with gamma 
distribution and log link 
Reynolds, 2007    
(USA) 
AF patients                       
(mean age 65 years) 
Fibrillation Registry Assessing 
Costs, Therapies, Adverse 
events, and Lifestyle registry 
Demographics, cardiac and non-
cardiac comorbidities, initial 
medical therapies, number of AF 
recurrences 
Inpatient, outpatient, prescribing OLS 
Rohrbacker, 2010         
(USA) 
AF patients                      
(18 years or older) 
Human Capital Management 
Services, Research Reference 
Database 
Age, gender, marital status, race, 
exempt status, full-time/part-time 
status, salary, location, Charlson 
Comorbidity Index 
Inpatient, outpatient, prescribing, 
short and long-term disability costs, 
productivity loss, workers’ 
compensation costs   
GLM with gamma 
distribution and log link 
Stewart, 2004 
(UK) 
AF patients                        
Commercial and government 
databases 
Not applicable 
Inpatient and outpatient visits and 
services, prescribing, long-term care 
services 
Not stated 
Wu, 2005                     
(USA) 
AF patients                       
(65 years or younger) 
Privately insured administrative 
database and Medicare (for       
direct costs) 
Demographics, employment status, 
comorbidities 
Inpatient and outpatient visits and 
services, prescribing, productivity   
loss 
  Multivariate two-part 
regression model 
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4.2.5 Cost components and results 
 
Inpatient and outpatient visits and services costs as well as prescribing costs were included 
in the majority of the models estimating the healthcare cost associated with AF [80-83, 85, 
86, 92, 94].  
 
Bennell (2015) identified the CHA2DS2-VASc , as the strongest predictor of costs for AF, 
estimated per patient until March 2012. In particular, the CHA2DS2-VASc, a clinical risk 
score used to predict the potential risk of stroke in patients with AF [30], was used to 
classify patients as having a moderate to high risk of stroke. In addition, the study 
identified three distinct phases in which AF related costs are incurred at different levels. In 
the acute phase following emergency department visits, patients are likely to incur high 
costs, which in turn stabilise in the long-term stable/chronic phase, and increase in the 
phase preceding death. In particular, it was found that the phase preceding death ($8,050 
(95% CI 7,666, 8,434)), compared with post emergency department visits ($1,876 (95% CI 
1,822, 1,931)), and stable/chronic phase ($640 (95% CI 624, 655)), was the phase with the 
highest AF related costs. In the phase preceding death, hospitalisation accounted for the 
majority of the incurred cost (72%), whereas outpatient costs and services, referred to as 
physician services, contributed to the overall cost with a modest 32% [80].  
 
Ghate (2011) indicated that patients with Intracranial Haemorrhage (ICH) or Gastro 
Intestinal (GI) bleeding, in the 12 month after warfarin starting date, were more likely to 
incur AF related healthcare costs; being respectively 64.4% and 49.0% higher than for 
patients who did not experience bleeding events [83].  
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Compared to the other studies, Hallinen (2006) adopted a slightly different approach by 
exploring costs associated with the use of warfarin. In addition to prescribing, inpatient and 
outpatient visits and services, the study included costs of nursing staff and those related to 
patients traveling to and from clinics. The estimated total cost per patient, at 12 month 
follow up and reported for the year 2002, was €589.82 (95% CI 586.68, 591.99) with the 
log-transformed Ordinary Least Square (OLS), and €616.00 (95% CI 579.98, 652.96) with 
the OLS-model [81]. 
 
For the majority of the studies, the approach of costing consisted in estimating the cost of 
comorbidities associated with AF, rather than estimating the cost of AF per se. Compared 
to the other studies, Holstenson (2011) focused only on cost related to cardiovascular 
disease, rather than all potential comorbidities, in patients affected by AF across different 
European countries. The estimated direct annual costs per patient were €933 in Greece, 
€1,383 in Italy, €698 in Poland, €1,316 in Spain, and €1,544 in the Netherlands [86].  
 
The cost of illness study carried out in Sweden and Germany found the cost incurred by 
AF patients to be driven by the consequences of AF, such as coronary heart and 
cerebrovascular disease leading to hospitalisation, rather than by the treatment of AF itself.  
The total annual costs per patient, €7,241 in Sweden and €5,586 in Germany estimated for 
the year 2005, was found to increase with age; however, the AF related total cost was 
lower for the age groups 65 years or older than in younger patients likely to incur indirect 
costs associated with productivity-loss [88].   
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Similarly, Nelson (2015) adopted a somewhat different costing approach compared to 
other studies, by estimating and comparing healthcare costs between newly anticoagulated 
patients with out-of-range (INR < 2, INR > 3) or in range (2 ≤ INR ≤ 3) INR values. Those 
with out-of-range INR incurred the highest overall healthcare cost, ranging from $3,419 to 
$5,126 and including hospital, outpatient, and pharmacy costs, than those with the optimal 
INR range [82].  
 
In Reynolds`s study (2007) the cost, associated with recurrent episodes of AF at 3 and 6 
months intervals, were estimated for patients in whom the first AF episode became 
permanent, and for those with a sinus rhythm of either 0, 1–2, or ≥3 indicating the 
recurrence of AF. The mean annual costs per patient, for year 2002, was $2,372, $3,385, 
$6,331, and $10,312 for each group respectively. Further, the recurrence of AF was found 
to increase the overall healthcare cost by $1,600 annually, and hospital cost being the cost 
element with greatest variation [87]. 
 
Rohrbacker (2010) estimating the cost of AF and cardiac arrhythmias in an employed 
population, found the annual costs being higher by $3,958 in the AF group compared to 
employees not affected by AF. Similarly, the cost for patients with cardiac arrhythmias 
exceeded, by $3,958, the cost for those without the condition. In addition, the number of 
absence days due to sick leave and short-term disability were considerably higher in the 
AF and cardiac arrhythmias groups than in the condition free employees [84].  
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Stewart (2004), evaluating the cost of AF for the whole AF population in the UK in 1995, 
identified hospitalisation and drug prescriptions, accounting for 50% and 20% respectively, 
as the cost components contributing the most to the overall AF direct cost of £244 million. 
Long-term nursing home care following hospital admission, accounted for an additional 
£46.4 million. Stewart’s study also predicted the overall direct and nursing home care cost 
to increase respectively by an additional £46.4 and £111 million for the year 2000 [91]. 
 
In Wu’s study (2005), the total AF related cost was estimated per patient, for the study 
period 1999-2002, for the whole AF population and for a sub set of patients with 
unemployment data available. For the latter group, to reflect the employer perspective, 
direct and indirect costs were estimated. For the whole AF population, the estimated 
annual total direct cost was ($15,553), significantly higher than the cost estimated for non-
AF patients ($3,204). For the subgroup with employment status, the estimated total cost 
was ($18,454) and ($3,461) for the AF and non-AF patients respectively. Indirect costs 
were higher in the non-AF patients accounting for 20% of the total cost, than in the AF 
patients where indirect costs represented only the 15% of the overall estimated healthcare 
cost [85]. 
 
4.3. Regression models for healthcare expenditure 
 
OLS and GLM are the two types of regression models that are routinely used in the 
analysis of costs within a healthcare context to explain variation in costs. In regression 
analysis, the residuals, often referred to as the error terms, indicate the difference between 
the actual value of the independent variable and the value predicted by the regression 
equation. For a regression model to be valid, the error terms must be constant, not 
following a specific pattern and have a mean of zero.  
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Generally, the distribution of the error term, in patient level healthcare costs, is 
characterised by a high degree of heteroscedasticity indicating important differences in the 
size of the residuals across values of a given independent variable. In other words, the 
residuals of healthcare costs are not randomly distributed around zero, and therefore the 
error variance may not be constant. It follows that heteroscedasticity implies the presence 
of a non-constant error variance violating the OLS assumption of constant variance. In the 
presence of heteroscedasticity, although the resulting coefficients will be unbiased, the 
estimates will be inefficient; hence, OLS cannot be used as the Best Linear Unbiased 
Estimator. An efficient and unbiased estimator will have a minimum variance and a 
difference between its expected value and the true value being estimated equal to zero. 
Adopting a log transformation approach for the OLS model may minimise the issues 
related to heteroscedasticity and skewness of the data. However, with this method, the 
error term is additive and a log scale variance proportional to the square of the mean 
indicates that the variance is not constant.  Hence, in a log transformed OLS model, the 
mean needs to be retransformed to the original scale of the data. Because retransformation 
returns the geometric mean, which is smaller than the mean of the raw cost data, a 
smearing factor needs to be applied to obtain estimates of the arithmetic mean. As defined 
by Duan (1983), the smearing factor is a “nonparametric estimate of the expected response 
on the untransformed scale after fitting a linear regression model on a transformed 
scale”[95]. However, the selection of a smearing factor is arbitrary and mainly depends on 
type of distribution of the log cost [93, 96]. For instance, when the distribution is normal 
and there is no difference between log variances, what is generally called a “common 
smearing factor” would be used. Alternatively, if the log variances differ, a “subgroup –
specific smearing factor” may be more suitable. OLS is part of the GLM family, and can 
also be represented as GLM regression with Gauss family and identity link. Nevertheless, 
comparatively to log OLS, in a GLM regression model, the mean of the covariates rather 
than the mean of the cost variable is transformed.  
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This is achieved by specifying a link function indicating the relationship between the mean 
and the linear predictor given by the explanatory variables, and the distributional family 
reflecting the relationship between the mean and the variance [93, 96]. 
 
Equation 1 shows the structure of the GLM model 
 
E(Y) = µ = g-1 (Xβ)                                             
                                                                                                                         (Equation 4.1) 
 
Where E(Y) is the expected value of Y (cost), (Xβ) the linear predictor and g the link 
function. In a GLM regression, characterised by a multiplicative error where the variance 
is proportional to the mean, predictions are made on the raw cost scale; consequentially no 
retransformation is required [93]. The most common distributional families reflecting the 
mean-variance relationship and link functions are reported in Table 4.2. Regression models 
for healthcare expenditure, such as GLM, OLS and log transformed OLS, can be compared 
by means of Akaike Information Criterion (AIC), which measures goodness of fit. Then, 
distributional families and link function can be tested as described in the methods section 
of this Chapter, to identify the best fitting ones for the set of data used in this cost analysis.   
 
Table 4.2 Distributional families   
Distributional families and Link functions 
Distributional 
families  
Gaussian                               
Poisson               
Gamma              
Inverse Gaussian 
Constant variance                                  
Variance proportional to mean                 
Gamma                                                      
Variance proportional to cube of mean 
Link function 
Identity                       
Square root                      
Log              
Reciprocal 
g(u)=xiβi                                                                
g(u)=xiβi²                                                
g(u)=exp(xiβi)                                           
g(u)=1/(xiβi) 
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4.4 Methods 
 
The present work extends the existing British study [91] in the use of individual-level 
linked data and by estimating healthcare costs that are not directly related to AF, but 
incurred by patients with AF in the 5 years following their first AF event. Therefore, any 
subsequent costs incurred by AF patients within the period described are included. In 
addition, while the existing study estimated the AF cost for the entire British population in 
1995, in this study the average AF related healthcare costs per person is estimated for a 
longer time-period ranging from 1997 to 2015. Further, in the present study, costs were 
estimated with an incidence-based approach. Cost analyses or cost of illness studies 
typically adopt either a prevalence or incidence based approach [97]. In the context of AF, 
the prevalence-based approach determines costs attributable to all cases of AF in a given 
year, while the incidence based approach estimates the new cases of AF in a given year, 
and then applies a lifetime cost estimate to the new cases [98]. 
 
In addition to a prevalence or incidence-based approach, a top-down or bottom-up strategy 
is typically adopted in cost of illness studies.  Top-down is generally suitable when costing 
homogenous services such as nursery and long-term care, as it assumes an equal 
distribution of resources between patients. With this approach, typically focused on 
national average costs, total expenditure is divided by total units of activity to derive a unit 
cost. This differs from the bottom-up approach where the calculation of unit costs is based 
on the resource utilisation measured at the patient level [98].  
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A further distinction between costing analyses is between the medicalized and the global 
comprehensive approaches. In the first case, only expenditures directly attributable to a 
particular disease are used for estimating the overall costs. While the medicalized approach 
can be used to identify highly specific expenditures, it may also lead to underestimation or 
overestimation of the economic burden of a given disease; this may happen when cost 
estimation is not adequately adjusted for confounders highly correlated with the disease of 
interest. Conversely, the global comprehensive approach, used in this analysis, includes all 
the expenditures incurred by a population with a particular disease [99]. These 
expenditures are not necessarily related to the disease of interest; for instance, expenditures 
related to orthopaedics surgery or cancer treatment incurred by a patient with AF, will 
count towards the global comprehensive cost of AF.  
 
 
4.4.1 Data preparation 
 
As described in the previous Chapter, after checking for data entry errors and removal of 
duplicate records, an initial AF cohort consisting of 278,286 individuals hospitalised with a 
diagnosis of AF or atrial flutter was identified. Based on clinical advice and the evidence 
that prevalence and incidence of AF typically increase exponentially from 50 years 
onwards [89], the analysis including individuals 50 years or older would be inclusive of all 
patients potentially at risk of AF. The choice on the age cut-off for the AF cohort was also 
based on the indication of oral anticoagulants for the AF population. Most AF patients in 
the cohort are also on direct oral anticoagulants, and patients who are 50 years or older are 
likely to be on anticoagulants only because of AF, while patients younger than 50 (only 
about 3% of AF patients in the cohort) could be on anticoagulants for reasons other than 
AF.  
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The final AF cohort as identified from SMR01 records for analysis consisted of 272,716 
patients. Individual-level data merging was then carried out with SMR00, PIS, care home 
census and mortality records as depicted in Figure 4.1. Incident AF events (ICD10 code 
I48) were identified using all six diagnostic positions in SMR01, with a look back period 
of five years to minimise double counting. Patients were followed up for five years 
following incident AF event in terms of their healthcare resource use, care home 
admissions and mortality. Since AF is often a precursor of stroke and cardiovascular 
conditions, an estimation of costs for a period of five years post AF event would allow us 
to fully capture costs associated with an AF patient.   
 
 
Figure 4.1 Data preparation    
Abbreviations: PIS=prescription information system, SMR01=Scottish morbidity records - 
general/acute inpatient day case dataset, SMR00=Scottish morbidity records - outpatient 
appointments and attendances, NRS=national health records. 
 
 
 
 
 
`
Patients with a known diagnosis
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4.4.2 Costing 
 
The cost analysis carried out in this Chapter quantifies and examines the distribution of 
inpatient, outpatient, prescribing and care home costs associated with AF over a five-year 
period.  In this section, the methods of assigning unit costs to each cost component are in 
turn described. 
 
Inpatient care costs 
Inpatient care costs were assigned utilising the latest (2013/2014) Scottish National Tariff 
(SNT), a list of standard average prices based on the HRGs system [100]. The SNT uses 
HRG4 for grouping clinically similar treatments that use similar levels of healthcare 
resources. More specifically, hospital admissions are grouped according to their 
corresponding patient operative procedures and diagnoses; this allows for the identification 
of groups and subgroups of patients, and the treatment they receive [101].   
 
For instance, in a case where a patient aged 58 is admitted to hospital with a primary 
diagnosis of cerebral infarction due to thrombosis of cerebral arteries (ICD-10 163.3) and 
the dominant procedure received is computed tomography scan (OPCS-4 U05.1)  
, the HRG4 code AA35A indicating stroke with severe complications and comorbidities 
will be used for the hospital admission. Secondary diagnoses and comorbidities may also 
be used for further differentiation of patients and identify any additional resource used 
[101]. In Scotland, the HRG based tariff was developed to support NHS health boards with 
what is known as “cross boundary flow activity “where boards can charge one another for 
individuals receiving treatment in one health board but residing in another. This system 
overcomes the impracticality of using average costs within specialties; indeed, costs may 
vary considerably depending on the treatment performed and the severity of the admission.  
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The SNT is published by ISD in the Scottish Health Service Costs, commonly referred to 
as the "Cost Book', and contains cost information on hospital and primary care services; 
therefore, allowing healthcare expenditure to be identified by specialty, type of admission 
and location.  Scottish healthcare costs are available at specialty level only [100].  
 
However, a cost weighting system allows estimating costs at more specific HRG level, 
where the relative cost weights obtained from English NHS reference costs are applied to 
the Scottish data. The underlying assumption for this mechanism is that the resource 
differential when comparing two procedures or conditions is the same in Scotland as in 
England. The SNT includes elective costs incurred during planned procedures, as well as 
non-elective costs attributed to emergency treatments. Because two typologies of costs are 
present within the SNT, the choice on whether an elective or non-elective cost should be 
attributed to a single episode is based on the admission type. For instance, if a patient is 
admitted and the admission type indicates that this is an emergency (e.g. patient injury-
road traffic accident) a non-elective cost should be used. Comparatively, in the case of a 
routine admission where a waiting list is planned, the corresponding elective cost for that 
specific episode will be applied [100].  
 
Once the total cost per episode is defined, the total cost for a Continuous Inpatient Stay 
(CIS) should also be determined. In Scotland, a CIS describes the entire duration of an 
inpatient stay in a hospital. A CIS can consist of several episodes, and is defined from the 
date of admission to the date of discharge and can span several specialties. However, the 
SNT is based on unit costs per spell rather than individual hospital episodes or a CIS [100]. 
A spell differs from a CIS as it combines all hospital episodes associated with a stay in 
hospital within the same specialty. Hence, the CIS needs to be partitioned into spells 
whenever a change in specialty occurs.  
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For instance, if a patient is admitted to a cardiology department and then transferred to 
thoracic surgery, two different spells will be observed and costed.  If within a CIS, two or 
more episodes are linked to the same specialty, only the highest incurred cost is taken into 
account, and the remaining episodes will be replaced with a zero cost. The process 
explaining how a cost per CIS using episode costing was obtained is graphically presented 
in Figure 4.2. 
 
 
Figure 4.2 Deriving a cost per CIS using per episode costing 
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Care home costs 
Care home costs, obtained from the care home census and based on length of stay or 
residency, reflect the average weekly charge for residents in care homes according to 
source of founding (publicly funded residents and self-funders) for the period 31st of 
March 2007- 31st of March 2015.  Care home residency was established from care home 
census records, reporting admission to a care home like structure. An average of care home 
charges for long stay residents was calculated using information on whether nursing care 
was provided or not (charge with nursing £694, without nursing £614). The average 
weekly care home charge was expressed per day (£93), so that only the effective days 
spent in a care home were costed [75]. 
 
 
Cost for outpatient attendances 
 
Costs for outpatient attendances were estimated by merging SMR00 with outpatient 
specialty costs published by ISD in the Scottish Health Service Cost [72]. The assignment 
of unit costs to outpatient clinics depended on whether this took place in an outpatient 
consultant or nurse led clinic. The first typology of clinics led by consultants (SMR00 
clinic type code 1 and 2) are mainly for consultation and embrace minor as well as 
complex and expensive treatments. The second typology of clinic is managed by nurses 
(SMR00 clinic type code 3) but can sometimes be supervised by consultants. The services 
provided by the nurse led clinic, may however not be costed separately, but rather be 
included in the consultant clinic report [72]. 
 
Prescription costs 
The cost of each prescription dispensed per patient was obtained from PIS [74]. Firstly, the 
price per unit was obtained by dividing the item price by the pack size. Secondly, the total 
number of items dispensed was obtained by multiplying the number of items dispensed by 
the number of instalments.  
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In Scotland prescriptions that are addictive or cause any significant harm if taken in high 
doses, are administered to patients in instalments. While this may not apply to the DOACs 
drugs prescribed for preventing stroke in patients with AF, addictive drugs such as 
methadone are likely to be prescribed in instalments. As the objective of the cost analysis 
is to estimate healthcare costs related to AF, all drugs prescribed for the AF cohort were 
included. This implies that aside from DOACs and warfarin, the cost of other non-AF 
related drugs, such as antidepressants or oncological treatments, were taken into account 
when estimating the total cost of prescriptions per patient in any given year between 2009 
and 2015. AF-related costs per patient where estimated per year. Hence, the costs of two or 
more CIS within one year were aggregated to reflect yearly hospital cost. Similarly, the 
total yearly outpatient costs were obtained by summing the costs of individual outpatient 
episodes occurring within one year. The same method was applied to charges for care 
home stays and prescription costs.  
 
4.4.3 Econometric model 
 
Healthcare expenditure data are typically characterised by: i) a significant proportion of 
zero-cost observations for individuals who have not utilised any healthcare resources in a 
given time period, and ii) a skewed distribution for positive costs. In the AF costing 
analysis, patients were followed up for 5 years from their incident AF event (the cost were 
estimated only for those patients that were still alive after the 5 years post AF incident 
event) but during this time not every patient incurs costs in each follow-up year. Therefore,  
a two-part model was used for estimating first, the probability of incurring any cost in a 
given year and second, the mean cost conditional on having incurred positive costs [93, 
96].  
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The first part of the model estimates the probability of using a healthcare service in a given 
time period as described in the following equation: 
Pr(𝐻𝐶𝐸𝑖𝑡 > 0) = 𝛼 +  𝛽1𝐴𝑖𝑡 +  𝛽2𝐺𝑖 + 𝛽3𝑌𝑖 + 𝛽4 ∑ 𝐹𝑖
5
𝑠=2
+ 𝛽5 ∑ 𝑆𝑖
5
𝑠=2
+ 𝛽6 ∑ 𝑈𝑖
8
𝑢=2
+ 
𝛽7 ∑ 𝐻𝑖
14
ℎ=2
+ 𝛽8 ∑ 𝐶𝑖𝑡
3
𝑐=2
+ (𝛽9 ∑ 𝐶𝑖𝑡
3
𝑐=2
∗ 𝐴𝑖𝑡)  +  𝑢𝑖                  
                                                                                           
                                                                                                                           (Equation 4.2) 
Where: A is age at the time of admission (reference category: 50 -54 age group);  G is sex 
(reference category: male); Y is year of admission; F is follow-up year (reference category: 
1st year); S is SIMD categories (reference category: most deprived (1)); U is the urban/rural 
classification (reference category: large urban area); H is health board of inpatient 
admission (reference category: Greater Glasgow & Clyde); C is the Charlson comorbidity 
index (reference category: no comorbidities);; 𝑢𝑖 is the error term for patient i at time t.    
 
The same explanatory variables were used in the second part of the model, with a gamma 
distribution and log link, estimating costs conditional on having incurred positive costs 
(Equation 4.3). 
 
𝐸[𝐻𝐶𝐸] = 𝑔(𝑥𝛽) 
                                                                                                                          (Equation 4.3) 
Where xβ is the linear predictor for HCE 
 
Mean costs per patient per year following their incident AF event were then calculated by 
multiplying first and second modelling part (Equation 4.4). 
𝐸[𝐻𝐶𝐸|𝑋] = Pr(𝐻𝐶𝐸 > 0|𝑋) ∗ 𝐸[𝐻𝐶𝐸|𝐻𝐶𝐸 > 0, 𝑋] 
                                                                                                                           (Equation 4.4)  
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A user-written STATA programme “glmdiagnostic.do” [96], performing four different 
tests simultaneously, was used to identify the most appropriate distributional family and 
link function. In particular, the modified Park test indicates the most appropriate family 
(Poisson, Gamma, Gaussian NLLS, Inverse Gaussian or Wald) for a given link function. 
The other three tests indicate the most plausible link function for a given distribution. More 
specifically, the Pregibon link test will check for the linearity of response, whereas, the 
Pearson correlation and the Modified Hosmer-Lemeshow tests will look at systematic bias 
in fit on the raw scale [96].  
 
4.4.4 Econometric model covariates 
 
The two-part model adjusted for age, sex, year of inpatient admission, socio-economic 
status, urban-rural classification, health board, comorbidities and mortality. These 
covariates are considered to be the main confounders that have an effect on costs incurred 
by an AF population, and were selected according to existing literature and clinical advice. 
The same set of covariates explain part one (estimates the probability of incurring any cost 
in a given year) and part two (estimates the mean cost conditional on having incurred 
positive costs) of the model. 
 
Age  
The model controlled for age because AF and associated comorbidities are age-related 
conditions, and may have an impact on the overall costs expected to increase as the AF 
cohort ages. Although hospital, outpatient and prescribing costs are expected to increase 
marginally with age, the cost for care home residency is assumed to increase substantially. 
As mentioned, only patients 50 years and older were included in the analysis. Patients’ age 
at admission is measured using categories, where the youngest (50-54 years) served as the 
reference group.  
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Sex 
To improve the accuracy of the costs estimates, the cost analysis focused on sex rather than 
gender; therefore the “not known” and the “non-specified” categories were excluded from 
the analysis. Further, it was assumed that costs vary between males and females, in 
particular those for care home residency.  
 
Socioeconomic status  
Variation in healthcare utilisation and associated costs and care home residency by socio-
economic status is controlled for using the SIMD. The SIMD reflects areas of multiple 
deprivation ranked from the most to the least deprived and expressed as categories defined 
by fifths of the distribution of deprivation. where the most and the least deprived areas are 
represented by 1 and 5 respectively [102]. The index is used in Scotland for shaping 
policies aimed at addressing issues related to areas with high levels of deprivation.  
In the econometric model, the least deprived category is used as a reference category for 
cost estimation, and any increase or decrease in AF cost is compared against this category. 
In particular, individuals in the most deprived areas may be more likely to be in hospital, as 
they may not have support from relatives at home, and therefore be more likely to have a 
longer length of stay. These patients may also incur higher hospital AF related cost than 
those in the least deprived area. 
 
Health Board Area 
In Scotland, there are 14 regional health boards responsible for the provision of healthcare 
[103]. Hence, potential differences in healthcare utilisation and prescribing costs may 
reflect variation in clinical practice and prescribing behaviour rather than the ability of 
patients to access care. Greater Glasgow & Clyde representing the largest health board is 
used as the reference category for estimating costs.  
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Geography 
Patients living in urban areas may have easier access to care compared to patients living in 
more remote areas, which is controlled for by including the 8-fold classification measuring 
rurality [104] . In the 8-fold classification, the large urban category serves as the reference 
category to compare against. According to Scottish Government definition, a large urban 
area is characterised by settlements of 125,000 or more people, as opposed to  very remote 
rural areas, which embraces a population of less than 3,000 people and a driving time of 
over 60 minutes to a settlement of 10,000 people or more [104]. Similar to health board 
areas, variations in costs for hospital, outpatient and care home utilisation are expected to 
be seen in for different geographical areas.  
 
Comorbidity index  
Patients with one or more comorbidities are expected to incur significantly higher costs 
than those with none. This was accounted for by including the CCI, which defines the 
severity of comorbidities, within a set of 17 pre-specified conditions, by assigning a weight 
from 1 to 6 to each category based on the adjusted risk of mortality. A single comorbidity 
score for each patient is obtained by summing all weights. While a higher score may 
suggest an increased risk of mortality, a score of zero indicates no comorbidities [78]. To 
assess whether including CCI may have improved the predictive ability of the model, the 
regression model described in this paragraph was compared against the same model 
adjusted for comorbidities, and model fit was compared using the AIC. A difference of 
0.04 suggested that there is no evidence of one being better than the other model. 
Nevertheless, the lowest AIC indicated the model including CCI as the model with the best 
fit for the given set of data.  The effect of any of the covariates described may depend on 
the particular level or value of any other explanatory variable, giving rise to what is known 
as interaction [105].  
 
Chapter 4                                                                                                                                                        82 
 
Interaction 
Based on expert clinical advice, one interaction term assuming an interaction of age with 
comorbidities was included in the econometric model. An interaction effect occurs if the 
effect of a given covariate depends on the value of another covariate. Intuitively, a linear 
relationship between age and comorbidities suggests that the level of comorbidities 
increases, as patients get older. [106]. 
 
4.5 Results 
 
4.5.1 Cohort characteristics 
 
At the time of first hospitalisation, outpatient clinic attendance or care home admission, of 
the 272,716 AF patients - (mean age of 71 years (SD 10.6)), the majority were identified in 
the two largest urban health board areas (Greater Glasgow & Clyde and Lothian), 
accounting for 22.3% and 14.9% respectively. This is also reflected in the categorisation of 
geographical areas, where large urban represented 38.5% and other urban areas represented 
29.7% of the total AF cohort.  
 
A greater proportion of patients live in areas belonging to the most deprived category 
compared with those living in the least deprived areas – SIMD category 1 and category 5 
representing 22.6% and 16.4% of the AF cohort respectively.  
 
Among those with inpatient admission, general medicine (34.7%) followed by geriatric 
medicine (10.7%) were the most frequently attended hospital specialties. Most AF patients, 
who had been hospitalised, had also been attending outpatient clinics; therefore, similar 
pattern were observed across the different characteristics. Cardiology represented the 
second most attended outpatient clinic (10.84%) preceded by ophthalmology (13.5%).  
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Of the 272,716 AF patients, 4,331 were admitted to a care home, of which 22.3% were 
readmitted to hospital with a median length of stay of four days (IQR 1.0-16.0). 
 
In the 5 years following the first AF incident event, the distribution of health board, 
geography and SIMD remained unchanged. On the other hand, the proportion of AF 
patients dying in the 5 years follow-up changed considerably.  Within the first year, about 
25% AF patients died; but much reduced percentages of mortality were observed for the 
remaining years of the 5-year follow-up.  An inverse trend was observed for the increase of 
number of patients with more than one comorbidity. 
 
In the 5 years following the incident AF event, the distribution of health board, geography 
and SIMD remained unchanged. During the first year about 25% of AF patients died; but 
lower rates of mortality were observed for years two to five. An inverse trend was 
observed for the increase of number of patients with more than one comorbidity.  
 
Furthermore, over the 5-year follow-up the composition of the most frequent specialties 
attended remained fairly unchanged. Similar trends were observed for the composition of 
the most frequently attended outpatient clinics; however, haematology was no longer listed 
among the top five.  
 
The proportion of patients admitted to a care home increased from 1.6% (time 0) to 2.0% 
(year 5), but the proportion of those admitted to hospital from a care home and median 
length of stay remained unchanged. Cohort characteristics and outcomes of patients who 
have either been admitted to hospital, a care home like structure, or attending outpatient 
clinics are presented in Table 4.3. 
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Table 4.3 Baseline characteristics and outcomes of AF patients 50 years or older 
                  
  Baseline characteristics and outcomes time 0 Follow-up year 1 Follow-up year 2 Follow-up year 3 Follow-up year 4 Follow-up year 5   
                  
  Number of patients  272,716 205,043 188,066 173,605 161,931 152,361   
  Mean age (SD) (range) 71 (10.6) (50-108) 70 (10.4) (50-103) 70 (10.4) (50-103) 69 (10.4) (50 - 103) 68 (10.5) (50 - 101) 68 (10.5) (50 - 101)   
Sex 
  Male  135,683 (49.8) 104,970 (51.2) 96,798 (51.5) 89,984 (51.8) 84,461 (52.2) 79,881 (52.4)   
  Female 137,033 (50.2) 100,073 (48.8) 91,268 (48.5) 83,621 (48.2) 77,470 (47.8) 72,480 (47.6)   
  Number of deaths  n/a 67,673 (24.8) 16,977 (8.3) 14,461 (7.7) 11,674 (6.7) 9,570 (5.9)   
Health boards 
  Greater Glasgow & Clyde 60,774 (22.3) 45,292 (22.1) 41,269 (21.9) 37,769 (21.8) 34,968 (21.6) 32,683 (21.5)   
  Lothian 40,498 (14.9) 30,334 (14.8) 27,788 (14.8) 25,655 (14.8) 23,902 (14.8) 22,500 (14.8)   
  Lanarkshire 30,105 (11.0) 22,842 (11.1) 20,881 (11.1) 19,309 (11.1) 18,064 (11.2) 17,061 (11.2)   
  Grampian 25,208 (9.2) 19,440 (9.5) 17,960 (9.5) 16,653 (9.6) 15,609 (9.6) 14,709 (9.7)   
  Tayside 24,468 (9.0) 17,502 (8.5) 15,951 (8.5) 14,700 (8.5) 13,616 (8.4) 12,753 (8.4)   
  Ayrshire & Arran 21,543 (7.9) 16,295 (7.9) 14,989 (8.0) 13,859 (8.0) 12,981 (8.0) 12,286 (8.1)   
  Highland 18,584 (6.8) 13,578 (6.6) 12,481 (6.6) 11,502 (6.6) 10,705 (6.6) 10,065 (6.6)   
  Fife 17,612 (6.5) 13,855 (6.8) 12,891 (6.9) 11,998 (6.9) 11,259 (7.0) 10,667 (6.0)   
  Forth valley 13,308 (4.9) 10,018 (4.9) 9,215 (4.9) 8,551 (4.9) 8,041 (5.0) 7,593 (4.0)   
  Dumfries & Galloway 9,645 (3.5) 7,364 (3.6) 6,780 (3.6) 6,314 (3.6) 5,911 (3.7) 5,545 (3.6)   
  Borders 7,148 (2.6) 5,480 (2.7) 5,068 (2.7) 4,700 (2.7) 4,435 (2.7) 4,203 (2.8)   
  Western isles 1,812 (0.7) 1,467 (0.7) 1,337 (0.7) 1,245 (0.7) 1,159 (0.7) 1,084 (0.7)   
  Shetland 1,009 (0.4) 813 (0.4) 750 (0.4) 698 (0.4) 665 (0.4) 626 (0.4)   
  Orkney 1,002 (0.4) 763 (0.4) 706 (0.4) 652 (0.4) 616 (0.4) 586 (0.4)   
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Table 4.3 Baseline characteristics and outcomes of AF patients 50 years or older (continued a) 
 
                  
  Baseline characteristics and outcomes time 0 Follow-up year 1 Follow-up year 2 Follow-up year 3 Follow-up year 4 Follow-up year 5   
                  
Geography 
  Large/urban 104,841 (38.5) 78,225 (38.2) 71,326 (37.9) 65,426 (37.7) 60,681 (37.5) 56,801 (37.3)   
  Other/urban 80,794 (29.7) 60,342 (29.4) 55,264 (29.4) 51,043 (29.4) 47,644 (29.4) 44,856 (29.4)   
  Accessible small towns 24,492 (9.0) 18,251 (8.9) 16,770 (8.9) 15,475 (8.9) 14,436 (8.9) 13,572 (8.9)   
  Remote small towns 8,126 (3.0) 6,055 (3.0) 5,536 (2.9) 5,136 (2.0) 4,775 (2.9) 4,524 (3.0)   
  Very remote small towns 3,712 (1.4) 2,882 (1.4) 2,642 (1.4) 2,449 (1.4) 2,301 (1.4) 2,179 (1.4)   
  Accessible rural 30,122 (11.1) 23,102 (11.3) 21,447 (11.4) 19,996 (11.5) 18,824 (11.6) 17,896 (11.7)   
  Remote rural 10,277 (3.8) 7,882 (3.8) 7,357 (3.9) 6,860 (3.0) 6,467 (4.0) 6,110 (4.0)   
  Very remote rural 9,908 (3.6) 7,900 (3.9) 7,343 (3.9) 6,858 (3.0) 6,457 (4.0) 6,084 (4.0)   
SIMD 
  1 61,686 (22.6) 44,494 (21.7) 40,225 (21.4) 36,668 (21.1) 33,759 (20.8) 31,355 (20.6)   
  2 61,704 (22.6) 45,255 (22.1) 41,154 (21.9) 37,734 (21.7) 35,038 (21.6) 32,769 (21.5)   
  3 54,937 (20.1) 41,610 (20.3) 38,285 (20.4) 35,408 (20.4) 33,024 (20.4) 31,120 (20.4)   
  4 49,448 (18.1) 38,196 (18.6) 35,385 (18.8) 32,928 (18.0) 30,984 (19.1) 29,392 (19.3)   
  5 44,933 (16.4) 35,486 (17.3) 33,015 (17.6) 30,865 (17.8) 29,124 (18.0) 27,723 (18.2)   
Comorbidity 
  no comorbidity 64,758 (23.8) 56,815 (27.7) 55,952 (29.8) 55,258 (31.8) 54,758 (33.8) 54,241 (35.6)   
  1 comorbidity 68,368 (25.1) 50,779 (24.8) 47,982 (25.5) 45,679 (26.3) 43,871 (27.1) 42,370 (27.8)   
  >1 comorbidities 139,590 (51.2) 97,449 (47.5) 84,132 (44.7) 72,668 (41.9) 63,302 (39.1) 55,750 (36.6)   
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Table 4.3 Baseline characteristics and outcomes of AF patients 50 years or older (continued b) 
 
                  
  
Baseline characteristics and 
outcomes time 0 Follow-up year 1 Follow-up year 2 Follow-up year 3 Follow-up year 4 Follow-up year 5   
                  
  INPATIENT               
  Length of stay 5.5 (3.2 -9.8) 4.8 (2.3-9.0) 4.5 (2.5-8.5) 4.2 (2.4-8.0) 4.0 (2.3 - 7.5) 4.0 (2.2 - 7.0)   
Most frequent specialty attended 
  General medicine 1,162,296 (34.7) 512,240 (39.1) 456,474 (39.0) 402,890 (38.9) 353,143 (38.8) 311,109 (38.7)   
  Geriatric medicine 358,641 (10.7) 162,068 (12.4) 137,258 (11.7) 113,977 (11.1) 93,520 (10.3) 77,040 (9.6)   
  Cardiology 263,414 (7.9) 129,737 (9.9) 121,278 (10.4) 113,374 (11.0) 105,769 (11.6) 98,982 (12.3)   
  General surgery (no vascular) 195,416 (5.8) 62,356 (4.8) 57,055 (4.9) 51,614 (5.0) 46,400 (5.1) 41,835 (5.2)   
  General surgery  179,613 (5.4) 51,971 (4.0) 47,247 (4.0) 42,298 (4.1) 37,893 (4.2) 33,761 (4.2)   
  OUTPATIENT               
  Median outpatient attendance (IQR) 2.0 (1.0 - 4.0) 2.0 (1.0 - 4.0) 2.0 (1.0 - 4.0) 2.0 (1.0 - 4.0) 2.0 (1.0 - 4.0) 2.0 (1.0 - 4.0)   
Most frequent outpatient clinic attended 
  Ophthalmology 732,525 (13.5) 1,975 (8.0) 1,975 (8.0) 1,975 (8.0) 1,975 (8.0) 1,975 (8.0)   
  Cardiology 588,174 (10.84) 3,406 (13.7) 3,406 (13.7) 3,406 (13.7) 3,406 (13.7) 3,406 (13.7)   
  Trauma and orthopaedic surgery 452,052 (8.33) 1,859 (7.5) 1,859 (7.5) 1,859 (7.5) 1,859 (7.5) 1,859 (7.5)   
  Haematology 335,872 (6.19) n/a n/a n/a n/a n/a   
  
General surgery (excluded 
vascularisation) n/a 1,408 (5.7) 1,408 (5.7) 1,408 (5.7) 1,408 (5.7) 1,408 (5.7)   
  Dermatology 304,168 (5.61) 1,304 (5.3) 1,304 (5.3) 1,304 (5.3) 1,304 (5.3) 1,304 (5.3)   
Care home 
  Number of patients admitted  4,331 (1.6) 3,486 (1.7) 3,197 (1.7) 3,298 (1.9) 3,077 (1.9) 3047 (2.0)   
  
Number of hospitalisations 
from care home  966 (22.3) 736 (21.1) 716 (22.4) 765 (23.2) 729 (23.7) 731 (24.0)   
  
Hospitalisations from care home, 
median length of stay (IQR) 4.0 (1.0 - 16.0) 4.0 (1.3 - 16.0) 3.9 (1.1 - 13.0) 3.9 (1.2 - 12.8) 3.8 (1.1 - 12.3) 3.8 (1.3- 12.5)   
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4.5.2 Econometric modelling diagnostic tests 
 
Based on the review of existing AF costing studies, GLM models were compared against 
OLS regression and log transformed OLS by means of AIC, which measures goodness of fit. 
When comparing the different models, GLM reported the lowest AIC (18.021) indicating 
the best fit for the given set of data, compared to OLS regression (AIC 20.025) and log 
transformed OLS (AIC 20.179). Following the statistical test conducted with the user-
written STATA programme “glmdiagnostic.do” to identify the most appropriate 
distributional family and link function, a Gamma distribution was identified as the best 
fitting distribution for the log link GLM model (Appendix I).  
 
 
4.5.3 Econometric modelling results 
 
Regression results for both modelling parts are presented in Table 4.4. However, the 
coefficients from the first modelling part have been converted into ORs (Appendix II, Table 
I) for ease of interpretation of the likelihood of utilising any health or social care services.  
Overall, an inversely U-shaped association between age and the likelihood of utilising any 
health or social care services was observed – a gradual increment in the likelihood in 
resource use with advancing age up to 80 years, when compared with the reference group 
(50-54 years), while patients 80 years or older showing a decreased probability of utilising 
healthcare services. However, this association was not observed in the second modelling 
part, estimating costs conditional on having incurred positive costs, where a gradient 
between age and costs indicated increasing costs as the cohort ages.  
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The use of health or social care services and associated costs decreases gradually in the first 
5 years following the first AF incident event. Further, a marginal increase in health or social 
care services utilisation was observed for patients living in the most deprived areas, when 
compared with patients living in areas with the lowest level of deprivation. For patients with 
comorbidities, the odds of utilising healthcare services were 1.74 (one comorbidity) and 2.20 
(two or more comorbidities) times higher compared to those with no comorbidities. 
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Table 4.4 Regression results: probability of healthcare resources utilisation and cost estimation 
              
  
Covariates 
Probability Probability   
  (1st modelling part) (2nd modelling part)   
    Coefficient (95%CI) Std. Err Coefficient (95%CI) Std. Err   
Age group (years) 
  50-54 Reference         
  55-59 0.297 (0.221, 0.374) 0.039 0.078 (0.023, 0.133) 0.028   
  60-64 0.428 (0.353, 0.502) 0.038 0.150 (0.099, 0.202) 0.026   
  65-69 0.497 (0.424, 0.569) 0.037 0.224 (0.173, 0.274) 0.026   
  70-74 0.542 (0.470, 0.613) 0.037 0.344 (0.295, 0.392) 0.025   
  75-79 0.650 (0.579, 0.722) 0.037 0.418 (0.370, 0.466) 0.024   
  80-84 0.567 (0.494, 0.639) 0.037 0.546 (0.496, 0.597) 0.026   
  85-89 0.510 (0.433, 0.588) 0.040 0.738 (0.683, 0.793) 0.028   
  90-max 0.285 (0.196, 0.373) 0.045 0.975 (0.907, 1.043) 0.035   
  Sex           
  Male  Reference         
  Female 0.023 (0.002, 0.044) 0.011 0.047 (0.033, 0.060) 0.007   
  Date of admission 0.206 (0.203, 0.208) 0.001 -0.057 (-0.059, -0.056) 0.001   
Follow-up years 
  1 Reference      
  2 -1.630 (-1.656, -1.603) 0.014 -0.177 (-0.188, -0.165) 0.006   
  3 -1.859 (-1.887, -1.831) 0.014 -0.142 (-0.154, -0.129) 0.007   
  4 -1.944 (-1.974, -1.915) 0.015 -0.030 (-0.043, -0.016) 0.007   
  5 -2.048 (-2.081, -2.014) 0.017 -0.032 (-0.049, -0.014) 0.009   
SIMD category 
  1 Reference         
  2 0.019 (-0.014, 0.051) 0.017 -0.050 (-0.070, -0.030) 0.010   
  3 -0.027 (-0.061, 0.007) 0.017 -0.077 (-0.099, -0.056) 0.011   
  4 -0.058 (-0.093, -0.023) 0.018 -0.110 (-0.132, -0.088) 0.011   
  5 -0.062 (-0.096, -0.027) 0.018 -0.157 (-0.179, -0.135) 0.011   
Geography 
  Large urban Reference         
  Other urban -0.170 (-0.201, -0.139) 0.016 -0.031 (-0.051, -0.012) 0.010   
  Accessible small towns -0.199 (-0.241, -0.157) 0.021 -0.051 (-0.077, -0.025) 0.013   
  Accessible rural -0.252 (-0.292, -0.212) 0.020 -0.063 (-0.089, -0.037) 0.013   
  Remote small towns -0.168 (-0.232, -0.104) 0.033 -0.015 (-0.057, 0.028) 0.022   
  Remote rural -0.361 (-0.418, -0.304) 0.029 -0.068 (-0.106, -0.030) 0.020   
  Very remote small towns -0.437 (-0.534, -0.341) 0.049 -0.097 (-0.161, -0.032) 0.033   
  Very remote rural -0.413 (-0.488, -0.339) 0.038 -0.085 (-0.139, -0.032) 0.027   
Health boards 
  Great Glasgow and Clyde Reference         
  Lothian -0.053 (-0.092, -0.015) 0.020 -0.054 (-0.076, -0.032) 0.011   
  Lanarkshire 0.006 (-0.034, 0.047) 0.021 -0.077 (-0.102, -0.053) 0.013   
  Ayrshire and Arran -0.427 (-0.471, -0.382) 0.023 -0.065 (-0.094, -0.035) 0.015   
  Grampian 0.022 (-0.024, 0.068) 0.023 -0.052 (-0.078, -0.025) 0.013   
  Tayside -0.498 (-0.540, -0.456) 0.021 -0.100 (-0.128, -0.072) 0.014   
  Fife -0.094 (-0.146, -0.042) 0.026 -0.025 (-0.059, 0.008) 0.017   
  Highland -0.196 (-0.258, -0.134) 0.032 -0.041 (-0.080, -0.002) 0.020   
  Forth Valley -0.546 (-0.597, -0.495) 0.026 -0.115 (-0.149, -0.080) 0.018   
  Dumfries and Galloway -0.339 (-0.400, -0.278) 0.031 -0.174 (-0.214, -0.133) 0.021   
  Borders -0.573 (-0.638, -0.509) 0.033 -0.107 (-0.154, -0.061) 0.024   
  Western Isles -1.295 (-1.409, -1.181) 0.058 0.145 (0.061, 0.229) 0.043   
  Orkney -0.487 (-0.641, -0.334) 0.078 0.001 (-0.118, 0.121) 0.061   
  Shetland -0.681 (-0.831, -0.532) 0.076 -0.064 (-0.200, 0.073) 0.070   
Comorbidity 
  no comorbidities Reference         
  1 comorbidity 0.552 (0.425, 0.678) 0.065 0.423 (0.339, 0.507) 0.043   
  >1 comorbidities 0.789 (0.606, 0.971) 0.093 0.917 (0.832, 1.002) 0.043   
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4.5.4 Cost estimates 
 
The estimated mean annual cost per AF patient was £3,114 (95% CI: £3,093, £3,215).  
Inpatient cost was £3,032 (95% CI: £3,006, £3,058) in the first year following the first AF 
incident event but dropped to £2,276 (95% CI: £2,233, £2,319) in the fifth year. Similarly, 
outpatient cost was £363 (95% CI: £360, £366) in the first year following the first AF 
incident event but dropped to £286 (95% CI: £282, £290) in the fifth year. Conversely, the 
cost of care home was £131 (95% CI: £121, £142) in the first year following the first AF 
incident event but dropped to £242 (95% CI: £220, £263) in the fifth year. 
 
As shown in Table 4.5, compared against the other health boards, patients residing in Great 
Glasgow and Clyde incurred the highest estimated cost of £3,370 (95% CI: £3,318, £3,423). 
Comparatively, patients living in Forth Valley incurred the lowest estimated cost of £2,742 
(95% CI: £2,657, £2,826). AF patients from large urban areas incurred the highest estimated 
cost of £3,273 (95% CI: £3,230, £3,315). Comparatively, the lowest estimated cost of 
£2,764 (95% CI: £2,590, £2,937) was incurred by AF patients living in “very remote rural 
areas”. Further, patients from the most deprived areas seemed to incur higher overall costs 
than those from the least deprived areas. A clear gradient of estimated costs decreasing from 
the most to the least deprived areas was observed. 
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Table 4.5 Average annual cost per AF patient by health board, geography and SIMD 
  
Category Mean cost (£) (95% CI) 
  
    
    
  Health board     
  Great Glasgow and Clyde 3,370 (3,318, 3,423)   
  Lothian 3,169 (3,111, 3,227)   
  Lanarkshire 3,123 (3,057, 3,189)   
  Ayrshire and Arran 2,949 (2,875, 3,022)   
  Grampian 3,210 (3,140, 3,281)   
  Tayside 2,808 (2,741, 2,875)   
  Fife 3,241 (3,144, 3,338)   
  Highland 3,140 (3,032, 3,248)   
  Forth Valley 2,742 (2,657, 2,826)   
  Dumfries and Galloway 2,686 (2,585, 2,786)   
  Borders 2,747 (2,626, 2,869)   
  Western Isles 2,979 (2,722, 3,236)   
  Orkney 3,115 (2,739, 3,490)   
  Shetland 2,808 (2,421, 3,195)   
  Geography     
  Large urban 3,273 (3,230, 3,315)   
  Other urban 3,090 (3,048, 3,132)   
  Accessible small towns 3,016 (2,947, 3,085)   
  Accessible rural 2,953 (2,889, 3,018)   
  Remote small towns 3,142 (3,015, 3,270)   
  Remote rural 2,883 (2,781, 2,986)   
  Very remote small towns 2,764 (2,590, 2,937)   
  Very remote rural 2,807 (2,666, 2,949)   
  SIMD (Scottish index of multiple deprivation)   
  1 3,359 (3,309, 3,408)   
  2 3,205 (3,159, 3,250)   
  3 3,095 (3,046, 3,144)   
  4 2,981 (2,933, 3,029)   
  5 2,843 (2,795, 2,891)   
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Costs incurred by female AF patients are higher than the costs observed in the male group. 
Table 4.6 shows males and females with an estimated cost of £3,036 (95% CI: £3,007, 
£3,064) and £3,192 (95% CI: £3,162, £3,223) respectively. While there was little difference 
between the total costs and the distribution of costs for inpatient, outpatient and prescription 
costs, the difference seemed more pronounced when comparing the care home component of 
costs (5.0% of total costs among males versus 7.3% of total costs among females).   
 
Table 4.6 Average annual cost per AF patient by sex and healthcare or care home sector 
          
  Category Cost estimates   
    Mean cost (£) (95%CI)   
  Male        
  Inpatient (%) 2,273 (74.8) (2,251, 2,294)   
  Outpatient (%) 323 (10.6) (320, 326)   
  Care home (%) 153 (5.0) (139, 168)   
  PIS (%) 263 (8.7) (260, 266)   
  Total 3,036 (3,007, 3,064)   
  Female       
  Inpatient (%) 2,323 (72.8) (2,301, 2,345)   
  Outpatient (%) 325 (10.2) (322, 328)   
  Care home (%) 233 (7.3) (218, 248)   
  PIS (%) 280 (8.8) (277, 283)   
  Total 3,192 (3,162, 3,223)   
 
The average annual cost per AF patient by age and for each health or care home sector is 
presented in Table 4.7. Considering the individual contribution of each cost component to 
the overall costs, inpatient costs were found to be the main cost driver across all age groups. 
While inpatient cost contribution remained constant with an average contribution of about 
75% to the overall cost for patients aged between 50 and 84 years, it decreased for patients 
over 85 years of age. Similar patterns were observed for outpatient and prescribing costs. On 
the contrary, the contribution of care home costs to the overall costs increased with age 
(0.6% for patients aged 50-54 years and approximately 19.7% for patients who are 90 years 
or older).  
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The contribution of each setting to the total health and care home costs by the number of 
existing comorbidities is presented in Table 4.8. While inpatient and total costs varied 
considerably with the number of comorbidities, outpatient and care home contributions 
remained fairly constant. 
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Table 4.7 Average annual cost per AF patient by age and healthcare or care home sector 
                      
  Age groups Hospital total cost (£)   Outpatient l total cost (£)   Care home total cost (£)   PIS total cost (£)     
    Mean (95%CI) % Mean (95%CI) % Mean (95%CI) % Mean (95%CI) %   
  50-54 1,857 (1,765, 1,948) 75 337 (324, 350) 13.6 16 (9, 41) 0.6 267 (250, 284) 10.8   
  55-59 2,065 (1,996, 2,135) 75.9 352 (342, 361) 12.9 17 (1, 36) 0.6 286 (274, 298) 10.5   
  60-64 2,091 (2,041, 2,141) 75.7 352 (345, 359) 12.7 26 (14, 39) 0.9 295 (286, 304) 10.7   
  65-69 2,152 (2,109, 2,195) 76.1 353 (348, 358) 12.5 33 (21, 45) 1.2 290 (284, 296) 10.3   
  70-74 2,247 (2,211, 2,283) 76.1 353 (349, 358) 12 63 (49, 77) 2.1 290 (285, 295) 9.8   
  75-79 2,344 (2,312, 2,376) 76.7 348 (343, 352) 11.4 84 (71, 97) 2.7 281 (277, 285) 9.2   
  80-84 2,469 (2,432, 2,506) 75.1 317 (313, 321) 9.6 235 (211, 258) 7.1 268 (265, 272) 8.1   
  85-89 2,665 (2,618, 2,712) 72.7 276 (271, 281) 7.5 472 (431, 513) 12.9 255 (250, 259) 7   
  90-max 2,765 (2,694, 2,836) 69.8 194 (187, 200) 4.9 779 (706, 852) 19.7 226 (220, 232) 5.7   
  Total 2,297 (2,282, 2,313) 74.3 324 (322, 326) 10.5 201 (190, 212) 6.5 271 (269, 273) 8.8   
 
 
Table 4.8 Average annual cost per AF patient by CCI and healthcare or care home sector 
                  
  Cost component No comorbidity cost (£)   1 comorbidity cost (£)   >1 comorbidity cost (£)     
    Mean (95%CI) % Mean (95%CI) % Mean (95%CI) %   
  Hospital 1,786 (1,767, 1,805) 74.9 2,253 (2,226, 2,280) 73.5 3,148 (3,110, 3,186) 73.4   
  Outpatient 285 (282, 288) 12.0 307 (304, 311) 10.0 409 (405, 414) 9.5   
  Care home 131 (117, 146) 5.5 219 (199, 239) 7.1 256 (235, 276) 6.0   
  PIS 185 (183, 188) 7.8 269 (266, 273) 8.8 386 (381, 391) 9.0   
  Total 2,384 (2,357, 2,412) 100 3,065 (3,026, 3,104) 100 4,289 (4,237, 4,340) 100   
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4.6 Discussion 
 
4.6.1 Cohort characteristics  
 
The descriptive analysis does not only provide an overview of patient characteristics, but 
also reveals important aspects related to AF. The mean age of 71 years reported for the 
cohort affected by AF in SMR01 is in line with the mean age suggested in the literature. As 
expected, general medicine and cardiology were identified as the specialties patients were 
admitted to most frequently over time. The high number of hospital episodes in geriatric 
medicine, is in line with the average age of patients. The highest number of hospitalisations 
was also expected in large affluent urban areas such as the Greater Glasgow & Clyde and 
Lothian with reasonable access to hospitals, and in areas with the highest index of 
deprivation for the reasons discussed in the previous section.    
 
Ophthalmology and cardiology were respectively the first and the second most attended 
outpatient clinic over time. Indeed, these specialties deal with age related conditions, 
which generally have a high prevalence in elderly patients. The attendance of the 
haematology outpatient clinic is also consistent with expectations, as patients on warfarin, 
to date the main oral anticoagulant treatment for the management of AF as a preventive 
measure for stroke, require constant monitoring of blood clotting rate to determine the 
effects of oral anticoagulants. While this is true at time of first attendance, in the 5-year 
follow-up haematology is no longer among the five most frequently attended outpatient 
clinic attended, presumably due to discontinuation of warfarin or switching to another 
OAC. Across health boards, geographical locations and socio-economic status, the 
proportion of outpatient clinics attended reflects the proportion of hospital episodes, 
indicating consistency between hospitalisation and follow-up visits.  
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4.6.2 Estimated cost of AF 
 
A greater proportion of AF patients was found in the most deprived areas, this combined 
with the likelihood of people living in the most deprived category having longer inpatient 
stays, may explain the difference in inpatient care utilisation between patients from the 
most and the least deprived areas, with associated costs being higher for the former group. 
As AF is more likely to affect the elderly [19], AF related costs were expected to increase 
with age. As health deteriorates with age, older age groups are assumed to make greater 
use of healthcare services, and therefore incur higher costs than younger age groups. 
However, age was found to have a modest impact on overall healthcare costs, being fairly 
consistent across age groups. This finding is in line with existing evidence indicating that 
healthcare expenditure depends not only on patients’ calendar age, but is also significantly 
associated with remaining lifetime [107].  
 
On the other hand, comorbidity had a considerable effect on the overall cost, increasing 
significantly in patients with more than one comorbidity compared to patients in other CCI 
categories.. Decreasing inpatient and outpatient costs for the oldest patients were offset by 
increasing care home costs, in particular for women. Indeed, the main cause for higher 
overall costs incurred by women is attributable to the higher likelihood for elderly women 
to reside in care homes. Interestingly, care home contribution to the overall costs was 
noticeably lower for patients with multiple comorbidities than for those with one 
comorbidity. This may suggest that sicker patients are more likely to be in hospital than in 
a care home.  
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To date, only one single study published in 2004 has estimated the cost of AF in Scotland; 
the authors estimated the cost of AF in 1995/1996, and projected these to the year 2000 
[91]. Previous work has focussed on a 12-months follow-up, which seems limited in order 
to capture all healthcare resource utilisation for AF patients. This analysis offers a longer 
follow-up and a contemporary estimate of healthcare costs related to AF including all 
relevant care settings. This analysis  offers a distinct advantage over previous work as 
costs, rather than being based on extrapolated rates using a prevalence-based approach 
[91], are estimated with an incidence-based method using patient-level morbidity records. 
Using an incidence-based approach to costing and a broad perspective to capture the 
majority of costs associated with AF, several routinely collected administrative datasets 
from Scotland were combined, including care home utilisation. A robust Scottish record 
linkage system, where administrative health data are routinely collected, allows Scotland to 
be at the forefront of research where patient data linkage is involved [14, 108].  
 
Existing analyses, including this one, regardless of econometric model choice and 
covariates used, show that costs due to inpatient admission are the main contributor to 
overall healthcare cost for AF patients; hospitalisation as the main cost driver was also 
identified by the previous Scottish study published in 2004 and using patient level data 
[91]. This is a pertinent finding that may well support future policies on opportunistic 
screening in the population at risk of AF, and in particular in Scotland where 1 in 3 patients 
with AF are currently undiagnosed [25]. The European AF management guidelines and the 
Scottish Cross-Party Group ‘Heart Disease and Stroke’, recently recommended that people 
who are 65 years or older and at risk of AF and associated comorbidities such as 
cardiovascular disease, diabetes or respiratory disease should be screened opportunistically 
in primary care, pharmacies or community settings. With rigorous screening and 
appropriate treatment, hospitalisations could be avoided and costs reduced [25, 109]. 
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Although capturing most healthcare sectors and related costs, it was not possible to obtain 
data on general practice consultations, as those data are currently not routinely available in 
Scotland. This, coupled with the potential risk of AF going undiagnosed and clinical 
miscoding of morbidity records, may lead to an underestimation of the size of the AF 
cohort and associated costs. Other limitations are mostly inherent to the nature of 
administrative data, such as missing records or incomplete data. Prescribing and care home 
data were only available from 2009 and 2012, so their contribution to overall AF related 
costs might be underestimated. Despite these limitations, it was possible to harness high 
quality patient-level linked data to identify a cohort of AF patients and to estimate AF 
related costs in Scotland.  
 
While the choice of a given costing method should be driven by the research question and 
the nature of the data, it is accepted that OLS or GLM, with different combinations as 
discussed in previous sections of this Chapter, are the two main approaches that should be 
employed in the costing of health care expenditure data. Clearly, the issues and the 
limitations inherent to the costing approaches mentioned should be taken into account 
when selecting the most appropriate regression model.  
 
4.7 Conclusions 
 
The inclusion of all available cost components is crucial for establishing overall costs, as 
these often extend beyond hospitalisation. The study identified hospitalisation as the main 
cost driver that may well support the implementation of AF screening policies that could 
potentially reduce costs for the most expensive healthcare setting, i.e. inpatient care.  
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Most importantly, the study concludes that patients’ age has a limited impact on the overall 
AF related cost, and therefore may contribute much less to future growth of AF related cost 
in an ageing Scottish population.  
 
This Chapter, combined with Chapter 1, provides an overview of the landscape of AF in 
Scotland in terms of epidemiology, disease management, treatment availability and overall 
costs. The next Chapter will offer an overview of the methods used in comparative-
effectiveness research, with a particular focus on PS based methods that will be tested and 
compared.  
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Chapter 5 Methods for comparative-effectiveness analysis 
5.1 Introduction 
 
Comparative-effectiveness research is a rapidly evolving field that provides clinicians, 
patients and policy makers with clinical evidence needed to make informed decisions 
concerning healthcare related issues. In particular, comparative-effectiveness research 
evaluates the relative effectiveness of different treatment options for a specific medical 
condition and in a selected population, and aims to reduce the gap between clinical research 
and clinical practice l [11, 110]. In this context, both RCTs and non-randomised studies 
(RWE) contribute to generating clinical evidence for the decision-making.  
 
Randomised controlled trials typically recognised as “gold standard” for providing 
evidence on efficacy, are designed for measuring efficacy in a controlled environment and 
in a selected population where the treatment under examination is randomly assigned. 
Randomisation ensures that differences in patient characteristics such as age, sex, 
comorbidities and disease severity, are similarly distributed between treatment groups; 
thus, the observed effect in the study population can be attributable to the difference in 
outcomes between treatment groups [41, 42, 111].  
 
In non-randomised studies (RWE), evidence on effectiveness is generated in an 
uncontrolled environment. The absence of randomisation does not allow for an unbiased 
comparison between patients who are exposed and those who are not exposed to the 
treatment under study. Hence, the observed differences in health outcomes between the 
groups may be influenced by the population characteristics or other additional factors rather 
than by the treatment effect. Nevertheless, RWE may provide additional insight concerning 
treatment safety and effectiveness of a treatment and in some cases may be the only 
available source of evidence if randomised data are not available. 
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In particular, RWE captures natural heterogeneity that reflects variation in patient 
population. In RCTs, patients are recruited according to certain demographic and clinical 
characteristics, and variation is reduced by applying exclusion criteria; this however 
contributes to the limited generalizability of RCTs. Further, unlike RCTs where evidence is 
generated in a controlled environment, RWE may capture inevitable differences in clinical 
practice [112].  
 
As stated in Chapter 4, a lack of randomisation in RWE studies gives rise to confounding 
by indication, occurring when the prognostic factors, such as disease severity, used for 
treatment selection also affect the outcome. For instance, if patients with more severe 
conditions receive more intense treatments. However, when comparing treatment 
effectiveness, the more intensive treatment may produce poorer outcomes [11].  A more 
practical example is provided by Kyriacou et al (2016) who identified potential 
confounding by indication in a clinical setting where the association between tracheal 
intubation during paediatric in-hospital cardiac arrest and survival were investigated. In 
particular, children with more severe conditions and lower probability of survival were 
more likely to be intubated. However, this likelihood was driven by the fact that having 
severe conditions is a strong predictor of both, mortality and clinical decision to intubate 
[113].  
  
Historically, regression adjustment has been used to address confounding in RWE; but over 
the last decade, there has been an increasing interest in the application of Propensity Score 
based (PS) methods, such as matching and inverse probability weighting (IPW), within the 
use of observational data in medical research. Propensity score methods attempt to mimic 
the RCTs process or randomisation by estimating the probability of treatment assignment 
conditional on observed baseline characteristics [11, 59].  
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Propensity score methods offer, as it will be discussed in the next section, several 
advantages over conventional regression methods [59]. However, while PS methods may 
reduce the bias due to observable confounders such as age, sex and existing previous 
history of stroke, other unobserved confounding, such as patients’ tolerability and access to 
healthcare may still bias the PS estimates. Propensity score methods can address observed 
confounding if the assumption of ‘no unobserved confounding’ is reasonable [114]. 
Therefore, in order to address both observed and unobserved confounding, different 
statistical methods such as instrumental variable, difference in differences and regression 
discontinuity should be used as an alternative to PS methods [115, 116]. An overview of 
these methods will be also be provided in the next section.  
 
In order to address the second Objective defined in Chapter 2, this Chapter explores, within 
the comparative-effectiveness framework and the DOAC case study, different PS methods 
for estimating the treatment effect comparing warfarin and DOACs, and assesses whether 
results for AF-related clinical outcomes differ depending on the PS method used. The 
motivation for concentrating on PS methods is that the main focus will be on observed 
confounders.  Further, for this analysis, to increase the overall sample size, a cohort termed 
“combined DOAC” was created to include users of either apixaban, dabigatran or 
rivaroxaban.  
 
The PS method, identified as the most robust, will inform the comparative-effectiveness 
model, in the subsequent Chapter where differences in effectiveness between DOACs and 
warfarin for several outcomes are assessed. In the following paragraphs, a brief description 
of all the instruments available to address observed and unobserved confounding will be 
provided.  
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5.2 Propensity score based techniques  
 
5.2.1 Propensity score 
 
Propensity score methods attempt to mimic the RCTs process or randomisation by 
estimating the probability of treatment assignment conditional on observed baseline 
characteristics [11, 59]. Typical PS methods are matching, IPW and the use of covariate 
adjustment with PS. In general, the underlying assumption for these methods is that 
balancing observed baseline characteristics would reduce bias [117]. The PS is generally 
estimated using a logistic regression model, where treatment status, being the dependent 
variable coded as 0/1, is regressed against observed baseline characteristics. For the PS to 
be valid, two conditions must hold. Firstly, treatment assignment must be independent of 
potential outcomes conditional on the observed baseline characteristics. Secondly, patients 
must have a positive probability of receiving either treatment [118]. 
 
The PS estimation involves several steps; to start with, covariates to be included should be 
selected according to certain characteristics. In general these variables should be measured 
baseline covariates associated with treatment assignment (e.g. blood pressure, weight or 
glucose level), covariates that are potential confounders affecting the outcome (e.g. age 
and sex) and variables that are true confounders affecting treatment assignment and the 
outcome of interest (e.g. comorbidity co-medication or life style factors such as smoking 
and alcohol consumptions) [59].  
 
As a second step, the PS distribution should be inspected graphically to ascertain whether 
an adequate overlapping distribution has been achieved. Distributions of the predicted 
probabilities between treatment groups should overlap to indicate that covariates for 
control and treatment groups are comparable [59, 117]. 
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Then, it should be established whether any of the covariates included in the model are 
satisfactory balanced. This is typically done by means of standardised differences 
comparing the mean of continuous and binary variables between treatment groups. In 
detail, for a continuous covariate, the standardised difference is obtained as indicated in 
Equation 5.2 [59].  
𝑑 =
(?̅?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − ?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
√((𝑠𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
2 + 𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2 )/2)
 
                                                                                                                           Equation (5.2) 
Where ?̅? treatment and  ?̅? control are the sample mean of the treated and untreated group 
respectively; S2treatment and S2control are the sample variance of the treated and untreated 
group respectively.  
 
For dichotomous variables, the standardised difference is obtained as described in Equation 
5.3 [59].  
𝑑 =
(?̂?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
√(((?̂?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡(1 − ?̂?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)) + (?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙(1 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙)))/2)
 
                                                                                                                           Equation (5.3) 
Where ?̂? treatment and  ?̂? control are the prevalence or mean of the dichotomous variable 
of the treated and untreated group respectively.  
 
While the approach described for calculating standardised differences works for PS 
matching and IPW methods, for PS covariate adjustment an approach calculating the 
conditional standardised difference is used instead (Appendix III, Equation III-1 – III-5).  
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For any of the PS method tested, differences in the means of covariates are considered 
negligible if the value is below the threshold of 0.1 standard deviation.  Although there is 
no universal agreement on what the threshold for the standardised difference should be, the 
threshold of 0.1 is now considered by researchers as an adequate measure for diagnostic 
purposes assessing covariates balance and imbalance [119]. Upon assessment of PS 
distribution and covariate balance/imbalance, the most appropriate matching or weighting 
method should be selected based on the best fitting model where covariates show the 
lowest standardised difference. Table 5.1 shows a summary of assumptions and advantages 
and disadvantages for the PS methods typically used: PS matching, IPW and covariate 
adjustment with PS.  
 
Table 5.1 PS methods 
Method Assumptions Advantage Disadvantage 
PS matching 
Groups are matched 
according to their 
propensity score 
Only propensity model 
specification is required.  
Propensity model specification 
is required. Significant 
proportion of individuals may 
be omitted when matching 
samples 
IPW 
A weight reflecting the 
probability of being 
exposed to a given 
treatment is given to each 
patient 
Only propensity model 
specification is required. 
Analysis is conducted on 
the entire cohort 
Propensity model specification 
is required 
Covariate 
adjustment 
with PS 
Outcome variable is 
regressed to the treatment 
status and the estimated 
propensity score 
Analysis is conducted on 
entire cohort 
Propensity and regression 
model specification is required 
 
Propensity score methods offers several advantages over the regression adjustment 
methods and differ in a number of ways; however, the latter has long been used to address 
confounding in RWE studies. Regression adjustment involves the use of a two-step 
estimator. Firstly, two separate regression equations for the treatment and the control group 
are estimated; then the differences estimated from the outcomes of the two groups are 
averaged across all individuals [59, 114].  
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Regression adjustment is often used in its simpler form, known as covariate adjustment, 
offering more flexibility by allowing for all relevant patient characteristics from the 
treatment and control group to be included into a single equation [114]. The main 
distinction between PS methods and regression or covariate adjustment methods consist in 
the following: the former model the probability of receiving treatment, the latter model the 
outcome of interest. Other differences between PS and regression methods consists in how 
the treatment effect is estimated. Regression or covariate adjustment estimates the 
conditional treatment effect (“treatment effect on the individual”); here the coefficient 
from the regression is interpreted as an estimated change in outcome while keeping all 
other variables constant. PS based methods estimate the marginal treatment effect 
(“treatment effect on the population”), where the outcome rates from matched or weighted 
population are just compared without referring to each patient’s characteristics. In practice, 
both conditional and marginal effects should lead to similar conclusions, but the latter will 
be closer to the treatment effect estimated in RCTs [11, 59].  
 
The main advantages of PS methods over regression adjustment consist in minimising the 
risk of model overfitting and offering ways for assessing model specification. In particular, 
the risk of overfitting is minimised by allowing for balanced comparison when several 
factors are associated with exposure. Further, propensity score methods allows for the 
inclusion of all observed covariates into a single propensity score; this is particularly 
relevant when the number of observed covariates is large in proportion to the number of 
patients or outcome events [116] .This is summarised in the following equation: 
𝑒𝑖 = 𝑃𝑟(𝑍𝑖 = 1|𝑋𝑖)                                 
                                                                                                              (Equation 5.1) 
 
Where PS (𝑒𝑖) is a balancing score that reflects the probability (𝑃𝑟) of patients being 
exposed to a given treatment (𝑍𝑖) conditional on the observed covariates (𝑋𝑖) 
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Evaluation of model specification, allowed by available diagnostics test, can indicate 
whether a PS model is correctly specified by assessing the distribution of the predicted 
probabilities and comparing the mean of continuous and binary variables between 
treatment groups. On the contrary, goodness-of-fit test for regression and covariate 
adjustment do not indicate whether the model is correctly specified [120].  
 
Despite the differences and advantages of PS methods, a double robust approach combines 
the PS estimators with regression or covariate adjustment; where the latter would control 
for residual imbalances between the treatment and control group in the PS models. The 
advantage of using a double robust approach consists in reducing the risk of model 
misspecification, as either the PS or the outcome regression model needs to be correctly 
specified [59, 121]. There are several possible causes of model misspecification in PS 
models, such as overfitting, omitting higher order terms (i.e. ignoring non-linearity), and 
incorrect functional form. These might refer to either PS equation, outcome equation, or 
both. As described by Austin (2007), PS model misspecification affects the covariate 
balance and result in a downward bias in the treatment effect estimate, due to the “non-
collapsibility” of marginal versus conditional causal effect [122].  
 
When regression adjustment and IPW are combined in a regression model, augmented 
IPW, using an augmentation term, is typically used as the estimator to correct for 
misspecification in the treatment model. However, this estimator may result in unstable 
scenarios where the treatment probabilities are close to zero; in these cases, a regression 
adjustment estimator using the inverse probability weights is used to adjust for the 
outcome model misspecification [117, 123]. Double robust is also used with matching, 
where the regression estimator adjusts for residual imbalances between the treatment and 
control group in the matched sample.  
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As reported by Kreif et al. (2014), this approach would produce less bias than the double 
robust methods using unstable IPW determining outcome and the PS models 
misspecification [121]. Further, Elze et al. (2017) used a double robust approach by using 
PS  as a covariate in the outcome model, along with other covariates reflecting patient 
characteristics and the treatment status [120].  
 
5.2.2 Matching 
 
Propensity score matching creates a sub-sample of treated and untreated groups sharing a 
similar PS value. This allows outcomes for the treated and the untreated to be directly 
compared [59]. In particular, when the outcome is continuous, such as a measurement on a 
numerical scale, the treatment effect is given by the difference in mean outcome between 
the treated and the untreated. On the other hand, when the outcome is dichotomous, 
indicating for instance those who experience a clinical event and those who do not, the 
treatment effect is given by the difference in proportion of patients who experience the 
event in the treated and the untreated groups within the matched sample [59, 118].  
 
In its simplest form, PS matching uses the nearest neighbour matching approach where, as 
the name implies, an individual from the treatment group is matched with another 
individual from the control group with the closest PS to that of the treated individual. 
However, if several individuals from the control group have PSs that are equally close to 
that of the treated individual, the individual from the control group is selected randomly 
[59, 117, 118, 124-126]. With this approach, the matching may be further improved by 
applying a caliper distance that specifies a threshold under which the PSs of matched 
individuals must stay. The issue with the caliper is that in the literature there is no 
agreement on what the maximal acceptable distance should be [127].  
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A key aspect of this PS method is selecting whether matching should be done with or 
without replacement. In the first case, any patient from the control group can be used 
several times for more than one treated individual. Replacement is particularly useful in 
settings were the treatment significantly outnumbers the control group. By contrast, 
matching without replacement allows patients from the control group to be matched 
against those in treatment group only once [59, 124-126]. 
 
A further distinction is between greedy and optimal matching. The greedy approach is 
based on an algorithm that makes best possible matching between treated and untreated 
individuals with close PS at each stage. With the greedy approach, a matched pair is not 
reused for further matching. On the contrary, with optimal approach a matched pair could 
be used several times, thus reducing PS differences within matched pairs [59, 117].  
 
With the PS matching method, a correct specification of the PS model may suffice [59, 
125-127]. Nevertheless, as mentioned, with a double robust approach, incorporating 
relevant covariates in both the PS matching model and the outcome regression model, will 
compensate for any potential covariate imbalance, and will further reduce the bias caused 
by residual differences in observed baseline covariates. However, while PS matching has 
largely been used in comparative-effectiveness research, there are limitations in its 
application. The generalizability of results may be an important issue when using the 
matching method as a significant proportion of individuals will be omitted when creating 
the matched sub-sample.  
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5.2.3 Inverse Probability Weighting 
 
An alternative PS method used to address observed confounding is IPW. The most 
common form for this method is Inverse Probability of Treatment Weighting (IPTW). 
With this approach, a weight, reflecting the probability of being exposed to a given 
treatment and equal to the reciprocal of the PS, is assigned to each patient in the treatment 
group, whereas a weight equal to the reciprocal of one minus the PS is assigned to patients 
in the control group [59, 128]: 
𝜔𝑖 =  
1
𝑒𝑖
+ 
1
1 − 𝑒𝑖
 
                                                                                             (Equation 5.4) 
 
 
 
Unlike the PS matching method, IPTW analysis is carried out on the entire cohort. 
Nevertheless, IPTW offers, along with matching, an important advantage over the 
covariate adjustment with PS approach, requiring only the PS model specification for a 
correct ATE estimation [123, 128, 129]. However, with poor PS overlap, the resulting 
extreme weights directly derived from PS may undermine the robustness of the model. 
Extreme weights, caused by a PS close to 0 for the treated or 1 for the control group, 
indicate that patients may have potentially been assigned to treatment regardless of their 
baseline characteristics. For instance, patients with high PS score maybe patients that, 
despite being eligible because of their characteristics to a given treatment, do not get the 
treatment. Conversely, patients with low propensity scores maybe patients that are on a 
given treatment despite not being the appropriate candidates [130]. In these circumstances, 
trimming is generally performed to remove individuals with extreme PS values from the 
analysis; observations with extreme PSs are removed if <0.1 or >0.9 for the treatment and 
the control group respectively [127, 131]. Alternatively, large weights can be truncated to 
the desired threshold. While there is no agreement on the optimal threshold, as reported in 
some studies, any weight greater than 10 is considered a large weight [128, 132].  
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While trimming and truncating may reduce any residual bias, excluding all individuals 
with extreme values may increase the covariate imbalance between treatment and control 
group [59, 120, 125, 126].  
 
IPW is typically used in the context of IPTW, but it has increasingly been employed as 
IPCW to address treatment switching or discontinuation issues within RCTs and with 
observational data [123, 128, 129, 133]. IPCW was firstly developed for RCTs to address 
treatment crossover and informative censoring. Thus, IPCW is particularly relevant in 
RCTs assessing new oncological treatments, where treatment switching typically occurs 
following disease progression. In this scenario, patients, being censored because starting 
oncological treatment before the protocol-defined progression, will have a different risk of 
treatment failure than those who stay on treatment [134]. Despite, its applications in RCTs, 
IPWC could also be used in the context of RWE where treatment switching is more likely 
to happen. In detail, with IPCW, the probability of being censored is used for estimating 
weights. In this setting, censoring is applied to those individuals who switch treatment, and 
the estimator assigns extra weights to individuals who are not censored but share similar 
characteristics with the switchers. The weights from IPCW are then added to those 
obtained from IPTW to obtain the overall weight reflecting ATE and censoring [128, 135, 
136]. 
 
5.2.4 Covariate adjustment with propensity score 
 
In the covariate adjustment approach, the treatment effect  is obtained from the regression 
coefficient of a fitted regression model where the outcome variable is regressed on the 
treatment status and the estimated PS [59]. Depending on whether the outcome is 
continuous or dichotomous, a regression model would be selected accordingly.  
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Covariate adjustment with PS overcomes the potential limitations encountered with PS 
matching by allowing for conducting analyses on the entire cohort rather than on the PS 
matched sample; so no observations are lost [59, 120]. However, as with IPW methods, 
extreme PSs maybe removed, but this, while reducing any residual bias, may reduce the 
sample size and increase the covariate imbalance between treatment and control group [59, 
120, 125, 126]. Other issues arising from the covariate adjustment approach include the 
correct specification of the regression model once the PS model is appropriately specified. 
In regression adjustment, the propensity score is included in the outcome equation; 
however, its relationship with the outcome is unknown and can be only assumed. Also, 
being the propensity score itself a function of the covariates, the inclusion of the propensity 
score as an additional covariate implies establishing a relation between the outcome and 
the covariates which is affected by the PS functional model, and might be different from 
the true functional form [137]. Because of the need for correctly specifying both the PS 
and the outcome model, this method is generally regarded as inefficient compared to other 
PS approaches. Nevertheless, including PS as an additional covariate, along with other 
covariates in the outcome model, thus resulting in a double robust approach, will increase 
the efficiency of the method [59, 114, 120].  
 
 
5.3 Unobserved confounding 
Different methods, such as regression adjustment and those based on PS estimation are 
typically used to reduce observed confounding inherent to observational data, and as 
discussed, PS based methods are particularly efficient in addressing confounding by 
indication. However, if in addition to observed confounders, unobserved confounders or 
other factors also affect the outcomes, different statistical methods may be used to correct 
for potential bias and estimate the treatment effect in the context of RWE. These methods 
are based on the use of instrumental variables, difference in differences and regression 
discontinuity. A brief description of these methods is provided below.  
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Instrumental variable  
The instrumental variable approach, allows the estimation of the causal effect of treatment 
on the outcome in a non-randomised setting in the presence of unobserved confounding. 
Therefore, instrumental variable can be considered as a method that resembles the 
treatment assignment process in RCTs where patients could randomly be separated into 
two distinctive subgroups according to, for instance, policy change or geographical 
differences [11, 138]. In a clinical context, different values of the instrumental variable for 
two groups may reflect different probabilities of receiving a treatment. In particular, if the 
treatment rate differs, but the outcome in the two groups does not, then the treatment 
cannot be indicated as the cause for causing the outcome. On the contrary, if the outcomes 
between the two groups differ, then the treatment could be indicated as the cause for the 
outcome; here, comparing outcomes for two groups with different values of instrumental 
variable would be the same as comparing groups that have been randomised for treatment 
allocation. 
 
For the instrumental variable approach to be an effective method to mitigate unobserved 
confounding, different assumptions must be tested and satisfied. In particular, the 
instrumental variable must be associated with exposure to the intervention, thus 
determining the treatment assignment; but at the same time, it must not be associated with 
the outcome variable. Finally, the instrumental variable must be associated to the outcome 
only because of the use of the intervention. However, in many cases it is very difficult to 
identify an instrument that satisfies the assumptions described [115]. In addition, it should 
be considered that instrumental variable estimates the local average treatment effect 
(LATE) that is the average treatment effect (ATE) estimated only for a specific population.  
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An instrumental variable could also, as suggested by Brookhart (2010) [138],  be used to 
assess the safety and effectiveness of a new treatment using hospital formularies and 
administrative data. In the example provided, a new treatment is introduced for the 
treatment of acute MI. While existing clinical evidence suggests that the new treatment is 
more effective than existing therapies, the new treatment is expensive and may cause side 
effects in certain patients; thus, the new treatment would only be added to the formulary of 
some hospitals. This would create a system where patients are randomly allocated to 
exposure; where patients are not randomized to hospitals, but formulary status is 
randomized to patients, in the sense that patients are not aware of hospitals' formularies 
[120].  
 
Difference in differences 
The difference in differences approach, controlling for unobserved differences, estimates 
the treatment effect by comparing changes over time in the outcome of interest between 
treatment and control group. This approach relies on the two central assumptions: 
“common time effects across groups” and “no composition changes within groups”. More 
specifically, this method assumes that unobserved characteristics of an individual are fixed 
over time. Hence, calculating the difference in outcomes in the same way as if neither 
group was exposed to the treatment. In addition to unobserved differences, this approach 
also controls for observed differences; thus minimising the risk of  omitted variable bias 
caused by unmeasured confounders or measurement error [139]. Historically, difference in 
differences has been employed in evaluation of health-care policies; however, it could be 
used for estimating the treatment effect whenever data are available for the period 
preceding treatment initiation and after, and for treatment and comparison groups.  
The main limitation of this method, however, consists in finding similar study groups, 
where treatment exposure is the only difference [140]. 
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Regression discontinuity 
Comparatively, with regression discontinuity, the treatment effect is estimated by 
comparing treatment exposure above and below a certain threshold of a given continuous 
variable for both, control and treatment group. Additional terms may be added to the model 
so that the slope can vary above and below a given threshold. As in the instrumental 
variable, regression discontinuity estimates  the LATE rather than the ATE  [116].  
 
Further, depending on whether the threshold affects treatment effect deterministically or 
probabilistically, regression discontinuity may have a sharp or fuzzy design. In the first 
case, a given threshold makes a clear distinction between those who receive the treatment 
(e.g. those above the given threshold) and those who do not (e.g. those above the given 
threshold). However, in reality, this is hardly the case, as there may be individuals in 
treatment group who do not receive the treatment, and individuals in the control group who 
receive the treatment. The fuzzy design addresses this issue with a probabilistic approach 
where the probability of receiving the treatment is higher above or below the given 
threshold.  
 
Because of its characteristics, regression discontinuity is generally regarded as the best 
approximation of an observational study to an RCT [115, 116, 141]. An example of 
regression discontinuity is represented by CD4 glycoproteins counts to establish eligibility 
for antiretroviral therapy among HIV-positive patient. Exogenous factors such as smoking 
and exercise will cause variability in the CD4 count measurement; this variability 
mimicking a random variable is then used for assessing whether observations are above or 
below a certain threshold ( in this case 200 cells/μL CD4 count); this will allow for 
estimating treatment effect and establishing treatment assignment [142]. 
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5.4 Methods 
5.4.1 Data sources and cohort 
Initially, all patients treated with either warfarin or DOACs were identified from PIS. 
Individual-level data linkage was then carried out with SMR01 and mortality records to 
identify AF patients, clinical events and calculate mortality rates. The clinical outcomes 
were identified from SMR01 according to ICD-10 and OPCS-4 codes.  
In this Chapter, the focus is on stroke-all (including ischaemic and haemorrhagic), major 
bleeding and all-cause mortality; details on the ICD-10 and OPCS-4 codes used for 
identifying clinical outcomes and mortality are provided in Chapter 6.  
 
In order to represent a typical cohort of anticoagulant users, the analysis was limited to 
patients who were 50 years or older at the time of the first OAC prescription. PIS records 
are available from 2009 onwards; therefore, to establish a cohort of patients with a first 
prescription of warfarin or DOACs, and no exposure to anticoagulation within one year 
prior to the index date, only patients starting anticoagulation from 2010 onwards were 
included in the analysis.  
 
Further, to ensure that only patients that were likely to have received OACs because of an 
AF diagnosis were included (ICD10 code I48X), any patients with a diagnosis other than 
AF were excluded from the analysis. Clinical codes for inclusion and exclusion criteria are 
presented in Table 5.2. In addition, a cohort including users of any DOAC “combined 
DOAC” was created to increase the overall treatment sample size and assess whether any 
of the PS approaches tested were sensitive to sample size.  
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Table 5.2 Inclusion and exclusion criteria 
Outcome Diagnostic, procedure and drug codes 
Inclusion criteria   
Atrial fibrillation ICD-10: I48  
Oral anticoagulant BNF: 02.08.02 
Exclusion criteria  
Mitral stenosis, valvular 
disease or heart valve 
replacement 
ICD-10: I05 – I08, I34 – I37, Q22, Q23, Z95.2 – Z95.4                             
OPCS-4: K02.3, K25.3, K25.4, K25.8, K25.9, K26.3, K26.4,                   
K29.1 – K29.4, K30.1, K31.1 
VTE ICD-10: I26, I63.6, I67.6, I80.1-I80.9, I81, I82.2- I82.9 
 
 
5.4.2 Propensity score model 
 
Different PS models comparing the effectiveness of DOACs against warfarin for three 
major AF related clinical outcomes (stroke, major bleeding and mortality) were produced. 
This was done in three major steps. Firstly, the PSs were estimated for each treatment, and 
then with aid of the NICE DSU document on the use of observational data to inform 
estimates of treatment effectiveness in technology appraisal, the PS methods to be tested 
were identified. In detail, based on the initial assessment of PS overlap between the 
treatment and the control group, the NICE DSU document indicates what method should 
be used to address observed confounding, as long as the assumption of no unobserved 
confounding is reasonable [114].  
 
The document suggests that with a good PS overlap, and by assuming that “a regression 
model is a good approximation of the effect of covariates on outcome” (best specification 
possible in terms of functional form and covariates), regression adjustment, on its own or 
as double robust combined with IPW, should be used. Alternatively, in cases where there is 
not a good approximation, the methods that should be used are IPW, on its own or as 
double robust combined with regression adjustment, or matching [114].  
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With a poor overlap, the guidelines suggest the use of matching methods to improve the 
overlap; then if a good or a moderate balance is obtained, regression methods should be 
applied on the matched sample. If poor overlap is still present following matching, 
trimming the sample may improve the overlap. With this approach, however, there is the 
risk of removing a large portion of individuals from the analysis, causing the estimates to 
refer to the treatment effect on the treated rather than the ATE. If after trimming, a poor 
balance is still persistent, it may not be possible to conduct the analysis assuming selection 
on observables [114]. Finally, PS model specification assessment was carried out to 
identify the most robust PS based method among the ones initially selected. In this step PS 
overlap was assessed for each of the methods identified and for each treatment group 
[114].  
 
PS estimation  
The PS estimation was carried out for each individual DOAC (apixaban, dabigatran and 
rivaroxaban), warfarin and the combined DOAC cohorts, resulting in five different PS 
models. Propensity scores were estimated with a logit model accounting for the following 
baseline characteristics of first time OAC users: age at the time of the first prescription, 
sex, SIMD, CHA2DS2-VASc and HAS-BLED score, ischaemic stroke or SE or TIA, 
vascular disease, hypertension, diabetes, cancer, prescription predisposing bleeding, and 
comorbidity. The PS in each of the five different PS models was estimated according to the 
full set of covariates listed above. The risk scores were calculated for each patient for the 
5-year periods prior to their first anticoagulation prescription.  
 
 
 
 
Chapter 5                                                                                                                                                        119 
 
The CHA2DS2-VASc is an extension of the previously developed CHADS2. The risk score 
of both tools depends on patients’ previous history of stroke, TIA, congestive heart failure, 
hypertension and diabetes identified in SMR01 according to their corresponding ICD10 
codes as shown in Table 5.3. Patient age, if over 65 years, is also included in the risk score 
equation. For the CHA2DS2-VASc, the risk score is calculated by also taking into account 
patients’ sex and age if greater than 75 years, and whether there is a prior history of 
vascular disease including MI, peripheral arterial disease, or aortic plaque. These are 
important risk predictors that may allow for a more accurate calculation of the potential 
risk of stroke in patients affected by AF [30, 143]. In the CHA2DS2-VASc tool, a point is 
given for each variable as described in Table 5.3; two points are given if a patient has a 
previous history of stroke or TIA [143].  
 
Although CHA2DS2-VASc is widely used, there were limitations in the development of the 
risk-predicting tool that could have an impact on predicting thromboembolic events. 
Firstly, information on the occurrence of thromboembolic events during the first year from 
the baseline survey was only available for 69% of patients. Secondly, the primary analysis 
was based on 1,084 patients that were not anticoagulated at baseline, and during the first 
year follow up, only 18% started anticoagulation [143]. In the PS models, CHA2DS2-VASc 
was entered as a categorical variable where the risk of stroke is represented by the 
following risk categories: low to moderate (0-1), moderate to high (2-3) and high (>=4). 
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Table 5.3 CHA2DS2-VASc - ICD-10 and OPCS-4 codes  
Variable  Diagnostic, procedure and drug codes 
Points             
if present 
Stroke or TIA ICD-10: I26, I63, I64, G45.8, G45.9, G46.3 - G46.7 2 
Congestive heart failure ICD-10: I11.0, I13.0, I13.2, I50 1 
Hypertension ICD-10: I10 - I15 1 
Vascular disease  ICD-10: I20 - I22, I70, I73.1, I73.8, I73.9, I74 1 
Diabetes mellitus 
ICD-10: E10, E11, E13, E14, G59.0, G63.2, H28.0, H36.0, 
M14.2, N08.3, O24.0, O24.1, O24.3 
1 
Sex Category (female)  not applicable 1 
Age ≥65 years not applicable 1 
Age ≥75 years not applicable 1 
 
The HAS-BLED scoring system, (Table 5.4), is similar to the one described for CHA2DS2-
VASc. The risk score is calculated according to age, history of hypertension, renal and 
liver disease, stroke, TIA and major bleeding [31, 144]. Alcohol intake and the use of 
drugs predisposing to bleeding such as aspirin, Clopidogrel, or non-steroidal anti-
inflammatory drugs, are two other important variables determining the potential risk of 
bleeding in AF patients. Alcohol intake was defined according to alcohol abuse related 
hospital admissions, and according to prescription of drugs used for alcohol dependence 
defined by BNF subsection 04.10.01 and identified from PIS records.  
Similarly, the use of drugs promoting bleeding was established according to BNF section 
02.09 and BNF subsection 10.01.01.  
 
As, laboratory data were not part of the administrative health datasets, labile INR 
indicating quality of anticoagulation by means of unstable or high INRs or poor time in 
therapeutic range was not included in determining the potential risk of bleeding.  However, 
as Poli et al. suggest, the redefined version of HAS-BLED, renamed HAS-BED and not 
taking into account the labile INR item, is still able to predict a high risk of bleeding [144].  
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The full list of variables and codes required for calculating the HAS-BLED risk score is 
reported in Table 5.4. In the PS models, HAS-BLED was entered as a categorical variable 
where the risk of bleeding is represented by the following risk categories: low to moderate 
(0-2), and moderate to high (>=4). 
 
Table 5.4 HAS-BLED - ICD-10 and OPCS-4 and BNF codes 
Variable  Diagnostic, procedure and drug codes 
Points             
if present 
Hypertension ICD-10: I10 - I15 1 
Renal disease 
ICD-10: I12, I13, N00 - N05, N07, N11, N14, N17 - N19, 
Q61 
1 
Liver disease ICD-10: B15.0, B16.0, B16.2, B19.0, K70 - K76 1 
Stroke or TIA ICD-10: I26, I63, I64, G45.8, G45.9, G46.3 - G46.7 1 
Major bleeding 
ICD-10: D62, H11.3, H35.6, H43.1, I60 – I62, J94.2, K25.0, 
K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, 
K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K29.0, 
K62.5, K92.0-92.2, N02, N95.0, R04, R31, R58 
1 
Alcohol intake 
ICD-10: E52, F10, G31.2, G62.1, G72.1, I42.6, K29.2, K70, 
K86.0, O35.4, T51, Z71.4, Z72.1                                              
BNF: 04.10.01         
1 
Drugs predisposing to bleeding BNF: 02.09, 10.01.01 1 
Age ≥65 years not applicable 1 
 
 
The previous history of stroke or SE or TIA, vascular disease, hypertension, diabetes, prior 
to OAC initiation, was ascertained from inpatient records. Further, previous history of 
cancer was included as it may be a reason for anticoagulation. All variables mentioned 
above and reflecting baseline characteristics that may influence treatment assignment were 
included in the PS models, as the variance inflation factor did not show evidence of 
collinearity. Because the PS method identified as the most robust will inform the 
comparative-effectiveness model in the subsequent Chapter, collinearity was also tested for 
standard and reduced DOACs (Appendix IV, Table IV-1).  
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PSs were estimated with the following equation: 
(0 < PS ≤ 1) = 𝛼 + 𝛽1𝐴𝑖 + 𝛽2𝐺𝑖 + ∑ 𝛽3𝑆𝑖
5
𝑠=2
+ ∑ 𝛽4𝐶𝐻𝑖
3
𝑠=2
+ 𝛽5𝐵𝑖 
+ ∑ 𝛽6𝐶𝑖
3
𝑐=2
+  𝛽7𝑆𝑖 + 𝛽8𝑉𝑖 + 𝛽9𝐻𝑖 + 𝛽10𝐷𝑖 + 𝛽11𝐶𝐴𝑖 + 𝛽12𝑃𝑖 +  𝑢𝑖 
                                                                                                              (Equation 5.5) 
Where A is age at the time of admission (reference category: 50 -54 age group); G is sex 
(reference category: male); S is SIMD category (reference category: most deprived 
category (1)); CH is the CHA2DS2-VASc score (reference category: 0-1); B is the HAS-
BLED score (reference category: 0-2); C is Charlson comorbidity index (reference 
category: no comorbidities); S,V,H,D,CA are stroke or SE or TIA, vascular disease, 
hypertension, diabetes and cancer (dummy variables 0=no event, 1=event); P is 
prescription predisposing bleeding (reference category: no prescription); 𝑢𝑖 is the error 
term for patient i 
 
PS models to be tested  
Assuming that the assumption of no unobserved confounding is reasonable, and in line 
with the objective of this Chapter, only PS based methods were tested in this section. In 
particular, PS matching, covariate adjustment including PS as covariate and a series of 
IPW methods were tested as shown in Figure 5.1. In this process, the PS distribution was 
assessed for each model to assess whether the cohorts were adequately balanced and to 
identify potentially extreme weights. As the use of DOACs for the prevention of stroke in 
the AF population is relatively new compared to warfarin, it was assumed that warfarin 
(the control) outnumbered the treatment group (DOACs); this was however tested and 
presented in the Results section.  
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Thus, the PS matching without replacement was selected as the most suitable PS matching 
method. In the covariate adjustment method, the only step required in the PS model was PS 
estimation. 
 
The IPW methods tested were IPTW and IPTW combined with IPCW. In the IPTW 
method, a weight, reflecting the probability of being exposed to the combined DOAC 
cohort and equal to the reciprocal of the PS, was assigned to each patient in the treatment 
group; the same process was carried out for each DOAC individually. A weight equal to 
the reciprocal of one minus the PS was assigned to patients in the warfarin group. In the 
trimmed IPTW, individuals with extreme PS values were removed from the analysis; these 
were PSs <0.1 for the DOAC cohorts and PSs >0.9 for the warfarin group.  
Typically, 5% of patients with the most extreme PS are excluded from the analysis; 
however, this seems to be arbitrary and clear guidelines on this matter are not currently 
available [120].  
 
In the IPW method combining IPTW with IPCW, two different sets of weights were 
estimated. The weights for IPTW were estimated as discussed. Those for IPCW were 
estimated by censoring patients who switch treatment (from warfarin to DOACs, from 
DOACs to warfarin, or between DOACs), and assigning weights to individuals who were 
not censored but shared similar characteristics with the switchers. Then, IPTW and IPCW 
weights were added to obtain the overall weight reflecting ATE and censoring. 
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Figure 5.1 Propensity score model selection  
Abbreviations: PS=propensity score, IPW=inverse probability weighting, IPTW=inverse 
probability of treatment weighting, IPCW= inverse probability of censoring weighting. 
Source: Adapted from, Faria et al. (2015). 
 
PS model specification assessment 
Following a selection of PS based models, adequacy of model specification was assessed 
graphically and by means of standardized difference, a measure generally used to compare 
the mean of variables between treatment groups. Differences in the means of covariates 
were considered negligible if below the threshold of 0.1 standard deviation [127].  
 
5.4.3 Outcome model 
 
Cox proportional hazards regression (time-to-event analysis) was used to compare risks 
between treatment groups for three major AF related clinical events: stroke-all (including 
haemorrhagic and ischaemic), major bleeding and all-cause mortality. Following a double 
robust approach, some of the covariates used in the PS models were used in the outcome 
models; these were age, sex, comorbidity, socio economic status, and year of prescription. 
This was done for all PS based methods tested.  
Check overlap between treated and 
untreated group
Methods assuming selection 
on observables
Matching,
Covariate adjustment with PS,
IPW (IPTW, IPTW+IPCW)
Trim the sample                     
to improve overlap
Check balance Check balance
Poor / moderate Good
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Following a continuous treatment approach [63], patients were censored if they switched 
or discontinued treatment; for each method, the risks of stroke, major bleeding or death 
(for patients exposed to either DOACs or warfarin) were estimated from anticoagulation 
initiation to the time of clinical event or death during a 2-year follow-up period. However, 
descriptive statics on treatment switching are reported at 2-year and 6-year follow-up. The 
first clinical event for each treatment was determined within a competing risk framework. 
In this analysis, treatment discontinuation, i.e. temporal gaps between consecutive 
prescriptions, was considered to be occurring if the gap exceeded a 28 days threshold, and 
the supply of the penultimate prescription did not fill the gap. The threshold was identified 
in a drug utilisation study using the same patient-level data utilised in this thesis [27]. 
 For the IPW method combining IPTW with IPCW, censoring was specifically modelled in 
the PS model.  
 
In this Chapter, the Cox model was used as a proof of concept, characteristics and 
assumptions of the Cox model will be discussed in more detail in Chapter 6. In addition to 
comparing PS models in terms of robustness by measuring the standardised differences for 
each covariate, the ATE, estimated with the outcome model for each of the clinical 
outcomes selected, was compared across method to assess whether and how it differs 
depending on the PS method used. The ATE estimates the treatment effect on the cohort of 
interest but could also selectively estimate the treatment effect only for those patients, that 
within the same cohort, are treated (treatment effect on the treated -ATT).  Because the 
focus of this analysis was estimating the treatment effect on the whole AF population, 
regardless of whether patients where on DOACs or warfarin, the ATE was estimated.  
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5.5 Results 
 
5.5.1 Cohort characteristics  
From the initial cohort of 166,182 patients on any OAC identified from the PIS between 
April 2009 and December 2015, a cohort of 165,627 patients on either warfarin or DOACs 
were identified. The final cohort resulted in 33,965 treatment naïve patients, of which 
26,387 were on warfarin, 3706 on apixaban, 484 on dabigatran and 3,388 on rivaroxaban. 
The diagram showing how the cohort for this analysis was obtained is presented in Figure 
5.2 
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Figure 5.2 Study population    
The initial study population, firstly identified from PIS, was linked to inpatients and mortality data to identify patients that were likely to have received oral 
anticoagulants because of an AF or atrial flutter diagnosis according to the ICD10 code I48X. Only patients 50 years or older and naïve to anticoagulation were 
included in the analysis, those with a history of valvular heart disease or venous thromboembolism were excluded.
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Overall, mean age of patients at the time of the first prescription was similar across all 
treatment groups. Across all treatments, patients with the highest risk of stroke measured 
using the CHA2DS2-VASc score represented the majority. This is clearly visible in the 
histogram (Figure V-1) presented in Appendix IV, indicating that most patients had a 
CHA2DS2-VASc score of 4 points (laying within the >=4 risk category) across all 
treatment groups. Patients with the lowest risk of bleeding measured using the HAS-BLED 
score represented the majority. Again, this is clearly visible in the histogram (Figure V-2) 
presented in Appendix III, indicating that most patients had a HAS-BLED score of 2 points 
(laying within the >=2 risk category) across all treatments; however, the proportion of 
patients with the lowest risk of stroke was higher in the dabigatran group than any other 
treatment group. Similarly, while most patients had no comorbidities across all treatment 
groups, those on dabigatran represented the biggest proportion (Appendix V, Figure V-3).  
Further, the proportion of patients with a history of stroke or SE or TIA was lower in the 
dabigatran group than any other treatment group. Over one third of patients on 
anticoagulation had hypertension, which is an important risk factor for stroke. In addition, 
the majority of patients across all treatment groups were also on medication predisposing 
to bleeding such as aspirin and non-steroidal anti-inflammatory drugs than patients on any 
other DOACs. Patients’ baseline characteristics are reported in Table 5.5 
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Table 5.5 Baseline characteristics 
Characteristics 
Apixaban Dabigatran Rivaroxaban Warfarin 
N(%) N(%) N(%) N(%) 
Cohort  3,706 484 3,388 26,387 
Sex         
Men 1,983 (53.51) 304 (62.81) 1,805 (53.28) 14,437 (54.71) 
Women 1,723 (46.49) 180 (37.19) 1,583 (46.72) 11,951 (45.29) 
Mean age (SD) 75 (10.26) 72 (10.44) 75 (10.23) 74 (9.23) 
SIMD (Scottish index of multiple deprivation) 
1 845 (22.80) 44 (9.09) 524 (15.47) 5,019 (19.02) 
2 737 (19.89) 89 (18.39) 613 (18.09) 5,637 (21.36) 
3 615 (16.59) 125 (25.83) 749 (22.11) 5,581 (21.15) 
4 642 (17.32) 132 (27.27) 828 (24.44) 5,305 (20.10) 
5 867 (23.39) 94 (19.42) 674 (19.89) 4,845 (18.36) 
CHA2DS2-VASc score         
0-1 826 (22.29) 164 (33.88) 697 (20.57) 5,547 (21.02) 
2-3 1,179 (31.81) 144 (29.76) 1,078 (31.82) 9,084 (34.43) 
>=4 1,701 (45.90) 176 (36.36) 1,613 (47.61) 11,756 (44.55) 
HAS-BLED       
0-2 2,338 (63.09) 347 (71.69) 2,178 (64.29) 16,878 (63.96) 
>=3 1,368 (36.91) 137 (28.31) 1,210 (35.71) 9,509 (36.04) 
Comorbidity         
no comorbidity 1,814 (48.95) 317 (65.50) 1,714 (50.59) 13,831 (52.42) 
1 comorbidity 883 (23.83) 83 (17.15) 769 (22.70) 5,974 (22.64) 
>1 comorbidities 1,009 (27.23) 84 (17.36) 905 (26.71) 6,582 (24.94) 
Stroke or TIA 543 (14.65) 43 (8.88) 502 (14.82) 3,490 (13.23) 
Vascular disease 633 (17.08) 70 (14.46) 601 (17.74) 4,778 (18.11) 
Hypertension 1,307 (35.27) 154 (31.82) 1,237 (36.51) 9,653 (36.58) 
Diabetes mellitus 528 (14.25) 62 (12.81) 476 (14.05) 3,558 (13.48) 
Cancer 321 (8.66) 41 (8.47) 290 (8.56) 1,982 (7.51) 
Drug causing bleeding 2267 (61.17) 282 (58.26) 1,974 (58.26) 17,373 (65.84) 
 
At 2-year follow-up, patients initiating anticoagulation with warfarin or dabigatran were 
more likely to discontinue compared to patients on other anticoagulation treatments. On 
the contrary, the majority of patients starting anticoagulation with apixaban where more 
likely to stay on treatment. Patients initiating anticoagulation with warfarin were also more 
likely to switch to rivaroxaban than any other DOAC. A much smaller proportion of 
patients also switched from DOAC to warfarin and from DOAC to DOAC. Findings for 
discontinuation and switching at 6 years were in line with those observed at 2 years follow-
up. The full description on patients switching and discontinuing is presented in Table 5.6. 
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Table 5.6 Treatment discontinuation or switching 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.2 Propensity score distribution 
 
The PSs for the DOACs versus warfarin comparison showed an adequate overlapping 
distribution, and no extreme PSs are observed (Figure 5.3). By contrast, when comparing 
DOACs individually against warfarin different scenarios emerged. The PSs generated from 
the apixaban versus warfarin analysis, graphically showed an adequate overlap, however 
extreme weights were observed for the apixaban group. In particular, 760 patients amongst 
the apixaban users had PSs <0.1(Figure 5.4). To avoid trimming a large proportion of 
patients (20% of individuals on apixaban) with extreme PS and causing further covariate 
imbalance, only 5% of patients with the most extreme PS were excluded from the analysis. 
Discontinuing/switching 
2-year follow-up  
N (%) 
 6-year follow-up 
 N (%) 
All patients   
Discontinue 11,366 (33.46) 13,239 (38.98) 
Switch warfarin to DOAC 2,146 (6.32) 3,568 (10.50) 
Switch DOAC to warfarin 150 (0.44) 164 (0.48) 
Switch DOAC to DOAC 196 (0.58) 214 (0.63) 
Warfarin      
Discontinue 9,980 (37.82) 11,502 (43.59) 
Switch to apixaban 746 (2.83) 1,360 (5.15) 
Switch to dabigatran 226 (0.86) 301 (1.14) 
Switch to rivaroxaban 1,174 (4.45) 1,907 (7.23) 
Apixaban      
Discontinue 348 (9.39) 410 (11.06) 
Switch to warfarin 30 (0.81) 31 (0.84) 
Switch to dabigatran 9 (0.24) 9 (0.24) 
Switch to rivaroxaban 35 (0.94) 35 (0.94) 
Dabigatran      
Discontinue 200 (41.32) 259 (53.51) 
Switch to warfarin 31 (6.40) 37 (7.64) 
Switch to apixaban 16 (3.31) 25 (5.17) 
Switch to rivaroxaban  37 (7.64) 42 (8.68) 
Rivaroxaban      
Discontinue 838 (24.73) 1,068 (31.52) 
Switch to warfarin 89 (2.63) 96 (2.83) 
Switch to apixaban 79 (2.33) 83 (2.45) 
Switch to dabigatran 20 (0.59) 20 (0.59) 
Chapter 5                                                                                                                                                        131 
 
 
Figure 5.3 PS distribution for combined DOACs and warfarin 
 
 
Figure 5.4 PS distribution for apixaban and warfarin 
 
The totality of the PS generated from the dabigatran versus warfarin comparison were 
extreme and had a poor overlap (Figure 5.5). In these cases, applying PS trimming or 
extreme weights truncation is clearly not feasible, and any PS method may give incorrect 
ATE estimates. 
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Figure 5.5 PS distribution for dabigatran and warfarin 
 
Despite an acceptable overlap of the PS distribution, 1,021 patients on rivaroxaban had 
extreme PS (Figure 5.6). As with apixaban, to avoid additional imbalance only 5% of 
patients with the most extreme PSs were excluded from the analysis. 
 
 
Figure 5.6 PS distribution for rivaroxaban and warfarin 
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5.5.3 Covariate balance assessment 
 
 
Combined DOACs versus warfarin  
Following the first graphical assessment on the PS models specification, the distribution of 
baseline covariates between treatment groups was assessed by means of standardized 
difference. As shown in Table 5.7, the unadjusted standardized differences indicated an 
adequate starting balance for the baseline characteristics of patients on any DOAC 
(combined DOACs) or on warfarin, with differences in the means of covariates below the 
threshold of 0.1 standard deviation. Overall, a good balance of patients’ covariates was 
obtained with every PS model tested. However, the standardised difference for CHA2DS2-
VASc score >=4, HAS-BLED score >=3 did not improve with the PS matching method. 
Nevertheless, the standardised difference for these patient characteristics was still below 
the threshold regardless of being adjusted or unadjusted. The same issue was encountered 
when adopting the IPW approach were no balance improvement was observed for the 
HAS-BLED score >=3 and having one comorbidity. 
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Table 5.7 Covariate imbalance assessment for combined DOACs vs. warfarin 
 
Abbreviations: SIMD=Scottish index of multiple deprivation, TIA=transient ischaemic attack.    
Women 0.014 0.008 0.003 0.010
Mean age (SD) 0.086 0.034 0.008 0.013
SIMD quintile 2 0.059 0.003 0.003 0.005
SIMD quintile 3 0.037 0.006 0.003 0.005
SIMD quintile 4 0.026 0.000 0.003 0.005
SIMD quintile 5 0.080 0.012 0.003 0.005
CHA2DS2-VASc score 2-3 0.058 0.004 0.005 0.004
CHA2DS2-VASc score >=4 0.030 0.034 0.005 0.004
HAS-BLED  score >=3 0.004 0.023 0.003 0.012
Comorbidity 1 comorbidity 0.006 0.001 0.002 0.007
Comorbidity >1 comorbidity 0.033 0.031 0.002 0.007
Stroke or TIA 0.033 0.027 0.003 0.010
Vascular disease 0.024 0.008 0.001 0.002
Hypertension 0.020 0.015 0.003 0.015
Diabetes mellitus 0.017 0.041 0.003 0.010
Cancer 0.040 0.020 0.000 0.005
Drugs causing bleeding 0.128 0.019 0.001 0.013
Characteristics Unadjusted PSM adjusted PS covariate adjusted IPTW adjusted
0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.300.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30
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Apixaban versus warfarin  
An overall adequate balance for baseline characteristics was also observed between 
apixaban and warfarin, where the standardised difference was further reduced for every 
covariate with the PS covariate adjustment and IPW method. However as previously 
observed, balance of stroke or TIA, vascular disease and diabetes mellitus, did not improve 
when using the PS matching method (Table 5.8).    
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Table 5.8 Covariate imbalance assessment for apixaban vs. warfarin 
 
Abbreviations: SIMD=Scottish index of multiple deprivation, TIA=transient ischaemic attack. 
Women 0.024 0.011 0.001 0.004
Mean age (SD) 0.061 0.017 0.012 0.021
SIMD quintile 2 0.036 0.022 0.001 0.001
SIMD quintile 3 0.117 0.012 0.001 0.002
SIMD quintile 4 0.071 0.006 0.001 0.003
SIMD quintile 5 0.124 0.042 0.001 0.003
CHA2DS2-VASc score 2-3 0.056 0.003 0.006 0.007
CHA2DS2-VASc score >=4 0.027 0.004 0.006 0.012
HAS-BLED  score >=3 0.018 0.006 0.002 0.007
Comorbidity 1 comorbidity 0.017 0.017 0.002 0.004
Comorbidity >1 comorbidity 0.049 0.029 0.002 0.006
Stroke or TIA 0.041 0.053 0.006 0.007
Vascular disease 0.027 0.031 0.001 0.000
Hypertension 0.027 0.024 0.000 0.004
Diabetes mellitus 0.022 0.025 0.001 0.001
Cancer 0.042 0.035 0.003 0.002
Drugs causing bleeding 0.097 0.019 0.002 0.004
Characteristics Unadjusted PSM adjusted PS covariate adjusted IPTW adjusted
0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30
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Dabigatran versus warfarin  
The standardized difference above the threshold reflected a substantial difference in the 
starting baseline characteristics of dabigatran and warfarin users. An adequate balance was 
however achieved for all covariates with the PS covariate adjustment method. Again, PS 
matching failed to provide an optimal balance in terms of patient characteristics between 
the dabigatran and warfarin groups. Similarly, improved balance was not achieved for 
every covariate when using the IPW approach. In particular, the balance for socio 
demographic characteristics captured by SIMD (category 2 and 5) and the covariate 
indicating the diagnosis of cancer, although still below the threshold, was suboptimal 
compared to the unadjusted initial baseline characteristics balance (Table 5.9). 
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Table 5.9 Covariate imbalance assessment for dabigatran vs. warfarin 
 
Abbreviations: SIMD=Scottish index of multiple deprivation, TIA=transient ischaemic attack. 
Women 0.165 0.000 0.024 0.023
Mean age (SD) 0.215 0.056 0.088 0.081
SIMD quintile 2 0.075 0.005 0.001 0.093
SIMD quintile 3 0.110 0.038 0.002 0.092
SIMD quintile 4 0.169 0.056 0.004 0.092
SIMD quintile 5 0.027 0.000 0.005 0.092
CHA2DS2-VASc score 2-3 0.100 0.059 0.005 0.082
CHA2DS2-VASc score >=4 0.167 0.026 0.027 0.082
HAS-BLED  score >=3 0.166 0.009 0.018 0.006
Comorbidity 1 comorbidity 0.159 0.006 0.010 0.041
Comorbidity >1 comorbidity 0.158 0.042 0.021 0.041
Stroke or TIA 0.139 0.015 0.028 0.025
Vascular disease 0.099 0.082 0.025 0.009
Hypertension 0.101 0.031 0.020 0.006
Diabetes mellitus 0.020 0.056 0.013 0.018
Cancer 0.035 0.126 0.016 0.040
Drugs causing bleeding 0.156 0.008 0.000 0.008
Characteristics Unadjusted PSM adjusted PS covariate adjusted IPTW adjusted
0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.300.00 0.10 0.20 0.30
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Rivaroxaban versus warfarin  
An overall good starting balance was also observed for the baseline characteristics of 
rivaroxaban and warfarin users. However, the mean age of patients at the time of the first 
prescription, SIMD (category 3) and the use of drugs causing bleeding, seemed to some 
extent differ between the two treatment groups. While, the PS methods brought the balance 
for those covariates below the 0.1 threshold, the balance for HAS-BLED score >=3 and 
hypertension did not improve with any of the methods tested (Table 5.10). 
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Table 5.10 Covariate imbalance assessment for rivaroxaban vs. warfarin 
 
Abbreviations: SIMD=Scottish index of multiple deprivation, TIA=transient ischaemic attack
Women 0.029 0.023 0.010 0.009
Mean age (SD) 0.156 0.024 0.013 0.026
SIMD quintile 2 0.082 0.005 0.005 0.005
SIMD quintile 3 0.023 0.033 0.005 0.004
SIMD quintile 4 0.104 0.003 0.005 0.001
SIMD quintile 5 0.039 0.021 0.005 0.008
CHA2DS2-VASc score 2-3 0.055 0.002 0.004 0.016
CHA2DS2-VASc score >=4 0.061 0.024 0.004 0.023
HAS-BLED  score >=3 0.007 0.031 0.012 0.016
Comorbidity 1 comorbidity 0.013 0.001 0.007 0.002
Comorbidity >1 comorbidity 0.043 0.041 0.007 0.009
Stroke or TIA 0.046 0.023 0.010 0.012
Vascular disease 0.010 0.008 0.002 0.006
Hypertension 0.001 0.021 0.015 0.008
Diabetes mellitus 0.016 0.050 0.010 0.007
Cancer 0.039 0.047 0.005 0.006
Drugs causing bleeding 0.157 0.045 0.013 0.008
Characteristics Unadjusted PSM adjusted PS covariate adjusted IPTW adjusted
0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30
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5.6 Discussion 
 
In clinical practice, population case mix may diverge substantially, making a comparison 
of safety and effectiveness of two health interventions difficult. PS methods allow for 
reducing any potential imbalance between covariates and obtaining more homogenous and 
comparable treatment groups [59, 125].  When comparing combined DOACs, apixaban 
and rivaroxaban against warfarin, with the exception of the dabigatran versus warfarin 
analysis, a reasonable balance of baseline characteristics was observed even before 
adjusting with PS estimates.  However, in some cases the standardised difference indicated 
that the balance of certain baseline characteristics between treatments did not improve after 
PS adjustment. This occurrence is reported in the literature, and it seems to be common 
with the PS matching method [131].  
 
Overall patients on dabigatran were younger, with a low risk of stroke and with fewer 
comorbidities compared to patients on any other DOAC or warfarin. This seems to suggest 
that dabigatran was selectively prescribed to patients with lower risk of stroke and in 
general healthier than patients on either warfarin, apixaban or rivaroxaban. Evidence of 
selective prescribing of dabigatran in younger patients with lower risk of stroke has been 
reported in the literature [63]. Further, as expected, patients on either reduced dose 
apixaban or reduced dose rivaroxaban, where at greater risk or stroke, bleeding and had 
more comorbidities than patients on apixaban and rivaroxaban standard dose. As per 
clinical guidelines reduced dose apixaban and rivaroxaban are recommended for patients 
aged 80 years or older [16, 18].  
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Among the PS methods tested, PS covariate adjustment, less sensitive to sample size, was 
shown to be the most robust method. As discussed, this is one of the main advantages over 
the PS matching approach. From a sole sample size perspective, PS covariate adjustment 
and IPW methods offer the same advantage, but trimming of PS or truncation of extreme 
weights may reduce the sample size further.  
 
Theoretically, PS covariate adjustment is less robust than PS matching and IPW methods, 
as it is more sensitive to distributional assumptions and PS specification, therefore not 
reflecting the true treatment effect [123, 128, 129]. Nevertheless, PS covariate adjustment 
was found to be a valid option to adjust for confounding by indication and in some 
instances outperformed the other methods reporting much reduced standardised 
differences. When censoring was incorporated in an IPTW-IPCW model rather than being 
modelled explicitly, the results were in line with those generated with other methods.  
Moreover, PS methods may not necessarily perform better than conventional standard 
regression. In particular, Elze and colleagues (2017) found that in the presence of 
substantial covariate imbalance with individuals with very large weights, IPW methods 
give inaccurate treatment effect estimates. In the case studies evaluated, after truncation, 
the estimated treatment effect moved towards the crude treatment effect, indicating the 
inadequacy of these methods in adjusting for covariate imbalance in the presence of heavy 
weights.  On the other hand, the performance of PS matching and standard covariate 
adjustment were comparable, although PS matching gave less accurate estimates in some 
instances [104]. 
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5.7 Limitations  
 
The analysis carried out provides an overview of the PS based methods used to address 
confounding by indication; however, there were a number of limitations inherent to the 
nature of RWE and PS based methods. Firstly, the relatively small size of the cohorts did 
not allow the analysis to test for PS by stratification, a method involving the stratification 
of individuals into mutually exclusive subgroups according to their estimated PS [59]. In 
this method, individuals are typically divided into five distinct subgroups using the 
quintiles of the estimated PS; this will consent the treated and the untreated groups to have 
similar PS values and comparable distributions of measured baseline covariates. However, 
PS by stratification does not seem to perform optimally in datasets with few outcomes [59, 
120].  
 
A further constraint in this analysis, concerns the limitation of PS methods of addressing 
unmeasured confounding which may still bias the estimates. In particular, it is recognised 
that confounding by indication is the main source of confounding in newly marketed 
medications where early adopters are most likely to prescribe new drugs when they 
become available, whereas other prescribers may prefer to opt for existing drugs with 
proved and established clinical effectiveness [145]. While PS methods can address 
confounding by indication, there may still be unobserved confounders that are difficult to 
measure.  
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5.8 Conclusions  
 
Comparative-effectiveness research is rapidly evolving; in this context, RWE has a crucial 
role in supporting decision-making by generating clinical evidence for clinicians, patients 
and policy makers. Propensity score methods are powerful tools that mimic RCTs and 
address confounding by indication typical in RWE studies. However, PS methods have 
strengths and limitations that should be acknowledged. Propensity score matching and IPW 
methods are considered theoretically superior to PS covariate adjustment as the latter may 
be more prone to model misspecification.  
 
Nevertheless, in this study, PS covariate adjustment was found to be the most robust 
method, PS matching and IPW methods also performed well, but were excluded to avoid 
further sample size reduction. Therefore, the use of a single best method for reducing bias 
due to confounding by indication should be avoided, and the choice of adequate PS 
methods may vary according to the characteristics of the data. It follows that, as long as 
assumptions such as no unobserved confounding hold, several methods should be 
identified and tested.  
  
For the comparative-effectiveness of DOACs in the next Chapter, the choice of any PS 
model over another is unlikely to lead to divergent conclusions. Nevertheless, for the reasons 
discussed, PS used as a covariate is the approach that will be used for the comparative and 
cost-effectiveness analyses in the Chapters 6 and 7. 
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Chapter 6 Comparative-effectiveness analysis 
 
6.1 Introduction  
 
This Chapter builds on the work carried out in the previous Chapter where covariate 
adjustment with PS was identified as the best fitting PS model for the DOACs case study. 
As mentioned, PS methods are typically used in observational studies to address 
confounding by indication [59]. While the PS  model  described in Chapter 5 only focused 
on stroke, major bleeding and all-cause mortality, in this Chapter a more comprehensive 
comparative-effectiveness analysis is carried out including all primary outcomes reported 
in the pivotal RCTs and existing observational studies assessing efficacy and effectiveness 
of DOACs in the AF population [41-43, 58, 60, 61, 63]. In addition, although a Cox model 
was used as a proof of concept in Chapter 5 for comparing risks of selected clinical 
outcomes, in this Chapter a more rigorous approach (e.g. assessing proportionality 
violation) is adopted to identify the most appropriate method for the time-to-event analysis. 
Evidence on effectiveness of DOACs in clinical practice and in the long term is limited; 
thus, to address the third Objective of this thesis, this Chapter aims at providing further 
evidence to inform clinical practice in Scotland. Results estimated in this Chapter will be 
used to populate the cost-effectiveness model in Chapter 7.  
 
 
6.2 Methods – data 
 
Prior to executing the comparative-effectiveness analysis, three main preparatory steps 
were carried out. Firstly, the clinical outcomes were identified from SMR01 according to 
ICD-10 and OPCS-4 codes informed by the literature [37, 81, 112-114]. Then CHA2DS2-
VASc and HAS-BLED scores were calculated. As discussed, these are bespoke tools used 
to estimate the probability of having a stroke and bleeding in patients affected by AF 
according to pre-existing conditions and patient characteristics. Finally, as described in 
Chapter 5, PSs were calculated according to a series of patients’ baseline characteristics. 
Chapter 6                                                                                                                                                        146 
 
These steps are described in more detail in the following sections. The comparative-
effectiveness analysis was carried out on the same study population described in the 
previous Chapter (Figure 5.2). 
 
6.2.1 Clinical outcomes 
 
In order to define the full effectiveness and safety profile of DOACs, several additional 
clinical outcomes were included in the analysis. In particular, the effectiveness of DOACs 
was assessed with respect to stroke and various composites (stroke or SE, stroke or SE or 
TIA, stroke or SE or all-cause mortality) as shown in Table 6.1. The clinical outcome of 
stroke was defined by the inclusion of both ischaemic and haemorrhagic stroke. Other 
relevant clinical outcomes were MI, ICH and mortality due to all-cause, stroke or 
cardiovascular events.  The safety profile was defined by assessing the risk of GI and 
major bleeding (including haemorrhagic stroke, GI and other major bleeding events). ICD-
10 and OPCS-4 codes from SMR01 used to identify clinical outcomes, obtained from a 
recent study assessing the effectiveness of DOACs using the same patient level data 
utilised in this thesis, are presented in Table 6.1 [146]. 
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Table 6.1 Clinical outcomes - ICD-10 and OPCS-4 codes 
Outcome Diagnostic, procedure and drug codes 
Effectiveness   
Stroke-all 
ICD-10 for Ischaemic stroke: I63, I64, G46.3-G46.7                                   
OPCS-4 for Ischaemic stroke: U54.3                                                              
ICD-10 for Haemorrhagic stroke: I60-61 
Stroke or SE 
Same as Stroke-all plus                                                                                  
ICD-10 for SE: I74 
Stroke or SE or TIA 
Same as Stroke or SE plus                                                                             
ICD-10 for TIA: G45.8, G45.9 
Stroke or SE or mortality                    
(all-cause) 
Same as Stroke or SE plus                                                                             
death identified form NRS 
MI 
ICD-10: I21, I22                                                                                          
OPCS-4: K50.2, K50.3 
Mortality (all-cause) Death identified from NRS 
Mortality (stroke) 
death identified form NRS plus                                                                      
ICD-10 and OPCS-4 codes used for Stroke-all 
Mortality (cardiovascular) 
death identified form NRS plus                                                                      
ICD-10: I11, I13, I20-I26, I46, I47, I49, I50, I60, I61, I63, I64, I67, I73, I74 
Safety    
ICH ICD-10: I61 
GI bleeding 
ICD-10: K25.0, K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, 
K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K29.0, K62.5, K92.0-92.2 
Major bleeding 
Including Haemorrhagic stroke, GI bleeding plus                                         
ICD-10 codes for Other major bleeds:  D62, H11.3, H35.6, H43.1, I62, J94.2, 
N02, R04, R31, R58, N95.0 
 
 
6.2.3 PS model 
 
As discussed in Chapter 5, after establishing adequacy of the PS model specification by 
graphical inspection and by means of standardized difference, the PS model using the PS 
as a covariate resulted the most robust method compared to PS matching and various IPW 
approaches. The model using PS as a covariate was then selected as the model for the 
comparative-effectiveness analysis carried out in this Chapter. As described in Chapter 5 
and shown in Equation 5.5, PS were estimated using a logistic regression model according 
to the following baseline characteristics: age at the time of the first prescription, sex, 
SIMD, prescription predisposing bleeding, comorbidity CHA2DS2-VASc and HAS-BLED 
scores, previous history of ischaemic stroke or SE or TIA, vascular disease, hypertension, 
diabetes, and cancer.  
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6.3 Methods – model 
 
Prior to conducting the comparative-effectiveness analysis, in addition to identifying 
clinical outcomes and calculating scores, an assessment of the proportionality assumption 
for the Cox proportional hazards model was carried out; proportionality is the main 
assumption that has to be satisfied for a semi-parametric or a parametric model to be valid 
[147, 148].  In general, the Cox proportional hazards model is a semi-parametric model 
indicating no association between estimated parameters and time, and assuming 
proportional hazards. The general hazard model can be written as follows: 
ℎ(𝑡, 𝑋) = ℎ0(𝑡) ∗ exp(𝛽𝑋) 
                                                                                                                           (Equation 6.1) 
Where ℎ0(𝑡) is the baseline hazard function when all explanatory variables X are set to 
zero, and (𝛽𝑋) is the linear predictor. The hazard rate (h) at time (t) is then obtained by 
multiplying the baseline hazard function by the exponential form of the linear predictor 
[149].         
 
While a semi-parametric model only provides estimates at a fixed time point, a parametric 
model is generally used to extrapolate the survival curves beyond the observed follow-up 
times in order to match a specific time horizon. Thus, parametric models are particularly 
useful in economic evaluation [148, 149]. Parametric models that can be parametrised as a 
proportional hazards model follow distributions such as Exponential, Weibull and 
Gompertz, which are monotonic with time; thus, the distributional assumption implies that 
the hazard has a specific shape [150, 151].  
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In particular, in the Exponential model, the simplest parametric model, the hazard function 
is constant over time and can be written as follows [150]:  
ℎ(𝑡) = 𝜆 𝑓𝑜𝑟 𝑂 ≤ 𝑡 <∞ 
                                                                                                                           Equation (6.2) 
Where λ is a positive constant and t is time.  
 
In the Weibull distribution depending on the shape and scale parameter, the hazard rate is 
assumed to increase (γ > 1) or decrease (γ < 1) monotonically over time, thus offering 
more flexibility than the exponential model. This is also a characteristic of the Gompertz 
distribution. However, while the Weibull distribution is linear with respect to the log of 
time, the Gompertz distribution has a log-hazard function, which is linear with respect to 
time [150, 151]. Approaches for assessing proportionality and addressing proportionality 
violation, whenever present, will be elucidated in the next sections. In addition, details on 
the sensitivity analysis, carried out to assess the risk of an event associated with apixaban 
and rivaroxaban, compared to warfarin, when administered at their reduced doses, will be 
discussed.  
 
6.3.1Proportionality assumption assessment  
 
Following the NICE Decision Support Unit (DSU) guidelines on how to select the most 
suitable survival model for economic evaluation, log-cumulative hazard plots were 
produced for assessing the type of hazard in the observed patient-level data, and establish 
whether proportional hazards can be assumed [150]. In other terms, the ratio between 
hazards for patients in different treatment groups  must be constant over time 
[148].Violation of the proportional hazard assumption may lead to overestimating the 
effect of predictor variables associated with increased hazard ratios over time.  
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Similarly, the effect of covariates linked to decreased hazard ratios over time may be 
underestimated [148]. The log-cumulative hazard plot was obtained for all clinical 
outcomes by plotting the log of the negative log of the estimated survival density function 
versus the log of time. For the proportionality assumption to be satisfied, the two lines, one 
for each treatment, should be fairly parallel and not crossing [148].   
 
6.3.2 Methods for addressing proportionality violation  
Non-parallel or crossing log-cumulative hazard plots may suggest a lack of proportionality 
and different methods may be used to address proportionality violation. With the counting 
process approach, time is split into time intervals to identify the time-periods in which 
proportionality is met. While this approach to some extent could be a valid alternative to a 
conventional semi-parametric model, such as Cox proportional hazard model, a sufficient 
sample size for all time-periods is required [148]. Another option for dealing with 
proportionality violation is stratification, where the whole sample is stratified into 
subgroups according to any categorical variable interacting with time. Hence, a good 
stratification variable is often age. With this approach, the baseline hazard function would 
differ between specified subgroups [148].  
 
Accelerated failure time models are other potential alternatives for the analysis of time-to-
event data whenever proportionality is not met. With this approach, the predictors act 
multiplicatively on the time rather than on the hazard scale, therefore providing a measure 
of event time ratio rather than hazard ratio.   Further, proportionality violation could be 
addressed by including interactions between time and predictive variables that are time 
dependent.  
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If the interactions are not statistically significant, proportionality cannot be rejected, and it 
is assumed that there is no violation of the proportionality assumption. Testing time 
dependent variables is comparable to testing for scaled Schoenfeld residuals on functions 
of time. In particular, Schoenfeld residuals corresponds to the difference between the 
observed and expected value for the covariate of interest.  In this test, non-proportionality 
is assumed if the slope of the scaled residuals is equal to zero, and the plotted residuals 
against time show a uniform pattern [147, 148].  
 
According to the DSU guidelines, when proportionality is not met, other approaches may 
be considered. In particular, if plots do not produce parallel lines, a piecewise model may 
be used. In piecewise parametric models, generally used when variable hazards are 
observed over time, different models are fitted to different time-periods. As exponential 
models are typically used with piecewise parametric models, the different time periods will 
have constant hazard rates [150]. Other parametric models, such as Weibull and Gompertz, 
may also be considered, but the hazard will be assumed to be varying over time. 
Parametric models are typically used for extrapolating the hazard rates beyond the 
observed data; however piecewise parametric models may not be particularly informative 
when applied to the extrapolated portion of the survival curve as hazards are not observed 
[148, 150].  
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6.3.3 Time-to-event analysis  
 
After establishing from the proportionality assumption assessment that the proportionality 
was violated across almost the entirety of the clinical outcomes, data were split into 2-year 
intervals to identify the point where proportionality assumptions were met. However, with 
time intervals, most of the events have not been estimated for the apixaban group, as most 
of the events where happening within the first 2 years since anticoagulation initiation. For 
dabigatran, the number of events was less than 10 for most of the outcomes. Whenever the 
number of clinical events was less than 5, due to disclosure restrictions, the sign < 5 was 
used instead (Appendix VI, Table VI-1). As in most time intervals events were not 
experienced, the HRs for several outcomes across the different treatment comparisons were 
not estimated or were associated with a broad confidence interval indicating small sample 
size and a low number of observed events (Appendix VI, Table VI-2). 
 
While stratification could have been a valid alternative to address proportionality violation, 
it was not a practical option as dividing the cohort into subsamples would reduce the 
sample size further, making the estimation of hazards for several clinical outcomes 
problematic as observed when splitting the time into intervals. Missing proportionality 
could also be addressed by ATF models that provide a measure of event time ratio rather 
than hazard ratios. This approach however does not express differences in risks as the Cox 
model does [148, 150]; thus making it unpractical to compare the output from this analysis 
with those reported in other comparative-effectiveness studies of DOACs.  
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Hence, in the final Cox model, proportionality violation was addressed by introducing 
interaction terms between time and the variables violating the proportionality assumption, 
thus creating time varying covariates. With this approach, if the interactions are not 
statistically significant, proportionality cannot be rejected and it is assumed that there is no 
violation of the proportionality assumption; therefore, only statistically significant 
interactions were included in the final model [152].   
 
As proportionality was addressed by introducing time varying covariates, the semi-
parametric Cox proportional hazards regression model was then used to compare risks of 
the clinical outcomes described in the previous paragraphs across the different treatments. 
While PS methodologies account for differences in baseline characteristics, as described in 
Chapter 5, there might still be residual bias after applying the scores; thus, the final Cox 
proportional hazards model was adjusted for age, sex and comorbidities, resulting in the 
following equation: 
                                            
ℎ𝑖(𝑡) = ℎ0(𝑡) ∗ exp (𝛽1𝐼𝑖 + 𝛽2𝑃𝑖 + 𝛽3𝐴𝑖 + 𝛽3𝐺𝑖 + 𝛽4 ∑ 𝐶𝑖𝑡
3
𝑐=2
 
 
) 
                                                                                                                           (Equation 6.3)    
Where I is the intervention (reference category: control), P is the propensity score, A is age 
at the time of first event (reference category 50-54 age group); G is sex (reference 
category: male); C is the Charlson comorbidity index (reference category: no 
comorbidities).  
Note: to relax the proportionality assumption, time interactions were included for the 
variables violating the proportional hazard assumption.  
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The cohort for the time-to-event analysis, as described in Chapter 5, represents a typical 
cohort of anticoagulant users, who were 50 years or older at the time of the first OAC 
prescription. The final cohort resulted in 33,965 first time OAC users, of which 26,387 
were on warfarin, 3,706 on apixaban, 484 on dabigatran and 3,388 on rivaroxaban.  
 
Following a continuous treatment approach, the risks of AF related clinical events or death 
with combined dose DOACs (including standard and reduced doses) compared to warfarin 
were estimated from anticoagulation initiation to the time of first clinical event or death; 
patients, followed for 2 and 6 year, were censored if they switched or discontinued 
treatment. In particular, it was decided to follow patients for 2 years to match the follow-up 
reported in the pivotal RCTs [41-43]. The choice of following patients for 6 years, 
although the time intervals indicated that patients on DOACs experienced most of the 
clinical events within the first 2 years from anticoagulation initiation, was instead based on 
the PIS data availability covering the time period 2010-2015.   
 
The rationale for censoring patients discontinuing treatment, was based on the approach 
taken in the pivotal RCTs [41-43] and on the evidence that discontinuation happens in real 
-world scenarios. To reflect what happens in clinical practice, unlike in RCTs, patients 
were also censored if they switched between anticoagulation treatments. For instance, a 
patient would be censored if started anticoagulation treatment with warfarin, experienced a 
stroke and then switched to apixaban. Thus, censoring switchers allowed to establish to 
what treatment an occurring event was attributable to. 
 
Because patients can be at risk of more than one mutually exclusive event, time-to-event  
for each clinical outcome for each treatment comparison was determined within a 
competing risk framework, where patients can experience only one first event of the 
several competing first events [153]. 
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 In other words, the risk for the first event to occur is estimated in the presence of 
competing events; for instance, the risk of experiencing the first stroke is estimated in 
presence of other possible outcomes such as CHI, MI or death.  
 
Event rates for each treatment arm were reported for 100 person-years. In detail, the 
number of events divided by the total exposure time (person-time), from initiation of 
anticoagulation to the clinical outcome of interest, is multiplied by 100 to obtain the final 
100 person-years event rate.  
 
In addition, the crude incidence of events over time, PS unadjusted and not accounting for 
the presence of competing risk, is presented in the form of Kaplan Meier curves. Incidence 
of events, PS adjusted and accounting for competing events, is depicted as cumulative 
incidence curves. Stata version 14 was used for the statistical analysis.   
 
6.3.4 Sensitivity analysis  
 
Existing observational studies have reported differences in the risk of stroke and mortality 
when DOACs were administered at different doses [60-62]. Therefore, sensitivity analyses 
discerning apixaban and rivaroxaban doses were carried out to identify any risk reduction 
of the main clinical outcomes. While it was possible to conduct time-to-event analyses on 
standard and reduced dose for the apixaban and rivaroxaban cohorts, it was not possible to 
perform the same analysis for the dabigatran treatment group due to sample size.  
 
In particular, the objective of the sensitivity analysis was to establish whether apixaban and 
rivaroxaban are accountable for increased risk of stroke and mortality when administered 
as a reduced dose. The PS model used for the sensitivity analysis was the same that was 
employed for the main analysis in Chapter 5, where the model is described in detail.  
Chapter 6                                                                                                                                                        156 
 
Tests for collinearity in the analyses for the standard and reduced dose apixaban and 
rivaroxaban were also performed in Chapter 5 and the variance inflation factor did not 
show any evidence of collinearity (Appendix IV, Table IV-1). Thus, the PS model was 
again specified according to the following baseline characteristics: age at the time of the 
first prescription, sex, SIMD, prescription predisposing bleeding, comorbidity CHA2DS2-
VASc and HAS-BLED scores, previous history of ischaemic stroke or SE or TIA, vascular 
disease, hypertension, diabetes, and cancer. The assessment of the proportionality 
assumption was carried out for standard and reduced dose apixaban and rivaroxaban. 
Kaplan Meier curves and cumulative incidence curves, as for the main analysis, were also 
be presented. 
 
6.4 Results 
As observed when assessing the proportionality assumptions for the Cox model (Appendix 
VI, Table VI-1), patients on DOACs, experienced most of the clinical outcomes within the 
first 2 years from anticoagulation initiation. Further, patients on DOACs were exposed to 
the treatment for a much shorter period of time, compared to those on warfarin. Thus, the 
findings for the time-period beyond the first 2 years from anticoagulation initiation did not 
provide a complete picture, but were included in order to utilise all observational data 
available.  
 
6.4.1 Cohort characteristics  
 
The comparative-effectiveness analysis in this Chapter, was carried out on the same cohort 
of patients described in Chapter 5. However, the sensitivity analysis was carried out on AF 
patients that were either on standard (apixaban 5m, rivaroxaban 20 mg), or reduced dose 
(apixaban 2.5mg, rivaroxaban 15 mg) DOACs.  
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Due to the relatively small sample size of dabigatran, it was not possible to discern 
standard and reduces dose regimen. Thus, in this section, baseline characteristics of 
patients that were on either standard or reduced dose apixaban and rivaroxaban are 
presented.  
 
Patients on apixaban and rivaroxaban reduced dose were on average older at the time of 
the first prescription than those on standard dose. Patients on reduced dose were also at a 
higher risk of stroke, measured using the CHA2DS2-VASc score, compared to those on 
standard dose. This is clearly visible in the histogram (Figure VII-1) presented in Appendix 
VII, indicating that for scores >=4, patients on reduced dose represents the majority. 
 
The risk of bleeding, measured with the HAS-BLED score, was also higher for patients on 
reduced dose apixaban and rivaroxaban, compared to those on standard dose. Again, this is 
clearly visible in the histogram (Figure VII-2) presented in Appendix VII, indicating that 
for scores >=3, patients on reduced dose represents the majority. Further, the proportion of 
patients with more than one comorbidity (Appendix VII, Figure VII-3), and the proportion 
of patients with a history of AF related conditions was higher in reduced dose groups than 
in patients on standard dose regimen. Patients’ baseline characteristics are reported in 
Table 6.2. 
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Table 6.2 Baseline characteristics (standard and reduced dose) 
Characteristics 
Apixaban 5mg  Apixaban 2.5mg Rivaroxaban 20 mg Rivaroxaban 15mg 
N (%) N (%) N (%) N (%) 
Cohort  2,784 922 2,735 518 
Sex         
Men 1,672 (60.06) 311 (33.73) 1,533 (56.05) 210 (40.54) 
Women 1,113 (39.98) 610 (66.16) 1,202 (43.95) 308 (59.46) 
Mean age (SD) 72 (9.35) 84 (7.17) 73 (8.14) 83 (8.16) 
SIMD (Scottish index of multiple deprivation) 
1 635 (22.81) 210 (22.78) 412 (15.06) 97 (18.73) 
2 544 (19.54) 193 (20.93) 467 (17.07) 116 (22.39) 
3 471 (16.92) 144 (15.62) 608 (22.23) 111 (21.43) 
4 494 (17.74) 149 (16.16) 678 (24.79) 114 (22.01) 
5 641 (23.02) 226 (24.51) 570 (20.84) 80 (15.44) 
CHA2DS2-VASc score         
0-1 798 (28.66) 28 (3.04) 648 (23.69) 20 (3.86) 
2-3 1,001 (35.96) 178 (19.31) 932 (34.08) 106 (20.46) 
>=4 986 (35.42) 715 (77.55) 1,155 (42.23) 392 (75.68) 
HAS-BLED       
0-2 1,873 (67.28) 465 (50.43) 1,839 (67.24) 246 (47.49) 
>=3 912 (32.76) 456 (49.46) 896 (32.76) 272 (52.51) 
Comorbidity         
no comorbidity 1,477 (53.05) 337 (36.55) 1,458 (53.31) 200 (38.61) 
1 comorbidity 655 (23.53) 228 (24.73) 624 (22.82) 105 (20.27) 
>1 comorbidity 652 (23.42) 357 (38.72) 653 (23.88) 213 (41.12) 
Stroke or TIA 368 (13.22) 175 (18.98) 394 (14.41) 97 (18.73) 
Vascular disease 446 (16.02) 187 (20.28) 460 (16.82) 123 (23.75) 
Hypertension 937 (33.66) 370 (40.13) 959 (35.06) 228 (44.02) 
Diabetes mellitus 410 (14.73) 118 (12.80) 367 (13.42) 93 (17.95) 
Cancer 225 (8.08) 96 (10.41) 227 (8.30) 49 (9.46) 
Drug causing bleeding 1,706 (61.28) 561 (60.85) 1,566 (57.26) 323 (62.36) 
 
6.4.2 Comparative-effectiveness 
The log-cumulative hazard plots for each comparison are presented and discussed in detail 
in Appendix VIII, Figure VIII-1‒VIII-9; while the test of significance for the time-varying 
covariates carried out for each variable included in each Cox model, is presented in 
Appendix VIII, Table VIII-1. In addition, the crude estimates depicted in the Kaplan Meier 
curves for each comparison are presented and discussed in detail in Appendix IX, Figure 
IX-1‒IX-9. The estimates accounting for PS and competing risk adjustments are shown 
graphically and discussed in detail in the cumulative incidence curves in Appendix X, 
Figure X-1‒X-9. Although, not particularly informative, HRs for all clinical events at 6-
year follow-up are presented in Appendix XI Figure XI-1 for completeness.  
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Apixaban versus warfarin 
Patients on apixaban had higher absolute event rates than warfarin across all clinical 
outcomes (Table 6.3). Hazard ratios (HRs) for all clinical events are presented in Figure 
6.1. No difference in risk was observed for any of the clinical outcomes when comparing 
efficacy and safety profiles of apixaban versus warfarin.  
 
Dabigatran versus warfarin 
Absolute clinical event rates for patients on dabigatran were generally lower than the rates 
observed in the warfarin group (Table 6.3). The trend was inverted for GI bleeding rates, 
which were higher in the dabigatran than the warfarin group. The same trend was observed 
for major bleeding and mortality due to stroke; however, the difference in event rates 
between treatments is negligible. No difference in risk was observed for most of the 
clinical outcomes when comparing efficacy and safety profiles of dabigatran versus 
warfarin (Figure 6.1).  However, the risk of GI bleeding was found to be greater in the 
dabigatran group than in the warfarin group.  
 
Rivaroxaban versus warfarin 
Patients on rivaroxaban had higher event rates than warfarin users across all clinical 
outcomes (Table 6.3). There were no differences in risk of stroke and stroke composites 
between rivaroxaban and warfarin patients (Figure 6.1). However, when all-cause 
mortality was included in the stroke composite, an increased risk for the rivaroxaban 
treatment group was observed. When evaluated separately, patients on rivaroxaban showed 
an increased risk of all-cause mortality compared to those on warfarin. Similarly, the risk 
of mortality due to cardiovascular conditions was greater in the rivaroxaban group.   
When assessing the safety profile, increased risks of GI bleeding and major bleeding were 
observed for patients on rivaroxaban compared to the warfarin treatment group. 
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Table 6.3 Number of events and event rates for DOACs and warfarin 
Outcome 
Apixaban Dabigatran Rivaroxaban Warfarin 
events and 
(event rates) 
events and 
(event rates) 
events and 
(event rates) 
events and 
(event rates) 
Stroke all 54 (2.16) <5 (<0.80) 66 (2.18) 537 (1.35) 
Stroke or SE 57 (2.28) <5 (<0.80) 68 (2.25) 575 (1.45) 
Stroke or SE or TIA 71 (2.84) 5 (0.80) 80 (2.64) 718 (1.81) 
Stroke or SE or mortality 
(all cause) 
215 (8.61) 24 (3.84) 325 (10.73) 2122 (5.34) 
MI 40 (1.60) <5 (<0.80) 27 (0.89) 312 (0.79) 
Major bleeding 116 (4.64) 22 (3.52) 191 (6.31) 1298 (3.27) 
ICH 14 (0.56) not estimated 16 (0.53) 83 (0.21) 
GI bleeding 40 (1.60) 13 (2.08) 65 (2.15) 428 (1.08) 
Mortality (all cause) 159 (6.36) 20 (3.20) 258 (8.52) 1558 (3.92) 
Mortality (stroke) 9 (0.36) <5 (<0.80) 16 (0.53) 87 (0.22) 
Mortality (cardiovascular) 89 (3.56) 12 (1.92) 124 (4.09) 827 (2.08) 
 
Note: event rates are estimated per 100 person-years. Due to disclosure restrictions, in the case of 
fewer than five events, “<5” was reported. 
 Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial 
infarction, ICH=intracranial haemorrhage, GI=gastrointestinal. 
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 Figure 6.1  Hazard ratios since first prescription, DOACs vs. warfarin 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
 
 
Apixaban
Stroke all 0.90 (0.65 -1.25)
Stroke or SE 0.88 (0.64 -1.21)
Stroke or SE  or TIA 0.89 (0.67 -1.18)
Stroke or SE or mortality (all cause) 0.97 (0.82 -1.14)
MI 1.34 (0.90 -1.98)
Major bleeding 0.88 (0.71 -1.10)
ICH 1.50 (0.75 -3.02)
GI bleeding 0.87 (0.60 -1.26)
Mortality (all cause) 0.99 (0.82 -1.20)
Mortality (stroke) 0.73 (0.32 -1.66)
Mortality (cardiovascular) 1.04 (0.80 -1.36)
Dabigatran
Stroke all 0.53 (0.20 -1.41)
Stroke or SE 0.49 (0.18 -1.32)
Stroke or SE  or TIA 0.49 (0.20 -1.19)
Stroke or SE or mortality (all cause) 0.74 (0.50 -1.11)
MI 0.44 (0.11 -1.78)
Major bleeding 1.04 (0.68 -1.59)
ICH Not estimated
GI bleeding 2.04 (1.17 -3.56)
Mortality (all cause) 0.82 (0.53 -1.27)
Mortality (stroke) 1.62 (0.39 -6.63)
Mortality (cardiovascular) 0.95 (0.54 -1.69)
Rivaroxaban
Stroke all 1.02 (0.77 -1.34)
Stroke or SE 0.98 (0.75 -1.29)
Stroke or SE  or TIA 0.92 (0.72 -1.18)
Stroke or SE or mortality (all cause) 1.28 (1.13 -1.46)
MI 0.81 (0.53 -1.23)
Major bleeding 1.30 (1.10 -1.53)
ICH 1.45 (0.81 -2.62)
GI bleeding 1.34 (1.01 -1.79)
Mortality (all cause) 1.39 (1.20 -1.61)
Mortality (stroke) 1.42 (0.78 -2.57)
Mortality (cardiovascular) 1.28 (1.04 -1.57)
Outcome  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring DOACs       Favouring  warfarin
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6.4.3 Sensitivity analysis  
 
The log-cumulative hazard plots for each comparison are presented and discussed in detail 
in Appendix XII, Figure XII-1‒XII-9; while the test of significance for the time-varying 
covariates carried out for each of variable included in each Cox model, is presented in 
Appendix XII, Table XII-1. In addition, the crude estimates depicted in the Kaplan Meier 
curves for each comparison are presented and discussed in detail in Appendix XIII, Figure 
XIII-1‒XIII-9. The estimates accounting for PS and competing risk adjustments are shown 
graphically and discussed in detail in the cumulative incidence curves in Appendix X, 
Figure X-1‒X-9. As in the main analysis, for completeness, HRs for all clinical events at 6-
year follow-up are presented in Appendix XV Figure XV-1 (apixaban) and Figure XV-2 
(rivaroxaban).  
 
Apixaban standard and reduced dose  
Comparing apixaban against warfarin, the difference in event rates for any of the outcomes 
was considerably higher for patients on the reduced dose apixaban than it was for those on 
the standard dose (Table 6.4).  Absolute event rates for both apixaban doses were higher 
than the rates in the warfarin group. No risk differences for any of the clinical outcomes 
were observed between apixaban and warfarin regardless of the dose administered (Figure 
6.2). 
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Table 6.4 Number of events and event rates for 2 years since first prescription, apixaban 
standard (5 mg) and reduced dose (2.5 mg) 
Outcome 
Apixaban 5 mg Apixaban 2.5 mg 
event and (event rates)  event and (event rates)  
Stroke all 35 (1.82) 19 (3.28) 
Stroke or SE 37 (1.93) 20 (3.46) 
Stroke or SE or TIA 45 (2.34) 26 (4.49) 
Stroke or SE or mortality (all cause) 127 (6.61) 88 (15.21) 
MI 24 (1.25) 16 (2.77) 
Major bleeding 87 (4.53) 29 (5.01) 
ICH 9 (0.47) 5 (0.86) 
GI bleeding 29 (1.51) 11 (1.90) 
Mortality (all cause) 91 (4.74) 68 (11.75) 
Mortality (stroke) 5 (0.26) 4 (0.69) 
Mortality (cardiovascular) 49 (2.55) 40 (6.91) 
 
Note: event rates are estimated per 100 person-years.  
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
 
 
Figure 6.2 Hazard ratios since first prescription, apixaban standard (5 mg) and reduced dose 
(2.5 mg) vs. warfarin 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
Rivaroxaban standard and reduced dose  
Apixaban 5 mg
Stroke all 0.90 (0.62 -1.33)
Stroke or SE 0.88 (0.61 -1.28)
Stroke or SE  or TIA 0.88 (0.63 -1.23)
Stroke or SE or mortality (all cause) 0.93 (0.76 -1.14)
MI 1.26 (0.79 -2.03)
Major bleeding 0.93 (0.73 -1.19)
ICH 1.36 (0.60 -3.05)
GI bleeding 0.93 (0.61 -1.42)
Mortality (all cause) 0.95 (0.75 -1.21)
Mortality (stroke) 0.82 (0.30 -2.27)
Mortality (cardiovascular) 0.99 (0.71 -1.37)
Apixaban 2.5 mg
Stroke all 0.87 (0.53 -1.43)
Stroke or SE 0.87 (0.54 - 1.41)
Stroke or SE  or TIA 0.89 (0.58 - 1.36)
Stroke or SE or mortality (all cause) 0.96 (0.76 -1.21)
MI 1.63 (0.93 -2.87)
Major bleeding 0.80 (0.54 - 1.18)
ICH 1.73 (0.62 -4.84)
GI bleeding 0.76 (0.40 - 1.44)
Mortality (all cause) 0.99 (0.75 - 1.29)
Mortality (stroke) 0.64 (0.21 - 1.97)
Mortality (cardiovascular) 1.03 (0.72 - 1.47)
Outcome  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring apixaban       Favouring  warfarin
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For patients on reduced dose rivaroxaban, the all-cause mortality rate was higher than with 
warfarin. (Table 6.5). Increased risk of major bleeding, all-cause mortality and mortality due 
to cardiovascular conditions were observed for patients on rivaroxaban standard 20 mg dose 
compared to those on warfarin (Figure 6.3). An increased risk of GI bleeding and any major 
bleeding was observed for patients on the reduced 15 mg dose compared to those on 
warfarin. 
 
Table 6.5 Number of events and event rates for 2 years since first prescription, rivaroxaban 
standard (20 mg) and reduced dose (15 mg) 
Outcome 
Rivaroxaban 20 mg Rivaroxaban 15 mg 
event and (event rates)  event and (event rates)  
Stroke all 52 (2.17) 10 (2.30) 
Stroke or SE 54 (2.26) 10 (2.30) 
Stroke or SE or TIA 63 (2.63) 12 (2.76) 
Stroke or SE or mortality (all cause) 245 (10.23) 69 (15.86) 
MI 16 (0.67) 10 (2.30) 
Major bleeding 145 (6.06) 41 (9.42) 
ICH 13 (0.54) 2 (0.46) 
GI bleeding 43 (1.80) 20 (4.60) 
Mortality (all cause) 192 (8.02) 59 (13.56) 
Mortality (stroke) 12 (0.50) 3 (0.69) 
Mortality (cardiovascular) 87 (3.63) 32 (7.36) 
 
Note: event rates are estimated per 100 person-years.  
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
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Figure 6.3 Hazard ratios since first prescription, rivaroxaban standard (20 mg) and reduced 
dose (15 mg) vs. warfarin 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal 
 
 
 
6.5 Discussion 
Evidence from clinical practice offers the opportunity to assess how well treatment works 
in real life under uncontrolled conditions. This type of evidence typically gathered from 
observational studies, poses some important challenges such as confounding and selection 
bias, which, as discussed in Chapter 5, can be mitigated but not eliminated. Hence, 
additional evidence from real-world scenarios can be used as a supplement rather than a 
substitute to the robust evidence coming from RCTs, where treatment efficacy is measured 
under specific conditions.  
 
Rivaroxaban 20 mg
Stroke all 1.09 (0.80 -1.47)
Stroke or SE 1.05 (0.78 -1.42)
Stroke or SE  or TIA 0.97 (0.74 -1.28)
Stroke or SE or mortality (all cause) 1.36 (1.18 -1.56)
MI 0.69 (0.41 -1.16)
Major bleeding 1.30 (1.08 -1.56)
ICH 1.57 (0.83 -2.96)
GI bleeding 1.20 (0.86 -1.69)
Mortality (all cause) 1.47 (1.25 -1.73)
Mortality (stroke) 1.51 (0.78 -2.91)
Mortality (cardiovascular) 1.28 (1.01 -1.62)
Rivaroxaban 15 mg
Stroke all 0.72 (0.38 -1.37)
Stroke or SE 0.68 (0.36 -1.29)
Stroke or SE  or TIA 0.65 (0.36 -1.16)
Stroke or SE or mortality (all cause) 1.14 (0.88 -1.46)
MI 1.34 (0.69 -2.59)
Major bleeding 1.56 (1.13 -2.16)
ICH 0.94 (0.22 -4.00)
GI bleeding 2.12 (1.31 -3.42)
Mortality (all cause) 1.29 (0.98 -1.69)
Mortality (stroke) 0.89 (0.27 -3.02)
Mortality (cardiovascular) 1.25 (0.86 -1.81)
Outcome  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring rivaroxaban       Favouring  warfarin
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In this section, the evidence from Scottish clinical practice is discussed and compared 
against the evidence from RCTs and other observational studies discussed in Chapter 1.   
However, while it is essential to acknowledge the importance of the evidence generated 
from indirect comparison by means of NMA as discussed in Chapter 1, such evidence 
cannot be compared with the findings from this analysis not covering DOAC to DOAC 
comparison. 
 
The descriptive statistics of patients on either standard or reduced dose DOACs, confirms, 
as discussed in Chapter 5, that older and sicker patients were more likely to be on reduced 
dose apixaban or rivaroxaban.  A striking finding from this comparative-effectiveness 
analysis is the increased risk of mortality associated with rivaroxaban. The increased risk of 
mortality may be linked to selective prescribing, a mechanism determined by the possibility 
of DOACs being prescribed according to the patients’ clinical profile [154, 155], and 
acknowledged in two observational studies [62, 63]. For instance, in Larsen’s study (2016), 
dabigatran was selectively prescribed to younger patients with lower risk of stroke and less 
renal impairment [63]. Similarly, Nielsen (2017) reported that patients who were sicker and 
older were more likely to be on rivaroxaban than on warfarin [61]. Presumably, sicker and 
older patients may not be able to cope with the burden associated with warfarin and the 
constant INR monitoring. Thus, while patients on warfarin may discontinue or switch 
treatment prior to death, those on DOACs may be dying while on treatment, but of causes 
that are age related and not linked to AF [62]. While the findings may rise some concerns 
over the use of rivaroxaban, Larsen (2016) and Nielsen (2017) acknowledged that despite 
using PS methods, allowing for addressing confounding by indication, some unmeasured 
residual confounding and selective prescribing behaviour would persist. Therefore, further 
research will be needed to access whether the association between the use of rivaroxaban 
and the risk of mortality is a true association [61, 63].  
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As described by Vinogradova (2018), selective prescribing may also have an effect on the 
increased risk of bleeding in patients on warfarin compared to those on DOACs. This 
translates into bleeds being more likely to be detected in warfarin patients who are 
regularly monitored for their INR [62]. It is possible that, in the study dataset, patients on 
DOACs will be sicker than patients treated with warfarin; this is something that cannot be 
captured fully by the CCI. Similarities and differences with other studies are discussed in 
the next sections and presented in Appendix XVI (Figure XVI-1, XV-2 for standard dose 
and XV-3 for reduced dose).  
 
Similarity and differences with other studies 
 
Apixaban 
The findings regarding GI bleeding in the ARISTOTLE clinical study [42] were confirmed 
in this comparative-effectiveness analysis where no risk difference was found between 
apixaban and warfarin patients at 2 years from anticoagulation initiation. The finding from 
this analysis, however, differed from those reported in one observational study (Ntaios 
(2017)) where a risk reduction of GI bleeding was found for patients on apixaban 
[58] .Further, the risk difference for stroke between apixaban and warfarin, although 
reduced, was not statistically significant. In the ARISTOLTE trial, a significant risk 
reduction for stroke in apixaban patients compared to those on warfarin was observed. 
However, when stroke was assessed according to specific subtypes, no risk difference was 
reported for ischaemic or unspecified stroke [42]. In contrast, Nielsen (2017) distinguished 
between doses [61] and found no risk differences for stroke between patients on apixaban 
2.5 mg reduced dose and those on warfarin. Similar findings were reported by 
Vinogradova (2018) where the effectiveness of apixaban compared to warfarin was 
assessed at 5 mg standard and 2.5 mg reduced dose [62]. 
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 Hence, in analysis carried out in this Thesis, differences in the risk for stroke between 
patients on any apixaban dose and patients treated with warfarin seem to be much closer to 
those observed in clinical practice than those reported in the ARISTOTLE study.  
 
Dabigatran  
A full comparison of results from this comparative-effectiveness analysis with findings 
from the RE-LY trial was not possible, since the ability to assign patients to different dose 
regimen was limited due to sample size [41]. In the RE-LY study, a minimum of 18,000 
patients were enrolled to obtain an 84% power ensuring that the upper bound of the 97.5% 
confidence interval of the risk of the primary outcome would fall below 1.46. The findings 
for the risk of stroke are in line with those observed in the RE-LY trial for patients 
receiving dabigatran at a reduced dose. Similarly, findings from RE-LY suggesting an 
increased risk of GI bleeding in patients treated with dabigatran 150 mg compared to those 
on warfarin were confirmed in this analysis and in a meta-analysis of observational studies 
[58].  
 
Rivaroxaban 
When comparing the risk of stroke and safety profiles (risk of bleeding) between patients 
on rivaroxaban and those on warfarin, the findings are comparable to those reported in the 
ROCKET-AF trial [43]. In the ROCKET-AF trial, the risk ratio of major bleeding was not 
estimated as a single clinical outcome, but event rates were reported for each body site. 
Major bleeding was associated with an event rate of 3.6% per 100 patient years for patients 
on rivaroxaban, whereas patients on warfarin had an event rate of 3.4% [43]. In the clinical 
study, the biggest contributor to major bleeding was GI bleeding with an event rate of 
3.2% for rivaroxaban patients compared to an event rate of 2.2% for patients on warfarin 
[43].  
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The findings on the risk of stroke between patients on rivaroxaban and those on warfarin 
were also comparable to those reported in an observational study by Gorst-Rasmussen 
(2016), where no risk difference was observed between treatment group doses [60].  
 
The sensitivity analysis showed an increase of GI bleeding in patients treated with reduced 
dose rivaroxaban, but no differences were observed for standard dose compared to 
warfarin. The findings for the standard dose are in line with those reported by Vinogradova 
(2018) [62], while those for the reduced dose may be due to selection bias resulting from 
people with greater risk of bleeding being more likely to be given rivaroxaban reduced 
dose. This is backed up by the baseline characteristics for DOACs standard and reduced 
dose previously presented in Table 6.2, and the histogram presented in Appendix VII 
(Figure VII-2). A different pattern was observed when looking at the risk of all-cause 
mortality, where it was observed an increased risk of mortality for patients on rivaroxaban 
standard dose but not for those on 15 mg reduced dose. While findings on the risk of 
mortality associated with reduced dose rivaroxaban are comparable to the risk reported in 
the ROCKET-AF trial [43], the increased risk of mortality observed for patients receiving 
the standard dose matches results reported by Nielsen (2017)[61] and Gorst-Rasmussen 
(2016) [60]. However, in these two observational studies, the increased risk of all-cause 
mortality was found for patients receiving rivaroxaban 15 mg reduced dose [60, 61].  
 
6.6 Limitations 
The comparative-effectiveness analysis carried out provides evidence on how DOACs 
work in clinical practice and whether this class of drugs offer a clear advantage in 
preventing stroke and other important pathologies in the AF population. Nevertheless, this 
analysis was constrained by a number of limitations.   
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Firstly, the relatively low number of events, as in the case of dabigatran, may undermine 
the robustness of the findings. The pivotal RCTs have identified the optimal number of 
events and participants needed to test the hypothesis of DOACs non-inferiority in 
preventing the primary outcome of stroke or SE. However, with observational data, it is 
not possible to determine the number of events needed to obtain a robust statistical power.  
 
Although the number of events observed in the dabigatran group is clearly a limitation of 
this Thesis, the analyses for each treatment group were carried out to get an indication of 
effect of dabigatran in preventing stroke and other AF related comorbidities in a real-world 
setting. Nevertheless, as the evidence from this analysis suggest that patients are 
increasingly switching from warfarin to DOACs, additional observational data may be 
available in the future. 
 
The potential risk of clinical miscoding of morbidity records is another possible limitation 
of the study that should be acknowledged. Further, given the nature of observational data 
and non-randomised evidence, when estimating the ATE, there will always be some 
residual bias due to observed confounders, even if PS methods are applied. Unobserved 
confounders, not dealt with in this analysis, such as patients’ tolerability or access to 
healthcare, may generate additional bias.  
 
In addition, the proportionality assumption of the Cox model should be assessed 
cautiously, and several approaches should be tested to address possible violation of this 
assumption before selecting the final model for analysis. Ultimately, depending on the 
scope of the research, the Cox model may still offer the most appropriate method for 
estimating the ATE, even when the proportionality assumption is violated.  
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6.7 Conclusions 
 
This analysis provides RWE that apixaban is at least as effective as warfarin for the 
prevention of stroke and AF associated comorbidities, but also highlights some safety and 
effectiveness concerns regarding the use of rivaroxaban. The increased risk of bleeding and 
mortality associated with rivaroxaban is in line with findings from other observational 
studies. However, the difference in risk of mortality may be caused by true association or 
bias from selective prescribing.  Methods to deal with selective prescribing and reduce 
confounding by indication exist, as the PS method used in this analysis, but as these issues 
can be mitigated, and not entirely eliminated, there will always be a risk of residual 
selection bias even when adequate methods are sufficiently adjusted for selective 
prescribing. Thus, further research will be needed to confirm the association between the 
use of rivaroxaban and the risk of mortality. Further, the evidence on dabigatran gives an 
indication of the effect in preventing stroke and AF associated comorbidities; but given the 
sample size and the number of events observed, the findings are less robust compared to 
those obtained for apixaban and rivaroxaban. Nevertheless, the evidence provided in this 
analysis allows for an assessment of how well treatments work in a non-randomised 
setting, and the additional evidence provided in this study should be used as a supplement 
rather than a substitute to the robust evidence coming from RCTs. 
 
In this Chapter, event rates and risks of major clinical events associated with AF have been 
estimated and compared against those reported in the pivotal RCTs [41-43] and existing 
observational studies [60-62]; thus allowing for identifying the main differences between 
the findings generated with a randomised and a non-randomised approach. Most of the 
estimated event rates and HRs from the analysis in this Chapter will be utilised to populate 
the cost-effectiveness model needed for the economic evaluation of DOACs, which is 
carried out and discussed in Chapter 7. 
Chapter 7                                                                                                                                                        172 
 
Chapter 7 Economic evaluation 
 
7.1 Introduction 
 
Economic evaluation is the preferred method for the appraisal of treatments or healthcare 
programmes including the identification, measurement, valuation and comparison of costs 
and consequences of the alternatives being considered [156]. This Chapter focuses on the 
economic evaluation of DOACs using RWE of effectiveness. While several comparative-
effectiveness studies have assessed the effectiveness of DOACs in clinical practice [58, 60, 
61, 63, 157] RWE on the cost-effectiveness is still limited, as in most cost-effectiveness 
studies, the effectiveness parameters were extracted from the pivotal RCTs [41-43]. To 
date, no cost-effectiveness study from UK perspective has used findings from RWE studies 
to show whether DOACs are cost-effective in clinical practice. To meet the fourth 
objective described in Chapter 2, a review of existing studies assessing the cost-
effectiveness of DOACs compared to warfarin in the AF population, reflecting the UK 
clinical practice and adopting the NHS perspective was carried out. Then the identified 
model was updated with patient level data to establish whether DOACs are a cost-effective 
option to warfarin for AF patients in Scottish clinical practice. 
 
7.1.1 Cost utility analysis  
 
A common objective of economic evaluation techniques, within the healthcare framework, 
is to evaluate the level of health benefits and effects in relation to the level of resource use 
[151, 156]. Cost Utility Analysis (CUA), is the preferred type of economic evaluation in 
HTA as it uses Quality Adjusted Life Years (QALYs) as generic outcome measure, which 
provides a common currency for measuring gains in life expectancy and Health Related 
Quality of Life (HRQoL) that reflect the effectiveness of interventions [158, 159]. One 
QALY represents one year in perfect health, while death is associated with zero QALYs.  
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Individual preferences under uncertainty, obtained from the general population expressed 
as health state utilities, are combined with the time spent in a given health state to calculate 
the number of total QALYs accumulated in that given health state. Health utilities are 
typically measured with generic instruments such as EQ-5D, SF-6D, Health Utilities Index 
or other instruments that measure condition specific health utilities [158, 160, 161].  
 
Despite the availability of different instruments, NICE recommends the use of EQ-5D for 
measurement and valuation of HRQoL. Because EQ-5D, extensively researched and 
validated, is not disease specific, it can be used for most diseases areas, thus allowing for 
comparisons of interventions across disease areas[162]. The design of EQ-5D allows for 
capturing a broad spectrum of level of health across five different dimensions: mobility, 
ability to self-care, ability to undertake usual activities, pain and discomfort, anxiety and 
depression. Each dimension comprises 5 levels (or 3 in the first EQ-5D version) of 
perceived problems. For each of the possible unique health states, given by combining 
dimensions with level, utility scores are obtained through the application of valuation 
methods such as visual analogue scale, time trade-off or standard gamble [160, 163]. 
In particular, visual analogue scale records respondents’ self-reported health on a single 
line ranging from 0 to 100; where the lower and upper end represent worst and best 
possible health state respectively [161].  
 
Time trade-off measures with a scaling method the relative amount of time that patients 
would be willing to trade-off in order to survive in a given health state. Patients may 
choose to stay in their ill state or improve their health status with a reduced life 
expectancy. Standard gamble, typically used in economics to measure preferences, reflect 
the risk that patients would be willing to take in a two-way outcome scenario [161]. 
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 Here, patients are asked to choose between a sure outcome (living the remaining life 
expectancy in a particular health state) or gamble for a state of optimal health or instant 
death [161, 164]. 
 
In CUA, costs are generally classified as direct, indirect and intangible. While direct costs 
reflect expenses directly associated with a condition such as prescription drugs, medical 
equipment and patient transportation; indirect or productivity costs reflect the costs 
incurred because of productivity losses resulting from morbidity or mortality associated 
with a given condition. On the other hand, intangible costs are these experienced because 
of pain or adverse events, and cannot directly be measured in monetary terms [151, 156, 
165]. In CUA, cost-effectiveness is expressed as Incremental Cost-Effectiveness Ratio 
(ICER), obtained by the difference in expected cost divided by the difference in QALYs of 
two interventions. The calculation for the ICER is presented in the following equation:  
ICER = 
∆𝐶 (𝐶1− 𝐶0)
∆𝐸 (𝐸1− 𝐸0)
 
                                                                                                                           (Equation 7.1) 
Where C1 and C0 are the cost for intervention and control group; and E1 and E0 represent 
the effectiveness measure for intervention and control group. 
 
In the UK, interventions with an ICER below the threshold  (an indication of  Willingness 
To Pay (WTP)) of £20,000 per QALY gained are deemed cost-effective [156, 166]. 
However, an ICER greater than £20,000 may still be accepted for reimbursement if there 
are concerns that QALYs (generated by EQ-5D) may not adequately reflect the health gain 
as a result of an intervention for a given disease area. Further, other factors such as ethics 
and lack of alternative treatments are taken into account for reimbursement purposes. This 
is often the case with orphan or end of life drugs [162]. 
 
Chapter 7                                                                                                                                                        175 
 
The ICER, generally used for presenting results from CUA, could also be expressed as 
Incremental Net Monetary Benefit (INMB), a summary statistics that provide information 
on the size or scale of the interventions being evaluated. A positive INMB indicates that an 
intervention is cost-effective compared to the alternatives for a given threshold.  
 Specifically, INMB is obtained by multiplying the incremental utility (QALY) by the 
threshold, and then subtracting the incremental cost [156]. The calculation for the INMB is 
presented in the following equation:  
INMB= (∆𝐸 ∗ 𝑊𝑇𝑃) − ∆𝐶  
                                                                                                                           (Equation 7.2) 
 
7.1.2 Data source 
 
The data needed in economic evaluation are generally extracted from different evidence 
sources including RCTs, systematic reviews, and existing economic evaluation studies. 
The duration of the studies however, as in the case of most RCTs, may have a follow-up 
limited to a few years; therefore, a decision analytic model generating evidence that goes 
beyond the limited duration of a study may be required.  While some of the parameters of 
the model can be generated, or extrapolated from the study, such as cost of the intervention 
and long-term survival, more often multiple external sources will be needed to complement 
the evidence generated within-study. Informing the model parameters using several data 
sources, besides the evidence generated from within-trial RCTs, is a standard practice in 
economic evaluation.  
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However, designing the health economics component from the very early stage of trial 
design would allow to collect relevant information related to resource use and health 
related quality of life, taking into account specificities related to the intervention (e.g. 
impact on intermediate, rather than final outcomes) or to the context (e.g. multinational 
trials).  This would produce reliable estimates of cost-effectiveness that can subsequently 
be extrapolated for a long-term time horizon and incorporated into an economic model 
[151, 156]. 
 
7.1.3 Models in economic evaluation 
 
Analytical models, reflecting the clinical pathway of any health condition, and depicting 
different consequences according to the interventions adopted, are at the core of economic 
evaluation. The structure of a model would normally depend on the clinical pathway. In 
general, decision trees, Markov models or discrete event simulation (DES) models are 
used. Decision trees are the simplest model structure, here distinct branches represent 
clinically meaningful pathways and associated health outcomes. At the point of branches 
intersection, often referred to as node, a probability indicating the occurrence and non-
occurrence of a specific event must be specified. These probabilities are then multiplied by 
costs and outcomes assigned, to obtain the expected values of outcomes and associated 
costs for each treatment being evaluated [151, 167]. 
 
Markov models employ mutually exclusive health states that can be occupied sequentially 
at any given time.  Markov models are stochastic models, which exploit memory-less 
properties, where the probability for a cohort of moving from one health state to another 
does not depend on previous events, but only on the present health state.  
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In a Markov model, moving from one health state to another depends on the probability of 
transitioning between states, and cycles are used to indicate discrete time-periods. 
Typically, in scenarios where clinical events are relatively rare, the cycle length could be 
one year; similarly, if clinical events occur more frequently, or the rate changes rapidly 
over time, the cycle length may be shorter. Costs and utilities are accumulated during each 
cycle according to the time spent in each state or the transition between states [151, 156].  
A Markov model may not be appropriate when modelling conditions or clinical events 
requiring transition probabilities to change over time. However, the issue concerning time 
dependency of transition probabilities can be handled by having independent transition 
probabilities for each cycle. For example, when comparing mortality, this can be done with 
life tables, allowing transition probabilities to change as the cohort ages. As per Office of 
National Statistics definition, life tables indicate “trends for the UK and constituent 
countries in the average number of years people will live beyond their current age 
measured by "period life expectancy", analysed by age and sex” [77].  
 
Time dependency and the memory-less nature of cohort Markov models can also be dealt 
with using a DES approach. This maintains the concept of health state and discrete cycles 
but models the system as a series of events occurring over time. The risk of these events 
depends on individual patient characteristics and changes over time as more events are 
experienced. This feature of DES is particularly useful in modelling complex pathways 
where future events are likely to depend on patients’ clinical history. Thus, DES may be 
particularly useful for conditions were clinical measures such as body mass index and 
blood pressure are recorded.  
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Nevertheless, DES implementation and execution is computationally more intensive than 
the more conventional Markov approach, requiring patient-level data to obtain time-to- 
event estimates and associated distributions [167]. Further, the computational burden limits 
the flexibility of a DES model to assess parameter uncertainty. This is a major concern 
with the Probabilistic Sensitivity Analysis (PSA), a type of sensitivity analysis based on 
the probability distribution of parameters and used to assess uncertainty around the 
findings, as it requires two levels of simulation for estimating a single expected value and 
for sampling from distribution. In other words,  if 10,000 simulations are needed for the 
two level simulation, 100 million simulations would be required at the patient level; thus, 
compared to a Markov model, DES would require a much larger number of simulations 
[151, 168].  
 
Methods to reduce the computational burden and simulation time, such as Gaussian 
process [169] and ANOVA  methods [170] have been proposed. However, simulation 
studies comparing outputs from Markov and DES models have shown that these models 
produced very similar results; and have highlighted that differences in the results mostly 
depend on assumptions and available evidence, rather than the simulation method adopted 
[171, 172].  For instance, Brown’s simulation study (2000) compared a cohort-based 
model versus a patient level model, and found that the former predicted higher rates of 
mortality and MI but fewer strokes. However, this was mainly determined by model 
differences in terms of model structure, assumptions and evidence used [172].  
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7.2 Review of economic models 
 
To date several cost-effectiveness studies, employing a wide range of model structures and 
assumptions, have been developed to assess the relative value of different treatment 
strategies for the prevention of stroke in the AF population. This review aims at identifying, 
in existing studies, common model features that best reflect the UK clinical practice and 
perspective. The present review, is an extension of the existing Limone’s systematic review 
(2013) assessing studies on cost-effectiveness of DOACs (including apixaban, dabigatran 
and rivaroxaban) for stroke prevention in the AF population [173]. An additional study, 
also carried out by Limone and colleagues [174], aided the identification of the best fit for 
purpose model for this Chapter, by highlighting common flaws in published models 
evaluating the cost-effectiveness of pharmacological interventions in preventing stroke in 
the AF population.  
 
The existing systematic review by Limone et.al [174], searched MEDLINE, EMBASE, 
National Health Service Economic Evaluation Database, Health Technology Assessment 
and Tufts Cost-Effectiveness Analysis Registry from 2008 to 2012.  Then, a quality 
assessment of models was conducted using the Quality of Health Economics Analyses 
(QHES) rating scale, a validated measure containing 16 items to evaluate the quality of 
conduction and reporting of cost-effectiveness analyses. The scores in the rating scale 
range from 0 to 100, moving from the lowest to the highest possible quality. In Limone’s 
critical appraisal, only models obtaining a QHES score of 80 were considered of high 
quality [166].  
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In the existing review, 18 economic evaluation were identified; of these 4 assessed 
apixaban, 9 assessed dabigatran (150 mg, 110 mg) and 4 assessed rivaroxaban. Warfarin 
was the main comparator in almost all cost-effectiveness models assessed. 
The majority of the models identified in Limone’s review (2013) reported share a common 
core structure taken from the Sorensen and Gage models [175, 176], designed for 
evaluating the cost-effectiveness of dose adjusted warfarin. In the earliest model designed 
by Gage and colleagues in 1995, a Markov model was built, using a time horizon of 10 
years, to evaluate the expected outcomes of three treatment alternatives (warfarin, aspirin 
and no therapy) for 65 years or older patients with an history of NVAF. The model 
included 10 health states for each of the three options (well, moderate-severe stroke, mild 
stroke, moderate-severe stroke, second stroke, mild ICH, moderate-severe ICH, death), and 
patients remained in the “well” state until TIA, stroke, haemorrhage or death occurred.  
 
The second stroke health state was included to capture the effect of previous events on 
future events. Further, important anticoagulation related adverse clinical events such as MI 
and extra-cranial bleeds were not included in the model. The model also allowed for 
switching from warfarin to aspirin in case of bleed and from aspirin to warfarin if stroke 
was experienced [176]. The Sorensen model is an extension of the Gage model where, 
while sharing a very similar structure, additional health states such as ischemic stroke and 
SE were included [175]. In addition , almost all studies identified in Limone’s review 
(2013) employed Markov models, only one study used a DES  approach [173]. As 
previously discussed, the DES approach still maintains the concept of health state and 
discrete cycles as with the Markov approach, but models the system as a series of events 
occurring over time [151]. 
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Despite common structures shared between models, Limone identified a noteworthy 
variation in the complexity and the assumptions made. In particular, the complexity was 
reflected in the number of health states included. Among the apixaban models, all 4 models 
included the MI state, 3 included minor bleeding, and only 1 model included SE.  
Similarly, among the dabigatran models, all 13 models included the MI state, 11 included 
minor bleeding, and only 8 models included SE. In the rivaroxaban models, MI and minor 
bleeding were included in all 4 models, but only 3 of those also modelled SE [173]. As 
Limone pointed out, the omission could have occurred because the difference in risk 
between treatments for the outcomes of interest was not statistically significant. For 
instance, the risk reduction for MI was not statistically significant in the RE-LY and 
ROCKET-AF trials; similarly, SE did not reach statistical significance in the ARISTOTLE 
and RE-LY clinical studies [41-43, 174].  
 
Another common issue identified in most of the cost-effectiveness models critically 
appraised by Limone, concerns the way INR control and time in therapeutic range was 
dealt with. While most of the models included adjusted dose warfarin as a treatment 
alternative, the rate of clinical outcomes such as stroke or bleeding was not always 
adequately adjusted according to INR control and time in therapeutic range.  
This could be an issue as the time in therapeutic range measured in a controlled 
environment, as in RCTs, may be higher than the one recorded in clinical practice.  
Thus, the lack of event rates adjustment in the cost-effectiveness models, may lead to 
conclusions diverging from those drawn when RWE is utilised [173, 174].  
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7.2.1 Review - methods  
 
To reflect UK clinical practice, only cost-effectiveness studies adopting the UK NHS 
perspective were included in the review. The existing systematic review from Limone 
(2013) included cost-effectiveness studies published up to 2012 [173]; hence, a further 
search was conducted, through MEDLINE and EMBASE databases, to identify any other 
relevant studies carried out between 2012 and 2018. The syntax for the search strategy is 
reported in Appendix XVII. The following items for each study were extracted: 
perspective, interventions, base-case population characteristics, model type and 
assumptions, time horizon, discount rate, drug discontinuation or switching, results and 
source of uncertainty. 
 
 A clear reference to the AF population and the inclusion of costs-effectiveness evaluation 
were the two main selection criteria. Models evaluating the cost-effectiveness of DOACs in 
a population either than AF, e.g. VTE was excluded. While several studies have assessed 
the cost-effectiveness of DOACs adopting different country specific perspective 
assumptions, this review focused entirely on the studies evaluating the three main DOACs 
(apixaban, dabigatran and rivaroxaban) and adopting the UK perspective. A critical 
appraisal of the methodology and reporting of the identified models, except for government 
reports, was conducted using the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist for the items to include when reporting economic 
evaluations of health interventions [177].  
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7.2.2 Review - results  
 
The literature search, after removing duplicates, initially identified 227 studies (Figure 
7.1). Of these, 29 were not reporting an economic study, 24 were review articles, 8 were 
not comparing DOACs, 3 were not in English language, leaving with 27 studies eligible for 
further assessment. Of these 27, a total of 5 articles assessing the cost-effectiveness of 
DOACs in the AF population, and adopting a UK perspective were identified [178-182].  
 
Figure 7.1 Results of literature search 
 
A description for each study identified the literature search and included in the review is 
reported in Table 7.1. 
 
Population 
The base-population characteristics are generally matching those of the RCTs; where, on 
average patients suitable for anticoagulation therapy and with different levels of risk of 
stroke initiated anticoagulation treatment at 70 years of age [41-43].   
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Interventions 
The cost-effectiveness of apixaban was assessed in the 5 studies identified where standard 
dose apixaban was assessed against dabigatran, rivaroxaban and warfarin [178-182]. Of 
those, 3 studies included aspirin as an additional intervention as an alternative to 
anticoagulation discontinuation due to a series of clinical events such MI, ICH or major 
bleeding [178, 179, 181]. The cost-effectiveness of dabigatran was investigated in 4 of 5 
studies identified [179-182] where dabigatran was assessed at different doses (dabigatran 
110 mg, dabigatran 150 mg and sequential dabigatran) against apixaban, rivaroxaban and 
warfarin. Aspirin was included as an alternative intervention in 2 of these studies [179, 
181]. The cost-effectiveness of rivaroxaban was also investigated in 4 of the studies 
identified [179-182]; and of these, 2 studies [179, 181] included aspirin as an alternative 
interventions to anticoagulation treatments.  
 
Model type 
 
All studies identified employed Markov models. An important element that became 
evident when scrutinising the existing models was that the majority, as the ones identified 
in Limone`s review (2013) [173], share a common core structure taken from the Sorensen 
and Gage models [175, 176]. The models also were populated with the safety and efficacy 
data of the pivotal RCTs (Aristotle, RE-LY, and ROCKET-AF) [41-43]. Two of these 
models [178, 182] also included evidence from the AVERROES trial [47].  
 
There were however, differences in complexity reflected by the number of health states 
used.  In particular, Dorian’s model included the following 11 health states: healthy with 
AF, ischaemic stroke (mild, moderate, and severe), haemorrhagic stroke (mild, moderate, 
and severe), SE, MI, treatment discontinuation and death [178].  
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The manufacturer model for apixaban reported 18 health states: health with AF, ischaemic 
stroke (mild, moderate, severe and fatal), haemorrhagic stroke (mild, moderate, severe and 
fatal), SE (fatal and non-fatal), MI, ICH (fatal and non-fatal), other major bleeds, clinically 
relevant non-major bleeds, cardiovascular hospitalisations, death [182]. Lip’s model (2014) 
[179] was the same as the one presented by Dorian (2014) [178].  
 
In Sterne’s model (2017), the AF cohort enters the model in the “AF well” state, those are 
patients who are healthy and with AF. The cohort may then experience Stroke, MI, major 
bleed, ICH or die at any time. Over time, patients could again experience Stroke, MI, 
major bleed, ICH, but this time the risk of experiencing an event would depend on 
previous event history. This would result in 17 health states [180]. Verhoef’s model (2014) 
only included 9 health states: healthy with AF, ischaemic stroke, TIA, MI, SE, ICH, extra-
cranial haemorrhage, disability and death.   
 
Cycle length 
As indicated in all of the models adopting the UK perspective, and specified by the time 
horizon, patients were followed for their lifetime. The time horizon, indicating the time 
frame of the analysis, is divided into equal increments of time (Markov cycles) during 
which transition from one state to another can be made. The majority of the models 
adopted a cycle length of 6 weeks [178, 179, 182], thus reflecting the frequency of 
recurrent events following a first stroke or any other main clinical event associated with 
AF. Sterne (2017) and Verhoef (2014) adopted cycle lengths of 3 and 1 months, 
respectively [180, 181]. Further, the model transition probabilities indicating the 
probability of moving from one health state to another were derived, from all of the 
studies, from RCTs that assessed the efficacy and safety of the DOAC under consideration 
[41-43]. Additional evidence on DOACs effectiveness was generated from NMA carried 
out by apixaban manufacturer [182] and Sterne (2017) [180].  
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Assumptions- HRQOL  
Several assumptions were made regarding the level of utilities between treatments and the 
risk of experiencing relevant clinical events between health states. In particular, Dorian 
(2014) [178] and Lip (2014) [179] assumed the same level of utility decrement between 
DOACs and aspirin (being one of the comparators in addition to warfarin), while the 
apixaban manufacturer model assumed a level of disutility (decrement in utility) only 
associated with warfarin, and same risk of MI for apixaban and dabigatran [182].  
 
Assumptions -effectiveness 
Further, Lip (2014) assumed the recurrence of ischaemic or haemorrhagic stroke and the 
rate of all-cause mortality being the same across treatments [179]. In addition, the apixaban 
manufacturer model and Sterne (2017) assumed the relative treatment effect being constant 
over time. Sterne, also assumed  the same probability of dying for patients with a history of 
clinically relevant bleeding, ICH or stroke [180, 182].    
 
Assumptions discontinuation and switching  
In the all studies identified, assumptions were made around drug discontinuation and 
switching. Primarily, patients who discontinued anticoagulation therapy due to ICH or 
major bleeding events switched to aspirin or interrupted treatment. Discontinuation and 
switching rates were based on those observed in RCTs [41-43].  
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Results 
In most studies, all DOACs were deemed cost-effective compared to warfarin with an 
ICER well below the £20,000 threshold [178-180, 182]. Overall DOACs were found to 
have a high probability, greater than 80%, of being cost-effective compared to warfarin 
[43]. However, Verhoef (2014) reported considerably lower probabilities of DOACs being 
cost-effective at £20,000, with less than 50% for apixaban and dabigatran standard dose 
and 5% for rivaroxaban 20 mg [181] .   
 
Sensitivity analysis and key drivers 
The risk of stroke and ICH and all-cause mortality were among the clinical parameters the 
mostly influenced the cost-effectiveness models. Other impactful parameters were the cost 
associated with clinical events or treatments. In particular, treatment and INR monitoring 
costs were identified as key drivers in the majority of the cost-effectiveness studies 
identified [178, 179, 181, 182]. 
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Table 7.1 Cost-effectiveness studies identified in the review 
 
Study Interventions Population 
Model type  
(perspective, 
cycle length  
and assumptions) 
Discontinuation                                     
and switching 
 Results  Sensitivity analysis and key drivers         
Dorian, 2014 Apixaban 10 mg 
daily, warfarin 5 
mg (average) 
daily, aspirin 
150 mg daily 
70 years mean 
age with AF   
and suitable 
for VKA 
therapy.    70 
years mean 
age with AF    
and not 
suitable for 
VKA therapy. 
Markov decision model, UK 
perspective, lifetime 
horizon, cycle length (6 
weeks).                                             
Data source: AVERROES 
and ARISTOTLE trials                                                       
Assumption: risk of stroke 
recurrence not treatment 
specific, same utility 
decrements for apixaban and 
aspirin, no apixaban efficacy 
for secondary stroke 
prevention, drug 
discontinuation and 
switching. 
Discontinuation of apixaban 
and switch to Aspirin due to 
ICH (56% of patients), or 
interrupt treatment for 6 
weeks (44% of patients).   
Discontinuation of aspirin 
and switch to Warfarin due 
to ischaemic stroke or SE. 
Permanent discontinuation of 
treatment due to 
haemorrhagic stroke or MI. 
Apixaban vs warfarin £11,909   
(97% at £20,000 threshold).                                                                 
Apixaban vs aspirin £7,196     
(99% at £20,000 threshold).                                                                   
Main drivers: apixaban risk of stroke, 
apixaban utility decrement, apixaban 
other death rate, daily cost apixaban, 
aspirin stroke rate.
Edwards, 
2012 
(manufacturer 
model) 
Apixaban,                             
dabigatran 150 
mg/110 mg,       
dabigatran 110 
mg, rivaroxaban,                        
warfarin. 
70 years mean 
age with AF   
and suitable 
for VKA 
therapy. 70
years mean 
age with AF    
and not 
suitable for 
VKA therapy. 
Markov decision model, UK 
perspective,                 
lifetime horizon,                    
cycle length (6 weeks).                                             
Data source: AVERROES 
and ARISTOTLE trial                                     
Assumptions: same risk of 
MI and level of other-cause 
discontinuation for apixaban 
and dabigatran, constant 
relative treatment effect 
across CHADS2 score 
categories, disutility 
associated with treatment 
and not age adjusted, drug 
discontinuation and 
switching. 
Discontinuation of 
anticoagulation due to MI or 
haemorrhagic stroke.                       
Discontinuation of aspirin 
(as second line treatment) 
and switch to warfarin due to 
ischaemic stroke or SE.                
Switching to aspirin or no 
treatment due to ICH, major 
bleed or other causes. 
Apixaban vs warfarin £11,008     
(80% at £20,000 threshold).                                                                                                                          
Dabigatran 110 mg dominated by 
dabigatran blend.                                                                                    
Rivaroxaban extendedly dominated by 
apixaban.                                        
Dabigatran blend extendedly dominated by 
apixaban. 
Main drivers: apixaban vs warfarin: 
warfarin disutility, risk of ICH,
ischaemic stroke or other-cause 
mortality, INR monitoring costs, 
QALYs discount rate.  
Main drivers: apixaban vs rivaroxaban 
or Dabigatran, risk of ICH, ischaemic 
stroke or other-cause mortality, 
apixaban absolute risk of stroke, 
second-line aspirin risk of stroke. 
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Table 7.1 Cost-effectiveness studies identified in the review (continued a) 
* Incremental net monetary benefit 
 
 
 
 
 
Study Interventions Population 
Model type  
(perspective, 
cycle length  
and assumptions) 
Discontinuation                                     
and switching 
 Results  Sensitivity analysis and key drivers         
Lip, 2014 Apixaban 5 mg 
twice daily,   
dabigatran 150 mg 
twice daily,    
dabigatran 110 mg 
twice daily,    
rivaroxaban 20 mg 
once daily, aspirin,                                
adjusted dose 
warfarin. 
70 years 
mean age 
with AF    
and suitable 
for VKA 
therapy. 
Markov decision model, UK 
perspective, lifetime horizon,                                 
cycle length (6 weeks).                                        
Data source: ARISTOTLE, RE-
LY and ROCKET-AF trials                                                
Assumptions: recurrence of 
ischaemic or haemorrhagic 
stroke same for all treatments, 
case fatalities and all-cause 
mortality rates same for all 
treatments, same utility 
decrement for DOACs and 
aspirin. 
Discontinuation of 
anticoagulation and switch 
to aspirin due to bleeding 
events. 
Apixaban vs dabigatran 150 mg £9,611            
(83% at £20,000 threshold).                                  
Apixaban vs dabigatran 110 mg £4,497 
(98% at £20,000 threshold).                                                                                        
Apixaban vs rivaroxaban 20 mg £5,305 
(85% at £20,000 threshold).                                                                    
Main drivers: Drugs prices, ICH and 
stroke rates, and hospitalisation rates. 
Sterne, 
2017 
Apixaban 5 mg 
twice daily,        
dabigatran  150 mg 
twice daily,    
rivaroxaban 20 mg 
once daily,                                 
adjusted dose 
warfarin. 
70 years 
mean age 
with AF    
and suitable 
for VKA 
therapy. 
Markov decision model, UK 
perspective, 30 years time 
horizon, cycle length (3 months).                                       
Data source: ARISTOTLE, RE-
LY and ROCKET-AF trials and 
NMA.                                               
Assumptions: future risk of 
death for bleeds and ICH same 
as stroke, events rate and relative 
treatment effects independent of 
age, similar post-ICH and post-
ischaemic stroke management 
costs, drug discontinuation and 
switching. 
Discontinuation of 
dabigatran and switch to 
warfarin due to MI. 
Switching to no treatment 
due to ICH or haemorrhagic 
stroke. Switching from 
DOAC to warfarin, or the 
reverse, due to ischaemic 
stroke bleeding, SE or TIA. 
Apixaban 5 mg £7,533*                          
(close to 60% at £20,000/£30,000 
threshold).                                                                   
Dabigatran 150 mg £5,279*.                                                                                                                           
Rivaroxaban 20 mg £6,365*.                                                               
Main drivers: apixaban low rates of 
MI, ICH and clinical relevant bleeding. 
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Table 7.1 Cost-effectiveness studies identified in the review (continued b) 
 
Study Interventions Population 
Model type 
(perspective,  
cycle length  
and assumptions) 
Discontinuation                                     
and switching 
Results Sensitivity analysis and key drivers          
Verhoef, 2014 Apixaban 5 mg 
twice daily, 
dabigatran 150 
mg twice daily,   
rivaroxaban 20 
mg once daily,     
coumarin 
derivatives,  
Aspirin 
70 years mean 
age with AF 
initiating 
anticoagulatio
n therapy. 
Markov decision model,   
UK perspective,                 
lifetime horizon,                                
cycle length (1 month)                                                               
Data source: ARISTOTLE, 
RE-LY and ROCKET-AF 
trials.                                                     
Assumptions: frequency of 
INR yearly measurements, 
event rates stable after 2 
years, about one third of 
ischaemic stroke assumed 
TIA, drug switching. 
Discontinuation of 
anticoagulation and switch to 
aspirin due to ICH. 
Apixaban 5 mg €11,470 (£10,058) ** 
(35% at £20,000 threshold).                                                                                                                              
Dabigatran 150 mg €11,171 (£9,796) ** 
(41% at £20,000 threshold).                                                                        
Rivaroxaban 20 mg €16,949 (£14,862) ** 
 (5% at £20,000 threshold).                                                                                    
Apixaban 5 mg                                                                                                             
(35% at £20,000 threshold).        
Dabigatran 150 mg                                                                                                 
(41% at £20,000 threshold).                                        
Rivaroxaban 20 mg                                                                                                 
(5% at £20,000 threshold).                                        
Main drivers: time in range, risk of ICH 
for rivaroxaban, cost of apixaban. 
                                                                              
 
** Cost converted from euro to British pound 
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7.2.3 Review – discussion 
 
The models appraised with the CHEERS tool were in general of good quality. However, 
for all models, a rational and a justification for the choice of the discount rate and health 
outcomes used as the measure of benefit was not provided. Nevertheless, it is appreciated 
that most models in economic evaluation adopting the NHS perspective, typically use a 
3.5% discount rate for cost and utilities, and use QALYs as the outcome measure as per 
NICE reference case recommendations [183]. Another common issue identified in most of 
the models identified was a lack of reporting methods for adjusting estimated unit cost. In 
particular it was not clear how and whether costs where inflated. The complete CHEERs 
checklists for each of the identified study is reported in Appendix XVIII (Table XVIII-
1−XVIII-4).  
 
Different models evaluating the cost-effectiveness of DOACs have been developed, and 
although a common structure borrowed from the Sorensen and Gage models [175, 176] is 
shared, they differ in terms of health state, assumptions and inputs used. These differences 
reflect different levels of complexity; however, the models evaluated also shared common 
features. For instance, all models assumed that patients started anticoagulation treatment at 
70 years of age, thus reflecting the age enrolment of the pivotal RCTs [41-43].  
 
Beyond a common core structure, the existing cost-effectiveness models, as the ones 
identified in the Limone’s review [173], were populated with the safety and efficacy data 
of the pivotal RCTs (Aristotle, RE-LY, ROCKET-AF) [41-43]. Dorian’s model (2014) 
[178] and the apixaban manufacturer model [182] also included evidence from the 
AVERROES trial [47] as they included aspirin as an alternative to anticoagulation 
discontinuation (patients discontinue anticoagulation with DOAC and switch to aspirin due 
to bleeding events) [178, 179, 181].  
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However, this implies the inclusion of a VKA unsuitable patient population, and may not 
be relevant for the cost-effectiveness analysis in this Chapter. The number of health states 
employed in each model reflected different levels of complexity. For instance, the 
manufacturer model for apixaban categorised ischaemic and haemorrhagic stroke 
according to four different levels of severity, and distinguished SE and ICH between fatal 
and fatal. Achieving this level of complexity may only be possible with availability of 
patient level data as in the RCTs. Nevertheless, even with real-world data it may not be 
feasible to categorise stroke according to severity [182]. Further, unlike all the other 
models identified in the review, Verhoef (2014) included disability as a health state; that is 
a disability from warfarin-associated intracranial and extra cranial haemorrhages [181].  
 
All models identified assessed apixaban [178-182], which was found to be a cost-effective 
option compared to warfarin. The ICERs for those models were below the NICE 
recommended threshold of £20,000, and in line with the most plausible ICER of £12,757 
identified by the Evidence Review Group (ERG), an external and independent academic 
group that reviews the manufacturer or sponsor’s evidence submission on behalf of NICE  
[184]. In the model where the dabigatran was compared against warfarin and found to be 
cost-effective [181], the ICER reported was again well below the £20,000 threshold and 
the most plausible ICER of £18,900 calculated by the ERG group.  
 
As mentioned, all the models identified in the review were Markov based models. Despite, 
the availability of patient-level data, the option of using a DES model was excluded for the 
reasons elucidated in the previous paragraph comparing Markov versus DES approaches. 
Specifically, for the DOACs case study, a DES model would generate a new set of 
probabilities for future events by updating patients’ health profiles over time according to 
their characteristics, risk scores, and their experience of clinical events [185].  
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However, in the cost-effectiveness analysis carried out in this Chapter, patients’ 
characteristics and risk scores for estimating risk of events were only measured at baseline; 
and, as it will be further discussed, the risk of future events were obtained from the 
literature [186]. Therefore, despite the availability of patient level data, Sterne’s model 
seemed the best alternative for the cost-effectiveness analysis undertaken in this Chapter.  
 
In particular, Sterne’s model seemed the most fit for purpose because of the ease of 
implementation, with no stroke severity distinction between mild, moderate and severe 
[180]. Currently, there is not sufficient evidence to assume that stroke severity depends on 
the anticoagulation treatment received [35]. Furthermore, health states for non-clinically 
relevant minor bleed were not included as they were assumed to have minimal impact on 
cost, quality of life and future risks. Hence, no distinction was made between bleed 
locations such as GI bleeding or other types of bleed [180]. The model also appeared to be 
inclusive of all the relevant health states including TIA and SE. Unlike other models [178, 
179, 182], TIA and SE health states were included but only for the acute phase. Further, 
TIA was used as an alternative to the reversible ischaemic neurological deficit -RIND 
(used to reflect recovery from a temporary stroke or TIA) to represent a non-disabling 
minor stroke [180].  
 
7.3 Methods 
 
The objective of this economic evaluation is to assess the cost-effectives of DOACs when 
compared to warfarin in Scottish clinical practice, from a clinical and economic 
perspective for the prevention of stroke in the AF population. In the base-case analysis, it 
was assumed that patients entered the model at 50 years of age. This assumption was based 
on clinical advice and the evidence that prevalence and incidence of AF typically increase 
exponentially from 50 years onwards [89].  
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Thus, the analysis including patients from the age of 50 would be inclusive of all patients 
potentially at risk of AF. The baseline characteristics were the same described for the AF 
cohort in Chapter 5 and Chapter 6.  However, a further subgroup analysis was carried out 
on a cohort of patients 70 years or older at the time of coagulation initiation. This is line 
with the anticoagulation starting age adopted in most cost-effectiveness models reviewed 
[178-182]. 
 
In the cost-effectiveness analysis, the DOACs, including apixaban, dabigatran and 
rivaroxaban, currently used in Scottish clinical practice, were compared against warfarin 
and also incrementally against each other. In addition to the main analysis, a set of 
subgroup analyses was carried out to assess the cost-effectiveness of apixaban and 
rivaroxaban, when administered at their standard or reduced dose; subgroup analysis was 
not possible for dabigatran due to sample size.  
 
Cost and outcomes were extrapolated for 50 years for a cohort of patients 50 years or 
older; thus, a lifetime horizon was adopted. Total costs and QALYs for each intervention 
were discounted at 3.5% as per NICE guidelines [184], and presented against warfarin and 
incrementally, according to their effectiveness, to identify dominance and extended 
dominance. These are concepts used in economic evaluation as described in the NICE 
reference case. 
 
While dominance is established when a given intervention is less effective and more costly 
compared to the previous alternative, extended dominance is determined by the ICER of an 
intervention being higher compared to the next more effective alternative [151]. As CUA is 
typically used in economic evaluations, QALY was used as the outcome measure 
reflecting differences in health benefits between interventions.   
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As per NICE reference case recommendation, the study adopted the NHS perspective 
[183]. The NHS perspective includes cost of treatment, administration and monitoring, and 
those related to service utilisation such as general practitioner visits and hospital 
admissions. Costs associated to management of treatment side effects may also be 
included. However, transportation, over the-counter purchases and indirect costs are not 
included.  
 
While a broader societal perspective may be relevant for this study, reflecting a series of 
social opportunity costs, as for instance those generated by reducing productivity loss, 
NICE recognise that the societal perspective may introduce bias against people not at work 
because of retirement age or unable to work because of health conditions.  
 
7.3.2 Model structure 
 
The multistate Markov model was developed based on the latest published DOAC cost-
effectiveness model, which adopted the UK perspective [180]. The model used in this 
economic evaluation maintained the Sterne’s model structure (2017) [180], but different 
assumptions were made. As in Sterne’s model (2017) [180], the same model structure is 
used for each treatment strategy with variations in event probabilities and associated 
utilities and costs. While the main structure, using a cycle length of 3 months is 
maintained, assumptions on treatment switching and discontinuation were not implemented 
as there were directly modelled in the treatment effectiveness estimation in Chapters 5 and 
6.  
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As shown in Figure 7.2 [180], the AF cohort enters the model in a “AF” state, patients may 
then experience Stroke, MI, major bleed, ICH or die at any time. Over time, patients could 
again experience Stroke, MI, major bleed, ICH, but this time the risk of experiencing an 
event would depend on previous event history. For instance, if patients move from MI to 
the MI+S health state, the risk of stroke will depend on the present risk of stroke, but also 
on the future risk of stroke for patients who had an MI.  Similarly, if patients move from 
MI+S to the ICH+MI+S health state, the risk of ICH will depend on the present risk of 
ICH, but also on the future risk of ICH for patients who had an MI and a stroke.  
 
Patients moving to the S+B+MI+ICH health state, may experience stroke, bleeding, MI or 
ICH; and again, the risk of moving into this health state will depend on previous event 
history. For patients who are moving from ICH+MI+S health state, the future risk of 
bleeding will depend on the previous history of ICH, MI and stroke.  
 
Patients may also experience TIA or SE; these however are considered temporary health 
states having only a short-term effect in terms of costs and utilities. On the other hand, 
stroke, ICH, MI and bleeding are expected to have some effect in the long-term, and 
therefore need to be modelled.  
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Figure 7.2 Multi-state Markov model for the prevention of stroke in the AF population 
Abbreviations: S=ischaemic stroke, MI= myocardial infarction, B= major bleeding, ICH= intracranial haemorrhage 
Source: Adapted from, Sterne et al. (2017). 
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7.3.3 Model inputs 
 
Event rates and transition probabilities 
In addition to the clinical outcomes described in Chapter 6, ischaemic stroke, TIA and SE 
were estimated individually to accommodate the transient role that these states have in the 
model. The effectiveness parameters were estimated following the same method described 
in Chapters 5 and 6. The cumulative incidence curves for DOACs any dose, standard dose, 
and reduced dose are presented in Appendix XIX (Figure XIX-1−XIX-6).  While the 
cumulative incidence curves generated in Chapter 6 show the ATE, those presented in 
Appendix XIX show the relative treatment effect, and therefore one single regression 
(where warfarin is the reference group) was run including all four treatment options 
represented by a dummy variable. Nevertheless, the interpretation in terms of probability 
of event is the same, and the HRs presented in this section diverge marginally from those 
presented in Chapter 6. The ICD 10 codes used for disease identification were previously 
discussed and presented in Chapter 6, Table 6.1.  
 
The model transition probabilities for each treatment and each clinical outcome were 
obtained by firstly converting warfarin event rates into probabilities, and then applying the 
HRs from the incremental time-to-event analysis to the warfarin event rates. The transition 
probabilities for warfarin were assumed to follow a beta distribution were α represents the 
number of events and β is obtained by subtracting the number of events from the number 
of person-years. The beta distribution, constrained on the interval 0-1, reflects the 
proportion of observed outcomes and represents the conjugate of the binomial distribution 
[151]. Warfarin event rates and transition probabilities are presented in Table 7.2.  
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Table 7.2 Warfarin event rates and transition probabilities 
    Beta distribution Transition probability        
(3 months cycle) Outcome Event rate α Β 
TIA 0.45  180 39,536 0.0011 
SE 0.12  49 39,667 0.0003 
Stroke 1.44  573 39,143 0.0036 
MI 0.99  393 39,323 0.0025 
Major bleeding 4.03  1,599 38,117 0.0100 
ICH 0.28  113 39,603 0.0007 
Mortality (all-cause) 5.30  2,104 37,612 0.0132 
 
Abbreviations: TIA=transient ischemic attack, SE=systemic embolism, MI= myocardial infarction, 
ICH= intracranial haemorrhage. 
 
Event rates were converted into transition probabilities according to the following equation 
[151]:  
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 1 − 𝑒𝑥𝑝(−𝑟𝑡) 
                                                                                                                           (Equation 7.3) 
Where r is the event rate and t the time.   
 
To obtain the transition probabilities, the event rates presented per 100 person-years, were 
firstly brought back to their original values, then the transition probability equation was 
applied. All transition probabilities where divided by 91.3125 to convert yearly values into 
3 months cycles transition probabilities for the Markov model. For instance, based on the 
event rate of TIA for warfarin of 0.0045 (or 0.45 per 100 person-years) the transition 
probability would be calculated as shown in the equation below:  
Warfarin TIA probability =1-exp(-(0.0045/365.25)*91.3125) = 0.0011             
                                                                                                                           Equation (7.4) 
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The transition probability for DOACs were obtained by multiplying the warfarin event 
rates by the HRs of DOACs clinical outcomes, then the transition probability equation (as 
described in Equation 7.4) was applied. For instance, based on the event rate of TIA for 
warfarin of 0.0045 (or 0.45 per 100 person-years) and the HR for apixaban of 0.87, the 
transition probability would be calculated as shown in the equation below: 
Apixaban TIA probability =1-exp(-((0.0045*0.87)/365.25)*91.3125) = 0.001            
                                                                                                                           Equation (7.5) 
 
All HRs and transition probabilities calculated for pooled, standard and reduced dose, are 
presented in Table 7.3. The number of events observed and estimated HRs for the 70 years 
or older subgroup are reported in Appendix XX (Table I). The HRs reflecting the treatment 
effect were assumed to follow a lognormal distribution, where the confidence limits 
calculated on the log scale indicate lognormal as the most appropriate distributional form 
for risk parameters [151].  
 
As in previous models, event rates and treatment effects were assumed independent of age; 
hence, the derived transition probabilities were homogenous throughout the model. 
However, life tables for Scotland were included in the model, thus allowing transition 
probabilities to change over time as the cohort ages [77].  
 
The probability of experiencing a clinical event depends on previous events history. For 
instance, if one patient on warfarin moves from the MI to the MI+S health state, the risk of 
stroke will depend on the actual risk of stroke associated with warfarin (estimated with the 
comparative-effectiveness methodology discussed in the previous Chapter), but also on the 
future risk of stroke for a patient who had an MI. The risk of future events in Table 7.4 are 
age and treatment independent, and assumed to follow a lognormal distribution.  
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The risks of future events, taken from Sterne`s model, are based on a study that estimated 
the risk of SE, TIA, MI and bleeding according to previous event history [186] and a study 
that estimated the risk of previous events on mortality [187]. Further, as there is no 
evidence available on the effect of bleeding on ICH and mortality, Sterne assumed that the 
effect of bleeding and ICH on mortality would be the same as stroke.   
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Table 7.3 DOACs HRs and transition probabilities 
Intervention        Transition 
probability        
(3 months cycle) 
(compared to warfarin) Outcome HR 95 % CI 
Standard 
error 
 Apixaban          
  TIA 0.87 (0.47 -1.63) 0.275 0.0011 
  SE 0.62 (0.17 -2.25) 0.415 0.0002 
  Stroke 0.86 (0.6 -1.23) 0.153 0.0032 
  MI 1.27 (0.86 -1.87) 0.243 0.0033 
  Major bleeding 0.85 (0.69 -1.05) 0.091 0.0092 
  ICH 1.54 (0.79 -3.02) 0.508 0.0011 
  Mortality (all-cause) 0.99 (0.83 -1.99) 0.092 0.0129 
Apixaban (standard dose)   
 
  
 
  TIA 0.82 (0.38 -1.78) 0.313 0.0010 
  SE 0.55 (0.12 -2.51) 0.428 0.0002 
  Stroke 0.91 (0.6 -1.39) 0.195 0.0034 
  MI 1.23 (0.77 -1.96) 0.282 0.0032 
  Major bleeding 0.91 (0.72 -1.15) 0.109 0.0099 
  ICH 1.42 (0.65 -3.13) 0.567 0.0010 
  Mortality (all-cause) 0.96 (0.77 -1.22) 0.113 0.0125 
Apixaban (reduced dose)   
 
  
 
  TIA 0.98 (0.40 -2.39) 0.457 0.0012 
  SE 0.85 (0.10 -6.95) 0.883 0.0003 
  Stroke 0.78 (0.44 -1.38) 0.219 0.0029 
  MI 1.52 (0.87 -2.66) 0.452 0.0040 
  Major bleeding 0.78 (0.53 -1.14) 0.156 0.0085 
  ICH 1.77 (0.64 -4.92) 0.890 0.0012 
  Mortality (all-cause) 1.01 (0.77 -1.32) 0.136 0.0132 
Dabigatran         
  TIA 0.44 (0.06 -3.18) 0.525 0.0005 
  SE* 1.00 (0.00 -0.00) 0.000 0.0003 
  Stroke 0.62 (0.23 -1.66) 0.294 0.0023 
  MI 0.43 (0.11 -1.76) 0.306 0.0011 
  Major bleeding 1.02 (0.67 -1.56) 0.211 0.0111 
  ICH* 1.00 (0.00 -0.00) 0.000 0.0007 
  Mortality (all-cause) 0.80 (0.52 -1.26) 0.176 0.0104 
 Rivaroxaban         
  TIA 0.65 (0.35 -1.22) 0.205 0.0008 
  SE 0.44 (0.10 -1.94) 0.396 0.0001 
  Stroke 0.95 (0.69 -1.30) 0.145 0.0036 
  MI 0.81 (0.54 -1.24) 0.163 0.0021 
  Major bleeding 1.29 (1.09 -1.52) 0.107 0.0140 
  ICH 1.52 (0.85 -2.73) 0.420 0.0011 
  Mortality (all-cause) 1.42 (1.23 -1.64) 0.098 0.0185 
Rivaroxaban (standard dose)   
 
  
  TIA 0.66 (0.33 -1.34) 0.234 0.0008 
  SE 0.59 (0.14 -2.57) 0.415 0.0002 
  Stroke 1.02 (0.72 -1.45) 0.174 0.0038 
  MI 0.70 (0.42 -1.18) 0.175 0.0018 
  Major bleeding 1.29 (1.07 -1.55) 0.115 0.0140 
  ICH 1.58 (0.84 -2.99) 0.481 0.0011 
  Mortality (all-cause) 1.50 (1.27 -1.76) 0.117 0.0196 
Rivaroxaban (reduced dose)   
 
  
  TIA 0.51 (0.12 -2.11) 0.373 0.0006 
  SE* 1.00 (1.00 -1.00) 1.335 0.0003 
  Stroke 0.71 (0.35 -1.46) 0.249 0.0027 
  MI 1.40 (0.72 -2.69) 0.463 0.0037 
  Major bleeding 1.57 (1.14 -2.17) 0.252 0.0171 
  ICH 1.02 (0.24 -4.34) 0.740 0.0007 
  Mortality (all-cause) 1.32 (1.00 -1.73) 0.182 0.0172 
 
* Assumed no treatment effect difference between warfarin and dabigatran for SE and ICH. 
Abbreviations: TIA= transient ischaemic attack, SE=systemic embolism, MI=myocardial 
infarction, ICH=intracranial haemorrhage
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Table 7.4 Effect of previous events on future events (HRs) 
Risk factor  Future stroke  Future TIA/SE  Future ICH Future bleed Future mortality 
Stroke  4.00 (3.78, 4.22)  3.61 (3.44, 3.78)  1.64 (1.39, 1.94)  1.39 (1.27, 1.52) 1.32 (0.98. 1.77) 
ICH 1.78 (1.56, 2.03)   1.82 (1.62, 2.04)  10.2 (8.59, 12.2) 2.95 (2.57, 3.39) 1.32 (0.98, 1.77) 
Bleeding 1.32 (1.21, 1.44)  1.36 (1.26, 1.46)   3.54 (3.02, 4.17)  3.32 (3.06, 3.60) 1.32 (0.98, 1.77) 
MI 1.24 (1.17, 1.33)  1.29 (1.22, 1.36) 0.94 (0.78, 1.12)  1.24 (1.15, 1.35) 1.03 (0.73, 1.46) 
 
Abbreviations: ICH=intracranial haemorrhage, MI=myocardial infarction. 
Source: Sterne et al. (2017). 
 
 
 
7.3.4 Cost and utility inputs 
 
Cost inputs 
 
While effectiveness parameters were obtained from the survival analysis as previously 
described, cost and utility parameters were obtained from various sources. The cost for the 
clinical events occurring in the acute phase (first 3 months from anticoagulation initiation) 
were mainly obtained from the SNT 2013/2014 [100], and then averaged according to the 
level of activity identified in the NHS reference cost 2011/2012. The activity is measured 
according to the number of attendances, bed days, clients, episodes, tests, or other unit of 
activity appropriate to the service [188]. To match the clinical events from SNT and level 
of activity from the NHS reference cost, HRGs codes were used. However, while a more 
up to date version of the NHS reference cost is publicly available, the HRG codes did not 
match those reported in the SNT for the year 2013/2014; thus, HRG from the NHS 
reference cost for the year 2011/2012 were used. The cost of MI was double the amount of 
the reference cost, thus accounting for potential follow-up costs [180].  
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Acute management costs for ischaemic stroke and ICH, obtained from the Sterne model, 
are based a study assessing in the UK the acute and long-term costs of stroke in atrial 
fibrillation patients [189]. Costs for the post-acute phase were identified from the same 
study, and averaged according to the number of patients experiencing a non-disabling, 
moderately disabling or a totally disabling stroke [189].   
 
All costs were inflated to 2017/2018 prices, using the consumer price index for medical 
interventions, and are presented in Table 7.5 [190]. The unit cost for the DOACs were 
obtained from the 2018 BNF database [191-193], and calculated for a 3-month cycle; while 
the average drug and monitoring costs of warfarin were obtained from a NICE costing 
report on AF [194] cited in different cost-effectiveness studies. The unit cost of each 
DOAC (Table 7.6) is known and therefore assumed to be fixed. However, the cost of 
warfarin and associated monitoring typically varies significantly across clinical practice, 
and therefore a uniform distribution ranging from 50% to 150% of the mean cost was 
assumed [194].  
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Table 7.5 Costs of clinical events 
Event (Non-Elective) Cost £ (SD) Activity  HRG code 
Average           
weighted 
cost 
Inflated cost Distribution Source 
Acute phase cost               
Ischaemic stroke 10,844 (15,733)       12,705 (18,433) Normal (12,705, 1,448) Sterne (2017) 
ICH 10,683 (12,885)       12,517 (15,096) Normal (12,517, 3,661) Sterne (2017) 
TIA 1,368   AA29Z   1,495 Uniform (748, 2,243) Scottish National Tariff*, NHS reference cost** 
MI 2,518***   EB10Z 5,036 5,503 Uniform (2,752, 8,255) Scottish National Tariff*, NHS reference cost** 
SE 7,254           
3,549           
1,984 
1,545             
10,946          
2,473 
QZ17A     
QZ178      
QZ17C 
3,673 4,013 Uniform (2,007, 6,020) Scottish National Tariff*, NHS reference cost** 
Clinical relevant bleeding 4,783            
3,222              
625              
5,101           
3,369              
664                 
159 
16,116          
19,304          
2,806          
13,336        
16,491          
1,935       
FZ38D       
FZ38E       
FZ38F      
FZ43A     
FZ43B      
FZ43C      
VB07Z 
3,008 3,287 Uniform (1,644, 4,931) Scottish National Tariff*, NHS reference cost** 
Post-acute phase cost             
 
Non disabling (N=66) 2,135 (3,675)     3,370 (6368) 3,948 (7,461) Normal (3,948, 640) Sterne (2017) 
Moderately disabling (N=58) 4,165 (7,668)             
Totally disabling (N=12) 6,324 (14,898)             
 
Abbreviations: ICH=intracranial haemorrhage, TIA=transient ischaemic attack, MI=myocardial infarction, SE=systemic embolism 
*Scottish National Tariff (2013/2014)  
**NHS reference cost (2011/2012) 
***Double to include follow-up costs  
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Table 7.6 Cost of prescription drugs 
Intervention Size Cost per pack (£) Cost per day (£) Cost per 3 months cycle (£) 
Apixaban 2.5 mg 60 57.00 1.90 173.38 
Apixaban 5 mg 56 53.20 1.90 173.38 
Dabigatran 60 51.00 1.70 155.13 
Rivaroxaban 15 mg 100 180.00 1.80 164.25 
Rivaroxaban 20 mg 100 180.00 1.80 164.25 
Warfarin (including monitoring)      77.25 
 
Note: cost of warfarin inflated for 2017/2018 
Source: National Institute for Health and Care Excellence. BNF apixaban (2018), National Institute 
for Health and Care Excellence. BNF dabigatran (2018), National Institute for Health and Care 
Excellence. BNF rivaroxaban (2018), National Institute for Health and Care Excellence. Costing 
Report:  Atrial Fibrillation (2006). 
 
 
Utility inputs 
The utility parameters for the chronic health states were obtained from Sterne’s model 
[180], where the parameter for the AF HRQoL was identified from a study that analysed 
factors such as age and comorbidities, determining the level of utilities in patients 
diagnosed with any type of AF [160]. The utilities for stroke and ICH were identified from 
a study looking at the long-term HRQoL in the 4 years following a stroke [195]; while the 
utility for MI was taken from a study exploring factors such as gender and social class 
believed to influence self-perceived health following an MI [196].  
 
The utilities for acute health events were obtained by applying disutilities, assumed to last 
for 3 months, to the utilities of the chronic health states previously discussed. In particular, 
the disutilities for TIA, SE, stroke and major bleeding were obtained from a study 
assessing patient valuations of AF related health states [164]. The disutility for MI and 
ICH where obtained by subtracting the AF reference health state from the utility values for 
the acute phases identified respectively in Lacey (2003) [196] and Lenert (1997) [197].  
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The disutilities were capped at 0 and assumed to follow a Uniform distribution, ranging 
from 50-150% of the reported mean, whenever the uncertainty estimates and sample sizes 
were not available. Further, the utilities were multiplied by 0.25 to obtain a QALY value 
for a 3-month cycle [180]. Utility and disutility parameters with associated distributions 
are presented in Table 7.7.     
 
Table 7.7 Utility and disutility 
Component Utility/disutility (SD) Distribution 
Event utility     
Stable AF 0.779 Normal (0.779, 0.0045) 
Post Stroke 0.69 (0.18) Normal (0.69, 0.0205) 
Post MI 0.718 (0.243) Normal (0.718, 0.0163) 
Post ICH 0.74 (0.39) Beta (3.941, 1.385) 
Event disutility (first 3 months)   
Acute TIA -0.131 Uniform (-0.197, - 0.066) 
Acute SE -0.131 Uniform (-0.197, - 0.066) 
Acute Stroke -0.590 Uniform (-0.885, - 0.295) 
Acute MI* 0.683 (0.233) - Stable AF Normal (0.683, 0.0156) - Stable AF 
Acute Major bleeding  -0.03 Normal (-0.03, 0.001531) 
Acute ICH* 0.60 - Stable AF Normal (0.60, 0.064) - Stable AF 
 
* distribution capped at 0 
Abbreviations: MI=myocardial infarction, ICH=intracranial haemorrhage,  
TIA=transient ischaemic attack, SE=systemic embolism. 
Source: Sterne et al. (2017). 
 
Utility decrements were multiplied by the general population utility values used in Sterne’s 
model [180] and estimated by Kind et all (1999) (Table 7.8)  [76].  
 
Table 7.8 General population utility values by age and gender 
Age 
Male Female 
mean (SD)   Α Β mean (SD)   α β 
45-54 0.84 (0.27) 314.4 65.0 0.85 (0.23) 544.1 96.0 
55-64 0.78 (0.28) 330.4 93.2 0.81 (0.26) 526.6 123.5 
65-74 0.78 (0.28) 388.5 109.6 0.78 (0.25) 551.7 155.6 
75+ 0.75 (0.28) 191.2 63.7 0.71 (0.28) 406.4 166.0 
 
Source: Sterne et al. (2017) 
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7.3.5 Model assumptions 
 
In this model, a series of assumptions were made. Firstly, ICH, major bleeding and stroke 
were assumed to have the same effect on future risk of death; nevertheless, the mortality 
rate in AF patients relative to the general population was not assumed to change according 
to age. Similarly, relative treatment effects and event rates were assumed to be constant 
over time.  
 
Secondly, assumptions were made around the distribution of the cost of warfarin and the 
associated monitoring. The Uniform distribution ranging from 50% to 150% of the mean 
estimate reported in the NICE costing report on AF was assumed to reflect the uncertainty 
and the wide variation of warfarin and monitoring costs across clinical practice [194].  
 
In addition, stroke and ICH long-term management costs were assumed to be the same, and 
the cost of MI was assumed to be double the amount of the reference cost to account for 
any potential follow-up cost [180]. A further assumption was made about no SE and ICH 
risk difference between dabigatran and warfarin. This is because it was not possible to 
establish, due to the limited number of SE events and no ICH events estimated in the 
dabigatran arm, the actual risk of SE and ICH for each treatment. For the same reason, 
patients on reduced dose rivaroxaban and warfarin were assumed to have the same risk of 
SE. 
 
In this model, unlike other cost-effectiveness models on DOACs, no assumptions were 
made about treatment switching and discontinuation, as this was addressed in the time-to- 
event analysis where patients who switched or discontinued were censored. In addition, 
about a third of patients switched or discontinue anticoagulation within the first 2 years 
from therapy initiation.  
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Therefore, switching and discontinuation, in the long-term, may have limited effect on 
clinical outcomes. Full details on how treatment switching and discontinuation were 
included in the survival analysis were discussed in Chapters 5 and 6.  
 
7.3.6 Model uncertainty 
 
In addition to the base-case deterministic analyses, sensitivity analysis was carried out by 
means of PSA and one-way sensitivity analysis to assess the uncertainty around the 
findings and identify the key drivers. In particular, PSA, based on the probability 
distribution of each parameter, was used to assess parameter uncertainty [151, 168]. PSA 
represents parameters as distributions of possible mean values instead of single point 
estimates in a deterministic analysis.  
 
Combination of cost-effectiveness pairs presented in the cost-effectiveness plane reflect the 
number of iterations run in the model; and the location of this across the four quadrants on 
the cost-effectiveness plane would indicate whether an intervention is less or more 
effective and less or more costly than the comparator. In particular, for an intervention to 
be cost-effective, the mean values would lie in the northeast quadrant indicating that the 
intervention is more costly but also more effective compared to other alternatives. On the 
other hand, if an intervention were less costly and less effective, mean values would mostly 
lie in the southwest quadrant. The dominance of the new intervention or the control would 
be shown on the northwest and southeast quadrant respectively [151].  
 
The uncertainty around the cost-effectiveness results was also presented graphically by 
means of Cost-Effectiveness Acceptability Curves (CEAC), where the probability for each 
intervention of being cost-effective (on the y-axis) is plotted over a range of WTP 
thresholds (on the x-axis) [151, 168].  
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In addition, a series of one-way sensitivity analyses were carried out to assess the level of 
confidence and robustness of the findings. In the one-way sensitivity analyses, parameters 
thought to be key drivers are changed between their extreme values to evaluate the impact 
they have on the main conclusions of the cost-effectiveness analysis [151, 168]. The 
parameters selected were those that seemed to influence the most the conclusions of the 
assessed UK cost-effectiveness models. In particular, these were the risk of clinical events 
(tested at their lower and upper limits) and the cost of stroke and ICH incurred in the acute 
and chronic phase (increased and decreased by 20%). The risk of future clinical events, 
experienced as patients move across the model, may be determined by the previous event 
history; thus, the effect of previous events on future events was also tested.   
 
Further, because stroke and ICH may have a substantial impact on quality of life of an 
individual, the long term disutilities associated with stroke and ICH were included in the 
one-way sensitivity analysis. Further, in the sensitivity analysis the NICE recommended 
threshold of £20,000 per QALY was changed to £12,936 to assess whether setting a 
threshold lower than the recommended may affect the probability of any DOAC or 
warfarin being cost-effective. The £12,936 threshold has been indicated by Claxton et al. 
(2015) as the most relevant for economic evaluation in a UK context [198]. The threshold 
was based on an analysis that evaluated the impact of the marginal increases and decreases 
in the NHS total expenditure for the year 2008 across 23 programme budget categories 
(such as infectious diseases, circulatory disease and cancers). The impact estimated was 
then linked to QALYs [198].  
 
 
 
 
Chapter 7…………………………………………………………………………………………………………………………………211 
 
7.4 Results  
 
7.4.1 Base-case analysis 
 
Apixaban was found to be the most costly intervention over a patient’s lifetime, but also 
yielded more QALYs than any other DOAC or warfarin (Table 7.9). When compared 
against warfarin, apixaban and dabigatran were cost-effective at the £20,000 threshold, 
with dabigatran yielding a greater INMB. Rivaroxaban was dominated by warfarin, being 
more effective and less costly. When all interventions were compared incrementally, 
ranked from least to most effective with associated total QALY gained, rivaroxaban was 
again dominated by warfarin, while dabigatran was shown to be more cost-effective than 
apixaban at the £20,000 threshold.  
 
Table 7.9 Base-case deterministic analysis 
              
Interventions Total Cost (£) Total QALY Δ Cost (£) Δ QALY ICER INMB 
Compared to warfarin             
Warfarin 9,976 5.18        
Rivaroxaban 15,756 4.74 -5,780 -0.44 
Dominated 
by warfarin   
Dabigatran 15,402 5.94 5,426 0.76 7,139 9,774 
Apixaban 20,014 6.08 10,038 0.90 11,153 7,962 
Incremental             
Rivaroxaban 15,756 4.74         
Warfarin 9,976 5.18 -5,780 0.44 
Dominates 
rivaroxaban   
Dabigatran 15,402 5.94 5,426 0.76 7,139  9,774 
Apixaban 20,014 6.08 4,612 0.14 32,943 -1,812 
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7.4.2 Base-case uncertainty  
 
Probabilistic sensitivity analysis  
The uncertainty in the differences in costs and health outcomes between treatment 
alternatives are presented graphically in the cost-effectiveness plane (Figure 7.3). For 
apixaban and dabigatran, the cost-effectiveness pairs reflecting the number of iterations run 
in the model mostly fall in the northeast quadrant. This suggests that apixaban and 
dabigatran may yield better health outcomes than warfarin; however, for rivaroxaban the 
iterations clearly fall into the northwest quadrant suggesting that rivaroxaban may be 
associated with poorer health outcomes than warfarin. Further, most of the uncertainty 
seems to come from uncertainty around QALYs. 
 
 
Figure 7.3  Cost-effectiveness plane base-case analysis 
 
When assessing the uncertainty of DOACs of being cost-effective when compared against 
warfarin (Table 7.10), dabigatran showed a higher probability of being cost-effective 
(49.41 %) than apixaban (47.61%). Rivaroxaban being the least effective intervention had 
0% probability of being cost-effective.  
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Table 7.10 Uncertainty of base-case analysis 
Results Intervention 
(Probabilistic) Warfarin  Apixaban Dabigatran Rivaroxaban 
£20,000 WTP         
Prob. cost-effect (%) 2.98 47.61 49.41 0.00 
Prob. error (%) 97.02 53.29 50.59 100.00 
 
The probabilities of DOACs being cost-effective compared to warfarin are presented 
graphically in Figure 7.4, where CEACs indicate how the probabilities of DOACs change 
according to a series of WTP. For instance, as shown in Figure 7.4, dabigatran and 
warfarin converge at £8,000 WTP, indicating that dabigatran is more cost-effective than 
warfarin only above a WTP of £8,000 per QALY. Similarly, apixaban has a higher 
probability of being cost-effective than warfarin only beyond a WTP of £11,000 per 
QALY.  
 
 
Figure 7.4 CEACs base-case analysis 
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One-way sensitivity analysis  
As shown in Table 7.11, in the sensitivity analysis, assessing whether changing the 
threshold of £20,000 per QALY to £12,936 may affect the probability of any DOAC or 
warfarin being cost-effective, the probability of warfarin and dabigatran increased from 
2.98% to 14.15% and from 49.41% to 52.04% respectively. By contrast, the probability of 
apixaban decreased from 47.61% to 33.81%. Rivaroxaban, dominated by warfarin, was 
still the least effective intervention with 0% probability of being cost-effective.  
 
Table 7.11 Uncertainty sensitivity analysis 
Results Intervention 
(Probabilistic) Warfarin  Apixaban Dabigatran Rivaroxaban 
£12,936 WTP         
Prob. cost-effect (%) 14.15 33.81 52.04 0.00 
Prob. error (%) 85.85 66.19 47.96 100.00 
 
 
Apixaban  
In the one-way sensitivity analysis for apixaban, the risk of ICH, major bleeding, and 
mortality were identified as the key clinical parameters influencing the ICER of £11,153 
per QALY gained calculated in the base-case analysis. In particular, high uncertainty 
resulted by varying the risk of ICH (£6,123, £20,054), followed by major bleeding (£7,998, 
£17,044) and mortality (£9,619, £16,852). Although to a lesser extent, the risk of stroke 
(£10,532, £11,987) and MI (£10,338, £11,661) also had an impact on the base-case ICER. 
The risk of mortality due to previous events history was also found to influence the base-
case findings: risk mortality due to previous bleeding (£9,901 and £12,298), risk of 
mortality due to ICH (£10,099, £12,119).  
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The cost of ICH had an impact on the base-case findings but only in the acute phase 
(£10,096, £12,105); indeed, the ICERs (£10,924, £11,227) resulting from the lifetime long-
term cost of ICH in the chronic phase, diverged marginally from the ICER of the base-case 
analysis. All the other parameters tested had a negligible impact on the base-case ICER. 
The tornado diagram presenting the full one-way sensitivity analysis for apixaban is 
depicted in Figure 7.5.   
 
 
Figure 7.5 Apixaban vs. warfarin sensitivity analysis 
Note: for HRs, the Lower and Upper 95% CI were tested. Cost and disutility parameters were 
tested with an increased and a decrease of 20% to their base-case values.   
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, 
ICH= Intracranial Haemorrhage, MI=myocardial. 
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Dabigatran 
In the one-way sensitivity analysis for dabigatran, major bleeding, ICH and mortality a 
significant impact on the ICER of £7,139 per QALY gained calculated in the base-case 
analysis. In particular, high uncertainty resulted by varying the major bleeding (£3,398 
£43,140), followed by ICH (£414, £39,463) and mortality (£-6,792, £6,333). Further, to a 
lesser extent, the risk of stroke (£6,224, £9,132) and MI (£5,424, £7,849) also had an 
impact on the base-case ICER. All the other parameters tested had a negligible impact on 
the base-case ICER. The tornado diagram presenting the full one-way sensitivity analysis 
for dabigatran is depicted in Figure 7.6.   
 
 
Figure 7.6 Dabigatran sensitivity analysis 
Note: for HRs, the Lower and Upper 95% CI were tested. Cost and disutility parameters were 
tested with an increased and a decrease of 20% to their base-case values.   
Abbreviations: TIA=transient ischaemic attack, ICH= Intracranial Haemorrhage, MI=myocardial. 
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7.4.3 Subgroup analysis  
Deterministic analysis - standard dose 
In the deterministic subgroup analysis assessing the cost-effectiveness of apixaban and 
rivaroxaban at their standard dose (Table 7.12), rivaroxaban was still dominated by 
warfarin being less costly and more effective. Standard dose apixaban was cost-effective 
when compared to warfarin (INMB £7,413) but not cost-effective in the incremental 
analysis (INMB £ -2,361) and at £20,000 threshold.  
 
As pointed out, due to sample size, it was not possible to discern dabigatran into dose 
subgroups; therefore, in the subgroup analyses looking at different drug regimen the ICER 
and INMB for dabigatran were the same as the ones calculated in the base-case analysis 
indicating that dabigatran is cost-effective compared to warfarin.  
 
Table 7.12 Deterministic subgroup analysis (standard dose) 
              
Interventions Total Cost (£) Total QALY Δ Cost (£) Δ QALY ICER INMB 
Compared to warfarin             
Warfarin 9,976 5.18        
Rivaroxaban 15,641 4.74 5,665 -0.51 
Dominated 
by warfarin   
Dabigatran 15,402 5.94 5,426 0.76 7,139 9,774 
Apixaban 20,563 6.08 10,587 0.90 11,763 7,413 
Incremental             
Rivaroxaban 15,641 4.67         
warfarin 9,976 5.18 -5,665 0.51 
Dominates 
rivaroxaban   
Dabigatran 15,402 5.94 5,426 0.76 7,139  9,774 
Apixaban 20,563 6.08 5,161 0.14 36,864 -2,361 
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Probabilistic sensitivity analysis – standard dose 
The uncertainty in the differences in costs and health outcomes between treatment 
alternatives at their standard dose are presented graphically in the cost-effectiveness plane 
(Figure 7.7). The iterations run in the model for the DOACs were distributed in a very 
similar fashion to the one observed in the base-case analysis; sitting on the northeast 
quadrant for apixaban and dabigatran, and sitting on the northwest quadrant for 
rivaroxaban. As mentioned, dabigatran could not be divided into subgroups, but it was 
included in Figure 7.7 for completeness.  
 
 
Figure 7.7 Cost-effectiveness plane subgroup analysis (standard dose) 
 
When assessing the uncertainty of standard dose DOACs of being cost-effective against 
warfarin (Table 7.13), as in the base-case analysis, apixaban still showed a lower 
probability of being cost-effective (43.72%) than dabigatran (51.10%) at £20,000 
threshold, and it is even less likely to be cost-effective at £12,936 threshold. Apixaban was 
found to be cost-effective at £12,936 threshold with a positive INMB of £1,113. 
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Rivaroxaban standard dose was found to be the least effective intervention with 0% 
probability of being cost-effective at £20,000 and £12,936 thresholds. 
 
Table 7.13 Uncertainty subgroup analysis (standard dose) 
Results Intervention 
(Probabilistic) Warfarin  Apixaban Dabigatran Rivaroxaban 
£20,000 WTP         
Prob. cost-effect (%) 5.18 43.72 51.10 0.00 
Prob. error (%) 94.82 56.28 48.90 100.00 
£12,936 WTP         
Prob. cost-effect (%) 15.80 27.60 56.60 0.00 
Prob. error (%) 84.20 72.40 43.40 100.00 
 
 
The probability of DOACs (where apixaban and rivaroxaban are at their standard dose) 
being cost-effective compared to warfarin is presented graphically in Figure 7.8. The 
CEACs were very similar to the ones observed in the base-case analysis where apixaban 
was found to be cost-effective compared to warfarin only above a WTP of £11,000 per 
QALY. Similarly, dabigatran was shown to be cost-effective compared to warfarin only 
beyond a WTP of £7,000 per QALY.  
 
 
 
Figure 7.8 CEACs subgroup analysis (standard dose) 
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Deterministic analysis - reduced dose  
In the deterministic subgroup analysis assessing the cost-effectiveness of reduced dose 
apixaban and rivaroxaban (Table 7.14), rivaroxaban was still dominated by warfarin being 
less costly and more effective. Standard dose apixaban was cost-effective when compared 
to warfarin (INMB £9,017) but not cost-effective in the incremental analysis (INMB £ -
757) and at £20,000 threshold. As in standard dose analysis, dabigatran was included for 
completeness.  
 
Table 7.14 Deterministic subgroup analysis (reduced dose) 
              
Interventions Total Cost (£) Total QALY Δ Cost (£) Δ QALY ICER INMB 
Compared to warfarin             
Warfarin 9,976 5.18        
Rivaroxaban 14,338 4.61 4,412 -0.57 
Dominated 
by warfarin   
Dabigatran 15,402 5.94 5,426 0.76 7,139 9,774 
Apixaban 20,159 6.14 10,183 0.96 10,607 9,017 
Incremental             
Rivaroxaban 14,388 4.61         
warfarin 9,976 5.18 -4,412 0.57 
Dominates 
rivaroxaban   
Dabigatran 15,402 5.94 5,426 0.76 7,139  9,774 
Apixaban 20,159 6.14 4,757 0.20 23,785 -757 
 
 
Probabilistic sensitivity analysis – reduced dose 
The uncertainty in the differences in costs and health outcomes between treatment 
alternatives at their reduced dose are presented graphically in the cost-effectiveness plane 
(Figure 7.9). As in the base-case and subgroups analysis for standard dose apixaban and 
rivaroxaban, the scatter reflecting the number of iterations run in the model was clearly 
sitting in the northeast quadrant for apixaban and dabigatran (included for completeness). 
Comparatively, the iterations run for rivaroxaban are distributed more towards the 
northwest quadrant.  
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Figure 7.9 Cost-effectiveness plane subgroup analysis (reduced dose) 
 
When assessing reduced dose apixaban and rivaroxaban uncertainty of being cost-effective 
against warfarin (Table 7.15), unlike in the base-case and the standard dose subgroup 
analysis, apixaban shows a higher probability of being cost-effective (47.46%) than 
dabigatran (47.00%) at £20,000 threshold. However, the probability of reduced dose 
apixaban of being cost-effective (37.50%) was even lower than the one observed for 
dabigatran at £12,936 WTP. Rivaroxaban reduced dose was found to be the least effective 
intervention with 0% probability of being cost-effective at £20,000 and £12,936 thresholds. 
 
Table 7.15 Uncertainty subgroup analysis (reduced dose) 
Results Intervention 
(Probabilistic) Warfarin  Apixaban Dabigatran Rivaroxaban 
£20,000 WTP         
Prob. cost-effect (%) 5.47 47.46 47.00 0.07 
Prob. error (%) 94.53 52.54 53.00 99.93 
£12,936 WTP         
Prob. cost-effect (%) 16.00 37.50 46.10 0.40 
Prob. error (%) 84.00 62.50 53.90 99.60 
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The probability of apixaban and rivaroxaban reduced dose being cost-effective compared 
to warfarin is presented graphically in Figure 7.10. As in previous analyses, apixaban and 
dabigatran were found to be cost-effective compared to warfarin only above a WTP of 
£11,000 and £7,000 per QALY respectively.  
 
 
Figure 7.10 CEACs subgroup analysis (reduced dose) 
 
Deterministic analysis - AF patients 70 years or older 
In the deterministic subgroup analysis assessing the cost-effectiveness of DOACs in a 
cohort of AF patients 70 years or older (Table 7.16), apixaban was cost-effective compared 
to warfarin. Dabigatran and rivaroxaban were dominated by warfarin, being more effective 
and less costly. The same results were observed when all interventions were compared 
incrementally. 
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Table 7.16 Deterministic subgroup analysis (AF patients 70 years or older) 
              
Interventions Total Cost (£) Total QALY Δ Cost (£) Δ QALY ICER INMB 
Compared to warfarin             
Warfarin 8,760 4.18        
Rivaroxaban 10,739 3.45 1,979 -0.73 
Dominated 
by warfarin   
Dabigatran 
11,860 4.08 3,100 -0.10 
Dominated 
by warfarin  
Apixaban 10,667 4.33 1,907 0.15 12,713 1,093 
Incremental             
Rivaroxaban 10,739 3.45         
Dabigatran 11,860 4.08 1,121 0.63 1,779  
Warfarin 8,760 4.18 -3,100 0.10 
Dominates 
dabigatran  
Apixaban 10,667 4.53 1,907 0.15 12,713 1,093 
 
 
 
 
Probabilistic sensitivity analysis - AF patients 70 years or older 
The uncertainty in the differences in costs and health outcomes between treatment 
alternatives in the AF patients 70 years or older are presented graphically in the cost-
effectiveness plane (Figure 7.11). In this subgroup analysis, unlike base-case and previous 
subgroups analyses, the iterations run for apixaban and dabigatran did not fall into any 
specific quadrant, though the scatter for apixaban seems to be more distributed towards the 
northeast quadrant. Most of the uncertainty for apixaban and dabigatran seems to come 
from uncertainty around QALYs. The rivaroxaban scatter, falling in to the northwest 
quadrant, is hidden by the iterations run of dabigatran.  
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Figure 7.11 Cost-effectiveness plane subgroup analysis (AF patients 70 or older) 
 
When assessing the uncertainty of DOACs being cost-effective against warfarin in the AF 
patients 70 years or older (Table 7.17), apixaban (55.30%) was shown to have a much 
higher probability of being cos-effective than dabigatran (12.04%) when the threshold was 
set at £20,000. At £12,936 WTP, apixaban was still more likely to have a higher 
probability of being cost-effective than any other DOAC or warfarin. As in the base-case 
and previous subgroup analyses, rivaroxaban was found to be the least effective 
intervention with 0% probability of being cost-effective at any threshold.  
 
Table 7.17 Uncertainty subgroup analysis (AF patients 70 years or older) 
Results Intervention 
(Probabilistic) Warfarin  Apixaban Dabigatran Rivaroxaban 
£20,000 WTP         
Prob. cost-effect (%) 32.66 55.30 12.04 0.00 
Prob. error (%) 67.34 44.70 87.96 100.00 
£12,936 WTP         
Prob. cost-effect (%) 43.09 46.49 10.42 0.00 
Prob. error (%) 56.91 53.51 89.58 100.00 
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The probabilities of DOACs being cost-effective against warfarin in the AF patients 70 
years or older are presented graphically in Figure 7.12. Apixaban and warfarin CEACs 
converge at a WTP of about £12,000 indicating that apixaban is cost-effective at any WTP, 
with the WTP falling well below the £20,000 and £12,000 threshold.  
 
Figure 7.12 CEACs subgroup analysis (70 years or older AF patients) 
 
 
7.5 Discussion 
To date, economic evaluations, assessing the cost-effectiveness of DOACs in the AF 
population and adopting a UK perspective, were based on clinical efficacy taken from 
three pivotal RCTs: Aristotle (apixaban), RE-LY (dabigatran) and ROCKET-AF 
(rivaroxaban) [41-43]. RCTs provide robust evidence on efficacy measured under specific 
conditions, where randomisation is effective in minimising selection bias between two 
groups of individuals [59, 125]. Evidence from clinical practice offers the opportunity to 
investigate whether DOACs are cost-effective in real life under uncontrolled conditions. 
This type of evidence can complement cost-effectiveness conclusions generated with 
evidence coming from RCTs.  
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The findings from this analysis, to date the only UK economic evaluation using patient 
level data, are in line with existing evidence suggesting that apixaban and dabigatran are 
valid cost-effective options to warfarin for the prevention of stroke in the AF population 
[179-181]. However, the findings for the base-case analysis, based on the assumption 
discussed in Chapter 4 that prevalence and incidence of AF typically increase 
exponentially from 50 years onwards [89], were based on a cohort of patients starting 
anticoagulation at 50 years of age; thus including all age groups of patients potentially at 
risk of AF. This differs from the approach adopted in the other models assessed in this 
Chapter and the ones included in Limone’s review (2013), where it was assumed that 
patients started anticoagulation at 70 years of age [178-182]. Nevertheless, this assumption 
was tested in the subgroup analysis and apixaban was still cost-effective compared to 
warfarin at the £20,000 threshold. However, for dabigatran, assumptions had to be made 
on the risk of SE, stroke and MI. In particular, given that only one event was observed for 
the mentioned outcomes, it was assumed that there was no risk difference between 
dabigatran and warfarin. Therefore, the results for the patients 70 years or older on 
dabigatran should be interpreted cautiously. While the same assumption was made for the 
risk of SE for the rivaroxaban group, the results obtained were comparable to those 
observed in other analyses.   
 
According to the base-case findings, dabigatran may be indicated as the most favourable 
first line treatment having an ICER falling well below the £20,000 threshold, and a positive 
INMB greater than the one associated with apixaban compared to warfarin. Typically, the 
intervention associated with the greatest net benefit should be the preferred option even 
when less cost-effective than  any other intervention [151, 156]. Similar findings were 
reported in Verhoef’s study (2014), indicating dabigatran, still associated with substantial 
uncertainty, as the most cost-effective DOAC compared to warfarin in a UK setting [181].  
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Verhoef’s study however, assumed the same level of disutilities between DOACs to 
account for switching [181]. This approach was criticised by the ERG considering the 
assumption of equivalent disutility not robust and likely to be against apixaban [37]. 
Nevertheless, in the base-case analysis, both ICERS for apixaban and dabigatran are well 
below the £20,000 threshold, and have nearly the same probability of being cost- effective 
compared to warfarin.  
 
Unlike the existing evidence, rivaroxaban was not found to be cost-effective compared 
against warfarin. Nevertheless, in the studies including all DOACs and warfarin, 
rivaroxaban was dominated by either apixaban or dabigatran [179-182], thus, although 
cost-effective against warfarin, could not be recommended as first line treatment. The 
findings on rivaroxaban from this economic evaluation are mainly determined by the poor 
safety and effectiveness profile discussed in Chapter 6 assessing the comparative-
effectiveness of DOACs against warfarin. While increased risk of stroke and ICH 
compared to warfarin certainly has a significant impact on long-term costs, the increased 
risk of mortality offset the total cost incurred in the long term as patients on rivaroxaban 
would die sooner than patients on other anticoagulation treatments. This would also cause 
rivaroxaban patients gaining fewer QALYs, thus resulting in not being cost-effective 
compared to warfarin or the other two DOACs.  
 
Standard and reduced dose 
In this subgroup analysis, the cost-effectiveness of DOACs was evaluated to establish in 
which subset of patients any of the treatments evaluated provides the greatest value for 
money. The difference in ICERs and uncertainty between DOAC standard and reduced 
doses suggests that apixaban is more cost-effective when administered in a reduced dose 
regimen, but high uncertainty was associated with the findings.  
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However, this still provides an indication on whether reduced dose apixaban is cost-
effective in a real-world scenario. Previous studies have assessed the effectiveness of 
reduced dose apixaban in the UK [58, 62], but none evaluated the economic aspect.  
 
As per clinical guidelines recommendation, reduced dose of DOACs should be offered to 
patients who are typically 80 years or older with one or more of the following: high risk of 
bleeding and moderate to severe renal or hepatic impairment [16-18, 35-37]. Therefore, 
this subgroup analysis may give an indication that apixaban is more cost-effective in the 
older rather than in the younger population with AF and potentially associated 
comorbidities. These findings are backed up by the comparative-effectiveness analysis in 
Chapter 6, where reduced dose apixaban and rivaroxaban show a better safety and 
effectiveness profile than their corresponding standard dose. While this is true for apixaban 
and rivaroxaban, it was not possible to discern, due to sample size, standard and reduced 
dose for dabigatran. 
 
Sensitivity analysis  
In the one-way sensitivity analyses, as in previous cost-effectiveness studies, the risk of 
ICH, major bleeding and mortality associated with DOACs was shown to influence the 
ICERs [178, 180-182]. This was particularly evident in the apixaban sensitivity analysis, 
where the ICERs estimated with lower and upper confidence interval of the risk of ICH 
(£6,123, £20,054), major bleeding (£7,998, £17,044) and mortality (£9,619, £16,852) 
diverged substantially from the ICER estimated in the base-case (£11,153). Similarly, in 
the dabigatran sensitivity analysis, the ICERs estimated with lower and upper confidence 
interval of the risk of major bleeding (£3,398, £43,140) ICH (£414, £39,463), and 
mortality (-£6,792, £6,333) diverged substantially from the ICER estimated in the base-
case (£7,139).  
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Clearly, this difference is mirrored by the wide confidence intervals of fewer clinical 
events in a relatively small treatment arm, as in the case of dabigatran, and observed in the 
comparative-effectiveness analysis reported in Chapter 6.    
 
For costs and disutilities, only costs were found to have a tangible impact on the base-case 
ICERs. In particular, the cost of ICH in the acute phase was shown to influence the base-
case ICER of apixaban (£10,096, £12,119), and to a lesser extent the ICER of dabigatran 
(£6,705, £7,990). Existing evidence suggest that the INR monitoring costs has a significant 
impact on the cost-effectiveness of DOACs [173]. However, in this economic evaluation, 
the impact of INR monitoring cost was not tested as it was included in the cost of warfarin 
and assumed to vary significantly with a distribution ranging from -50% to +150% of the 
mean cost.     
 
7.6 Limitations 
 
This economic evaluation gives an indication on whether DOACs are valid cost-effective 
alternatives to warfarin for the prevention of stroke and associated comorbidities in real- 
world AF population. However, caution should be taken when interpreting the results as 
this study has some limitations and further research will be needed to reduce the level of 
uncertainty around the findings. 
 
As previously pointed out, residual bias, sample size and the number of observed events 
may undermine the robustness of the findings, which in turn may translate into uncertain 
conclusions for the cost-effectiveness analysis. Specifically, uncertainty exists about the 
risk of mortality associated with rivaroxaban that may be caused by true association or bias 
from selective prescribing.  
Chapter 7…………………………………………………………………………………………………………………………………230 
 
As elucidated in previous Chapters, methods to deal with selective prescribing and reduce 
confounding by indication exist, but as these issues can be mitigated and not entirely 
eliminated, there will always be a risk of residual selection bias. Thus, in the context of 
economic evaluation, observed and unobserved confounding represents a threat to the 
internal validity, as they might bias the incremental outcome, the incremental cost, or both, 
ultimately leading to incorrect decisions based on the estimated ICER. In addition, if 
dealing with unobserved confounding, it may be challenging to nest methods, such as 
instrumental variable and regression discontinuity, within a complex data structure of cost-
effectiveness analysis [199].  
 
Further, because of the relative small number of events observed in the dabigatran group, it 
was assumed that patients in the dabigatran and the warfarin group had the same risk of SE 
and ICH. Similarly, in the 70+ subgroup analysis, it was assumed that patients in the 
dabigatran and warfarin group had the same risk of SE and MI. These assumptions may 
underestimate or overestimate the effect of dabigatran. The assumption on the risk of SE is 
unlikely to bias the cost-effectiveness estimates as no difference in risk of SE between 
dabigatran and warfarin treatment group was observed in the RE-LY trial. The 
assumptions made on the risk of MI, however, would favour dabigatran over warfarin in 
the cost-effectiveness analysis; an increased risk of MI for dabigatran compared to the 
warfarin treatment group was reported in the RE-LY trial. On the other hand, the 
assumption made for the risk of ICH, would favour warfarin, as in the RE-LY trial a 
significant reduction of ICH was observed in the dabigatran treatment group [41]. 
Longer follow-up may reduce uncertainty, but as observed in the comparative-
effectiveness analysis, much of the clinical events are experienced within the first two 
years from anticoagulation initiation.  
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Nevertheless, a longer follow-up would be useful for confirming the patterns of treatment 
switching having a substantial impact on final risk of experiencing clinical events. Another 
important limitation of the study is attributable to the nature of observational data and in 
particular to the associated bias and unmeasured residual confounding amply discussed in 
Chapter 5 [59, 118].  
 
The lack of data on time spent in therapeutic INR range, not currently available in 
Scotland, is another potential limitation of this study, as existing evidence suggest that the 
INR range impact the cost-effectiveness of DOACs [181]. However, in RCTs, the effect of 
DOACs may have been overestimated, as the therapeutic INR between a range of 2.0 and 
3.0, was not maintained for some patients randomised to warfarin [41-43]. The availability 
of data regarding the time spent within therapeutic range for patients on warfarin would 
allow for a more accurate comparative effectiveness analysis of DOACs versus warfarin in 
real life. A high INR range is associated with increased risk of thromboembolic and 
haemorrhagic events, thus INR, used in the HAS-BLED score, is important in determining 
the potential risk of bleeding. However, as described in Chapter 6, the HAS-BED score, a 
redefined version of HAS-BLED and not taking into account the labile INR item, can be 
used to estimate the risk of bleeding [84] and used to estimate the comparative 
effectiveness of DOACs versus warfarin. Therefore, the lack of data on time spent in 
therapeutic INR range is unlikely to have a meaningful impact on this economic 
evaluation. Similarly, data on serum creatinine level, to establish the level of severity for 
kidney impairment, are not currently available at the national level.   
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Arguably, economic evaluations should include societal perspective reflecting the impact 
that an intervention may have on the welfare of the whole society; thus, costs derived from 
productivity loss may be factored in to the cost-effectiveness equation. In  the UK, 
however, economic evaluations assessing the relative efficiency of alternative interventions 
would adopt the NHS perspective [200].  
 
7.7 Conclusions 
 
This analysis, building on previous evidence from the comparative-effectiveness analysis, 
provides RWE that apixaban and dabigatran are at least as cost-effective as warfarin for the 
prevention of stroke and AF associated comorbidities. Apixaban seems to be more cost-
effective than warfarin when administered as a reduced dose. Rivaroxaban, being the least 
effective intervention, is not cost-effective. However, while the findings for apixaban, 
coupled with those from the comparative-effectiveness analysis, may inform future 
research and an impact on future prescribing patterns, those concerning dabigatran and 
rivaroxaban should be interpreted cautiously.  
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Chapter 8 Summary of main findings, policy implications and future research   
 
8.1 Main findings 
 
The analyses undertaken in this thesis have explored the potentials and highlighted 
methodological issues associated with RWE in context of HTA.  A major issue is that 
RWE may be inconsistently collected, and missing elements may lead to reduced 
statistically validity or may limit the potential for answering research questions. Sample 
size and the number of events are two other aspects that may challenge the use of RWE. In 
RCTs, the optimal number of events and participants needed to test hypothesis can be 
identified, whereas with real-world data it is not possible to determine the number of 
events need to obtain a robust statistical power. The biggest issue, however, is that RWE 
studies are subject to bias. While methods exist to control for bias, residual bias from 
unobserved factors may persist.  
 
The initial AF cohort consisting of 278,286 patients with a known diagnosis of AF or atrial 
flutter was identified from hospitalisation records (SMR01) for the 1997 – 2015 study 
period, while the cohort of those on any OAC consisting of 160,405 patients was identified 
from the prescribing records (PIS) for the 2009 – 2015 study period. The use of patient 
level data including inpatient admissions, outpatient attendance, prescribing, care home 
and mortality records has allowed for the first time in Scotland to explore different 
methodologies concerning costing and comparative-effectiveness estimation to address a 
series of research questions. For instance, the level of granularity of the available patient 
level data has allowed for a more precise estimation of AF related health care costs 
compared to what has been previously done in Scotland.  
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The methodological aspects of using RWE were mostly explored in Chapter 5, where 
different methods for comparative-effectiveness analysis were tested and compared. The 
availability of patient level data has also allowed for conducting an economic evaluation 
that best reflects the epidemiology of AF and clinical practice in Scotland; clinical advice, 
prevalence and incidence suggest that AF increases exponentially from 50 years onwards 
[89]. Existing economic evaluations, using evidence from RCTs, have assumed that 
patients were 70 years of age when starting anticoagulation therapy [173, 178-182]. The 
economic evaluation carried out in this thesis was based on a cohort of patients 50 years 
and older; thus, including all age groups of patients potentially at risk of AF.  
In the next paragraphs, the main findings followed by limitations and potential policy 
implications are discussed; in addition, areas of future research will be discussed.  
 
 
8.1.1 The inpatient, outpatient, prescribing and care home costs associated with 
Atrial Fibrillation  
 
Chapter 4 provided an overview of AF patient characteristics, including clinical and socio-
economic factors, and aimed at meeting the following objective: estimate and examine the 
composition of direct and indirect medical costs in AF using Scottish linked health data.  
 
In order to meet this objective, the existing evidence on cost of AF was reviewed to 
identify population, data, covariates, cost components and statistical methods used.  
Being able to estimate costs using an incidence-based method using patient-level morbidity 
records, rather than using extrapolated rates with a prevalence-based approach, this thesis 
was able to improve on existing methods by offering more precise cost estimates.  
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This was also achieved by using a longer follow-up, a contemporary cohort of AF patients 
and the inclusion of a variety of healthcare and social care settings. The costs associated 
with hospital inpatient stay were identified as the cost component that contributed the most 
to the overall AF related healthcare costs. Most importantly, age was found to have a 
modest impact on overall healthcare costs, which were found to be fairly consistent across 
age groups; thus, reinforcing findings from previous studies suggesting that healthcare 
expenditure depends not only on patients’ calendar age, but is also associated with 
remaining lifetime. 
 
AF related costs incurred by females were higher than the costs observed in the male 
group. While there was little difference between the total costs and the distribution of costs 
for inpatient, outpatient and prescription costs, the difference seemed more pronounced 
when comparing the care home component of costs. AF patients from large urban area 
showed the highest estimated cost, while patients living in “very remote rural areas” 
incurred the lowest estimated cost. Further, patients from the most deprived areas seemed 
to incur a higher level of AF related costs compared to those living in the least deprived 
areas. A clear pattern of estimated costs decreasing from the most to the least deprived 
areas was observed.  
 
This Chapter highlighted the importance of including all available cost components for 
establishing overall costs, as these often extend beyond hospitalisation.  
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8.1.2 Methods for comparative-effectiveness analysis 
 
Chapter 5 provided an overview of different methods generally used in comparative- 
effectiveness analysis to estimate the ATE, and highlighted the typical challenges in 
addressing observed and unobserved confounding inherent to the nature of RWE. This 
chapter aimed at meeting the following objective: explore, with a focus on PS based 
methods and the DOACs case study, methodological challenges in using RWE to estimate 
comparative-effectiveness analysis.    
 
In order to meet this objective, PS base methods including PS matching, IPW (IPTW, and 
IPTW combined with IPCW) and PS used as a covariate were tested. As in other RWE 
studies assessing the comparative effectiveness of DOACs the focus was on observed 
confounding, testing for unobserved confounding was beyond the scope of this Thesis, and 
therefore the assumption of ‘no unobserved confounding’ was made [114].  
 
The PS estimation was carried out for each individual DOAC (apixaban, dabigatran and 
rivaroxaban), warfarin and the combined DOAC cohorts, resulting in five different PS 
models. For each model, CHA2DS2-VASc and HAS-BLED risk scores were calculated.  
 
In this study, PS covariate adjustment was found to be the most robust method, PS 
matching and IPW methods also performed well, but were excluded to avoid further 
sample size reduction. While PS covariate adjustment is in theory more sensitive to 
distributional assumptions and PS specification [123, 128, 129], it was found to be the 
most robust method compared to PS matching and different variations of IPW (including 
IPTW, trimmed IPTW and IPTW combined with IPCW), as covariates showed the lowest 
standardised difference.  
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However, as results from this analysis suggest, the choice of the most adequate PS method 
depends on the characteristics of the available data; thus, the use of a single best method 
for reducing bias due to confounding should be avoided and several candidate models 
should be tested.   
 
8.1.3 Comparative-effectiveness analysis 
 
Chapter 6 assessed comparative-effectiveness and safety of DOACs and provided 
additional evidence to understand how effective DOACs are in Scottish clinical practice.  
Prior to conducting the comparative-effectiveness analysis, clinical outcomes were 
identified according to ICD-10 and OPCS-4 codes from SMR01 records; then CHA2DS2-
VASc and HAS-BLED risk scores were calculated. In addition, an assessment of the 
proportionality assumption for the Cox proportional hazards model was carried out, and 
the identified violation of proportionality was addressed with the use of time varying 
covariates.  
 
In the comparative-effectiveness analysis, the risk difference for stroke between apixaban 
and warfarin, although reduced, was not statistically significant; this differs from the risk 
reduction observed in the ARISTOLTE trial. In one observational study, Nielsen et al 
(2017) distinguished between doses [61] and found no risk differences for stroke between 
patients on apixaban 2.5 mg reduced dose and those on warfarin. Therefore, the risk of 
stroke reported in the analysis in Chapter 6 seems to be much closer to the one observed in 
clinical practice than the one reported in the ARISTOTLE study. In case of conflicting 
evidence, clinicians should balance that evidence and assess whether RCTs and RWE 
studies look at the same population, patients characteristics and outcomes.  
In particular, clinicians may be interested in aspects not investigated in RCTs such as 
treatment interactions with concomitant treatments, and longer follow-up [2, 7].  
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For what concerns DOACs, clinicians may be interested in the effect of standard and 
reduced dose apixaban and rivaroxaban compared to warfarin not investigated in the 
pivotal RCTs [41-43]. Thus, although residual confounding will always be a threat to the 
validity of RWE, the finding on apixaban supported by existing studies [58, 61, 62] can be 
trusted.  
 
Further, the comparative-effectiveness analysis confirmed the findings for the risk of GI 
bleeding reported in the ARISTOTLE clinical study [42] as no risk difference was found 
between apixaban and warfarin. However, the risk of GI bleeding differed from the one 
reported in another observational study (Ntaios (2017)) where a risk reduction was found 
for patients on apixaban [58]. When assessing the effectiveness of apixaban at standard and 
reduced dose, no risk differences were observed across clinical outcomes between 
apixaban and warfarin regardless of the dose administered.  
 
No difference in risk was observed for most of the clinical outcomes when comparing 
efficacy and safety profiles of dabigatran versus warfarin. The estimated risk of stroke is in 
line with the risk observed in the RE-LY trial for patients receiving dabigatran at a reduced 
dose. Similarly, risk of GI bleeding observed in the RE-LY trial for patients treated with 
dabigatran 150 mg compared to those on warfarin, were confirmed in the comparative-
effectiveness analysis and in a meta-analysis of observational studies [58]. Although the 
estimated difference in risk for most of the clinical outcomes for the dabigatran and 
warfarin comparisons was not statistically significant, the relatively small sample size and 
low number of events observed may undermine the robustness of the findings. 
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No difference in risk was observed for stroke and stroke composites between rivaroxaban 
and warfarin patients; those findings are comparable to those reported in the ROCKET-AF 
trial [43] and in an observational study Gorst-Rasmussen (2016) [60]. When assessing 
DOACs at different doses, an increased risk of GI bleeding was observed for patients 
treated with reduced dose rivaroxaban, but no differences were observed for patients 
receiving the standard dose compared to warfarin. While findings on the risk of mortality 
associated with reduced dose rivaroxaban are comparable to the risk reported in the 
ROCKET-AF trial [43], the increased risk of mortality observed for patients receiving the 
standard dose matches results reported by Nielsen (2017) [61] and Gorst-Rasmussen 
(2016) [60]. However, in these two observational studies, the increased risk of all-cause 
mortality was found for patients receiving rivaroxaban 15 mg reduced dose [60, 61].  
 
This study provides real-world evidence that apixaban is as effective as warfarin for the 
prevention of stroke and AF associated comorbidities; the evidence concerning dabigatran 
and rivaroxaban should be interpreted cautiously. Although the cost-effectiveness 
estimates for dabigatran are not robust, due to limited number of events observed, they 
may still give an indication of whether dabigatran is cost-effective in preventing stroke and 
other AF related comorbidities in a real-world setting.  For rivaroxaban, further research is 
needed to assess whether the association between the use of rivaroxaban and the risk of 
bleeding and mortality is a true association.  
 
8.1.4 Economic evaluation 
 
Chapter 7 focused on the economic evaluation of DOACs using RWE of effectiveness, and 
aimed at meeting the following objective: Update, with RWE data, existing cost-
effectiveness analysis of DOACs for the prevention of stroke in patients with AF in 
Scotland.  
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In order to meet this objective, a review of existing economic models was undertaken to 
identify the most appropriate model in the UK context. Then, the Sterne model (2017), 
identified as the most suitable model and accounting for limitations identified in previous 
models, was updated with RWE. The findings from this analysis are in line with existing 
evidence suggesting that apixaban and dabigatran are cost-effective compared to warfarin 
for the prevention of stroke in the AF population [179-181]. However, apixaban and 
dabigatran were found to be cost-effective when patients entered the model at 50 years of 
age, thus including all patients potentially at risk of AF. Dabigatran, yielding a greater 
INMB than apixaban may be indicated as the most favourable first line treatment; similar 
findings were reported by Verhoef (2014), indicating dabigatran as the most cost-effective 
DOAC compared to warfarin in a UK setting [181]. Nevertheless, the probability of 
apixaban and dabigatran being cost-effective compared to warfarin was negligible. Further, 
this probability was more marked when assessing the cost-effectiveness of interventions at 
£12,936 threshold, where apixaban and dabigatran had a probability of about 30% and 
50%, respectively, of   being cost-effective. Rivaroxaban (at any dose) was not found to be 
cost-effective compared to warfarin; while existing evidence suggest the contrary [179-
182], in the existing studies rivaroxaban is dominated by either apixaban or dabigatran.  
 
8.2 Limitations 
 
In Chapter 4, the cost analysis was to some extent limited by missing records or incomplete 
data, in addition to potential risk of clinical miscoding in the morbidity records. For 
instance, the poor level of completeness of CHI numbers or other patient identifiers still 
makes linking SMR00 with other datasets rather challenging. In addition, prescribing and 
care home data were only available from 2009 and 2012, so that their contribution to 
overall AF related costs might be underestimated.  
Chapter 8                                                                                                                                                        241 
 
Propensity score methods are powerful tools for addressing confounding by indication 
typical in newly marketed prescription drugs [145]. However, even after the application of 
these methods, residual bias due to observed confounders may persist. Propensity Score 
methods may reduce this bias due to observable confounders; however, other unmeasured 
or residual confounding, such as patients’ tolerability, access to healthcare and selective 
prescribing may still bias the estimates. Therefore, the findings of the comparative-
effectiveness-analysis (Chapter 6) and the economic evaluation (Chapter 7) should be 
interpreted in the light of this.   
 
The relative small sample size of dabigatran, coupled with a few observed events of stroke, 
the composite of stroke including SE and TIA, and mortality due to stroke, was an 
important limitation of this Thesis. Although the findings concerning dabigatran in Chapter 
6 are not robust, due to the limited number of events observed, they may still give an 
indication of the effect of dabigatran in preventing stroke and other AF related 
comorbidities in a real-world setting.  
 
The relative small sample size and the relative small number of events observed in the 
dabigatran group, was also a major issue for the economic evaluation in Chapter 7, as 
several assumptions had to be made.  In particular, it was assumed that patients in the 
dabigatran and the warfarin group had the same risk of SE and ICH. Similarly, in the 70+ 
subgroup analysis, it was assumed that patients in the dabigatran and warfarin group had 
the same risk of SE and MI. As explained in the limitation subsection of the economic 
evaluation in Chapter 7, these assumptions may underestimate or overestimate the effect of 
dabigatran. 
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The complexity of conducting analyses in the National-Safe-Haven platform was a further 
limitation of this study. While the National-Safe-Haven offers a high-powered computing 
service, secure analytic environment and secure file transfer [15], merging and 
manipulating datasets may be problematic due to data space restrictions. For this reason, it 
was not possible to create a single master file, where all the observations of the cohorts for 
each analysis were included. With more data space available, creating a single master file 
would be the first step towards a more efficient data manipulation. 
 
8.3 Policy implications 
 
Real-world evidence is increasingly important for informing healthcare policy issues; and 
the availability of government data, coupled with bespoke centres such as the Health Data 
Research UK, has the potential to answer various policy questions. This thesis has shown 
the potential of Scottish administrative data to generate RWE in the context of HTA, in 
general and with reference to AF and the DOACs case study.  
 
Real-world evidence is increasingly used in the reimbursement process, as HTA agencies 
may request additional evidence to enhance the understanding of elements of uncertainty.  
In this context, RWE, providing a more comprehensive understanding of treatment safety 
and effectiveness, could be used for the reassessment of prescription drugs, for instance 
every 2 or 3 years, to warrant post-approval reimbursement.  HTA decisions are often 
based on immature and limited RCT data, and therefore should be regularly revisited. 
Currently there is no formal process in place; however, this Thesis has demonstrated that 
Scottish administrative data can be used systematically to set up a framework where RWE 
can be used for the reassessment of prescription drugs by SMC.  
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Despite in present work sample size and the relative small number of events, particularly 
for dabigatran, were a major concern for the validity of the findings, more data will be 
available, and therefore more robust conclusions can be drawn. Thus, this Thesis can 
recommend the use of Scottish administrative data to generate RWE for the re-evaluation 
of HTA decisions.   
 
Atrial fibrillation has significant implications on health care costs, putting additional 
financial burden on the NHS. Within a broader societal perspective, AF may also have a 
significant impact on productivity loss. Rohrbacker (2010) has demonstrated that benefit, 
costs, number of absence days due to sick leave and short-term disability were significant 
for individuals affected by AF or cardiac arrhythmias [84]. In particular, as shown in this 
thesis, different cost components contribute to overall AF related healthcare costs, with 
inpatient admission being the main driver. This is a pertinent finding that may well support 
future policies on opportunistic screening in the population at risk of AF, and especially in 
Scotland where 1 in 3 patients with AF are currently undiagnosed [25]. For instance, the 
European AF management guidelines and the Scottish Cross-Party Group ‘Heart Disease 
and Stroke’, has identified AF as a priority area and recommended that people who are 65 
years or older and at risk of AF and associated comorbidities should be screened 
opportunistically in primary care, pharmacies or community settings. The group 
highlighted the need for rigorous screening in order to reduce inpatient admission and 
associated costs [25, 109].  
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This thesis provides additional evidence on the comparative and cost-effectiveness of 
DOACs, which would be of great value to the decision makers. In particular, the RWE 
from this study suggests that apixaban is at least as effective as warfarin for the prevention 
of stroke in the AF population; and cost-effective for patients who start anticoagulation 
treatment at the age of 50. Although in Scotland rivaroxaban is no longer recommended for 
the prevention of stroke in the AF population, the increased risk of bleeding and mortality 
associated with rivaroxaban, may raise concerns over its use where rivaroxaban is 
recommended for other indications or target populations. Therefore, the systematic used of 
administrative data can be used to identify issues that have the potential of changing the 
prescribing framework. For instance, based on the results from the Cardiovascular 
Outcomes for People Using Anti-coagulation Strategies (COMPASS) study [201], reduced 
dose rivaroxaban used in conjunction with aspirin is now recommended for restricted use 
for the prevention of atherothrombotic events in adults at high risk of ischaemic events 
[202].  
 
8.4 Future research 
 
Real-world evidence is increasingly used in HTA and is expected to have a growing 
importance in the context of the value-based pricing approach adopted by the UK 
government. The rationale for adopting a value-based pricing approach is that NICE 
appraisal may not adequately capture the full value of an intervention, where aspects such 
as innovation and social benefit are not factored in. For instance, RWE may allow for 
better estimates of healthcare costs and utilisation, thus increasing transparency in health 
outcomes. This, in turn, would let payers and manufacturers to assess performance on 
individual basis and pay only for good outcomes for drugs being used in clinical practice 
[203].  
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An important aspect of the value-based pricing is the pharmaceutical price regulation 
scheme, a voluntary agreement between the department of health of UK government and 
the pharmaceutical industry. The scheme allows companies to set the price for new 
branded drugs, thus incentivising innovation, but put a limit on the profit that companies 
can make from the NHS. Following expiry of the voluntary scheme in 2014, it has now 
been renegotiated coming into force on the 1th of January 2019 [203].  
 
Future research, where the role of RWE in the context of HTA is assessed, should perhaps 
have a more defined value-based pricing approach. Using the DOACs case study, 
additional value of this class of drugs could be shown in a number of ways. Firstly, 
supplementary cost-effectiveness analysis should be carried out with additional evidence 
coming from the DOAC to DOAC non-randomised comparison, to establish which 
intervention is more cost-effective in clinical practice not just in relation to warfarin. This 
evidence is available for Scotland and reported in a recent study assessing the effectiveness 
of DOACs using the same patient level data utilised in this thesis [38].  Future research 
including this additional evidence would reduce the uncertainty regarding the cost-
effectiveness of DOACs in the real-world AF population. Secondly, in order to include a 
wider societal perspective, future research may be able to include indirect costs associated 
with productivity-loss by, for example, linking morbidity and prescribing data to national 
data from the Department for Work and Pensions.  
 
Further, given the advancement of pharmacogenomics in the medical field, up to date 
evidence may also include safety and efficacy data obtained with a pharmacogenomics 
approach as this would allow for a more defined value of an intervention.  
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Pharmacogenomics is a relatively new branch of pharmacology that studies drug response 
by correlating gene expression with the drug’s efficacy and toxicity, in order to develop 
safer medicines “personalized” to a person genetic makeup [204]. While, to date, there is 
no strong evidence supporting the use of pharmacogenomics testing in improving safety 
and efficacy of DOACs, the genes of interest have been identified and future research will 
be needed to quantify the added value of testing. As recognised in a recent clinical review 
of the pharmacogenomics of DOACs, this will pose some fundamental policy questions on 
whether budgets should be allocated for the purchase on new oral anticoagulants, or 
improving current care with warfarin by implementing a pharmacogenetic-guided dosing 
system [205].  
 
Additional comparative and cost-effectiveness analyses should also include evidence from 
Edoxaban. This DOAC was approved by SMC in 2015 for the prevention of stroke in the 
AF population [39], and in the near future RWE for Scotland should be available.  
 
8.5 Conclusions  
The body of work of this thesis contributes to defining the role of RWE in the context of 
HTA in a number of ways, but also acknowledges the challenges of using RWE and 
highlights its complementary role with RCTs in generating solid evidence for decision-
making. This thesis has also shown how these challenges could be addressed, providing a 
case study for existing guidelines designed to guide on the use of observational data in 
comparative-effectiveness studies  [114, 150]. Most importantly, this thesis has provided 
additional evidence concerning AF related health care costs, comparative-effectiveness and 
cost-effectiveness of DOACs that could potentially have relevant policy implications. 
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Appendices 
 
Appendix I: Econometric modelling test to identify family and link function 
 
 Family distribution and link function  
  
Log link Identity link 
Chi2 P-value Chi2 P-value 
Family         
Gamma 5.12 0.024 5.80 0.016 
Poisson  45.44 0.000 45.77 0.000 
Gaussian NLLS 126.91 0.000 134.17 0.000 
Inverse Gaussian or Wald 247.88 0.000 254.09 0.000 
Link         
Pearson Correlation Test   0.445   0.419 
Pregibon Link Test   0.384   0.392 
Modified Hosmer and Lemeshow   0.032   0.015 
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Appendix II: Regression interactions and Odd Ratios conversion 
 
Table II-1 Regression interactions 
 
              
  
Covariates 
Probability Probability   
  (1st modelling part) (2nd modelling part)   
    Coefficient (95%CI) Std. Err Coefficient (95%CI) Std. Err   
Interaction: age (year) - Charlson score (1 comorbidity) 
  50-54 Reference         
  55-59 -0.260 (-0.408, -0.111) 0.076 -0.073 (-0.173, 0.028) 0.051   
  60-64 -0.365 (-0.511, -0.219) 0.074 -0.108 (-0.204, -0.013) 0.049   
  65-69 -0.400 (-0.541, -0.260) 0.072 -0.131 (-0.224, -0.038) 0.048   
  70-74 -0.425 (-0.563, -0.287) 0.070 -0.184 (-0.276, -0.093) 0.047   
  75-79 -0.500 (-0.637, -0.363) 0.070 -0.199 (-0.288, -0.109) 0.046   
  80-84 -0.550 (-0.687, -0.412) 0.070 -0.203 (-0.295, -0.110) 0.047   
  85-89 -0.595 (-0.738, -0.453) 0.073 -0.243 (-0.341, -0.145) 0.050   
  90-max -0.697 (-0.852, -0.543) 0.079 -0.268 (-0.383, -0.153) 0.059   
Interaction: age (year) - Charlson score (>1 comorbidities) 
  50-54 Reference         
  55-59 -0.176 (-0.385, 0.034) 0.107 -0.016 (-0.120, 0.088) 0.053   
  60-64 -0.188 (-0.390, 0.015) 0.103 -0.121 (-0.218, -0.024) 0.050   
  65-69 -0.257 (-0.453, -0.061) 0.100 -0.230 (-0.325, -0.135) 0.048   
  70-74 -0.385 (-0.578, -0.193) 0.098 -0.345 (-0.436, -0.254) 0.047   
  75-79 -0.495 (-0.686, -0.304) 0.097 -0.432 (-0.522, -0.342) 0.046   
  80-84 -0.622 (-0.813, -0.430) 0.098 -0.483 (-0.576, -0.390) 0.047   
  85-89 -0.758 (-0.953, -0.563) 0.100 -0.550 (-0.647, -0.452) 0.050   
  90-max -0.890 (-1.096, -0.685) 0.105 -0.712 (-0.825, -0.599) 0.058   
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Table II-2 Regression coefficients conversion to Odd Ratios  
of healthcare resources utilisation 
 
        
  Covariates OR (95%CI)   
        
Age group (years) 
  50-54 Reference   
  55-59 1.35 (1.25 -1.45)   
  60-64 1.53 (1.42 -1.65)   
  65-69 1.65 (1.53 -1.77)   
  70-74 1.72 (1.60 -1.85)   
  75-79 1.92 (1.78 -2.06)   
  80-84 1.76 (1.64 -1.90)   
  85-89 1.67 (1.54 -1.80)   
  90-max 1.33 (1.22 -1.45)   
  Sex     
  Male  Reference   
  Female 1.02 (1.00 -1.04)   
  Date of admission 1.23 (1.17 -1.28)   
Follow-up years 
  1 Reference   
  2 0.20 (0.19 -0.20)   
  3 0.16 (0.15 -0.16)   
  4 0.14 (0.14 -0.14)   
  5 0.13 (0.12 -0.13)   
 SIMD     
  1 Reference   
  2 1.02 (0.99 -1.05)   
  3 0.97 (0.94 -1.01)   
  4 0.94 (0.91 -0.98)   
  5 0.94 (0.91 -0.97)   
 
Note: the probability of using healthcare resources increases up to 80 
years. No differences in resource utilisation is observed between males 
and females. In the 5 years post AF incident event, a small decrement in 
resource utilisation is observed over time.  A marginal increase is 
observed for patients living in the most deprived areas compared with 
patients living in areas with the lowest level of deprivation. 
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Table II-2 Regression coefficients conversion to Odd Ratios  
of healthcare resources utilisation (continued) 
 
        
  Covariates OR (95%CI)   
        
 Geography     
  Large urban Reference   
  Other urban 0.84 (0.82 -0.87)   
  Accessible small towns 0.82 (0.79 -0.85)   
  Accessible rural 0.78 (0.75 -0.81)   
  Remote small towns 0.85 (0.79 -0.90)   
  Remote rural 0.70 (0.66 -0.74)   
  Very remote small towns 0.65 (0.59 -0.71)   
  Very remote rural 0.66 (0.61 -0.71)   
Health boards     
  Great Glasgow and Clyde Reference   
  Lothian 0.95 (0.91 -0.99)   
  Lanarkshire 1.01 (0.97 -1.05)   
  Ayrshire and Arran 0.65 (0.62 -0.68)   
  Grampian 1.02 (0.98 -1.07)   
  Tayside 0.61 (0.58 -0.63)   
  Fife 0.91 (0.86 -0.96)   
  Highland 0.82 (0.77 -0.87)   
  Forth Valley 0.58 (0.55 -0.61)   
  Dumfries and Galloway 0.71 (0.67 -0.76)   
  Borders 0.56 (0.53 -0.60)   
  Western Isles 0.27 (0.24 -0.31)   
  Orkney 0.61 (0.53 -0.72)   
  Shetland 0.51 (0.44 -0.59)   
  Comorbidity     
  no comorbidities Reference   
  1 comorbidity 1.74 (1.53 -1.97)   
  >1 comorbidities 2.20 (1.83 -2.64)   
 
Note: the use of health or social care services decreases significantly in 
areas other than large urban. Aside from Lanarkshire and Grampian, 
patients are less likely to utilise health or social care services than 
patients in Great Glasgow and Clyde. Patients with comorbidities are 
more likely to make use of health or social care services than those with 
no comorbidities.  
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Appendix III: Conditional standardised difference  
 
 
For a continuous covariate, the conditional standardised difference is obtained in the 
following steps: 
 Step 1 - the continuous baseline covariate, denoted by X, is calculated according to 
Equation III-1[127]𝑋 = 𝛼0 + 𝛼1𝑇 +  𝛼2𝑍 +  𝛼3𝑇 × 𝑍 + ɛ, ɛ~𝑁(0, 𝜎
2 
                                                                                                                        Equation (III-1) 
Where Z indicates the estimated propensity score and T indicates treatment status (T=1 
indicates treated, while T=0 indicates untreated) 
 
Step 2 – for each subject in the sample, as shown in Equation III-2 [127], the following 
quantity is estimated 
?̂?1 + ?̂?3 𝑍
?̂?
 
                                                                                                                        Equation (III-2) 
Step 3 – The estimated X (Equation III-1) is then used to estimate the standardised 
difference as shown in Equation III-3 [127] 
 
𝑑 =
(?̅?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 −  ?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
√((𝑠𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
2 + 𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2 )/2)
 
                                                                                                                        Equation (III-3) 
Where ?̅? treatment and  ?̅? control are the sample mean of the treated and untreated group 
respectively; S2treatment and S2control are the sample variance of the treated and untreated 
group respectively.  
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For a continuous covariate, the conditional standardised difference is obtained in the 
following steps: 
Step 1 - the continuous baseline covariate, denoted by X, is calculated according to 
Equation III-1 
𝑙𝑜𝑔𝑖𝑡 (Pr(𝑥 = 1)) = 𝛼0 + 𝛼1𝑇 +  𝛼2𝑍 +  𝛼3𝑇 × 𝑍 
 
                                                                                                                        Equation (III-4) 
Where Z indicates the estimated propensity score and T indicates treatment status (T=1 
indicates treated, while T=0 indicates untreated) 
 
Step 2 – for each subject in the sample, as shown in Equation III-2 [127], the following 
quantity is estimated 
?̂?1 + ?̂?3 𝑍
?̂?
 
                                                                                                                     Equation (III-5) 
Step 3 - The estimated predicted probability (Equation III-4) is then used to estimate the 
standardised difference as shown in Equation III-6 [127] 
 
𝑑 =
(?̂?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 −  ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
√(((?̂?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡(1 − ?̂?𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)) + (?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙(1 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙)))/2)
 
                                                                                                                        Equation (III-6) 
Where ?̂? treatment and  ?̂? control are the prevalence or mean of the dichotomous variable 
of the treated and untreated group respectively. 
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Appendix IV: Collinearity test (Table I) 
 
Covariates 
      Standard dose Reduced dose 
Apixaban Dabigatran Rivaroxaban Apixaban 5 mg  Rivaroxaban 20 mg Apixaban 2.5 mg Rivaroxaban 15 mg  
Age 2.55 2.54 2.54  2.55  2.54  2.52  2.53 
Sex               
Women 1.44 1.44 1.44  1.44  1.44  1.44  1.44 
SIMD (Scottish index of multiple deprivation)             
2 1.65 1.68 1.69  1.65  1.68  1.67  1.68 
3 1.64 1.69 1.7  1.65  1.69  1.67  1.68 
4 1.63 1.67 1.69  1.64  1.69  1.65  1.66 
5 1.63 1.64 1.65  1.63  1.65  1.63  1.63 
CHA2DS2-VASc score             
0-2 2.79 2.79 2.79 2.79   2.79  2.81  2.81 
>=4 6.41 6.4 6.41  6.38  6.39  6.43  6.42 
HAS-BLED             
>=3 2.78 2.78 2.79  2.76  2.78  2.80  2.80 
Comorbidity             
1 comorbidity 1.23 1.22 1.23  1.23  1.23  1.23  1.23 
>1 comorbidity 1.67 1.66 1.67  1.67  1.67  1.67  1.67 
Stroke or TIA 1.33 1.32 1.33  1.32  1.33  1.32  1.32 
Vascular disease 1.25 1.25 1.25  1.25  1.25  1.25  1.25 
Hypertension 1.98 2.01 1.99  2.00  1.99  2.00  2.00 
Diabetes mellitus 1.27 1.26 1.26  1.27  1.27  1.26  1.26 
Cancer 1.11 1.11 1.11  1.11  1.11  1.11  1.10 
Drug causing bleeding 1.26 1.26 1.26  1.26  1.26  1.26  1.26 
Mean 1.98 1.98 1.99  1.97  1.98  1.98  1.98 
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Appendix V: Baseline characteristics for patients on anticoagulants 
 
 
 
Figure V-1 CHA2DS2VAS distribution by DOACs and warfarin 
 
CHA2DS2-VAS score 
7 72 (1.94) 9 (1.86) 68 (2.01) 439 (1.66)
8 9 (0.24) <5 (1.03) 5 (0.15) 52 (0.20)
5 535 (14.44) 48 (9.92) 496 (14.64) 3,622 (13.73)
6 234 (6.31) 17 (3.51) 249 (7.35) 1,672 (6.34)
3 678 (18.29) 68 (14.05) 619 (18.27) 5,123 (19.41)
4 851 (22.96) 100 (20.66) 795 (23.47) 5,971 (22.63)
1 566 (15.27) 97 (20.04) 487 (14.37) 3,864 (14.64)
2 501 (13.52) 76 (15.70) 459 (13.55) 3,961 (15.01)
Apixaban N(% ) Dabigatran N(% ) RivaroxabanN(% ) Warfarin N(% )
0 260 (7.02) 67 (13.84) 210 (6.20) 1,683 (6.38)
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Figure V-2 HAS-BLED distribution by DOACs and warfarin 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAS-BLED score 
7 <5 (0.13) 0 (0.00) <5 (0.15) <5 (0.02)
8 0 (0.00) 0 (0.00) 0 (0.00) <5 (0.02)
5 96 (2.59) 7 (1.45) 87 (2.57) 533 (2.02)
6 9 (0.24) 0 (0.00) 9 (0.27) 57 (0.22)
3 877 (23.66) 89 (18.39) 752 (22.20) 6,448 (24.44)
4 385 (10.39) 41 (8.47) 361 (10.66) 2,467 (9.35)
1 842 (22.72) 133 (27.48) 768 (22.67) 5,696 (21.59)
2 1,312 (35.40) 170 (35.12) 1,229 (36.28) 10,117 (38.34)
Apixaban N(% ) Dabigatran N(% ) RivaroxabanN(% ) Warfarin N(% )
0 184 (4.96) 44 (9.09) 181 (5.34) 1,065 (4.04)
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Figure V-3 Charlson Comorbidity Index distribution by DOACs and warfarin 
CCI Apixaban N(% ) Dabigatran N(% ) RivaroxabanN(% ) Warfarin N(% )
0 1,814 (48.25) 317 (65.50) 1,714 (50.59) 13,831 (52.42)
2 496 (13.38) 39 (8.06) 432 (12.75) 3,282 (12.44)
1 883 (23.83) 83 (17.15) 769 (22.70) 5,974 (22.64)
4 140 (3.78) 15 (3.10) 113 (3.34) 823 (3.12)
3 241 (6.50) 21 (4.34) 231 (6.82) 1,698 (6.43)
6 26 (0.70) <5 (1.03) 23 (0.68) 170 (0.64)
5 51 (1.38) <5 (1.03) 50 (1.48) 339 (1.28)
8 20 (0.54) <5 (1.03) 20 (0.59) 116 (0.44)
7 9 (0.24) <5 (1.03) 13 (0.38) 49 (0.19)
10 6 (0.16) 0 (0.00) 7 (0.21) 25 (0.09)
9 14 (0.38) 0 (0.00) 10 (0.30) 64 (0.24)
12 <5 (0.13) 0 (0.00) <5 (0.15) 7 (0.03)
11 <5 (0.13) 0 (0.00) <5 (0.15) 9 (0.03)
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Appendix VI: Proportionality hazard assumption (number of events, event rates and 
HRs estimates with time intervals) 
Table VI-1 Number of events and event rates estimated with time intervals 
 
Note: due to disclosure restrictions, in the case of fewer than five events, the sign < 5 was used 
instead. Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, ICH=intracranial 
haemorrhage, GI=gastrointestinal  
 
 
 
 
Outcome 
time intervals Apixaban Dabigatran Rivaroxaban Warfarin 
(2 years) 
Events  
(event rates) 
Events  
(event rates) 
Events  
(event rates) 
Events  
(event rates) 
  0-730 61 (2.27) 5 (0.56) 85 (2.33) 704 (1.12) 
Stroke all 731-1,460 no event 5 (0.56) < 5 (0.03) 286 (0.45) 
 1,461-2,186 no event no event < 5 (0.03) 68 (0.11) 
  0-2,186 61 (2.27) 10 (1.12) 87 (2.39) 1,058 (1.68) 
  0-730 65 (2.42) 5 (0.56) 87 (2.39) 754 (1.20) 
Stroke or SE 731-1,460 no event 5 (0.56) < 5 (0.05) 307 (0.49) 
  1,461-2,186 no event no event < 5 (0.03) 69 (0.11) 
  0-2,186 65 (2.42) 10 (1.12) 90 (2.47) 1,130 (1.80) 
  0-730 81 (3.02) 6 (0.67) 100 (2.47) 941 (1.50) 
Stroke or SE 731-1,460 no event 6 (0.67) < 5 (0.08) 375 (0.60) 
or TIA 1,461-2,186 no event no event < 5 (0.03) 83 (0.13) 
  0-2,186 81 (3.02) 12 (1.35) 104 (2.85) 1,399 (2.22) 
  0-730 240 (8.95) 29 (3.25) 378 (10.38) 2,720 (4.32) 
 Stroke or SE  731-1,460 < 5 (0.04) 18 (2.02) 26 (0.71) 1,280 (2.03) 
 or death 1,461-2,186 no event no event < 5 (0.05) 313 (0.50) 
  0-2,186 241 (8.98) 47 (5.27) 406 (11.14) 4,313 (6.85) 
  0-730 46 (1.71) < 5 (0.45) 30 (0.82) 423 (0.67) 
MI 731-1,460 < 5 (0.04) < 5 (0.11) < 5 (0.08) 158 (0.25) 
  1,461-2,186 no event no event < 5 (0.00) 30 (0.05) 
  0-2,186 47 (1.75) 5 (0.56) 33 (0.91) 611 (0.97) 
  0-730 127 (4.73) 26 (2.92) 223 (6.21) 1,718 (2.73) 
Major bleed 731-1,460 no event 6 (0.67) 8 (0.22) 645 (1.02) 
  1,461-2,186 no event no event < 5 (0.00) 111 (0.18) 
  0-2,186 127 (4.73) 32 (3.59) 231 (6.34) 2,474 (3.93) 
  0-730 16 (0.60) no event 18 (0.49) 117 (0.19) 
ICH 731-1,460 no event < 5 (0.11) no event 53 (0.08) 
  1,461-2,186 no event no event no event 6 (0.01) 
  0-2,186 16 (0.60) < 5 (0.11) 18 (0.49) 176 (0.28) 
  0-730 43 (1.60) 14 (1.57) 74 (2.03) 565 (0.90) 
GI bleed 731-1,460 no event no event < 5 (0.08) 200 (0.32) 
  1,461-2,186 no event no event no event 33 (0.05) 
  0-2,186 43 (1.60) 14 (1.57) 77 (2.11) 798 (1.27) 
  0-730 176 (6.56) 24 (2.69) 292 (8.02) 1,980 (3.15) 
 Mortality  731-1,460 < 5 (0.04) 13 (1.46) 24 (0.66) 978 (1.55) 
 (all-cause) 1,461-2,186 no event no event < 5 (0.03) 244 (0.39) 
  0-2,186 177 (6.60) 37 (4.15) 317 (8.70) 3,202 (5.09) 
  0-730 10 (0.37) < 5 (0.22) 19 (0.52) 106 (0.17) 
 Mortality 731-1,460 no event < 5 (0.11) < 5 (0.03) 46 (0.07) 
 (stroke) 1,461-2,186 no event no event no event 6 (0.01) 
  0-2,186 10 (0.37) 3 (0.34) 20 (0.55) 158 (0.25) 
  0-730 100 (3.73) 13 (1.46) 146 (4.01) 1,050 (1.67) 
 Mortality 731-1,460 no event < 5 (0.45) 12 (0.33) 467 (0.74) 
 (cardiovascular) 1,461-2,186 no event no event < 5 (0.03) 99 (0.16) 
  0-2,186 100 (3.73) 17 (1.91) 159 (4.36) 1,616 (2.57) 
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Table VI-2 HRs estimated with time intervals 
Outcome 
time intervals Apixaban vs. warfarin Dabigatran vs. warfarin Rivaroxaban vs. warfarin 
(2 years)  HR 95% CI  HR 95% CI  HR 95% CI  
  0-730 0.96 (0.70, 1.30) 0.52 (0.21, 1.25) 1.16 (0.91, 1.48) 
Stroke all 731-1,460 not estimated 1.71 (0.70, 4.18) 0.19 (0.03, 1.39) 
  1461-2,186 not estimated not estimated 35.85 (4.64, 262.03) 
  0-2,186 0.94 (0.69, 1.27) 0.79 (0.42, 1.47) 1.10 (0.87, 1.40) 
  0-730 0.95 (0.70, 1.27) 0.48 (0.20, 1.16) 1.10 (0.87, 1.40) 
Stroke SE 731-1,460 not estimated 1.61 (0.66, 3.93) 0.36 (0.09, 1.47) 
  1,461-2,186 not estimated not estimated 35.54 (4.73, 267.10) 
  0-2,186 0.93 (0.69, 1.25) 0.73 (0.39, 1.37) 1.06 (0.84, 1.34) 
  0-730 0.94 (0.73, 1.23) 0.46 (0.21, 1.03) 1.00 (0.80, 1.25) 
Stroke or SE 731-1,460 not estimated 1.49 (0.66, 3.37) 0.41 (0.13, 1.30) 
Or TIA 1,461-2,186 not estimated not estimated 23.79 (3.18, 178.02) 
  0-2,186 0.93 (0.72, 1.21) 0.70 (0.39, 1.23) 0.97 (0.78, 1.20) 
  0-730 1.03 (0.89, 1.21) 0.73 (0.50, 1.05) 1.33 (1.18, 1.50) 
Stroke or SE 731-1,460 0.63 (0.09, 4.49) 1.43 (0.89, 2.29) 1.19 (0.80, 1.78) 
or TIA 1,461-2,186 not estimated not estimated 16.18 (3.98, 65.81) 
  0-2,186 1.02 (0.88, 1.19) 0.89 (0.66, 1.18) 1.32 (1.18, 1.47) 
  0-730 1.37 (0.95, 1.98) 0.67 (0.25, 1.79) 0.76 (0.52, 1.13) 
MI 731-1,460 4.83 (0.64, 36.27) 0.53 (0.07, 3.78) 0.96 (0.30, 3.09) 
  1,461-2,186 not estimated not estimated not estimated 
  0-2,186 1.41 (0.98, 2.03) 0.63 (0.26, 1.52) 0.77 (0.53, 1.12) 
  0-730 0.89 (0.73, 1.09) 0.94 (0.64, 1.39) 1.30 (1.12, 1.52) 
Major bleed 731-1,460 not estimated 0.85 (0.38, 1.92) 0.73 (0.36, 1.48) 
  1,461-2,186 not estimated not estimated not estimated 
  0-2,186 0.88 (0.72, 1.08) 0.92 (0.65, 1.30) 1.26 (1.09, 1.46) 
  0-730 1.39 (0.74, 2.61) not estimated 1.24 (0.72, 2.12) 
ICH 731-1,460 not estimated not estimated not estimated 
  1,461-2,186 not estimated not estimated not estimated 
  0-2,186 1.36 (0.73, 2.53) 0.38 (0.05, 2.69) 1.11 (0.66, 1.88) 
  0-730 0.88 (0.62, 1.26) 1.76 (1.03, 3.01) 1.37 (1.05, 1.78) 
GI bleed 731-1,460 not estimated not estimated 0.87 (0.27, 2.78) 
  1,461-2,186 not estimated not estimated not estimated 
  0-2,186 0.87 (0.61, 1.25) 1.38 (0.81, 2.35) 1.32 (1.02, 1.71) 
  0-730 1.06 (0.88, 1.27) 0.80 (0.54, 1.20) 1.41 (1.23, 1.62) 
Mortality 731-1,460 0.87 (0.12, 6.23) 1.35 (0.78, 2.34) 1.47 (0.96, 2.23) 
(all-cause) 1,461-2,186 not estimated not estimated 10.61 (1.47, 76.52) 
  0-2,186 1.05 (0.87, 1.25) 0.93 (0.67, 1.29) 1.40 (1.24, 1.60) 
  0-730 0.79 (0.37, 1.73) 1.39 (0.34, 5.69) 1.60 (0.93, 2.78) 
Mortality 731-1,460 not estimated 2.83 (0.37, 21.61) 2.00 (0.25, 16.11) 
(stroke) 1,461-2,186 not estimated not estimated not estimated 
  0-2,186 0.77 (0.35, 1.67) 1.68 (0.53, 5.33) 1.57 (0.92, 2.68) 
  0-730 1.17 (0.91, 1.49) 0.84 (0.49, 1.46) 1.37 (1.13, 1.65) 
Mortality 731-1,460 not estimated 0.92 (0.34, 2.47) 1.59 (0.87, 2.88) 
(cardiovascular) 1,461-2,186 not estimated not estimated 22.63 (3.07, 167.05) 
  0-2,186 1.15 (0.90, 1.47) 0.86 (0.53, 1.38) 1.39 (1.16, 1.66) 
 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, ICH=intracranial 
haemorrhage, GI=gastrointestinal  
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Appendix VII: Baseline characteristics for patients on anticoagulants (standard and reduced dose) 
 
 
 
 Figure VII-1 CHA2DS2VAS distribution by DOACs (standard and reduced dose)  
 
 
0 250 (8.98) 10 (1.08) 203 (7.42) 3 (0.58)
CHA2DS2-VAS score Apixaban 5 mg N(% ) Apixaban 2.5 mg N(% ) Rivaroxaban 20 mg N(% ) Rivaroxaban 15 N(% )
2 473 (16.99) 28 (3.04) 417 (15.25) 22 (4.25)
1 548 (19.68) 18 (1.95) 445 (16.27) 17 (3.28)
4 532 (19.11) 319 (34.60) 589 (21.54) 174 (33.59)
3 528 (18.97) 150 (16.27) 515 (18.83) 84 (16.22)
6 112 (4.02) 122 (13.23) 163 (5.96) 76 (14.67)
5 306 (10.99) 229 (24.84) 354 (12.94) 121 (23.36)
8 <5 (0.18) 6 (0.65) <5 (0.18) <5 (0.97)
7 32 (1.15) 40 (4.34) 45 (1.65) 20 (3.86)
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Figure VII-2 HAS-BLED distribution by DOACs (standard and reduced dose) 
 
 
 
7 <5 (0.18) 0 (0.00) 0 (0.00) <5 (0.97)
8 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
5 53 (1.90) 43 (4.66) 47 (1.72) 40 (7.72)
6 8 (0.29) <5 (0.54) 6 (0.22) <5 (0.97)
3 607 (21.80) 270 (29.28) 592 (21.65) 133 (25.68)
4 243 (8.73) 142 (15.40) 251 (9.18) 96 (18.53)
1 689 (24.75) 153 (16.59) 643 (23.51) 90 (17.37)
2 1,006 (36.14) 306 (33.19) 1,022 (37.37) 153 (29.54)
HASBLED score Apixaban 5 mg N(% ) Apixaban 2.5 mg N(% ) Rivaroxaban 20 mg N(% ) Rivaroxaban 15 N(% )
0 177 (6.36) 7 (0.76) 174 (6.36) 3 (0.58)
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Figure VII-3 Charlson Comorbidity Index distribution by DOACs (standard and reduced dose) 
11 <5 (0.18) <5 (0.54) <5 (0.18) 0 (0.00)
12 <5 (0.18) 0 (0.00) <5 (0.18) 0 (0.00)
9 8 (0.29) 6 (0.65) 10 (0.37) <5 (0.97)
10 <5 (0.18) <5 (0.54) <5 (0.18) <5 (0.97)
7 6 (0.22) 3 (0.33) 8 (0.29) <5 (0.97)
8 13 (0.47) 7 (0.76) 15 (0.55) <5 (0.97)
5 26 (0.93) 25 (2.71) 24 (0.88) 19 (3.67)
6 11 (0.40) 15 (1.63) 16 (0.59) 13 (2.51)
3 148 (5.32) 93 (10.09) 158 (5.78) 52 (10.04)
4 84 (3.02) 56 (6.07) 62 (2.27) 43 (8.30)
1 655 (23.53) 228 (24.73) 624 (22.82) 105 (20.27)
2 347 (12.46) 149 (16.16) 354 (12.94) 78 (15.06)
CCI Apixaban 5 mg N(% ) Apixaban 2.5 mg N(% ) Rivaroxaban 20 mg N(% ) Rivaroxaban 15 N(% )
0 1,477 (53.05) 337 (36.55) 1,458 (53.31) 200 (38.61)
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Appendix VIII: Proportionality hazard assumption (plots of goodness of fit)  
 
Apixaban versus warfarin 
Seemingly, for the majority of the clinical outcomes assessed, plots were straight lines but 
not necessarily parallel, and were crossing at different time points. Figure VIII-1 assessing 
the proportional hazards assumption for stroke, TIA and SE in the apixaban versus 
warfarin comparison, clearly indicates proportionality violation, where log-cumulative 
hazard lines are crossing several times. Comparable trends of proportionality violation 
were observed in Figure VIII-2 looking at MI, ICH, major and GI bleeding. The log-
cumulative hazard plots for mortality due to stroke and, arguably mortality due to 
cardiovascular conditions, presented in Figures VIII-3 b and VIII-3 c, are the only ones 
that show proportionality.  
 
 
Dabigatran versus warfarin 
Overall proportionality violation is observed for most of the clinical outcomes. Unlike to 
what is observed in the apixaban plots, the log-cumulative hazard lines for stroke, TIA and 
SE are not crossing (Figure VIII-4 a‒VIII-4 c). However, these plots are not straight lines 
either; therefore, it is difficult to establish whether the proportionality assumption is met. 
Due to a small dabigatran sample size and a relatively small number of events, the plot for 
ICH only included the log-cumulative hazard lines for warfarin (Figure VIII-5c). Other 
differences with apixaban plots are seen for mortality due stroke and cardiovascular 
conditions (Figure VIII-6 b, VIII-6 c), where crossing lines clearly show proportionality 
violation.  
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Rivaroxaban versus warfarin 
As for apixaban and dabigatran, proportionality violation can be observed throughout most 
of the clinical outcomes. Violation is particularly evident in the plots showing MI (Figure 
VIII-8 a) and mortality due to stroke (Figure VIII-9 b) where log-cumulative hazard lines 
are crossing several times.  
 
 
Table VIII-1 shows that overall, age and CCI where the variables violating the 
proportionality assumption across all treatments and clinical outcomes.  
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Figure VIII-1 a (stroke-all)                                                                                        Figure VIII-1 b (stroke or SE)  
                    
Figure VIII-1 c (stroke or SE or TIA)                                                                      Figure VIII-1 d (stroke or mortality-all-cause)          
  
Figure VIII-1: log-cumulative hazard plot for stroke, SE and TIA (apixaban vs. warfarin)                                                                                    
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure VIII-2 a (MI)                                                                                                   Figure VIII-2 b (major bleeding)     
  
Figure VIII-2 c (ICH)                                                                                                 Figure VIII-2 d (GI bleeding)           
   
 Figure VIII-2: log-cumulative hazard plot for MI, ICH and bleeding (apixaban vs. warfarin) 
 Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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 Figure VIII-3 a (mortality-all-cause)                                                                       Figure VIII-3 b (mortality-stroke) 
  
Figure VIII-3 c (mortality-cardiovascular)                                                                          
 
Figure VIII-3: log-cumulative hazard plot for mortality (apixaban vs. warfarin)
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Figure VIII-4 a (stroke-all)                                                                                        Figure VIII-4 b (stroke or SE)  
            
Figure VIII-4 c (stroke or SE or TIA)                                                                       Figure VIII-4 d (stroke or mortality-all-cause)     
  
Figure VIII-4: log-cumulative hazard plot for stroke, SE and TIA (dabigatran vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure VIII-5 a (MI)                                                                                                   Figure VIII-5 b (major bleeding) 
  
Figure VIII-5 c (ICH)                                                                                                 Figure VIII-5 d (GI bleeding) 
  
Figure VIII-5: log-cumulative hazard plot for MI, ICH and bleeding (dabigatran vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
Due to disclosure restrictions, in the case of fewer than five events, “<5” was reported. 
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Figure VIII-6 a (mortality-all-cause)                                                                        Figure VIII-6 b (mortality-stroke) 
  
Figure VIII-6 c (mortality-cardiovascular)                  
 
 Figure VIII-6: log-cumulative hazard plot for mortality (dabigatran vs. warfarin)
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Figure VIII-7 a (stroke-all)                                                                                        Figure VIII-7 b (stroke or SE)  
  
Figure VIII-7 c (stroke or SE or TIA)                                                                      Figure VIII-7 d (stroke or mortality-all-cause) 
  
Figure VIII-7: log-cumulative hazard plot for stroke, SE and TIA (rivaroxaban vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
   
 
 
                                                                                                                                                                          271 
 
Figure VIII-8 a (MI)                                                                                                   Figure VIII-8 b (major bleeding) 
  
Figure VIII-8 c (ICH)                                                                                                 Figure VIII-8 d (GI bleeding)      
  
Figure VIII-8: log-cumulative hazard plot for MI, ICH and bleeding (rivaroxaban vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
  
 
                                                                                                                                                                          272 
 
Figure VIII-9 a (mortality-all-cause)                                                                        Figure VIII-9 b (mortality-stroke)      
  
Figure VIII-9 c (mortality-cardiovascular)          
 
Figure VIII-9: log-cumulative hazard plot for mortality (rivaroxaban vs. warfarin) 
        
                                                                                                                                                                          273 
 
Table VIII-1 Proportionality hazard assumption test of significance  
 
Outcome 
p-value 
treatment age sex CCI SIMD year PS 
Apixaban               
Stroke all 0.150 0.001 0.297 0.001 0.336 0.904 0.130 
Stroke or SE 0.088 0.001 0.182 0.001 0.370 0.910 0.189 
Stroke or SE or TIA 0.133 0.001 0.283 0.001 0.124 0.905 0.095 
Stroke or SE or mortality (all-cause) 0.164 0.000 0.015 0.001 0.927 0.501 0.948 
MI 0.979 0.872 0.495 0.001 0.460 0.120 0.298 
Major bleeding 0.961 0.560 0.948 0.001 0.451 0.886 0.086 
ICH 0.335 0.039 0.345 0.001 0.445 0.385 0.523 
GI bleeding 0.839 0.503 0.416 0.018 0.724 0.183 0.625 
Mortality (all-cause) 0.102 0.007 0.072 0.000 0.371 0.263 0.388 
Mortality (stroke) 0.573 0.984 0.861 0.002 0.944 0.573 0.899 
Mortality (cardiovascular) 0,080 0.907 0.777 0.001 0.955 0.171 0.124 
Dabigatran               
Stroke all 0.134 0.001 0.311 0.001 0.065 0.799 0.069 
Stroke or SE 0.136 0.001 0.232 0.001 0.054 0.837 0.091 
Stroke or SE or TIA 0.111 0.001 0.321 0.001 0.063 0.800 0.078 
Stroke or SE or mortality (all-cause) 0.184 0.001 0.573 0.001 0.218 0.582 0.069 
MI 0.691 0.941 0.653 0.001 0.566 0.173 0.646 
Major bleeding 0.633 0.903 0.668 0.025 0.936 0.936 0.072 
ICH 1.000 0.283 0.319 0.002 0.496 0.522 0.531 
GI bleeding 0.520 0.713 0.486 0.658 0.474 0.179 0.825 
Mortality (all-cause) 0.517 0.005 0.053 0.001 0.763 0.314 0.774 
Mortality (stroke) 0.272 0.670 0.945 0.003 0.791 0.714 0.871 
Mortality (cardiovascular) 0.197 0.969 0.772 0.001 0.829 0.240 0.888 
Rivaroxaban               
Stroke all 0.082 0.006 0.200 0.001 0.228 0.969 0.828 
Stroke or SE 0.075 0.004 0.132 0.001 0.299 0.945 0.879 
Stroke or SE or TIA 0.182 0.011 0.183 0.001 0.060 0.994 0.380 
Stroke or SE or mortality (all-cause) 0.791 0.001 0.173 0.001 0.368 0.439 0.595 
MI 0.704 0.998 0.442 0.001 0.229 0.291 0.527 
Major bleeding 0.365 0.409 0.945 0.005 0.366 0.817 0.701 
ICH 0.074 0.215 0.496 0.006 0.694 0.307 0.578 
GI bleeding 0.309 0.852 0.309 0.077 0.229 0.168 0.744 
Mortality (all-cause) 0.657 0.010 0.154 0.001 0.902 0.254 0.691 
Mortality (stroke) 0.585 0.436 0.786 0.038 0.575 0.416 0.312 
Mortality (cardiovascular) 0.415 0.681 0.304 0.001 0.678 0.191 0.835 
 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, ICH=intracranial 
haemorrhage, GI=gastrointestinal 
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Appendix IX: Kaplan Meier curves 
 
 
Apixaban versus warfarin 
 
The crude estimates over time indicate that overall the probability of surviving is higher for 
patients on warfarin than those on apixaban. While for apixaban the survival curves are 
estimated within the first two years from anticoagulation initiation, for warfarin patients 
the estimates expand beyond the 2 years across all clinical outcomes. This is mainly due to 
patients on apixaban being exposed to treatment for a much shorter period of time; 
consequently, patients on apixaban overall experienced far fewer clinical events than 
patients on warfarin. The Kaplan Meier curves indicate that overall at 2-year follow-up, the 
proportion of patients free of event is higher in the warfarin rather than in the apixaban 
group (Figure IX-1‒IX-3). This suggests that, over time, patients on apixaban are more 
likely to have an event, such as stroke or bleeding, than patients who are on warfarin; thus, 
the probability of surviving is higher for patients on warfarin then those on apixaban. 
While this seems to be true for the composite of stroke and mortality (Figure IX-1 d), MI, 
ICH (Figure IX-2 a, IX-2 c) and mortality (Figure IX-3 a, IX-3 c), no difference in the 
probability of surviving is observed for the various composites of stroke including SE and 
TIA(Figure IX-1 a ‒ IX-2 c) and bleeding (Figure IX-2 a, IX-2 c) in the first year from 
anticoagulation initiation.   
 
Dabigatran versus warfarin 
The Kaplan Meier curves indicate that overall at 2-year follow-up, the proportion of 
patients free of event is higher in the dabigatran rather than in the warfarin group (Figure 
IX-4‒IX-6). However, the probability of survival from MI for patients on dabigatran is 
based on less than 10 events. While this seems to be true for most of the outcomes, the 
probability of survivals seems to be inverted for GI bleeding (Figure IX-5 d) and mortality 
due to stroke (Figure IX-6 a).  
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Rivaroxaban versus warfarin 
The Kaplan Meier curves indicate that overall at 2-year follow-up, the proportion of 
patients free of event is higher in the warfarin rather than in the apixaban group (Figure IX-
7‒IX-9). While this is true for the composite of stroke and mortality (Figure IX-7 d), ICH 
(Figure IX-8 c), bleeding (Figure IX-8 b, Figure IX-8 d) and mortality (Figure IX-9 a ‒ IX-
9 c), the probability of survivals seems to be inverted for MI (Figure IX-8 a). No difference 
in the probability of surviving is observed for the various composites of stroke including 
SE and TIA (Figure IX-7 a ‒ IX-7 c).  
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Figure IX-1 a (stroke-all)                                                                                           Figure IX-1 b (stroke or SE)  
  
Figure IX-1 c (stroke or SE or TIA)                                                                         Figure IX-1 d (stroke or mortality-all-cause)          
  
Figure IX-1: Stroke, SE and TIA (apixaban vs. warfarin)                                                                                     
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure IX-2 a (MI)                                                                                                      Figure IX-2 b (major bleeding)     
  
Figure IX-2 c (ICH)                                                                                                    Figure IX-2 d (GI bleeding)           
  
Figure IX-2: MI, ICH and bleeding (apixaban vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal    
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Figure IX-3 a (mortality-all-cause)                                                                           Figure IX-3 b (mortality-stroke) 
  
Figure IX-3 c (mortality-cardiovascular)                                                                          
 
Figure IX-3: Mortality (apixaban vs. warfarin) 
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Figure IX-4 a (stroke-all)                                                                                           Figure IX-4 b (stroke or SE)  
  
Figure IX-4 c (stroke or SE or TIA)                                                                         Figure IX-4 d (stroke or mortality-all-cause)     
  
Figure IX-4: Stroke, SE and TIA (dabigatran vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure IX-5 a (MI)                                                                                                      Figure IX-5 b (major bleeding) 
              
Figure IX-5 c (ICH)                                                                                                    Figure IX-5 d (GI bleeding) 
  
Figure IX-5: MI, ICH and bleeding (dabigatran vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the Kaplan Meier curve was not reported 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure IX-6 a (mortality-all-cause)                                                                           Figure IX-6 b (mortality-stroke) 
  
Figure IX-6 c (mortality-cardiovascular)                  
 
Figure IX-6: Mortality (dabigatran vs. warfarin) 
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Figure IX-7 a (stroke-all)                                                                                           Figure IX-7 b (stroke or SE)  
  
Figure IX-7 c (stroke or SE or TIA)                                                                         Figure IX-7 d (stroke or mortality-all-cause) 
  
Figure IX-7: Stroke, SE and TIA (rivaroxaban vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure IX-8 a (MI)                                                                                                      Figure IX-8 b (major bleeding)  
  
Figure IX-8 c (ICH)                                                                                                    Figure IX-8 d (GI bleeding)      
  
Figure IX-8: MI, ICH and bleeding (rivaroxaban vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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 Figure IX-9 a (mortality-all-cause)                                                                          Figure IX-9 b (mortality-stroke)      
  
Figure IX-9 c (mortality-cardiovascular)          
 
Figure IX-9: Mortality (rivaroxaban vs. warfarin) 
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Appendix X: Cumulative incidence curves 
 
Apixaban versus warfarin 
 
While for apixaban, the cumulative incidence curves were estimated within the first two 
years from anticoagulation initiation, for warfarin patients the estimates expanded beyond 
the 2 years across all clinical outcomes. As pointed out this is mainly due to patients on 
apixaban being exposed to the treatment for a much shorter period of time and 
experiencing most of the events within the first 2 years from anticoagulation initiation. In 
general, the probability of an event to occur, as depicted in the cumulative incidence curves 
(Appendix X, Figure X-1‒Figure X-3), indicated that overall within the first 2 years from 
therapy initiation, patients on apixaban were more likely to have an event than patients 
who were on warfarin; nevertheless, in the first year from starting therapy, the difference in 
risk seemed to be negligible. 
 
Dabigatran versus warfarin 
 
Overall, the probability of experiencing a clinical event in the dabigatran group is lower 
than the probability observed in the warfarin treatment arm (Appendix X, Figure X-4‒
Figure X-6). The cumulative incidence curves reflecting the probability of experiencing an 
event were not reported if associated with less than five events (Figure X-5 a, Figure X-5 c 
and Figure X-6 b). As shown in Figure X-5 b, the direction of the probability of 
experiencing a major bleeding event changes over time. Further, Figure X-5 d seems to 
suggest that at 2 years from anticoagulation initiation, patients on dabigatran are more 
likely to experience a GI bleeding event. 
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Rivaroxaban versus warfarin 
 
For most of the clinical outcomes, the probability for an event to occur seems to be greater 
in rivaroxaban than in the warfarin treatment group (Appendix X, Figure XI-7‒X-9); 
however, the cumulative incidence curve for MI does not seem to follow a clear pattern. 
Following the first 2 years from anticoagulation initiation, the probability of SE or TIA 
occurring appear to increase for warfarin patients; but only a few events are observed 
(Figure X-7 c). 
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Figure X-1 a (stroke-all)                                                                                            Figure X-1 b (stroke or SE)  
  
Figure X-1 c (stroke or SE or TIA)                                                                           Figure X-1 d (stroke or SE or mortality-all-cause) 
  
Figure X-1: Stroke, SE and TIA (apixaban vs. warfarin)  
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack                                                                                         
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Figure X-2 a (MI)                                                                                                        Figure X-2 b (major bleeding) 
    
Figure X-2 c (ICH)                                                                                                      Figure X-2 d (GI bleeding)           
  
Figure X-2: MI, ICH and bleeding (apixaban vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure X-3 a (mortality-all-cause)                                                                             Figure X-3 b (mortality-stroke)           
  
Figure X-3 c (mortality-cardiovascular)                                                                          
 
Figure X-3: Mortality (apixaban vs. warfarin) 
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Figure X-4 a (stroke-all)                                                                                             Figure X-4 b (stroke or SE)  
  
Figure X-4 c (stroke or SE or TIA)                                                                           Figure X-4 d (stroke or mortality-all-cause)           
  
Figure X-4: Stroke, SE and TIA (dabigatran vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure X-5 a (MI)                                                                                                        Figurer X-5 b (major bleeding)           
  
Figure X-5 c (ICH)                                                                                                      Figure X-5 d (GI bleeding)           
  
Figurer X-5: MI, ICH and bleeding (dabigatran mg vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure X-6 a (mortality-all-cause)                                                                             Figure X-6 b (mortality-stroke)           
         
Figure X-6 c (mortality-cardiovascular)                                                                          
 
Figure X-6: Mortality (dabigatran vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
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Figure X-7 a (stroke-all)                                                                                             Figure X-7 b (stroke or SE)  
  
Figure X-7 c (stroke or SE or TIA)                                                                           Figure X-7 d (stroke or mortality-all-cause)           
  
Figure X-7: Stroke, SE and TIA (rivaroxaban vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure X-8 a (MI)                                                                                                       Figure X-8 b (major bleeding)           
  
Figure X-8 c (ICH)                                                                                                     Figure X-8 d (GI bleeding)           
  
Figure X-8: MI, ICH and bleeding (rivaroxaban mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure X-9 a (mortality-all-cause)                                                                             Figure X-9 b (mortality-stroke)           
  
Figure X-9 c (mortality-cardiovascular)                                                                          
 
Figure X-9: Mortality (rivaroxaban vs. warfarin)
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Appendix XI: Hazard ratios for 6 years follow-up 
 
 
Figure XI-1: Hazard ratios for 6 years since first prescription, DOACs vs. warfarin 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
 
 
 
 
 
Apixaban
Stroke all 0.89 (0.64 -1.23)
Stroke or SE 0.87 (0.64 -1.20)
Stroke or SE  or TIA 0.87 (0.66 -1.16)
Stroke or SE or mortality (all cause) 0.96 (0.81 -1.13)
MI 1.31 (0.89 -1.94)
Major bleeding 0.88 (0.71 -1.09)
ICH 1.47 (0.73 -2.96)
GI bleeding 0.86 (0.59 -1.25)
Mortality (all cause) 0.99 (0.81 -1.19)
Mortality (stroke) 0.72 (0.32 -1.63)
Mortality (cardiovascular) 1.03 (0.79 -1.34)
Dabigatran
Stroke all 0.66 (0.30 -1.48)
Stroke or SE 0.62 (0.28 -1.38)
Stroke or SE  or TIA 0.65 (0.33 -1.31)
Stroke or SE or mortality (all cause) 0.85 (0.60 -1.20)
MI 0.54 (0.17 -1.67)
Major bleeding 1.10 (0.75 -1.61)
ICH 0.62 (0.09 -4.44)
GI bleeding 1.76 (1.01 -3.06)
Mortality (all cause) 0.92 (0.63 -1.35)
Mortality (stroke) 1.42 (0.35 -5.80)
Mortality (cardiovascular) 0.98 (0.58 -1.67)
Rivaroxaban
Stroke all 0.96 (0.73 -1.26)
Stroke or SE 0.94 (0.72 -1.23)
Stroke or SE  or TIA 0.89 (0.70 -1.13)
Stroke or SE or mortality (all cause) 1.26 (1.11 -1.42)
MI 0.78 (0.52 -1.17)
Major bleeding 1.27 (1.08 -1.49)
ICH 1.36 (0.76 -2.43)
GI bleeding 1.31 (0.99 -1.74)
Mortality (all cause) 1.37 (1.19 -1.58)
Mortality (stroke) 1.45 (0.81 -2.57)
Mortality (cardiovascular) 1.30 (1.06 -1.59)
Outcome  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring DOACs       Favouring  warfarin
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Appendix XII: Proportionality hazard assumption (plots of goodness of fit for 
standard and reduced dose) 
 
 
Apixaban versus warfarin 
 
Very similar trends can be observed when assessing proportionality assumptions violation 
plots for apixaban reduced and standard dose (Figure XII-1‒XII-6). However, violation for 
stroke and stroke composites in apixaban standard dose (Figure XII-1 a‒XII-1c) seems to 
be less evident. 
 
Rivaroxaban versus warfarin 
The plots assessing proportionality for the standard dose of 20 mg rivaroxaban seem to 
follow the same patterns observed in the proportionality assessment of any dose 
rivaroxaban. Comparatively, When assessing proportionality violation of reduced 
rivaroxaban, the assumption of proportionality seem to be satisfied for some clinical 
outcomes such stroke (Figure XII-10 a), MI (Figure XII-11 a), ICH (Figure XII-11 c), GI 
bleeding (Figure XII-11 d),all-cause mortality (Figure IXI-12 a), and mortality due to 
cardiovascular conditions (Figure XII-12 c). 
 
Table XII-1 (standard dose) and XII-2 (reduced dose) shows that overall, age and CCI 
where the variables violating the proportionality assumption across all treatments and 
clinical outcomes.  
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Figure XII-1 a (stroke-all)                                                                                          Figure XII-1 b (stroke or SE)  
  
Figure XII-1 c (stroke or SE or TIA)                                                                        Figure XII-1 d (stroke or mortality-all-cause)    
  
Figure XII-1 log-cumulative hazard plot for stroke, SE and TIA (apixaban 5 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack  
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Figure XII-2 a (MI)                                                                                                     Figure XII-2 b (major bleeding)         
              
Figure XII-2 c (ICH)                                                                                                   Figure XII-2 d (GI bleeding)         
  
Figure XII-2: log-cumulative hazard plot for MI, ICH and bleeding (apixaban 5 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure XII-3 a (mortality-all-cause)                                                                          Figure XII-3 b (mortality-stroke)    
  
Figure XII-3 c (mortality-cardiovascular)         
 
Figure XII-3: log-cumulative hazard plot for mortality (apixaban 5 mg vs. warfarin) 
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Figure XII-4 a (stroke-all)                                                                                          Figure XII-4 b (stroke or SE)  
  
Figure XII-4 c (stroke or SE or TIA)                                                                        Figure XII-4 d (stroke or mortality-all-cause)           
  
Figure XII-4 log-cumulative hazard plot for stroke, SE and TIA (apixaban 2.5 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XII-5 a (MI)                                                                                                     Figure XII-5 b (major bleeding)           
  
Figure XII-5 c (ICH)                                                                                                   Figure XII-5 d (GI bleeding)  
  
Figure XII-5: log-cumulative hazard plot for MI, ICH and bleeding (apixaban 2.5 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure XII-6 a (mortality-all-cause)                                                                          Figure XII-6 b (mortality-stroke)           
     
Figure XII-6 c (mortality-cardiovascular) 
 
Figure XII-6: log-cumulative hazard plot for mortality (apixaban 2.5 mg vs. warfarin
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Figure XII-7 a (stroke-all)                                                                                          Figure XII-7 b (stroke or SE) 
  
  Figure XII-7 c (stroke or SE or TIA)                                                                      Figure XII-7 d (stroke or mortality-all-cause)          
  
Figure XII-7: log-cumulative hazard plot for stroke, SE and TIA (rivaroxaban 20 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
  
 
 
                                                                                                                                                                          305 
 
Figure XII-8 a (MI)                                                                                                     Figure XII-8 b (major bleeding)      
  
Figure XII-8 c (ICH)                                                                                                   Figure XII-8 d (GI bleeding) 
  
Figure XII-8: log-cumulative hazard plot for MI, ICH and bleeding (rivaroxaban 20 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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 Figure XII-9 a (mortality-all-cause)                                                                         Figure XII-9 b (mortality-stroke) 
   
 Figure XII-9 c (mortality-cardiovascular)         
             
Figure XII-9: log-cumulative hazard plot for mortality (rivaroxaban 20 mg vs. warfarin) 
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Figure XII-10 a (stroke-all)                                                                                        Figure XII-10 b (stroke or SE)  
  
Figure XII-10 c (stroke or SE or TIA)                                                                      Figure XII-10 d (stroke or mortality-all-cause)           
  
Figure XII-10: log-cumulative hazard plot for stroke, SE and TIA (rivaroxaban 15 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XII-11 a (MI)                                                                                                   Figure XII-11 b (major bleeding)           
           
Figure XII-11 c (ICH)                                                                                                 Figure XII-11 d (GI bleeding)           
  
Figure XII-11: log-cumulative hazard plot for MI, ICH and bleeding (rivaroxaban 15 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure XII-12 a (mortality-all-cause)                                                                        Figure XII-12 b (mortality-stroke)          
  
Figure XII-12 c (mortality-cardiovascular)         
 
Figure XII-12: log-cumulative hazard plot for mortality (rivaroxaban 15 mg vs. warfarin)
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Table XII-1 Proportionality hazard assumption test of significance (standard dose) 
 
Outcome 
p-value 
treatment age sex CCI SIMD year PS 
Apixaban 5 mg               
Stroke all 0.154 0.065 0.125 0.001 0.293 0.878 0.289 
Stroke or SE 0.168 0.055 0.074 0.001 0.344 0.902 0.339 
Stroke or SE or TIA 0.287 0.069 0.107 0.001 0.124 0.901 0.257 
Stroke or SE or mortality (all-cause) 0.930 0.004 0.114 0.001 0.997 0.493 0.464 
MI 0.787 0.826 0.461 0.001 0.449 0.212 0.969 
Major bleeding 0.214 0.946 0.931 0.002 0.152 0.695 0.155 
ICH 0.395 0.170 0.367 0.010 0.730 0.450 0.506 
GI bleeding 0.756 0.632 0.596 0.017 0.284 0.127 0.105 
Mortality (all-cause) 0.648 0.038 0.130 0.001 0.391 0.250 0.854 
Mortality (stroke) 0.115 0.727 0.877 0.020 0.926 0.387 0.403 
Mortality (cardiovascular) 0.084 0.964 0.863 0.004 0.946 0.148 0.758 
Rivaroxaban 20 mg               
Stroke all 0.359 0.001 0.259 0.001 0.417 0.940 0.709 
Stroke or SE 0.318 0.001 0.173 0.001 0.467 0.913 0.774 
Stroke or SE or TIA 0.589 0.001 0.247 0.001 0.086 0.936 0.491 
Stroke or SE or mortality (all-cause) 0.881 0.001 0.241 0.001 0.499 0.471 0.885 
MI 0.834 0.973 0.514 0.001 0.098 0.277 0.166 
Major bleeding 0.741 0.328 0.941 0.005 0.861 0.893 0.188 
ICH 0.162 0.261 0.562 0.005 0.456 0.358 0.278 
GI bleeding 0.246 0.921 0.302 0.105 0.527 0.173 0.772 
Mortality (all-cause) 0.593 0.002 0.243 0.001 0.877 0.291 0.960 
Mortality (stroke) 0.621 0.835 0.886 0.008 0.374 0.637 0.066 
Mortality (cardiovascular) 0.696 0.820 0.200 0.001 0.632 0.258 0.698 
 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, ICH=intracranial haemorrhage, 
GI=gastrointestinal 
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Table XII-2 Proportionality hazard assumption test of significance (reduced dose) 
 
 
Outcome 
p-value  
treatment age sex CCI SIMD year PS 
Apixaban 2.5 mg               
Stroke all 0.108 0.245 0.105 0.001 0.124 0.946 0.077 
Stroke or SE 0.095 0.218 0.060 0.001 0.145 0.982 0.091 
Stroke or SE or TIA 0.273 0.268 0.110 0.001 0.134 0.932 0.068 
Stroke or SE or mortality (all-cause) 0.061 0.001 0.072 0.001 0.888 0.536 0.779 
MI 0.464 0.965 0.557 0.001 0.607 0.189 0.880 
Major bleeding 0.189 0.943 0.842 0.001 0.278 0.707 0.180 
ICH 0.109 0.358 0.532 0.009 0.949 0.395 0.883 
GI bleeding 0.508 0.646 0.566 0.042 0.673 0.134 0.889 
Mortality (all-cause) 0.087 0.006 0.107 0.001 0.323 0.309 0.216 
Mortality (stroke) 0.982 0.691 0.913 0.001 0.942 0.610 0.939 
Mortality (cardiovascular) 0.333 0.502 0.857 0.001 0.977 0.187 0.528 
Rivaroxaban 15 mg               
Stroke all 0.503 0.000 0.413 0.001 0.499 0.794 0.209 
Stroke or SE 0.335 0.000 0.278 0.001 0.533 0.796 0.200 
Stroke or SE or TIA 0.273 0.000 0.455 0.001 0.219 0.825 0.054 
Stroke or SE or mortality (all-cause) 0.261 0.001 0.017 0.001 0.989 0.505 0.772 
MI 0.707 0.950 0.650 0.001 0.342 0.121 0.896 
Major bleeding 0.399 0.087 0.629 0.003 0.350 0.970 0.165 
ICH 0.824 0.083 0.330 0.009 0.196 0.486 0.791 
GI bleeding 0.840 0.735 0.371 0.037 0.422 0.210 0.946 
Mortality (all-cause) 0.462 0.132 0.058 0.001 0.526 0.233 0.682 
Mortality (stroke) 0.448 0.516 0.769 0.001 0.767 0.624 0.417 
Mortality (cardiovascular) 0.112 0.398 0.581 0.001 0.855 0.170 0.356 
 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, ICH=intracranial 
haemorrhage, GI=gastrointestinal 
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Appendix XIII: Kaplan Meier curves (standard and reduced dose) 
 
 
 Apixaban versus warfarin 
 
The crude estimates over time indicate the same probability of surviving for patients on 
either warfarin or standard dose apixaban (Figure XIII-3 ‒ XIII-6). While this is true for 
most of the outcomes, the probability of surviving from MI and ICH (Figure XIII-3 a, 
XIII-3 c) is greater for warfarin group than in the in the standard dose apixaban group; 
however, the probability of survival is inverted for the mortality due to stroke outcome 
(Figure XIII-3 B). The crude estimates for the reduced dose apixaban versus warfarin 
comparison indicate that the probability of surviving is higher for patients on warfarin than 
those on apixaban for each of the outcome assessed (Figure XIII-4 ‒ XIII-6). 
 
Rivaroxaban versus warfarin 
The crude estimates over time indicate that the probability of surviving is higher for 
patients on warfarin than those on rivaroxaban standard dose (Figure XIII-7 ‒ XIII-9).  
While this is true for most of the outcomes, the probability of surviving is inverted for 
patients experiencing an MI (Figure XIII-8 a). As for patients on standard dose 
rivaroxaban, over time, the probability of surviving is lower for patients on reduced dose 
rivaroxaban than for those on warfarin (Figure XIII-10‒XIII-12).  
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Figure XIII-1 a (stroke-all)                                                                                        Figure XIII-1 b (stroke or SE)  
  
Figure XIII-1 c (stroke or SE or TIA)                                                                       Figure XIII-1 d (stroke or mortality-all-cause)    
  
Figure XIII-1 Stroke, SE and TIA (apixaban 5 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack  
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Figure XIII-2 a (MI)                                                                                                   Figure XIII-2 b (major bleeding)         
            
Figure XIII-2 c (ICH)                                                                                                 Figure XIII-2 d (GI bleeding)  
        
Figure XIII-2: MI, ICH and bleeding (apixaban 5 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal 
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Figure XIII-3 a (mortality-all-cause)                                                                        Figure XIII-3 b (mortality-stroke)    
  
Figure XIII-3 c (mortality-cardiovascular)         
 
Figure XIII-3: Mortality (apixaban 5 mg vs. warfarin) 
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Figure XIII-4 a (stroke-all)                                                                                        Figure XIII-4 b (stroke or SE) 
   
Figure XIII-4 c (stroke or SE or TIA)                                                                       Figure XIII-4 d (stroke or mortality-all-cause)           
  
Figure XIII-4 Stroke, SE and TIA (apixaban 2.5 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XIII-5 a (MI)                                                                                                   Figure XIII-5 b (major bleeding)           
  
Figure XIII-5 c (ICH)                                                                                                 Figure XIII-5 d (GI bleeding)  
  
Figure XIII-5: MI, ICH and bleeding (apixaban 2.5 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal 
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Figure XIII-6 a (mortality-all-cause)                                                                       Figure XIII-6 b (mortality-stroke)           
  
Figure XIII-6 c (mortality-cardiovascular) 
     
 Figure XIII-6: Mortality (apixaban 2.5 mg vs. warfarin) 
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Figure XIII-7 a (stroke-all)                                                                                        Figure XIII-7 b (stroke or SE) 
  
Figure XIII-7 c (stroke or SE or TIA)                                                                      Figure XIII-7 d (stroke or mortality-all-cause)          
  
Figure XIII-7: Stroke, SE and TIA (rivaroxaban 20 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XIII-8 a (MI)                                                                                                   Figure XIII-8 b (major bleeding)      
  
Figure XIII-8 c (ICH)                                                                                                 Figure XIII-8 d (GI bleeding) 
  
Figure XIII-8: MI, ICH and bleeding (rivaroxaban 20 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
                                                                                                                                                                          321 
 
Figure XIII-9 a (mortality-all-cause)                                                                        Figure XIII-9 b (mortality-stroke) 
  
Figure XIII-9 c (mortality-cardiovascular)         
     
Figure XIII-9: Mortality (rivaroxaban 20 mg vs. warfarin) 
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Figure XIII-10 a (stroke-all)                                                                                      Figure XIII-10 b (stroke or SE)  
  
Figure XIII-10 c (stroke or SE or TIA)                                                                    Figure XIII-10 d (stroke or mortality-all-cause)           
  
Figure XIII-10: Stroke, SE and TIA (rivaroxaban 15 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XIII-11 a (MI)                                                                                                 Figure XIII-11 b (major bleeding)           
  
Figure XIII-11 c (ICH)                                                                                               Figure XIII-11 d (GI bleeding)           
  
Figure XIII-11: MI, ICH and bleeding (rivaroxaban 15 mg vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the Kaplan Meier curve was not reported 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal 
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Figure XIII-12 a (mortality-all-cause)                                                                      Figure XIII-12 b (mortality-stroke)          
  
Figure XIII-12 c (mortality-cardiovascular)         
 
Figure XIII-12: Mortality (rivaroxaban 15 mg vs. warfarin) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
P
ro
b
a
b
il
it
y
 o
f 
su
rv
iv
a
l 
                                                                                                                                                                          325 
 
Appendix XIV: Cumulative incidence curves (standard and reduced dose) 
 
Apixaban versus warfarin 
 
The cumulative incidence curves for apixaban standard and reduced dose are presented in 
Appendix XIV (Figure XIV-1‒XIV-6). Overall, the cumulative incidence curves for 
standard dose apixaban (Figure XIV-1‒XIV-3) did not show any difference in the 
probability of events occurring at 2 years since first prescription for most of the clinical 
outcomes. Nevertheless, patients on standard dose apixaban appeared to be at a greater risk 
of experiencing MI or ICH than those on warfarin. The probability of experiencing an MI 
event, however, seemed to be greater only after about 6 months from anticoagulation 
initiation (Figure XIV-2 a). On the other hand, for most of the clinical outcomes at 2 years 
from anticoagulation initiation, the probability of an event to occur seemed to be greater in 
the reduced dose apixaban than in the warfarin treatment group (Figure XIV-4‒XIV-6). 
However, the cumulative incidence curves, indicating the occurrence of major and GI 
bleeding in the reduced dose apixaban group, did not seem to follow a clear pattern (Figure 
XIV-5 b, XIV-5 d).  
 
Rivaroxaban versus warfarin 
The cumulative incidence curves for rivaroxaban standard and reduced dose are presented 
in Appendix XIV (Figure XIV-7‒XIV-12). Overall, for most of the clinical outcomes at 2 
years from anticoagulation initiation, the probability of an event to occur seemed to be 
greater in the standard dose rivaroxaban than in the warfarin treatment group (Figure XIV-
7‒XIV-9). However, patients on standard dose rivaroxaban seemed to be at a greater risk 
of experiencing MI, following the 2 years since treatment initiation, than those on warfarin.  
Aside from risk of MI, similar patterns were observed in the cumulative incidence curves of 
reduced dose rivaroxaban (Figure XIV-10‒XIV-12).  
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Figure XIV-1 a (stroke-all)                                                                                        Figure  XIV-1 b (stroke or SE)  
  
Figure XIV-1 c (stroke or SE or TIA)                                                                       Figure XIV-1 d (stroke or SE or mortality-all-cause)           
  
Figure XIV-1: Stroke, SE and TIA (apixaban 5 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XIV-2 a (MI)                                                                                                   Figure XIV-2 b (major bleeding)           
  
Figure XIV-2 c (ICH)                                                                                                  Figure XIV-2 d (GI bleeding)           
  
Figure XIV-2: MI, ICH and bleeding (apixaban 5 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure XIV-3 a (mortality-all-cause)                                                                        Figure XIV-3 b (mortality-stroke)           
  
Figure XIV-3 c (mortality-cardiovascular) 
 
Figure XIV-3: Mortality (apixaban 5 mg vs. warfarin) 
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Figure XIV-4 a (stroke-all)                                                                                        Figure XIV-4 b (stroke or SE)  
  
Figure XIV-4 c (stroke or SE or TIA)                                                                       Figure XIV-4 d (stroke or SE or mortality-all-cause) 
  
Figure XIV-4: Stroke, SE and TIA (apixaban 2.5 mg vs. warfarin)  
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack                                                                                         
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Figure XIV-5 a (MI)                                                                                                   Figure XIV-5 b (major bleeding) 
  
Figure XIV-5 c (ICH)                                                                                                 Figure XIV-5 d (GI bleeding)           
  
Figure XIV-5: MI, ICH and bleeding (apixaban 2.5 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
 
 
 
 
 
                                                                                                                                                                          331 
 
Figure XIV-6 a (mortality-all-cause)                                                                        Figure XIV-6 b (mortality-stroke)           
  
Figure XIV-6 c (mortality-cardiovascular)                                                                          
 
Figure XIV-6: Mortality (apixaban 2.5 mg vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
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Figure XIV-7 a (stroke-all)                                                                                        Figure XIV-7 b (stroke or SE)  
  
Figure XIV-7 c (stroke or SE or TIA)                                                                       Figure XIV-7 d (stroke or mortality-all-cause)           
  
Figure XIV-7: Stroke, SE and TIA (rivaroxaban 20 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XIV-8 a (MI)                                                                                                   Figure XIV-8 b (major bleeding)           
  
Figure XIV-8 c (ICH)                                                                                                 Figure XIV-8 d (GI bleeding)           
  
Figure XIV-8: MI, ICH and bleeding (rivaroxaban 20 mg vs. warfarin) 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
 
 
 
 
 
                                                                                                                                                                          334 
 
Figure XIV-9 a (mortality-all-cause)                                                                        Figure XIV-9 b (mortality-stroke)           
  
Figure XIV-9 c (mortality-cardiovascular)                                                                          
 
Figure XIV-9: Mortality (rivaroxaban 20 mg vs. warfarin) 
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Figure XIV-10 a (stroke-all)                                                                                      Figure XIV-10 b (stroke or SE)  
  
Figure XIV-10 c (stroke or SE or TIA)                                                                     Figure XIV-10 d (stroke or mortality-all-cause)           
  
Figure XIV-10: Stroke, SE and TIA (rivaroxaban 15 mg vs. warfarin) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack 
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Figure XIV-11 a (MI)                                                                                                 Figure XIV-11 b (major bleeding)           
  
Figure XIV-11 c (ICH)                                                                                               Figure XIV-11 d (GI bleeding)           
  
Figure XIV-11: MI, ICH and bleeding (rivaroxaban 15 mg vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: MI=myocardial, ICH= intracranial haemorrhage, GI=gastrointestinal  
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Figure XIV-12 a (mortality-all-cause)                                                                      Figure XIV-12 b (mortality-stroke)           
  
Figure XIV-12 c (mortality-cardiovascular)                                                                          
 
Figure XIV-12: Mortality (rivaroxaban 15 mg vs. warfarin) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
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Appendix XV: Hazard ratios for 6 years follow-up (standard and reduced dose) 
 
 
 
 
Figure XV-1: Hazard ratios 6 years since first prescription, apixaban (standard and reduced 
dose) vs. warfarin 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
 
 
 
 
 
 
 
 
 
 
 
 
Apixaban 5 mg
Stroke all 0.90 (0.61 -1.31)
Stroke or SE 0.87 (0.60 -1.27)
Stroke or SE  or TIA 0.87 (0.62 -1.21)
Stroke or SE or mortality (all cause) 0.94 (0.77 -1.14)
MI 1.22 (0.76 -1.96)
Major bleeding 0.92 (0.73 -1.18)
ICH 1.34 (0.60 -3.01)
GI bleeding 0.92 (0.60 -1.4)
Mortality (all cause) 0.96 (0.76 -1.21)
Mortality (stroke) 0.83 (0.30 -2.28)
Mortality (cardiovascular) 0.98 (0.71 -1.35)
Apixaban 2.5 mg
Stroke all 0.86 (0.52 -1.41)
Stroke or SE 0.85 (0.53 -1.38)
Stroke or SE  or TIA 0.88 (0.58 -1.35)
Stroke or SE or mortality (all cause) 0.94 (0.75 -1.19)
MI 1.67 (0.95 -2.93)
Major bleeding 0.80 (0.54 -1.18)
ICH 1.69 (0.61 -4.69)
GI bleeding 0.75 (0.4 -1.42)
Mortality (all cause) 0.97 (0.74 -1.27)
Mortality (stroke) 0.62 (0.2 -1.88)
Mortality (cardiovascular) 1.02 (0.72 -1.46)
Outcome  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring apixaban       Favouring  warfarin
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Figure XIV-2: Hazard ratios 6 years since first prescription, rivaroxaban (standard and 
reduced dose) vs. warfarin 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, 
ICH=intracranial haemorrhage, GI=gastrointestinal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rivaroxaban 20 mg
Stroke all 1.04 (0.77 -1.40)
Stroke or SE 1.00 (0.75 -1.35)
Stroke or SE  or TIA 0.94 (0.72 -1.23)
Stroke or SE or mortality (all cause) 1.31 (1.14 -1.51)
MI 0.67 (0.40 -1.11)
Major bleeding 1.26 (1.05 -1.51)
ICH 1.49 (0.80 -2.79)
GI bleeding 1.17 (0.84 -1.63)
Mortality (all cause) 1.43 (1.22 -1.67)
Mortality (stroke) 1.46 (0.76 -2.81)
Mortality (cardiovascular) 1.27 (1.01 -1.60)
Rivaroxaban 15 mg
Stroke all 0.69 (0.36 -1.31)
Stroke or SE 0.72 (0.39 -1.32)
Stroke or SE  or TIA 0.68 (0.39 -1.19)
Stroke or SE or mortality (all cause) 1.15 (0.90 -1.47)
MI 1.32 (0.69 -2.55)
Major bleeding 1.59 (1.16 -2.18)
ICH 0.90 (0.21 -3.82)
GI bleeding 2.14 (1.34 -3.42)
Mortality (all cause) 1.29 (0.99 -1.69)
Mortality (stroke) 0.85 (0.26 -2.86)
Mortality (cardiovascular) 1.30 (0.90 -1.87)
Outcome  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring rivaroxaban       Favouring  warfarin
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Appendix XVI: Comparison of results with RCTs and observational studies 
 
 
Figure XVI-1 Comparison of results with RCTs and observational studies  
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, ICH=intracranial 
haemorrhage, GI=gastrointestinal 
Apixaban
Stroke all 0.90 (0.65 -1.25) 0.79 (0.65 -0.95) 0.95 (0.75 -1.19)
Stroke or SE 0.88 (0.64 -1.21) 0.79 (0.66 -0.95) 0.67 (0.46 -0.98)
Stroke or SE  or TIA 0.89 (0.67 -1.18) Not estimated Not estimated
Stroke or SE or mortality (all cause) 0.97 (0.82 -1.14) Not estimated Not estimated
MI 1.34 (0.90 -1.98) 0.88 (0.80 -0.97) Not estimated
Major bleeding 0.88 (0.71 -1.10) 0.69 (0.60 -0.80) 0.55 (0.48 -0.63)
ICH 1.50 (0.75 -3.02) 0.42 (0.30 -0.58) 0.45 (0.31 -0.63)
GI bleeding 0.87 (0.60 -1.26) 0.89 (0.70 -1.15) 0.63 (0.42 -0.95)
Mortality (all cause) 0.99 (0.82 -1.20) 0.89 (0.80 -1.00) 0.65 (0.56 -0.75)
Mortality (stroke) 0.73 (0.32 -1.66) Not estimated Not estimated
Mortality (cardiovascular) 1.04 (0.80 -1.36) Not estimated Not estimated
Dabigatran
Stroke all 0.53 (0.20 -1.41) Not estimated 0.96 (0.80 -1.16)
Stroke or SE 0.49 (0.18 -1.32) Not estimated 0.93 (0.77 -1.14)
Stroke or SE  or TIA 0.49 (0.20 -1.19) Not estimated Not estimated
Stroke or SE or mortality (all cause) 0.74 (0.50 -1.11) Not estimated Not estimated
MI 0.44 (0.11 -1.78) Not estimated Not estimated
Major bleeding 1.04 (0.68 -1.59) Not estimated 0.83 (0.65 -1.05)
ICH Not estimated Not estimated 0.42 (0.37 -0.49)
GI bleeding 2.04 (1.17 -3.56) Not estimated 1.20 (1.06 -1.36)
Mortality (all cause) 0.82 (0.53 -1.27) Not estimated 0.63 (0.52 -0.76)
Mortality (stroke) 1.62 (0.39 -6.63) Not estimated Not estimated
Mortality (cardiovascular) 0.95 (0.54 -1.69) 0.95 (0.54 -1.69) Not estimated
Rivaroxaban
Stroke all 1.02 (0.77 -1.34) 0.85 (0.70 -1.03) 0.89 (0.76 -1.04)
Stroke or SE 0.98 (0.75 -1.29) 0.88 (0.75 -1.03) 0.87 (0.71 -1.07)
Stroke or SE  or TIA 0.92 (0.72 -1.18) Not estimated Not estimated
Stroke or SE or mortality (all cause) 1.28 (1.13 -1.46) Not estimated Not estimated
MI 0.81 (0.53 -1.23) 0.81 (0.63 -1.06) Not estimated
Major bleeding 1.30 (1.10 -1.53) 1.04 (0.90 -1.20) 1.00 (0.92 -1.08)
ICH 1.45 (0.81 -2.62) 0.67 (0.47 -0.93) 0.64 (0.47 -0.86)
GI bleeding 1.34 (1.01 -1.79) Not estimated 1.24 (1.08 -1.41)
Mortality (all cause) 1.39 (1.20 -1.61) 0.85 (0.70 -1.02) 0.67 (0.35 -1.30)
Mortality (stroke) 1.42 (0.78 -2.57) Not estimated Not estimated
Mortality (cardiovascular) 1.28 (1.04 -1.57) 0.89 (0.73 -1.10) Not estimated
Outcome
Analysis RCTs Meta-analysis of observational studies
 HR 95% Conf. Interval  HR 95% Conf. Interval  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00
Favouring DOACs       Favouring  warfarin
0.25 0.50 1.00 2.00 4.00 0.25 0.50 1.00 2.00 4.00
Favouring DOACs       Favouring  warfarin Favouring DOACs       Favouring  warfarin
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Figure XVI- 2 Comparison of results with RCTs and observational studies (standard dose) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, ICH=intracranial 
haemorrhage, GI=gastrointestinal 
 
 
 
Apixaban 5 mg
Stroke all 0.90 (0.62 -1.33) 1.07 (0.79 -1.46) Vinogradova,2018 (UK)
Stroke systemic embolism 0.88 (0.61 -1.28) Not estimated
Stroke systemic embolism TIA 0.88 (0.63 -1.23) Not estimated
Stroke systemic embolism death 0.93 (0.76 -1.14) Not estimated
Myocardial infarction 1.26 (0.79 -2.03) 0.00 (0.00 -0.00)
Major bleeding 0.93 (0.73 -1.19) 0.62 (0.62 -0.62) Vinogradova,2018 (UK)
Intracranial bleeding 1.36 (0.60 -3.05) 0.41 (0.41 -0.41) Vinogradova,2018 (UK)
Gastrointestinal bleeding 0.93 (0.61 -1.42) 0.81 (0.81 -0.81) Vinogradova,2018 (UK)
Mortality 0.95 (0.75 -1.21) 0.98 (0.98 -0.98) Vinogradova,2018 (UK)
Mortality due to stroke 0.82 (0.30 -2.27) Not estimated
Mortality due to cardiovascular 0.99 (0.71 -1.37) Not estimated
Rivaroxaban 20 mg
Stroke all 1.09 (0.80 - 1.47) 0.97 (0.78 -1.20) (Vinogradova,2018 (UK)              
Stroke systemic embolism 1.05 (0.78 -1.42) Not estimated
Stroke systemic embolism TIA 0.97 (0.74 -1.28) 0.72 (0.51 -1.01) Gorst-Rasmussen, 2016 (Denmark)  
Stroke systemic embolism death 1.36 (1.18 -1.56) Not estimated
Myocardial infarction 0.69 (0.41 -1.16) Not estimated
Major bleeding 1 1.30 (1.08 -1.56) 1.06 (0.92 -1.40) Vinogradova,2018 (UK)                  
Intracranial bleeding 1.57 (0.83 -2.96) 0.85 (0.63 -1.14) Vinogradova,2018 (UK)              
Gastrointestinal bleeding 1.20 (0.86 -1.69) 1.14 (0.93 -1.40) Vinogradova,2018 (UK)                
Mortality 1 1.47 (1.25 -1.73) 0.93 (0.75 -1.16) Gorst-Rasmussen, 2016 (Denmark)   
Mortality 2 Not estimated 1.10 (0.99 -1.21) Vinogradova,2018 (UK)                
Mortality due to stroke 1.51 (0.78 -2.91) Not estimated
Mortality due to cardiovascular 1.28 (1.01 -1.62) Not estimated
Outcome
Analysis Observational studies - standard dose
 HR 95% Conf. Interval  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00 0.25 0.50 1.00 2.00 4.00
Favouring DOACs       Favouring  warfarin Favouring DOACs       Favouring  warfarin
                                                                                                                                                                          342 
 
 
 
Figure XVI-3 Comparison of results with RCTs and observational studies (reduced dose) 
Abbreviations: SE=systemic embolism, TIA=transient ischaemic attack, MI=myocardial infarction, ICH=intracranial 
haemorrhage, GI=gastrointestinal 
 
Apixaban 2.5 mg
Stroke all 1 0.87 (0.53 -1.43) 1.14 (0.89 -1.46) Nielsen, 2017 (Denmark)
Stroke all 2 1.16 (0.81 -1.67) Vinogradova, 2018 (UK)
Stroke systemic embolism 0.87 (0.54 -1.41) 1.15 (0.90 -1.47) Nielsen, 2017 (Denmark)
Stroke systemic embolism TIA 0.89 (0.58 -1.36) Not estimated
Stroke systemic embolism death 0.96 (0.76 -1.21) Not estimated
Myocardial infarction 1.63 (0.93 -2.87) Not estimated
Major bleeding 1 0.80 (0.54 -1.18) 1.02 (0.74 -1.41) Nielsen, 2017 (Denmark)
Major bleeding 2 Not estimated 0.68 (0.52 -0.90) Vinogradova, 2018 (UK)
Intracranial bleeding 1.73 (0.62 -4.84) 0.44 (0.23 -0.82) Vinogradova, 2018 (UK)
Gastrointestinal bleeding 0.76 (0.40 -1.44) 0.70 (0.45 -1.09) Vinogradova, 2018 (UK)
Mortality 1 0.99 (0.75 -1.29) 1.61 (1.43 -1.82) Nielsen, 2017 (Denmark)
Mortality 2 1.27 (1.12 -1.45) Vinogradova, 2018 (UK)
Mortality due to stroke 0.64 (0.21 -1.97) Not estimated
Mortality due to cardiovascular 1.03 (0.72 -1.47) Not estimated
Rivaroxaban 15 mg
Stroke all 1 0.72 (0.38 -1.37) 1.02 (0.77 -1.34) Nielsen, 2017 (Denmark)
Stroke all 2 1.27 (0.92 -1.75) Vinogradova, 2018 (UK)
Stroke systemic embolism 0.68 (0.36 -1.29) 0.99 (0.76 -1.30) Nielsen, 2017 (Denmark)
Stroke systemic embolism TIA 0.65 (0.36 -1.16) 0.46 (0.26 -0.82) Gorst-Rasmussen, 2016 (Denmark)
Stroke systemic embolism death 1.14 (0.88 -1.46) 0.00 (0.00 -0.00)
Myocardial infarction 1.34 (0.69 -2.59) 0.00 (0.00 -0.00)
Major bleeding 1 1.56 (1.13 -3.42) 1.18 (0.93 -1.50) Nielsen, 2017 (Denmark)
Major bleeding 2 1.25 (1.01 -1.55) Vinogradova, 2018 (UK)
Intracranial bleeding 0.94 (0.22 -4.00) 0.86 (0.52 -1.42) Vinogradova, 2018 (UK)
Gastrointestinal bleeding 2.12 (1.31 -3.42) 1.34 (0.98 -1.83) Vinogradova, 2018 (UK)
Mortality 1 1.29 (0.98 -1.69) 1.47 (1.19 -1.82) Gorst-Rasmussen, 2016 (Denmark)
Mortality 2 1.43 (1.27 -1.61) Nielsen, 2017 (Denmark)
Mortality 3 1.29 (1.14 -1.45) Vinogradova, 2018 (UK)
Mortality due to stroke 0.89 (0.27 -3.02) 0.00 (0.00 -0.00)
Mortality due to cardiovascular 1.25 (0.86 -1.81) 0.00 (0.00 -0.00)
Outcome
Analysis Observational studies - standard dose
 HR 95% Conf. Interval  HR 95% Conf. Interval
0.25 0.50 1.00 2.00 4.00 0.25 0.50 1.00 2.00 4.00
Favouring DOACs       Favouring  warfarin Favouring DOACs       Favouring  warfarin
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Appendix XVII: Literature search strategy 
 
1. Atrial fibrillation/ 
2. Markov/ 
3. Markov state transition model/ 
4. Markov simulation/ 
5. Markov chain/  
6. Markov processes/ 
7. semi-Markov/ 
8. 2 or 3 or 4 or 5 or 6 or 7 
9. decision analys*.mp. 
10. decision analytic/ 
11. decision tree/ 
12. decision model/ 
13. 9 or 10 or 11 or 12  
14. warfarin/ 
15. coumarins/ 
16. vitamin K antagonists/  
17. Apixaban/ 
18. Dabigatran/ 
19. Rivaroxaban/ 
20. Anticoagulants/ 
21. Aspirin/ 
22. OAC/ 
23. NOAC/ 
24. DOAC/ 
25. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24  
26. cost-effectiveness  
27. cost effectiveness  
28. 26 or 27 
29. 8 and 13 and 25 and 28 
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Appendix XVIII:  CHEERS Checklist of items to include when reporting economic evaluations of health interventions  
 
Table XVIII-1 CHEERS Checklist (Dorian,2014)  
 
Section/item  
 
Item No  
 
Recommendation  
 
Reported on page No /line No  
Title and abstract       
Title 1 
Identify the study as an economic evaluation or use more specific terms such as “cost-
effectiveness analysis”, and describe the interventions compared. 
Page 1897. 
Abstract 2 
Provide a structured summary of objectives, perspective, methods (including study design and 
inputs), results (including base-case and uncertainty analyses), and conclusions. 
Page 1897. 
Introduction       
Background and objectives 3 
Provide an explicit statement of the broader context for the study. Present the study question 
and its relevance for health policy or practice decisions. 
Page 1898. 
Methods       
Target population and subgroups 4 
Describe characteristics of the base-case population and subgroups analysed,                                
including why they were chosen. 
Descriptive characteristics presented in page 1898-
1900. Descriptive of the subgroup analysed in 
presented in Appendix SB. 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. Page 1898. 
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated. Page 1898. 
Comparators 7 Describe the interventions or strategies being compared and state why they were chosen. Page 1898. 
Time horizon 8 
State the time horizon(s) over which costs and consequences are being evaluated and say why 
appropriate. 
Page 1901. 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. Page 1901, method section. Reported but not justified. 
Choice of health outcomes 10 
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their 
relevance for the type of analysis performed. 
Page 1901, method section. Reported but not justified. 
Measurement of effectiveness 11a 
Single study-based estimates: Describe fully the design features of the single effectiveness 
study and why the single study was a sufficient source of clinical effectiveness data. 
Not applicable. 
Measurement of effectiveness 11b 
Synthesis-based estimates: Describe fully the methods used for identification of included 
studies and synthesis of clinical effectiveness data. 
Appendices SA and SB. 
Measurement and valuation of 
preference-based outcomes 
12 
If applicable, describe the population and methods used to elicit preferences for outcomes. Not applicable. 
Estimating resources and costs 13a 
Single study-based economic evaluation: Describe approaches used to estimate resource use 
associated with the alternative interventions. Describe primary or secondary research methods 
for valuing each resource item in terms of its unit cost. Describe any adjustments made to 
approximate to opportunity costs. 
Not applicable. 
Estimating resources and costs 13b 
Model-based economic evaluation: Describe approaches and data sources used to estimate 
resource use associated with model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit cost. Describe any adjustments 
made to approximate to cost opportunity cost. 
Appendices SC, page 25-30. 
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Table XVIII-1 CHEERS Checklist (Dorian, 2014), continued  
 
Section/item  
  
Item No 
 
Recommendation  
 
Reported on page No/line No  
Currency, price date, and 
conversion 
 
14 
Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods 
for converting costs into a common currency base and the exchange rate. 
Costs were inflated to 2011 values, Appendix SC, page 25. 
Methods for adjusting estimated unit cost are not reported. 
Methods for converting costs into a common currency is not 
applicable.  
Choice of model 
 
15 
Describe and give reasons for the specific type of decision analytical model used. Providing 
a figure to show model structure is strongly recommended. 
Page 1898. 
Assumptions  16 Describe all structural or other assumptions underpinning the decision-analytical model. Appendix SC, page 5-17. 
Analytical methods 
 
17 
Describe all analytical methods supporting the evaluation. This could include methods for 
dealing with skewed, missing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments (such as half cycle corrections) to 
a model; and methods for handling population heterogeneity and uncertainty. 
Appendix SC, page 33 (model validation).                                 
Appendix SC, page 36-51 (dealing with uncertainty). 
Results        
Study parameters 
 
18 
Report the values, ranges, references, and, if used, probability distributions for all 
parameters. Report reasons or sources for distributions used to represent uncertainty where 
appropriate. Providing a table to show the input values is strongly recommended. 
Appendices SC, page 49-65. 
Incremental costs and outcomes 
 
19 
For each intervention, report mean values for the main categories of estimated costs and 
outcomes of interest, as well as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios. 
Page 1902-1903 
Characterising uncertainty 
 
20a 
Single study-based economic evaluation: Describe the effects of sampling uncertainty for 
the estimated incremental cost and incremental effectiveness parameters, together with the 
impact of methodological assumptions (such as discount rate, study perspective). 
Not applicable 
Characterising uncertainty 
 
20b 
Model-based economic evaluation: Describe the effects on the results of uncertainty for all 
input parameters, and uncertainty related to the structure of the model and assumptions. 
Page 1902 (one-way sensitivity analysis), page 1904 
(probabilistic sensitivity analysis).  
Characterising heterogeneity 
 
21 
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of patients with different baseline 
characteristics or other observed variability in effects that are not reducible by more 
information. 
Appendices SC, page 70-87. 
Discussion        
  
 
22 
Summarise key study findings and describe how they support the conclusions reached. 
Discuss limitations and the generalisability of the findings and how the findings fit with 
current knowledge. 
Page 1904-1905. 
Other        
Source of funding 
 
23 
Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other non-monetary sources of support. 
Page 1905. 
Conflicts of interest 
 
24 
Describe any potential for conflict of interest of study contributors in accordance with 
journal policy. In the absence of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors recommendations. 
Page 1905. 
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Table XVIII-2 CHEERS Checklist (Lip, 2014) 
 
Section/item 
 
Item No 
 
Recommendation 
 
Reported on page No/line No 
Title and abstract       
Title 1 
Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, 
and describe the interventions compared. 
Page 192. 
Abstract 2 
Provide a structured summary of objectives, perspective, methods (including study design and inputs), results 
(including base-case and uncertainty analyses), and conclusions. 
Page 192. 
Introduction       
Background and objectives 3 
Provide an explicit statement of the broader context for the study. Present the study question and its relevance 
for health policy or practice decisions. 
Page 193. 
Methods       
Target population and subgroups 4 Describe characteristics of the base-case population and subgroups analysed, including why they were chosen. 
 Page 196-197, Table I. 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. Page 193. 
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated. Page 193. 
Comparators 7 Describe the interventions or strategies being compared and state why they were chosen. Page 193. 
Time horizon 8 State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate. Page 193. 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. 
Page 199, method section. Reported 
but not justified. 
Choice of health outcomes 10 
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the 
type of analysis performed. 
Page 199, method section. Reported 
but not justified. 
Measurement of effectiveness 11a 
Single study-based estimates: Describe fully the design features of the single effectiveness study and why the 
single study was a sufficient source of clinical effectiveness data. 
Not applicable. 
Measurement of effectiveness 11b 
Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis 
of clinical effectiveness data. 
Appendix A. 
Measurement and valuation of 
preference-based outcomes 
12 If applicable, describe the population and methods used to elicit preferences for outcomes. 
Not applicable. 
Estimating resources and costs 13a 
Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the 
alternative interventions. Describe primary or secondary research methods for valuing each resource item in 
terms of its unit cost. Describe any adjustments made to approximate to opportunity costs. 
Not applicable. 
Estimating resources and costs 13b 
Model-based economic evaluation: Describe approaches and data sources used to estimate resource use 
associated with model health states. Describe primary or secondary research methods for valuing each resource 
item in terms of its unit cost. Describe any adjustments made to approximate to cost opportunity cost. 
Page 200. 
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Table XVIII-2 CHEERS Checklist (Lip, 2014), continued 
 
Section/item  
 
Item No 
 
Recommendation 
 
Reported on page No/line No 
Currency, price date, and 
conversion 
14 
Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting 
estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs 
into a common currency base and the exchange rate. 
It is only stated that the cost in the model are 
reflected in 2011 British pounds, but no additional 
info is provided.  
Choice of model 15 
Describe and give reasons for the specific type of decision analytical model used. Providing a figure to 
show model structure is strongly recommended. 
Page 193. 
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Page 194-195. 
Analytical methods 17 
Describe all analytical methods supporting the evaluation. This could include methods for dealing with 
skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to 
validate or make adjustments (such as half cycle corrections) to a model; and methods for handling 
population heterogeneity and uncertainty. 
Page 200 (dealing with uncertainty). 
Results       
Study parameters 18 
Report the values, ranges, references, and, if used, probability distributions for all parameters. Report 
reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table 
to show the input values is strongly recommended. 
Not reported. 
Incremental costs and outcomes 19 
For each intervention, report mean values for the main categories of estimated costs and outcomes of 
interest, as well as mean differences between the comparator groups. If applicable, report incremental 
cost-effectiveness ratios. 
Page 201 
Characterising uncertainty 20a 
Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated 
incremental cost and incremental effectiveness parameters, together with the impact of methodological 
assumptions (such as discount rate, study perspective). 
Not applicable 
Characterising uncertainty 20b 
Model-based economic evaluation: Describe the effects on the results of uncertainty for all input 
parameters, and uncertainty related to the structure of the model and assumptions. 
Page 202 (one-way sensitivity analysis), page 205 
(probabilistic sensitivity analysis).  
Characterising heterogeneity 21 
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by 
variations between subgroups of patients with different baseline characteristics or other observed 
variability in effects that are not reducible by more information. 
Not reported. 
Discussion       
  
22 
Summarise key study findings and describe how they support the conclusions reached. Discuss 
limitations and the generalisability of the findings and how the findings fit with current knowledge. 
Page 205-207. 
Other       
Source of funding 23 
Describe how the study was funded and the role of the funder in the identification, design, conduct, and 
reporting of the analysis. Describe other non-monetary sources of support. 
Page 207. 
Conflicts of interest 24 
Describe any potential for conflict of interest of study contributors in accordance with journal policy. In 
the absence of a journal policy, we recommend authors comply with International Committee of 
Medical Journal Editors recommendations. 
Page 207. 
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Table XVIII-3 CHEERS Checklist (Sterne, 2017) 
 
Section/item  
 
Item No 
 
Recommendation  
 
Reported on page No/line No 
Title and abstract       
Title 1 
Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness 
analysis”, and describe the interventions compared. 
Page VII. 
Abstract 2 
Provide a structured summary of objectives, perspective, methods (including study design and inputs), 
results (including base-case and uncertainty analyses), and conclusions. 
Page VII. 
Introduction       
Background and objectives 3 
Provide an explicit statement of the broader context for the study. Present the study question and its 
relevance for health policy or practice decisions. 
Page XIV. 
Methods       
Target population and subgroups 4 
Describe characteristics of the base-case population and subgroups analysed, including why they were 
chosen. 
Brief description of the base population in 
page 16. No subgroup analysis considered. 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. Page 15.  
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated. Page 15.  
Comparators 7 Describe the interventions or strategies being compared and state why they were chosen. Page 16. 
Time horizon 8 
State the time horizon(s) over which costs and consequences are being evaluated and say why 
appropriate. 
Page 24. 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. Page 22. 
Choice of health outcomes 10 
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for 
the type of analysis performed. 
Page 22, method section. Reported but not 
justified. 
Measurement of effectiveness 11a 
Single study-based estimates: Describe fully the design features of the single effectiveness study and 
why the single study was a sufficient source of clinical effectiveness data. 
Not applicable. 
Measurement of effectiveness 11b 
Synthesis-based estimates: Describe fully the methods used for identification of included studies and 
synthesis of clinical effectiveness data. 
Page 7-13. 
Measurement and valuation of 
preference-based outcomes 
12 If applicable, describe the population and methods used to elicit preferences for outcomes. 
Not applicable. 
Estimating resources and costs 13a 
Single study-based economic evaluation: Describe approaches used to estimate resource use associated 
with the alternative interventions. Describe primary or secondary research methods for valuing each 
resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity 
costs. 
Not applicable. 
Estimating resources and costs 13b 
Model-based economic evaluation: Describe approaches and data sources used to estimate resource use 
associated with model health states. Describe primary or secondary research methods for valuing each 
resource item in terms of its unit cost. Describe any adjustments made to approximate to cost 
opportunity cost. 
Page 30-32 
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Table XVIII-3 CHEERS Checklist (Sterne, 2017), continued 
 
Section/item  
 
Item No 
 
Recommendation 
 
Reported on page No/line No 
Currency, price date, and 
conversion 
14 
Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods 
for converting costs into a common currency base and the exchange rate. 
Costs were inflated to 2013-2014 values, page 30. Methods for 
adjusting estimated unit cost are not reported. Methods for 
converting costs into a common currency is not applicable.  
Choice of model 15 
Describe and give reasons for the specific type of decision analytical model used. 
Providing a figure to show model structure is strongly recommended. 
Page 24-26. 
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Page 99, Table 68. 
Analytical methods 17 
Describe all analytical methods supporting the evaluation. This could include methods for 
dealing with skewed, missing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments (such as half cycle corrections) to 
a model; and methods for handling population heterogeneity and uncertainty. 
Page 33-34. 
Results       
Study parameters 18 
Report the values, ranges, references, and, if used, probability distributions for all 
parameters. Report reasons or sources for distributions used to represent uncertainty where 
appropriate. Providing a table to show the input values is strongly recommended. 
Page 30-34. 
Incremental costs and outcomes 19 
For each intervention, report mean values for the main categories of estimated costs and 
outcomes of interest, as well as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios. 
Page 90 (no ICERs were reported, INB was reported instead). 
Characterising uncertainty 20a 
Single study-based economic evaluation: Describe the effects of sampling uncertainty for 
the estimated incremental cost and incremental effectiveness parameters, together with the 
impact of methodological assumptions (such as discount rate, study perspective). 
Not applicable 
Characterising uncertainty 20b 
Model-based economic evaluation: Describe the effects on the results of uncertainty for all 
input parameters, and uncertainty related to the structure of the model and assumptions. 
Page 92-93 (probabilistic sensitivity analysis).  
Characterising heterogeneity 21 
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of patients with different baseline 
characteristics or other observed variability in effects that are not reducible by more 
information. 
Not reported 
Discussion       
  
22 
Summarise key study findings and describe how they support the conclusions reached. 
Discuss limitations and the generalisability of the findings and how the findings fit with 
current knowledge. 
Page 261-262 
Other       
Source of funding 23 
Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other non-monetary sources of support. 
Page VIII 
Conflicts of interest 24 
Describe any potential for conflict of interest of study contributors in accordance with 
journal policy. In the absence of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors recommendations. 
Page III 
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Table XVIII-4 CHEERS Checklist (Verhoef, 2014) 
 
Section/item  
 
Item No 
 
Recommendation 
 
Reported on page No/line No 
Title and abstract       
Title 1 
Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and 
describe the interventions compared. 
Page 451. 
Abstract 2 
Provide a structured summary of objectives, perspective, methods (including study design and inputs), results 
(including base-case and uncertainty analyses), and conclusions. 
Page 451. 
Introduction       
Background and objectives 3 
Provide an explicit statement of the broader context for the study. Present the study question and its relevance for 
health policy or practice decisions. 
Page 452. 
Methods       
Target population and subgroups 4 Describe characteristics of the base-case population and subgroups analysed, including why they were chosen. Not reported. 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. Page 452. 
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated. Page 452. 
Comparators 7 Describe the interventions or strategies being compared and state why they were chosen. Page 452. 
Time horizon 8 State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate. Page 452. 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. Page 455. 
Choice of health outcomes 10 
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of 
analysis performed. 
Page 454. 
Measurement of effectiveness 11a 
Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single 
study was a sufficient source of clinical effectiveness data. 
Not applicable. 
Measurement of effectiveness 11b 
Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of 
clinical effectiveness data. 
Page 453. 
Measurement and valuation of 
preference-based outcomes 
12 If applicable, describe the population and methods used to elicit preferences for outcomes. 
Not applicable. 
Estimating resources and costs 13a 
Single study-based economic evaluation: Describe approaches used to estimate resource use associated with the 
alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of 
its unit cost. Describe any adjustments made to approximate to opportunity costs. 
Not applicable. 
Estimating resources and costs 13b 
Model-based economic evaluation: Describe approaches and data sources used to estimate resource use associated 
with model health states. Describe primary or secondary research methods for valuing each resource item in terms of 
its unit cost. Describe any adjustments made to approximate to cost opportunity cost. 
Page 455. 
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Table XVIII-4 CHEERS Checklist (Verhoef, 2014), continued 
 
Section/item  
 
Item No 
 
Recommendation 
 
Reported on page No/line No 
Currency, price date, and 
conversion 
14 
Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods 
for converting costs into a common currency base and the exchange rate. 
Costs were inflated to 2012 values, page 455. Methods for 
adjusting estimated unit cost are not reported. Methods for 
converting costs into a common currency is not applicable.  
Choice of model 15 
Describe and give reasons for the specific type of decision analytical model used. Providing 
a figure to show model structure is strongly recommended. 
Page 453. 
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model. Page 452-454. 
Analytical methods 17 
Describe all analytical methods supporting the evaluation. This could include methods for 
dealing with skewed, missing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments (such as half cycle corrections) to 
a model; and methods for handling population heterogeneity and uncertainty. 
Page 455 (dealing with uncertainty). 
Results       
Study parameters 18 
Report the values, ranges, references, and, if used, probability distributions for all 
parameters. Report reasons or sources for distributions used to represent uncertainty where 
appropriate. Providing a table to show the input values is strongly recommended. 
Page 454-455. 
Incremental costs and outcomes 19 
For each intervention, report mean values for the main categories of estimated costs and 
outcomes of interest, as well as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios. 
Page 456-457. 
Characterising uncertainty 20a 
Single study-based economic evaluation: Describe the effects of sampling uncertainty for 
the estimated incremental cost and incremental effectiveness parameters, together with the 
impact of methodological assumptions (such as discount rate, study perspective). 
Not applicable. 
Characterising uncertainty 20b 
Model-based economic evaluation: Describe the effects on the results of uncertainty for all 
input parameters, and uncertainty related to the structure of the model and assumptions. 
Page 457 (one-way sensitivity analysis), page 
457(probabilistic sensitivity analysis).  
Characterising heterogeneity 21 
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of patients with different baseline characteristics 
or other observed variability in effects that are not reducible by more information. 
Page 456-457. 
Discussion       
  
22 
Summarise key study findings and describe how they support the conclusions reached. 
Discuss limitations and the generalisability of the findings and how the findings fit with 
current knowledge. 
Page 457-459. 
Other       
Source of funding 23 
Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other non-monetary sources of support. 
Page 460. 
Conflicts of interest 24 
Describe any potential for conflict of interest of study contributors in accordance with 
journal policy. In the absence of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors recommendations. 
Not reported. 
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Appendix XIX: Cumulative incidence curves (cost-effectiveness)  
Figure XIX-1 a (stroke-ischaemic)                                                                            Figure XIX-I b (TIA)  
  
Figure XIX-1 c (SE)                                                                                                    Figure XIX-1 d (MI) 
  
Figure XIX-1 Stroke, TIA, SE, MI (any dose) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported. 
Abbreviations: TIA=transient ischaemic attack, SE=systemic embolism, MI=myocardial 
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Figure XIX-2 a (major bleeding)                                                                              Figure XIX-2 b (ICH)           
  
Figure XIX-2 c (mortality-all-cause)                                                                                                      
 
Figure XIX-2 Major bleeding, ICH, mortality (any dose) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: ICH= intracranial haemorrhage 
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Figure XIX-3 a (stroke-ischaemic)                                                                            Figure XIX-3 b (TIA)  
  
Figure XIX-3 c (SE)                                                                                                    Figure XIX-3 d (MI) 
  
Figure XIX-3 Stroke, TIA, SE, MI (standard dose) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: TIA=transient ischaemic attack, SE=systemic embolism, MI=myocardial 
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Figure XIX-4 a (major bleeding)                                                                               Figure XIX-4 b (ICH)           
  
Figure XIX-4 c (mortality-all-cause)                                                                        
 
Figure XIX-4 Major bleeding, ICH, mortality (standard dose) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: ICH= intracranial haemorrhage 
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Figure XIX-5 a (stroke-ischaemic)                                                                            Figure XIX-5 b (TIA)  
  
Figure XIX-5 c (SE)                                                                                                    Figure XIX-5 d (MI) 
  
Figure XIX-5 Stroke, TIA, SE, MI (reduced dose) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: TIA=transient ischaemic attack, SE=systemic embolism, MI=myocardial 
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Figure XIX-6 a (major bleeding)                                                                               Figure XIX-6 b (ICH)                                                                          
  
              Figure XIX-6 c (mortality-all-cause)                                                                        
 
Figure XIX-6 Major bleeding, ICH, mortality (reduced dose) 
Note: due to disclosure restrictions, in the case of fewer than five events, the cumulative incidence curve was not reported 
Abbreviations: ICH= intracranial haemorrhage
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Appendix XX: DOACs HRs for AF patients 70 years or older (Table I)  
Intervention         
(compared to warfarin) Outcome HR 95 % CI 
Standard 
error 
Events and 
(event rates) 
 Apixaban         
  TIA 0.75 (0.36, 1.53) 0.272 29 (1.29) 
  SE 0.62 (0.13, 3.00) 0.499 10 (0.58) 
  Stroke 0.65 (0.42, 0.98) 0.138 <5 (0.29) 
  MI 1.41 (0.93, 2.14) 0.298 35 (2.04) 
  Major bleeding 0.80 (0.63, 1.02) 0.098 88 (5.13) 
  ICH 1.20 (0.55, 2.64) 0.481 9 (0.52) 
  Mortality (all-cause) 1.01 (0.83, 1.23) 0.100 143 (8.34) 
Apixaban (standard dose)        
  TIA 0.53 (0.18, 1.50) 0.281 17 (1.46) 
  SE 0.42 (0.05, 3.45) 0.451 <5 (0.43) 
  Stroke 0.64 (0.38, 1.08) 0.171 <5 (0.43) 
  MI 1.39 (0.83, 2.34) 0.369 19 (1.63) 
  Major bleeding 0.85 (0.64, 1.13) 0.122 60 (5.16) 
  ICH 0.86 (0.29, 2.54) 0.476 <5 (0.43) 
  Mortality (all-cause) 0.97 (0.75, 1.25) 0.125 75 (6.45) 
Apixaban (reduced dose)        
  TIA 1.05 (0.43, 2.58) 0.482 12 (2.17) 
  SE 1.02 (0.12, 8.51) 1.104 6 (1.09) 
  Stroke 0.65 (0.35, 1.20) 0.204 <5 (0.90) 
  MI 1.59 (0.90, 2.81) 0.462 16 (2.90) 
  Major bleeding 0.77 (0.52, 1.14) 0.155 28 (5.07) 
  ICH 1.89 (0.67, 5.33) 0.999 5 (0.90) 
  Mortality (all-cause) 1.02 (0.78, 1.34) 0.141 68 (12.30) 
Dabigatran        
  TIA 0.96 (0.24, 3.89) 0.686 <5 (1.52) 
  SE* 1.00 (1.00, 1.00) 0.000 <5 (1.52) 
  Stroke 1.00 (1.00, 1.00) 0.167 <5 (1.52) 
  MI 1.00 (1.00, 1.00) 0.236 <5 (1.52) 
  Major bleeding 1.54 (1.04, 2.28) 0.307 26 (7.88) 
  ICH 1.00 (1.00, 1.00) 0.712 <5 (1.52) 
  Mortality (all-cause) 0.82 (0.53, 1.28) 0.186 20 (6.06) 
 Rivaroxaban        
  TIA 0.73 (0.39, 1.36) 0.231 41 (1.92) 
  SE 0.29 (0.04, 2.23) 0.303 <5 (0.25) 
  Stroke 0.85 (0.60, 1.19) 0.148 12 (0.56) 
  MI 0.81 (0.53, 1.26) 0.182 24 (1.12) 
  Major bleeding 1.29 (1.08, 1.54) 0.117 162 (7.57) 
  ICH 1.61 (0.90, 2.88) 0.478 16 (0.75) 
  Mortality (all-cause) 1.42 (1.23, 1.65) 0.106 245 (11.45) 
Rivaroxaban (standard dose)      
  TIA 0.77 (0.38, 1.54) 0.274 31 (1.95) 
  SE 1.00 (1.00, 1.00) 0.000 not estimated 
  Stroke 0.90 (0.61, 1.32) 0.177 9 (0.57)  
  MI 0.71 (0.41, 1.24) 0.202 14 (0.88) 
  Major bleeding 1.26 (1.03, 1.55) 0.131 115 (7.24) 
  ICH 1.76 (0.93, 3.31) 0.568 13 (0.82) 
  Mortality (all-cause) 1.49 (1.26, 1.76) 0.127 177 (11.14) 
Rivaroxaban (reduced dose)      
  TIA 0.52 (0.13, 2.17) 0.380 8 (1.95) 
  SE 1.50 (0.19, 11.70) 1.570 <5 (1.22) 
  Stroke 0.70 (0.34, 1.41) 0.257 <5 (1.22) 
  MI 1.26 (0.63, 2.51) 0.443 9 (2.20) 
  Major bleeding 1.63 (1.18, 2.24) 0.267 42 (10.25) 
  ICH 1.04 (0.24, 4.38) 0.763 <5 (1.22) 
  Mortality (all-cause) 1.29 (0.98, 1.70) 0.180 59 (14.40) 
* Assumed no treatment effect difference between warfarin and dabigatran for SE and ICH. 
Abbreviations: TIA= transient ischaemic attack, SE=systemic embolism, MI=myocardial 
infarction, ICH=intracranial haemorrhage. 
Note: due to disclosure restrictions, in the case of fewer than five events, “<5” was reported 
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